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9:30 a.m.
1015-167 Human Cardiosphere-Derived Adult Stem Cells 
Originate Exclusively From In Situ Cardiac Cells
Anthony J. White, Satoshi Matsushita, Lawrence S. Czer, Tarun Chakravarty, Kevin 
Burton, Ernst R. Schwarz, Darryl R. Davis, Jason Lee, Qi Wang, Nancy L. Reinsmoen, 
James S. Forrester, Eduardo Marbán, Raj Makkar, Cedars-Sinai Medical Center, Los 
Angeles, CA
Background: The aim of this study was to determine the origin of cardiosphere-derived 
cells (CDCs). CDCs are cardiac stem cells expanded in cell culture, from endomyocardial 
biopsies. An intermediate step involves formation of ﬂoating clusters of progenitor-rich 
cells (cardiospheres). Very large numbers of CDCs can reliably be produced in a matter of 
weeks. Intra-myocardial injection of CDCs results in improvement of LV function in rodent 
models of myocardial ischemia, and clinical trials are planned. A central unresolved issue 
is whether CDCs represent stem cells expanded from intrinsic cardiac progenitors, or 
stem cells seeded from an extra-cardiac site (contiguous tissue or blood borne).
Methods: Following informed consent, endomyocardial biopsies were obtained from 
cardiac transplant recipients (n=10, age 57±15 yr) during routine rejection screening biopsy 
procedures. CDCs were cultured from each biopsy. The origin of the CDCs was investigated 
by short-tandem nucleotide repeat (STR) testing, otherwise known as “genetic ﬁngerprinting”, 
performed on DNA from three sources - CDCs, donor heart, and recipient. In addition, in 
cases in which the donor was of the opposite sex to the recipient (n=2) the presence of X and 
Y chromosomes in the CDCs was examined using ﬂuorescence in situ hybridization (FISH).
Results: Eight of the 10 subjects were male, with all transplanted hearts originating 
from male donors. The average time from transplantation to cardiac biopsy was 283±484 
days. In all cases, no recipient DNA was detected in the CDCs by STR analysis. In the 
two cases in which a female patient had received a male donor heart, FISH staining 
indicated that all CDCs had an X and a Y chromosome (511 of 511 cells, and 74 of 74 
cells respectively), similarly indicating exclusively donor origin.
Conclusions: CDCs originate from an in situ cardiac source, with no detectable extra-
cardiac contribution. Our data indicate that cardiac tissue is required in order to grow 
CDCs for future clinical purposes.
9:30 a.m.
1015-168 Dimethyloxalylglycine-induced Hypoxia Inducible 
Factor-1A Stabilization and Akt Activation Contribute to 
the Protective Effect on Mesenchymal Stem Cells
Xianbao Liu, Jian-an Wang, Molly Ogle, Ling Wei, Department of Cardiology, Second 
Afﬁliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic 
of China, Department of Pathology, Medical University of South Carolina, Charleston, SC
Background: Mesenchymal stem cell (MSC) transplantation is a promising approach 
in the therapy of ischemic heart diseases, however, the poor viability of MSCs after 
transplantation critically limits the efﬁcacy of this new strategy. The goal of this study 
is to explore a method to enhance MSC survival. Here we hypothesized the prolyl 
hydroxylase inhibitor Dimethyloxalylglycine (DMOG) can promote MSC survival during 
serum deprivation.
Methods: The apoptotic model of serum deprivation was used in this study to mimic 
the microenvironment of ischemic heart diseases in vivo. MSCs were subjected to 24h 
serum deprivation in the presence or absence of DMOG. Apoptosis and cell death were 
assessed by caspase-3 staining and trypan blue staining respectively. The mitochondrial 
apoptotic pathway and PI3K/Akt cell survival pathway were evaluated by western blot to 
study the mechanisms.
Results: The apoptosis and cell death of MSCs were signiﬁcantly inhibited by DMOG 
in a dose dependent manner. The peak of protection was achieved at 1000 μM which 
reduced apoptotic and total cell death rate from 25.3±2.1% to 10.2±0.6%, 29.8±1.5% 
to 12.9±0.6% after 24h serum deprivation respectively. Hypoxia inducible factor-1A
expression and downstream protein glucose transporter-1 synthesis were remarkably 
induced after DMOG treatment. DMOG decreased cytochrome c release into cytosol and 
apoptosis inducing factor translocation into nucleus indicating both caspase dependent 
and independent apoptotic pathway were inhibited. Furthermore, DMOG promoted Akt 
phosphorylation which was blocked by a speciﬁc PI3K inhibitor wortmannin. Wortmannin 
abrogated the beneﬁcial effect of DMOG on MSC survival.
Conclusions: DMOG can effectively protect MSCs against apoptosis and cell death 
induced by serum deprivation; DMOG-induced HIF-1A stabilization and PI3K/Akt pathway 
contribute to the protective effect on MSC survival.
9:30 a.m.
1015-169 Immunosuppression Reduces Immune Responses and 
Enhances AAV-mediated SERCA2a Expression in a 
Canine Model of Cardiac Gene Transfer
Xiaodong Zhu, Charles McTiernan, Navin Rajagopalan, Hemal Shah, David Fischer, 
Yoshiya Toyoda, Dustin Letts, Jonathan Bortinger, Gregory Gibson, Kenneth McCurry, 
Michael Mathier, Barry London, University of Pittsburgh, Pittsburgh, PA
Background: The SERCA2a Ca2+ pump plays a central role in cardiac contractile 
properties. SERCA2a expression is decreased in heart failure (HF). Restoring SERCA2a 
in animal HF models improves cardiac functions. A clinical trial delivering SERCA2a using 
adeno-associated virus (AAV) is underway (CUPID, Celladon Corp.). Recent studies 
suggest that AAV-mediated gene transfer may cause inﬂammation. In this study, we used 
a canine model to test a) the safety and efﬁcacy of AAV6-mediated expression of human 
(h) SERCA2a and b) the role of immunosuppression in modulating expression.
Methods: Dogs were tachy-paced to induce HF, then received direct LV wall injection with 
5x1012 viral genomes of AAV6-hSERCA2a (AAV) or saline (S). Pacing continued post-
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9:30 a.m.
1015-165 Effect of Aging on MicroRNA Expression in the Fischer 
344/NNia x Brown Norway/BiNia Female Rat Heart
Jacqueline C. Fannin, Megan Neal, Sunil Kakarla, Anjaiah Katta, Satyanarayana 
Paturi1, Anil Gutta, Kevin Rice, Miaozong Wu, Nalini Santanam, Eric Blough, Marshall 
University, Huntington, WV, Joan C. Edwards School of Medicine, Huntington, WV
Background: Cardiovascular disease (CVD) is responsible for more than 50% of deaths 
in American women. The risk increases in women after menopause. Although not well 
understood it is thought that the profound impact of age on the risk of the occurrence, 
severity and prognosis of cardiovascular disease is due, in part, to age-associated 
changes in cardiovascular structure and/or function. It has been recently postulated that 
these changes may be due to microRNAs (miRNAs) which are small, noncoding RNAs 
that regulate gene expression at the post-transcriptional level. MicroRNAs have been 
shown to regulate processes such as cardiomyocyte growth as the over expression of 
miRNA-21, miRNA-195, and miRNA-208 has been shown to induce cardiac hypertrophy. 
We hypothesize that age-related changes in cardiac structure and function may be related 
to alteration in miRNA expression.
Methods: Echocardiographic and ECG assessments were performed to assay cardiac 
function in 6-, 26-, and 30-month-old female Fischer 344/NNia x Brown Norway/BiNia 
(F344XBN) rats (n=4/group). The expression of microRNAs was measured using 
quantitative RT-PCR and normalized to 5s rRNA levels.
Results: Compared to 6-month animals, cardiac mass in 26- and 30-month females was 
31% ± 3 and 51% ± 7 higher, respectively (p< 0.05). These age-associated changes 
in mass were accompanied by an increase in cardiac arrhythmias. The expression of 
miRNA-195 and miRNA-208 in 30-month hearts was found to be 51% ± 1 (p < 0.001) and 
41% ± 2 (p < 0.05) higher than that observed in the hearts of 6-month animals. Compared 
to 6-month animals, the expression of miRNA-21 in 26- and 30-month hearts was 42% ± 
4 and 13% ± 4 higher, respectively (p < 0.05).
Conclusions: These results indicate that expression of miR-21, miR-195, and miR-208 are 
altered in the aging hypertrophic female hearts of F344XBN rats. Further investigation of 
these microRNAs may help in understanding the etiology of CVD risk in the aging female.
9:30 a.m.
1015-166 The Urocortin 2-Induced Increase in Myocardial 
Distensibility Is Compromised in Heart Failure
Carmen Brás-Silva, Ana Patricia Fontes-Sousa, Susana Mendes, Monica Almeida, 
Adelino F. Leite-Moreira, Faculty of Medicine, Dept. of Physiology, Porto, Portugal
Background: The urocortin (Ucn) peptides are recently isolated members of the 
corticotropin-releasing factor family. It was previously demonstrated that Ucn2 acutely 
increases myocardial distensibility in healthy animals. In the present study it was our goal 
to characterize diastolic Ucn2 effects in the presence of heart failure.
Methods: New Zealand white rabbits were treated with Doxorubicin (1mg/kg, heart 
failure group) or with saline (control group), administered intravenously twice weekly for 8 
weeks, into the marginal ear vein. The effects of increasing concentrations of Ucn2 (10-10
to 10-6 M) were evaluated in isolated right papillary muscles (Krebs-Ringer: 1.8mM CaCl2,
35°C) from the heart failure group (n=7) and from the control group (n=11). Reported 
parameters include: active tension (mN/mm2), maximum velocities of tension rise and 
tension decline (dT/dtmax and dT/dtmin, respectively; mN/mm2/s), passive tension (mN/
mm2) and muscle length (L; L/Lmax). Only signiﬁcant results (mean±SEM, p<0.05) are 
given, expressed as % change from baseline.
Results: Ucn2 induced a concentration-dependent positive inotropic effect in muscles 
from the control group (at 10-6 M it increased 63.6±6.3% active tension and 185.1±14.6% 
dT/dtmax) that was exacerbated in the heart failure group (active tension increased 
91.3±16.7% and dT/dtmax increased 275.5±37.3%). In the control group Ucn2 also 
promoted a concentration-dependent increase in resting muscle length up to 1.012±0.004 
L/Lmax at the highest concentration. Correcting muscle length to its initial value resulted 
in a 27.7±8.3% decrease of passive tension, indicating a decrease in muscle stiffness 
and so an increase in myocardial distensibility. This effect was however attenuated in 
the presence of heart failure, once resting muscle length increase up to 1.0059±0.002 L/
Lmax, corresponding to a decrease of passive tension of only 14.3%±5.0%.
Conclusions: The present study demonstrated that the physiologic adaptation 
mechanism induced by Ucn2, that may allow the heart to reach the same diastolic volume 
with up to 28% lower ﬁlling pressures, is attenuated in heart failure.
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injection, and dogs were euthanized after 2- (AAV, n=5; S, n=2) or 6-Wk (AAV, n=6; S, n=2). 
Tissue/serum samples were analyzed for hSERCA2a expression (Western blot), histology 
(H+E), and immune responses (AAV6-neutralizing antibodies (NAB), AAV-induced leukocyte 
production of interferon (IFN, Elispot)). Additional non-paced dogs were injected as above 
and analyzed at 12-Wk (AAV, n=6; S, n=2); a parallel cohort (AAV, n=5; S, n=2) received 
prednisone+cyclosporine (P+C) immunosuppression starting 4-Wk post-injection.
Results: Cardiac expression of hSERCA2a was detected at the injection sites, with 
expression peaking at 2-Wk. Echocardiographic LV end diastolic and end systolic 
diameters decreased in 6-Wk treated HF dogs (4.4+/-0.4 to 3.4+/-0.8 mm, 3.3+/-0.6 to 
2.4+/-1.0 mm, p=0.05). Cardiac tissue from 12-Wk AAV injected P+C dogs had higher 
hSERCA levels (>2 times) relative to 12-Wk dogs without P+C. H+E analysis revealed 
cardiac inﬁltrates at AAV injected sites that were less marked in P+C dogs. Elispot showed 
development of AAV-reactive/IFNG secreting T-cells. Dogs receiving AAV developed AAV6 
NAB (>160) that were reduced to the baseline (<20) by 8-Wk P+C treatment.
Conclusions: Direct cardiac injection of AAV6-hSERCA2a in the dog promotes local robust 
hSERCA2a expression that is reduced by host immune responses. Immunosuppression 
alleviates the responses and sustains the hSERCA2a expression, which may be useful 
for human gene therapy.
9:30 a.m.
1015-170 Intermediate Dose of Pentaglobin Eradicates Inﬂammation 
in Parvo B19 and Adenovirus Positive Myocarditis
Bernhard Maisch, Hendrik Haake, Nadine Schlotmann, Sabine Pankuweit, University 
Hospital Giessen and Marburg, Marburg, Germany
Background: Effective treatment of viral myocarditis is a matter of controversy.
Methods: 152 consecutive pts with myocarditis according to the quantitative World Heart 
Federation Criteria (> 14 inﬁltrating cells/mm² by endomyocardial biopsy(EMB)) were 
analysed for infective cardiotropic agents. In 90 pts parvoviruses B19 (59,5%) and in 36 
pts adenoviruses (23,8%) were assessed by PCR as causative viral pathogens. All virus 
positive patients were treated with 10 g/day Pentaglobin® i. v.(enriched IgG, IgA and 
IgM preparation, Biotest) at day 1 and 3. After six months all patients were reevalutated 
clinically, 73 patients (48%) in addition by EMB.
Results: After Pentaglobin therapy, all patients demonstrated a signiﬁcant clinical 
improvement of the NYHA class, of exercise capacity and of LVEF (from 54,4 to 60,0%, 
p<0,005) independent from the respective virus. In 52 of 73 (71%) rebiopsied pts 
inﬂammation had resolved. In 17 of the 19 rebiopsied patients (90%) with a positive PCR 
for ADV before therapy no more virus DNA was recovered after treatment, inﬂammation 
had resolved completely. In Parvo B 19 myocarditis inﬂammation had resolved in 31 of the 
44 pts (70%), whereas Parvo B19 DNA was eradicated in only in 18 out of 44 pts(40%). In 
patients in whom both virus and inﬂammation were eliminated enddiastolic LV dimension 
decreased and EF increased signiﬁcantly (p<0,001).
Conclusions: Treatment with an intermediate dose of Pentaglobin is highly effective 
in resolving myocardial inﬂammation independent of the underlying viral etiology, but it 
eradicates adenoviral much better than Parvo B19 infection.
9:30 a.m.
1015-171 Molecular Imaging of Angiotensin Converting Enzyme-1 
Expression in the Myocardium of Angiotensin 
Converting Enzyme-1 Overexpressing Transgenic Rats
Todd K. Zynda, Artiom Petrov, Satoru Ohshima, Nobuhiro Tahara, Nezam Haider, 
Omer Aras, Amanda Donohue, Frank Femia, Shawn Hillier, John Joyal, John Babich, 
Jagat Narula, Vasken Dilsizian, University of California Irvine, Irvine, CA, University of 
Maryland, Baltimore, MD
Background: Increased expression of angiotensin converting enzyme 1 (ACE-1) is observed 
in the failed myocardium and is a potential marker for disease severity. We used Technetium-
99m labeled lisinopril (Tc-Lis) for ACE-1 over-expressing transgenic rats (Tg rats) to 
demonstrate the feasibility of noninvasive imaging of ACE-1 expression in the myocardium.
Methods: In this study, 21 Tg rats and 18 Sprague-Dawley (SD) rats were used. Non 
invasive images using micro SPECT/micro CT were obtained at 10min, 30min, 60 min, 
and 120min after Tc-Lis administration. Nine of 21 Tg and 8 of 18 SD received 0.6 mg/kg 
cold lisinopril (cold-Lis) 5 minutes prior to radiotracer administration. After in vivo imaging, 
the rat myocardium was explanted, ex vivo images acquired and the percent injected 
dose per gram (%ID/g) gamma-well counted, followed by assessment of ACE-activity and 
mRNA, and histological and immunohistochemical characterization.
RESULTS: Myocardial uptake of Tc-Lis was best observed at 120 min after tracer 
administration in the in vivo imaging. The quantitative uptake of Tc-Lis in the myocardium 
was higher in Tg than SD rats at each time-point after tracer injection; %ID/g uptake in 
Tg and SD rats at 30 min was 0.74 +/- 0.13 and 0.17 +/- 0.03%, respectively. The uptake 
reduced substantially in Tg and SD rats pre-treated with cold-Lis 0.05 +/- 0.008 and 0.05 
+/- 0.008%, respectively.
Conclusions: The present study demonstrates the feasibility of molecular imaging of 
ACE-1 receptors in myocardium. If clinically applicable, it is expected that this strategy 
will help identify patients susceptible to development of heart failure and also allow 
optimization of pharmacologic intervention.
9:30 a.m.
1015-172 Intravenous Cell Therapy Given to Rats With 
Monocrotaline-Induced Pulmonary Artery Hypertension 
Reduces Right Ventricular Hypertrophy and Improves 
Right Ventricular Function by Restoring Precapillary 
Pulmonary Artery Patency
Soban Umar, Paul Steendijk, Yvonne P. de Visser, Gerry T. Wagenaar, Cindy I. Schutte, 
Wilhelmina H. Bax, Daniel A. Pijnappels, Douwe E. Atsma, Martin J. Schalij, Ernst E. 
Van der Wall, Arnoud Van der Laarse, Department of Cardiology, Leiden University 
Medical Center, Leiden, The Netherlands
Background: Pulmonary artery hypertension (PAH) is a life-threatening disease for which 
standard treatment is inadequate. Novel therapies like stem cell therapy have been demonstrated 
to be very effective in experimental animals and in patients with PAH.We investigated whether 
bone marrow-derived mesenchymal stem cells (MSCs) obtained from rats with advanced stage 
of monocrotaline (MCT)-induced PAH and given to rats at 14 days after MCT administration 
were able to (i) reverse PAH, (ii) reverse right ventricular (RV) hypertrophy, (iii) improve RV 
function, and (iv) improve precapillary pulmonary arterial diameters.
Methods: Thirty rats were divided in three groups, being healthy rats that received i.v. 
PBS (control, n=10), MCT (60 mg/kg, n=10), MCT (60 mg/kg) 14 days later followed by 
i.v. administration of one million MSCs per rat (n=10). MSCs were obtained from rats 
which have been treated with MCT (60 mg/kg) for 28 days. At 28 days after MCT or PBS 
administration, RV function was assessed by combined pressure-conductance catheter, 
RV hypertrophy was quantiﬁed by weighing the RV free wall, interventricular septum (IVS) 
and LV wall, and lung tissue was examined by histology.
Results: At 28 days after MCT-treatment, rats had PAH (36.2±7.0 vs. 26±2.2 mmHg in 
control; p<0.001) and RV hypertrophy (RV/(IVS+LV) weight ratio=0.59±0.15 vs. 0.25±0.04 
in control; p<0.001). Lung tissue demonstrated severe narrowing of precapillary arterioles 
and concomitant thickening of arteriolar walls. If MSCs had been administered 14 days 
after MCT administration, PAH was strongly attenuated (30.2±2.4 mmHg; p<0.05 vs. MCT 
only), and RV/ (IVS+LV) weight ratio was near normal (0.32±0.07; p<0.005 vs. MCT only) 
and lung tissue demonstrated hardly any narrowing nor thickening of arterioles.
Conclusion: If rats with developing PAH were treated with MSCs obtained from rats 
with advanced stage of MCT-induced PAH, beneﬁcial effects have been demonstrated, 
suggesting that patients with PAH can be treated successfully using autologous MSCs.
9:30 a.m.
1015-173 Cardiac Pro-Oxidant Gene Expression Patterns 
Are Altered by Chronic Exposure to Particulate Air 
Pollutants. A Gene Chip Study
Boris Z. Simkhovich, Ruty Mehrian-Shai, Nancy Hsu, Simon M. Lin, Gang Feng, Michael 
T. Kleinman, Robert A. Kloner, Good Samaritan Hospital, Los Angeles, CA, University of 
California - Irvine, Irvine, CA
Background: Air pollution (AP) signiﬁcantly increases cardiovascular morbidity 
and mortality in the general population. Whether chronic exposure to AP alters gene 
expression of the myocardium is unknown.
Methods: Therefore Fisher 344 rats for a period of 3 months were exposed to ﬁltered air 
(FA), or ambient particles of different aerodynamic diameter (AD); i.e. coarse (CP, median 
AD 4 microns ), ﬁne (FP, median AD 0.7 micron) and ultraﬁne (UFP, median AD 0.06 micron, 
n=8 per group) in a particle concentrator equipped mobile unit located near a busy Southern 
California freeway. At the end of the exposure, hearts were subjected to gene expression 
proﬁling by using Illumina RatRef-12 bead chips covering over 22,000 rat transcripts.
Results: Fold ratio >1.5 (for both up- and down-regulated genes), and false discovery rate 
(FDR) adjusted p value of <0.05 were applied. In the UFP-treated group thioredoxin interacting 
protein (Txnip), a negative regulator of an antioxidant enzyme thioredoxin, and cytochrome 
P450 isoform (Cyp2e1) involved in primary metabolism of foreign substances including 
components of air pollutants, demonstrated signiﬁcant up-regulation (fold ratios 1.79 and 1.57 
respectively, FDR<0.05). No changes in the gene expression patterns were observed in the FP 
group. In the CP group there was also a trend towards increased Txnip expression (fold ratio 
1.43, FDR>0.05) and signiﬁcant increase in the Cyp2e1 expression (fold ratio 1.79, FDR<0.05). 
Changes in the expression patterns of both genes were conﬁrmed by quantitative RT-PCR.
Conclusions: Up-regulation of Txnip, a negative modulator of antioxidant thioredoxin 
complex, may increase the heart’s susceptibility to the damaging effects of air pollution-
generated reactive oxygen species, while up-regulation in Cyp2e1 may indicate activation 
of a defense-related mechanism to eliminate toxic components of air pollutants. To the 
best of our knowledge this is the ﬁrst study to show that chronic exposure to air pollutants 
alters the expression of genes within the myocardium - and one of these genes relates to 
the susceptibility to oxidative stress.
9:30 a.m.
1015-174 Congenital Absence of NOS3 Potentiates Left 
Ventricular Dysfunction in a Murine Model of Diet-
Induced Obesity and Chronic Pressure Overload
Roien Ahmadie, Jon-Jon Santiago, Tielan Fang, Khuong Le, Nazila Azordegan, Sheri 
Bage, Amy Kroeker, Sydney Harris-Janz, Zhaohui Zhao, Kristie Walker, Matthew 
Lytwyn, Elissavet Kardami, Mohammed Moghadasian, Davinder S. Jassal, University of 
Manitoba, Winnipeg, MB, Canada
Background: A high lipid diet (HLD) is causal to the induction of cardiomyocyte 
hypertrophy, ﬁbrosis, insulin resistance and hyperlipidemia leading to adverse left 
ventricular (LV) remodeling, which may be exacerbated in conditions of hemodynamic 
stress such as chronic pressure overload. Although nitric oxide (NO) and nitric oxide 
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synthase 3 (NOS3) plays a major protective role in LV remodeling after transverse aortic 
constriction (TAC), the nature of interaction between a HLD and NOS3 in a chronic heart 
failure model of metabolic syndrome remains undeﬁned.
Objective: To determine whether the congenital absence of NOS3 potentiates LV 
dysfunction in a murine model of diet induced obesity and chronic pressure overload.
Methods: In total, 60 C57Bl/6 wild-type (WT) mice and 60 NOS3 knockout (NOS3-/-) mice 
were randomized into four groups: a) WT+ low lipid diet (LLD); b) WT + HLD; c) NOS3-
/- + LLD; d) NOS3-/- + HLD for a total of three months. After one week of randomization 
to either diet, TAC was performed, followed by monthly echocardiograms. Fasting lipid 
proﬁles were evaluated at baseline and at the end of the study. At month 3, the hearts 
were removed for histopathological and Western blot analyses.
Results: After TAC, echocardiography revealed a decrease in LVEF in WT and NOS3-
/-
 mice fed a HLD compared to a LLD. NOS3-/- mice fed a HLD demonstrated a further 
reduced LVEF compared to WT mice fed a HLD after TAC (45±5% vs. 52±4%, p<0.05). 
Three months after TAC, LV weight was increased in WT and NOS3-/- mice fed a HLD as 
compared to a LLD respectively (0.25±0.01 g vs. 0.21±0.01 g (WT) and 0.28±0.1 g vs. 
0.22±0.01 g (NOS3-/-), p<0.05). There was increased myocyte hypertrophy and interstitial 
ﬁbrosis in NOS3-/- mice fed a HLD three months post TAC as compared to the other 
groups. Total serum cholesterol was increased 2.0 fold in WT mice and increased 2.5 fold 
in NOS3-/- mice at three months post TAC. High FGF-2, a marker of cardiac hypertrophy, 
was upregulated in NOS3-/- mice fed a HLD compared to WT mice.
Conclusions: In a chronic pressure overload state and hyperlipidemia, NOS3-/- mice 
demonstrated greater LV dysfunction, cardiac hypertrophy and ﬁbrosis as compared to 
WT mice.
9:30 a.m.
1015-175 Expression of MicroRNA-212 Is Increased in Left 
Ventricular Myocardium of Explanted Failed Human Hearts 
and in Dogs With Experimentally-Induced Heart Failure
Ramesh C. Gupta, Hani N. Sabbah, Henry Ford Hospital, Detroit, MI
Background: MicroRNAs are regulatory molecules consisting of 22 noncoding nucleotides that 
regulate gene expression. MicroRNAs have been shown to play a fundamental role in diverse 
biological and pathological processes. Recent studies have suggested that microRNA-212 
participate in the control of cardiac hypertrophy. Furthermore, expression of microRNA-212 in 
the adult heart is also believed to contribute to re-activation of the fetal gene program. Because 
compensatory cardiac hypertrophy and induction of the fetal gene program are characteristics 
of the failing heart, we tested the hypothesis that expression of microRNA-212 is increased in 
left ventricular (LV) myocardium of failed human and dog hearts.
Methods: LV tissue was obtained from 6 explanted failed human hearts due to ischemic 
cardiomyopathy (ICM), 6 failed human hearts due to idiopathic dilated cardiomyopathy 
(IDC), and 6 donor (DNR) hearts deemed not suitable for transplantation. LV tissue was 
also obtained from 6 dogs with coronary microembolization-induced heart failure and 6 
normal dogs. Low-molecular-weight RNAs were isolated using the mirVana microRNA 
Isolation Kit. microRNA-212 (hsa-miR-212) and microRNA-92 (hsa-miR-92, used as 
an internal control) assay kits were used to determine expression of microRNAs using 
speciﬁc TaqMan Gene Expression Master Mix in Real-Time PCR. Results were expressed 
in fold increase or decrease relative to human DNR or normal canine myocardium.
Results: Expression of microRNA-92 was similar in LV myocardium of DNR, ICM and IDC 
human hearts as well as in normal and failed dog hearts. Expression of microRNA-212 
was increased 5.43 fold in ICM and 4.66-fold in IDC hearts compared to DNR hearts. 
Similarly, expression of microRNA-212 was increased 5.13-folds in LV of heart failure 
dogs compared to normal dogs.
Conclusions: Expression of microRNA-212 is increased in failing human and dog LV 
myocardium regardless of etiology. Up-regulation of microRNA-212 in the failing LV can 
explain, in part, the processes that underlie the development of hypertrophy and induction 
of the fetal gene program in heart failure.
9:30 a.m.
1015-176 Improvement of Left Ventricular Remodeling and 
Function by Protease-Activated Receptor 1 Inhibition in 
Rats With Heart Failure After Myocardial Ischemia and 
Reperfusion
Jennifer L. Strande, Kasi V. Routhu, Leanne M. Harmann, Raymond Q. Migrino, John E. 
Baker, Medical College of Wisconsin, Milwaukee, WI
Background: Protease-Activated Receptor 1 (PAR1) inhibition has been shown to acutely 
reduce infarct size during ischemia and reperfusion. The purpose of this study was to 
determine whether PAR1 inhibition continued to protect against long-term reperfusion injury 
after ischemia by decreasing cardiac remodeling and preventing left ventricular failure.
Methods and Results: Rats were randomly assigned to 7 different groups and received 
either 30 min of anterior myocardial ischemia followed by 28 d of reperfusion or a sham 
surgery. The Control and Sham group received no treatment. The treatment groups 
received one dose of the PAR1 antagonist, SCH either before or after ischemia alone 
or with a continuous 28 d infusion of SCH. Echocardiography was performed at baseline 
and post-operatively at 3 d and 28 days. Infarct size and inﬂammation was assessed at 28 
d. Ischemia and chronic reperfusion in the Control group was associated with increased 
LV dimensions and volumes and decreased ejection fraction and fractional shortening 
when compared to the Sham group (EF: 41% Control vs. 79% Sham). SCH treatment 
inhibited these changes (EF:66-77%). The control rats also displayed decreased radial 
and circumferential strain when compared to the Sham rats. SCH treatment attenuated 
the decrease in myocardial strain. Furthermore, SCH treatment eliminated pulmonary 
remodeling and edema that resulted from 28 d of reperfusion. The attenuation of LV 
remodeling and failure with SCH was associated with a substantial decrease in infarct 
size and myocardial inﬂammation when compared to Control.
Conclusions: PAR1 inhibition preserves LV structure and function after ischemia and 
chronic reperfusion. The PAR1 antagonist also protected against clinical signs of heart 
failure including pulmonary edema. This protection is due to a decreased infarct size and 
associated myocardial inﬂammation. PAR1 may be an attractive and efﬁcacious target for 
the clinical treatment of ischemic cardiomyopathy.
9:30 a.m.
1015-177 Angiotensin II Induces Cardiac Systolic and Diastolic 
Dysfunction via Toll-Like Receptor 4 Mediated Up-
regulation of Oxidative Stress in Murine Heart
Susumu Matsuda, Seiji Umemoto, Hiroko Yoshino, Shinichi Itoh, Hiroki Aoki, Koichi 
Yoshimura, Murata Tomoaki, Masunori Matsuzaki, Department of Medicine and Clinical 
Science, Yamaguchi University Graduate School of Medicine, Ube, Japan
Background: Toll-like receptor 4 (TLR4) is involved in cardiovascular events. Angiotensin 
II (Ang II) also play an important role in cardiac hypertrophy and the development of 
heart failure. However, the relationship between TLR4 and Ang II in regulating oxidative 
stress and cardiac function remains unknown. We compared the effects of TLR4 on the 
oxidative stress, cardiac hypertrophy and function in Ang II or norepinephrine (NE)-
induced pressure overload in mice in vivo.
Methods: TLR4-/- and wild-type (WT) mice were randomized into two groups each, and 
given Ang II or NE for 2 weeks. Left ventricular end-diastolic dimension (LVEDd), LV 
end-systolic dimension (LVESd), fractional shortening (%FS), ejection fraction (EF), 
interventricular septum (IVS) as well as LV posterior wall thickness (LVPW) and transmitral 
ﬂow (TMF) were assessed by transthoracic echocardiography under light anesthesia. In 
each heart, we evaluated the wall-to-lumen (W/L) ratio and the perivascular ﬁbrosis. 
Superoxide content in the heart, we incubated frozen section of heart tissues with the 
dye hydroethidine staining.
Results: Both Ang II and NE induced a signiﬁcant increase in systolic blood pressures 
(SBP) in WT and TLR4-/- mice (p<0.05), while SBP and heart rates were not signiﬁcantly 
different among the four groups throughout the experiments. Ang II induced a signiﬁcant 
increase in IVS, LVPW, and a signiﬁcant decrease in EF, %FS and E/A ratio of TMF 
(p<0.05), and also demonstrated a greater LVESd (p<0.05) in WT mice, whereas TLR4-/-
mice showed little effects of Ang II on these indices, and LVEDd were not different among 
the four groups. Ang II also increased perivascular ﬁbrosis, W/L ratio, and heart weight/
body weight in WT mice compared with TLR4-/- mice. Furthermore, Ang II induced 5-fold 
signiﬁcant increase in superoxide content in the heart in WT mice, whereas only 2-fold 
increase in superoxide content in TLR4-/- mice. In contrast, NE treatment did not reach a 
statistical signiﬁcance in these indices.
Conclusions: TLR4 is the critical determinant factor for the increase in oxidative stress, 
cardiac hypertrophy, ﬁbrosis, and systolic and diastolic dysfunction in Ang II-induced 
hypertension in vivo.
9:30 a.m.
1015-178 Effects of Combination of Proliferative Agents and 
Erythropoeitin on Left Ventricular Remodeling Post-
Myocardial Infarction
Rosemeire M. Kanashiro-Takeuchi, Lauro M. Takeuchi, Joshua M. Hare, University of 
Miami, Miami, FL
Background: Erythropoeitin (EPO) has been reported to improve cardiac function after 
MI through promoting mobilization of endothelial progenitor cells to the injured heart 
and enhancing neovascularization. Here we tested the hypothesis that adding either 
human chorionic gonadrotrophin (hCG) or prolactin (PRL) followed by EPO may provide 
additional therapeutic beneﬁt through a regenerative mechanism.
Methods: MI induced by coronary artery ligation was performed in 6-month-old Wistar rats. 
Animals were randomly assigned to one of ﬁve treatment groups: control (n=6); human 
chorionic gonadotrophin (hCG, n=6); EPO (n=7); hCG + EPO (n=5) and prolactin + EPO 
(n=5). Cardiac structure and function was assessed by echocardiography at baseline, 
24h, 1, 2, 4 and 8 weeks post-MI. Apoptosis and cell proliferation were determined by 
TUNEL assay and immunostaining for Ki67, respectively.
Results: At baseline and after MI, echocardiographic parameters of LV size and function 
were similar in treated and untreated animals. After MI, chamber systolic dimension 
increased from 4.2±0.3 to 8.1±0.3 mm, p<0.05 in controls. Over and 8-week period, hCG, 
EPO and hCG + EPO but not PRL+EPO groups attenuated this increase (from 8.1±0.3 
to 7.2±0.2 mm, p<0.05 for each vs. control); however, in PRL+ EPO group (8.4 ±0.6 mm, 
p>0.05) it was not affected. Similarly a reduction in ejection fraction (EF) from 81±1 to 
45±4% (p<0.05) due to MI was ameliorated in these groups (57±3 %, p<0.05 for each 
vs. control) but not in PRL group (39±7% p>0.05). Myocyte and non-myocyte apoptosis 
was markedly reduced in all treated groups (p<0.01); however, Ki67 positive cells were 
only reduced in groups treated with EPO (p<0.05). The reduction in LV size and functional
decline as measured by repeated echocardiography was accompanied by reductions in 
MI size in the group treated with hCG (p<0.05).
Conclusion: Our ﬁndings revealed that hCG alone or in combination with EPO may be 
an effective therapeutic strategy to ameliorate post-MI remodeling. The absence of effect 
with PRL suggests a direct effect on the myocardium. Given the established safety proﬁle 
of hCG in humans, clinical trials may be warranted.
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9:30 a.m.
1015-179 Decreased S-Nitrosylation of the Calcium Release 
Channel RyR2 and Increased SR Ca Leak in Heart Failure
Adriana V. Treuer, Daniel R. Gonzalez, Joshua M. Hare, Interdisciplinary Stem Cell 
institute, Miller school of Medicine, University of Miami, Miami, FL
Background: In the cardiac muscle cell, the speciﬁc isoform of the ryanodine receptor 
(RyR2) mediates Ca2+ release from the sarcoplasmic reticulum. This channel is highly 
susceptible to redox modiﬁcations. Among these, S-nitrosylation has emerged as an 
important modiﬁcation in health and disease. We have previously shown in a mouse model 
that deﬁciency in RyR2 S-nitrosylation is detrimental for excitation-contraction coupling. 
Consequently, we tested the hypothesis that the level of activity and S-nitrosylation of 
RyR2 are altered in heart failure.
Methods: We studied the redox state of the RyR2 from hearts of spontaneously 
hypertensive-heart failure (SHHF) rats (n=9, ~ 22 months old) and Wistar-Kyoto 
(WKY) rats, as control (n=4, ~19 months old). S-nitrosylation was studied using the 
biotin-switch method and the relative content of free cysteines by the bimane assay. 
Superoxide was detected using DHE staining and xanthine oxidase by Western blotting 
and immunohistochemistry. Isolated cardiomyocytes were obtained enzymatically. Ca2+ 
transients were measured using fura-2 as indicator. Sarcoplasmic reticulum (SR) Ca2+ 
was estimated superfusing caffeine and diastolic Ca2+ leak was evaluated using an 
established protocol using tetracaine as RyR blocker.
Results: RyR2 from the SHHF rat hearts showed decreased S-nitrosylation and 
contained fewer free cysteines (p<0.05 vs. WKY), ﬁndings consistent with oxidation of 
the channel in the failing hearts. Superoxide production along with the expression of the 
superoxide-producing enzyme xanthine oxidoreductase were increased in the failing 
hearts (fourfold, p<0.05 vs. WKY). By studying the diastolic Ca2+ leak in a range of Ca2+ 
contents, analysis showed that for a given Ca2+ load, Ca2+ leak was increased in SHHF 
myocytes, denoting increased RyR2 activity, associated with decreased contractility.
Conclusions: Our results show that increased oxidative stress in heart failure induced 
modiﬁcations in the RyR2, including decreased S-nitrosylation. These redox modiﬁcations 
of RyR2 are associated with increased SR Ca2+ leak and decreased myocyte contractility. 
This highlights the importance of restoring the redox milieu in heart failure.
9:30 a.m.
1015-180 Expression of H11 Kinase Is Increased in Left 
Ventricular Myocardium of Explanted Failed Human 
Hearts and in Hearts of Dogs With Experimentally-
Induced Heart Failure
Ramesh C. Gupta, Hani N. Sabbah, Henry Ford Hospital, Detroit, MI
Background: Adenoviral-mediated overexpression of H11 kinase (H11K) in rat neonatal 
cardiomyocytes promotes cell hypertrophy and apoptosis. Over-expression of H11K 
was also shown to cause re-expression of the fetal gene program. We examined the 
expression of H11K in LV myocardium of failed human and dog hearts.
Methods: RNA was extracted and SDS-extract of homogenate, membrane and cytosol 
fractions was prepared from LV tissue of 6 explanted failed human hearts due to ischemic 
cardiomyopathy (ICM), 6 failed hearts due to idiopathic dilated cardiomyopathy (IDC), and 
6 normal donor (DNR) hearts. RNA and SDS extracts were also prepared from LV of 6 
dogs with microembolization-induced heart failure (HF) and 6 normal (NL) dogs. mRNA 
expression was measured with real-time PCR and protein expression with Western 
blotting and bands quantiﬁed in densitometric units (du).
Results: Data are shown in the table. mRNA expression of H11K increased signiﬁcantly in 
ICM and IDC hearts compared to DNR hearts and in HF dogs compared to NL dogs. H11K 
protein expression increased signiﬁcantly in homogenate and cytosol fractions but decreased in 
membrane fractions of ICM and IDC compared to DNR and in HF dogs compared to NL dogs.
Conclusions: mRNA and protein expression of H11K is increased in HF. The H11K 
translational modiﬁcation in HF is localized to the cytosol and may act as an intracellular 
trigger for cell hypertrophy and apoptosis.
*=p<0.05 vs. NL; †= p<0.05 vs. DNR
Dog Human
NL HF DNR ICM DCM
H11K mRNA (108 molecules/mg of 
total RNA) 1.0 ± 0.2
2.7 ± 
0.4* 9.0 ± 0.6
17.0 ± 
1.0†
24.0 ± 
2.0†
H11K Protein in LV Homogenate 
(du)(/b> 28 ± 4 86 ± 4* 54 ± 6
229 ± 
47† 307 ± 44†
H11K Protein in Membrane Fraction 
(du)
0.36 ± 
0.04
0.17 ± 
0.01*
0.45 ± 
0.03
0.21 ± 
0.03†
0.20 ± 
0.03†
H11K Protein in Cytosol Fraction 
(du)
2.42 ± 
0.10
4.85 ± 
0.18*
0.65 ± 
0.06
3.94 ± 
0.27†
3.90 ± 
0.22†
9:30 a.m.
1015-181 Cardiomyogenic Differentiation Potential of 
Mesenchymal Stem Cells Declines With Increase in 
Age: Rebuilding the Heart With Old or New Bricks?
Arti A. Ramkisoensing, Daniel A. Pijnappels, John van Tuyn, Hector A. Farias, Carolina 
L. Gomez, Antoine A. de Vries, Dick L. Ypey, Arnoud van der Laarse, Martin J. Schalij, 
Douwe E. Atsma, Leiden University Medical Center, Leiden, The Netherlands
Background: In cardiac cell therapy often autologous stem cells from adult patients are used as 
therapeutic agent. Whether the cardiomyogenic differentiation potential of stem cells depends on 
the host’s age is not studied in detail. Therefore we assessed, in an in vitro model, the capacity of 
neonatal and adult rat mesenchymal stem cells (MSCs) to differentiate into cardiomyocytes.
Methods: eGFP-labeled bone-marrow derived MSCs of 2-day old neonatal rats (nr) or 
10-weeks old adult rats (ar) were co-cultured with nr ventricular cardiomyocytes (CMCs) 
up to 10 days. Immunocytochemical analysis for cardiac protein expression, and whole-
cell patch clamp experiments to study action potential characteristics after gap junctional 
uncoupling were used to assess cardiomyogenic differentiation.
Results: After 3 days of co-culture, 34±5% and 30±6% of the nrMSCs showed positive 
diffuse staining for sarcomeric alpha-actinin and cardiac troponin-I, respectively, while less 
than 10% of the arMSCs stained positive. After 10 days, positive staining for these cardiac 
markers in nrMSCs increased to 63±6% and 60±4%, respectively, but now including 
17±5% (n=65) in typical sarcomeric cross-striation without signs of cell fusion. In contrast, 
20% (n=75) of the arMSCs showed positive diffuse staining for both cardiac markers. 
Interestingly, a fraction of arMSCs was fused with native nrCMCs (0.5% n=16), as indicated 
by the presence of heterokaryotic eGFP labeled, cross-striated cells. Importantly, at day 
10 of co-culture, nrMSC-derived CMCs (16%, n=9) were found to beat independently from 
surrounding nrCMCs in the presence of the gap junction uncoupler 2-APB, while showing 
action potential characteristics comparable to those of native nrCMCs (n=10). However, 
arMSCs were non-beating and showed no cardiac-like action potentials.
Conclusion: Neonatal rat (nr) mesenchymal stem cells (MSCs) are able to undergo 
functional cardiomyogenic differentiation upon co-culture with nr cardiomyocytes, in 
contrast to adult rat (ar) MSCs. However, arMSCs are able to fuse with nr cardiomyocytes, 
which might contribute to the subtle therapeutic effects of autologous cell therapy 
observed in the clinical setting.
9:30 a.m.
1015-182 Thrombomodulin Is Upregulated in Cardiomyocyte 
During Cardiac Hypertrophy and Promotes 
Cardiomyocyte Survival
Yi-Heng Li, Hsing-Chun Chung, Kou-Gi Shyu, Guey-Yueh Shi, Hua-Lin Wu, National 
Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan,ROC, Shin 
Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan,ROC
Background: Cardiac hypertrophy is a common response to pressure overload. 
It is associated with cardiomyocyte (CM) apoptosis and results in heart failure. 
Thrombomodulin (TM), traditionally known as an anticoagulant protein, was found to 
have unique effects on cellular proliferation, adhesion and inﬂammation. We examined 
TM expression in CM during cardiac hypertrophy and investigated the physiological 
signiﬁcance. Methods and Results: Data are expressed as mean±SE. Statistical 
analysis was performed using ANOVA followed by Bonferroni test. In hypertrophic human 
and mouse hearts, immunohistochemical study showed a signiﬁcant TM expression in 
CMs. In cardiac hypertrophy elicited by transverse aortic constriction (TAC) in mice, heart 
TM expression increased (baseline vs 1 vs 6 vs 12 wks after TAC, TM mRNA ratio: 1 vs 
0.74±0.13 vs 1.09±0.07 vs 2.04±0.29, p<0.05) in association with the increased heart 
weight/body weight ratio (3.91±0.09 vs 4.61±0.22 vs 4.97±0.19 vs 6.01±0.38 mg/g, 
p<0.01). Cultured neonatal rat CMs were stretched by vacuum to 20% of maximum 
elongation at 60 cycles/min. TM mRNA increased to a maximum of 4-fold over the control 
at 14 hrs after stretch (baseline vs 6 vs 12 vs 14 vs 24 hrs after stretch, TM mRNA 
ratio: 1 vs 2.95±0.38 vs 3.43±0.26 vs 4.08±0.44 vs 3.55±0.25, p<0.01). Quantiﬁcation 
of apoptotic DNA fragmentation was done using the Cell Death Detection ELISA kit in 
cultured neonatal rat CMs. TM reduced doxorubicin-induced CM apoptosis (saline vs 
10 vs 30 vs 50 ng/ml TM pretreatment, apoptosis ratio: 1 vs 0.67±0.03 vs 0.64±0.01 
vs 0.58±0.01, p<0.01). The CM caspase-3 activity was also reduced (saline vs 50 ng/
ml TM pretreatment, caspase-3 activity ratio: 1 vs 0.74±0.06, p<0.05). The cell size of 
CM was increased after stimulation with TM for 5 days (saline vs 10 vs 30 vs 50 ng/ml 
TM treatment, cell area ratio: 1 vs 1.47±0.30 vs 1.89±0.39 vs 2.09±0.47, p<0.01). TM 
treatment signiﬁcantly increased the extracellular signal-regulated kinase 1/2 (ERK1/2) 
phosphorylation in CM. Conclusions: There is a signiﬁcant TM expression in CMs during 
cardiac hypertrophy. TM promotes CM survival by reducing apoptosis and sustains CM 
hypertrophy in response to pressure overload.
9:30 a.m.
1015-183 Impact of Enhanced Expression and Secretion of Cell 
Proliferation Related Genes and Proteins in Adipose-
Derived Mesenchymal Stem Cells on Salvaging 
Vascular and Heart Failures: Insights From Microarray 
Analysis
Chiaki Nakanishi, Toshinari Tsubokawa, Masaaki Kawashiri, Noritoshi Nagaya, Masakazu 
Yamagishi, Division of Cardiovascular Medicine, Kanazawa University Graduate School of 
Medicine, Kanazawa, Kanazawa, Japan, Department of Regenerative Medicine and Tissue 
Engineering, National Cardiovascular Center Research, Osaka, Japan 
Background: Previous experimental studies indicated that adipose tissue-derived 
mesenchymal stem cells (A-MSC) has emerged as a possible alternative cell source 
to bone marrow-derived mesenchymal stem cell (B-MSC) for the treatment of vasular 
and heart failures. However, few data exist regarding the molecular foundation that 
explains the difference in biological behavior between A-MSC and B-MSC. Therefore, 
we examined expression of gene and secretory protein in A-MSC and B-MSC using 
microarray and ELISA.
Methods and Results: A-MSC and B-MSC were obtained from subcutaneous adipose 
tissue and bone marrow of adult Lewis rats weighing 200 ~ 250 g. During cultural 
process A-MSC proliferated 4-fold as rapidly as B-MSC, although A-MSC and B-MSC 
had comparable potential to differentiate into osteoblasts and adipocytes. In microarray 
analysis, 571 genes (1.8%) out of 31,099 genes were preferentially expressed (> 3-fold) 
in A-MSC, and a number of genes were associated with mitosis such as cyclin dependent 
kinase 2, cyclin B1, cyclin F and with immune response such as interleukin 1A, interleukin 
6, chemokine (C-C motif) ligand 20. In contrast, other 571 genes (1.8%) highly expressed 
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(> 3-fold) in B-MSC were associated with morphogenesis such as jagged 1, cadherin 
13, elastin and with development such as transforming growth factor B2, WNT1 inducible 
signaling pathway protein 2, actin G2. ELISA demonstrated that A-MSC secreted larger 
amounts of growth and antiapoptotic factors such as vascular endothelial growth factor 
and hepatocyte growth factor than B-MSC.
Conclusions: These results demonstrate that A-MSC expresses cell mitosis-related 
genes and secretes larger amounts of bioactive proteins than B-MSC, thus contributing 
to alternative cell source to B-MSC in the treatment of vascular and heart failures. The 
enhanced effects of combined treatment with A-MSC and B-MSC on these failures should 
further be sought.
9:30 a.m.
1015-184 Safety and Efﬁcacy of High-Dose Anakinra in 
Experimental Acute Myocardial Infarction
Fadi N. Salloum, Nicholas N. Hoke, Amit Varma, Benjamin Van Tassell, Stefano Toldo, 
Antonio Abbate, Virginia Commonwealth University Pauley Heart Center, Richmond, VA
Background: Interleukin-1 (IL-1) receptor antagonist (Ra) is a naturally occurring IL-1 blocker 
with a cardioprotective effect during acute myocardial infarction (AMI). Anakinra, recombinant-
human IL-1Ra, reduces heart failure in a mouse model of AMI. The aim of this study was to 
determine the optimal therapeutic dosing regimen for anakinra in experimental AMI.
Methods: Fifteen ICR mice underwent surgical coronary artery ligation. Five mice received 
anakinra 1 mg/kg daily, 5 received anakinra 100 mg/kg, and 5 received a matching volume 
of NaCl 0.9% for 7 days. All animals underwent transthoracic echocardiography before 
surgery, 24 hours and 7 days after surgery.
Results: Both doses of anakinra improved left ventricular end-diastolic diameter (LVEDD), 
end-systolic diameter (LVESD), and fractional shortening (LVFS) versus saline at 7 days 
(all p values <0.05 [see ﬁgure]). No signiﬁcant differences in LVEDD, LVESD, and LVFS 
were found between high and low dose treatment groups.
Conclusions: Treatment with higher dose anakinra (100 mg/kg) is safe during AMI and prevents 
adverse cardiac remodeling when compared to inactive treatment. However, high-dose anakinra 
provides no additional beneﬁts compared to standard dose anakinra (1 mg/kg). 
9:30 a.m.
1015-185 Mitochondrial Dysfunction in Heart Failure Affects 
Interﬁbrillar but Not Subsarcolemmal Mitochondria
Michael Schwarzer, Andrea Schrepper, Paulo Amorim, Gracjan Pytel, Friedrich W. Mohr, 
Torsten Doenst, University Leipzig - Heart Centre, Leipzig, Germany
Objectives: Pressure overload induced heart failure is correlated with signiﬁcant impairment 
in mitochondrial function. In normoxia >95% of the ATP is produced there. In heart muscle, 
two types of mitochondria exist. Subsarcolemmal mitochondria (SSM) presumably, 
providing ATP for basic cell function, and interﬁbrillar mitochondria (IFM), presumably 
providing energy for the contractile apparatus. We speculated that the respiratory capacities 
of these subpopulations are differentially affected by pressure overload.
Methods: Male Sprague-Dawley rats were subjected to transverse aortic constriction for 20 
weeks. Contractile function was assessed by echocardiography. Mitochondria were isolated 
by differential centrifugation and respiratory capacity was analyzed using a Clark electrode.
Results: Left ventricular posterior wall diameter was increased (LVPWD: 2,6±0,2 vs. 
1,4±0,2mm; p<0,05) after 10 weeks and resulted in reduced EF (53±8 vs. 75±6%; p<0,05) 
after 20 weeks, indicating heart failure. The mitochondrial marker enzyme, citrate synthase, 
was signiﬁcantly reduced in heart failure (U/100mg tissue: 15,3±2,0 vs. 24,6±2,1). State 
3 respiration of isolated SSM was unchanged with all substrates. In contrast respiratory 
capacity of IFM was impaired with complex-I substrates (natomsO/min/mg protein: 
glutamate 239±64 vs. 503±91, palmitoyl-carnitine 241±27 vs. 521±83 and pyruvate 198±14 
vs. 615±107; p<0,05) but unchanged with succinate as complex-II substrate.
Conclusion: Contractile dysfunction in heart failure is associated with signiﬁcant 
impairment of mitochondrial respiratory capacity. However this effect is limited to the 
interﬁbrillar mitochondria. The selective differences of the respiratory capacity of the IFM 
support the notion of IFMs main role in producing ATP for contractile function.
9:30 a.m.
1015-186 The Usefulness of Body Temperature Circadian Rhythm 
Variation as an Early Predictor of Decompensation in 
Cardiomyopathic Hamsters
Amany Ahmed, Sreedevi Gondi, Casey Cox, Shahzeb M. Munir, K. J. Shankar, Igor V. 
Stupin, Ed Sobash, Dejian Lai, Alan Brewer, James M. Wilson, S. Ward Casscells, Texas 
Heart Institute, Houston, TX, University of Texas HSC, Houston, TX
Introduction: We have previously shown that hypothermia is a signiﬁcant predictor of 
death in heart failure patients. We hypothesize that variations in the body temperature 
circadian rhythm (BTCR) precede the temperature decline and will be an early predictor 
of decompensation and death.
Methods: We observed 48 male BIO-TO-2 Syrian dilated cardiomyopathic hamsters and 
continuously monitored their temperature with an intraperitoneal transmitter until death. 
We used group mean cosinor analysis to determine the mesor, amplitude, and acrophase 
of the BTCR sinusoid and to establish whether there was a difference between values at 
baseline and death.
Results: Of the 45 hamsters included in the ﬁnal analysis, 44 had a decline in temperature 
8±4 days before death. Group mean cosinor analysis of the temperature data revealed a 
signiﬁcant (P<0.05) decrease in the amplitude of the BTCR 8 weeks before death (0.28; 
95% CI, 0.26-0.31) compared to baseline (0.36; 95% CI, 0.34-0.39). A Student t test 
conﬁrmed that the amplitude at 8 weeks before death was signiﬁcantly lower than that at 
both baseline (P=0.005) and 4 weeks after baseline (P=0.03). The acrophase and mesor 
did not signiﬁcantly change between baseline and death.
Conclusions: The decrease in the amplitude of the BTCR occurs before the temperature 
decline in cardiomyopathic hamsters. Continuous temperature monitoring may be useful 
in predicting decompensation in heart failure patients and in guiding treatment. 
9:30 a.m.
1015-187 Intranasal Administration of Atrial Natriutetic Peptide 
May Be Useful for the Treatment of Chronic Heart 
Failure in Rats
Tatsuji Kono, Akiko Soyama, Kazuhiko Yamane, Takao Tanaka, Yasushi Kitaura, Osaka 
Medical College, Osaka, Takatsuki, Japan
Background:Atrial natriutetic peptide (ANP) and angiotensin II act as mutual antagonists 
in the brain. In rats with chronic heart failure (CHF), a substantial decrease of ANP was 
found in the paraventricular nucleus (PVN) and supraoptic nucleus (SON), which are 
involved in cardiovascular and ﬂuid regulation. We have demonstrated that alpha-hANP 
administered intranasally may access the brain directly. We hypothesized that alpha-
hANP administered intranasally may be useful for the treatment of CHF. Methods:At
1 month after coronary ligation, forty survived rats with left ventricular (LV) dysfunction 
were assigned to either alpha-hANP administered intranasally at a dosage 200μg in 
10μL saline once a day for 1 month (ANP, n=20) or same amount of vehicle alone (CHF, 
n=20). Sham-operated rats (n=20) were used as controls.Results:In CHF compared with 
sham, although plasma ANP levels were elevated, immunohistochemical studies showed 
decreased expression of ANP and increased expression of angiotensin II type 1 receptor 
(AT-1) in PVN and SON. Compared with CHF, intranasal alpha-hANP signiﬁcantly 
increased expression of ANP and decreased expression of AT-1 receptor in PVN and 
SON, attenuated activation of sympathetic nerve and improved LV function.(*=p<0.05
vs. Sham, †=p<0.05 vs. CHF) Conclusions: Alpha-hANP administered intranasally may 
counteract central angiotensin II, suppress activated sympathetic nerve and may improve 
LV function in CHF. 
Table
Sham (n=20) CHF (n=20) ANP (n=20)
LV end-diastolic dimension (mm) 7.0±0.9 12.0±1.0* 9.2±1.1* †
LV fractional shortening (%) 49±7 11±2* 20±7*†
Mean aortic pressure (mmHg) 69±11 71±9 78±9
LV end-diastolic pressure (mmHg) 7±2 25±3* 13±6*†
Peak dp/dt (mmHg/sec) 4440±540 3180±480* 4140±410†
Negative dp/dt (mmHg/sec) 3980±310 2220±530* 3180±680*†
LV/BW (mg/g) 2.03±0.11 3.66±0.58* 3.03±0.47*†
Plasma ANP (pg/mL) 0.9±0.4 9.5±3.9* 4.9±3.9†
Plasma norepinephrine(pg/mL) 96.2±33.1 241.0±108.2* 28.4±8.6†
9:30 a.m.
1015-188 Derivation and Validation of a Novel Load Independent 
Index of Isovolumic Relaxation
Leonid Shmuylovich, Sandor J. Kovacs, Washington University School of Medicine, St 
Louis, MO
Background: Isovolumic pressure decline is characterized by the monoexponential and 
logistic time-constants of isovolumic pressure decay (IVPD) T, and TL. However, both T,
and TL are afterload dependent. In this work we derive a novel load-independent index of 
isovolumic pressure decay (LIIIVPD).
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Methods: We applied kinematic modeling to predict and derive a pressure contour-based 
LIIIVPD. For each IVPD contour, we mathematically extract an effective peak-restoring force 
driving pressure decay (FRestore) and peak-resistive force opposing pressure decay (FResist), 
thereby deﬁning coordinates in the FRestore vs FResist plane. The LIIIVPD is deﬁned as the 
dimensionless slope, called MLIIIVPD, of the linear regression between a set of IVPD contours 
plotted as points in the FRestore vs FResist plane. To validate load-independence, an average 
of 107 IVPD contours were analyzed in 25 subjects undergoing diagnostic catheterization, 
and the linearity of each subject’s FRestore vs FResist regression was assessed.
Results: The FRestore vs FResist relation was highly linear, with average r2=0.993±0.006. For 
all subjects, MLIIIVPD was found to be linearly correlated to subject averaged T (r2= 0.65), 
TL(r2=0.50), and dP/dtMIN (r2=0.63), as well as to ejection fraction (r2=0.52).
Conclusions: We conclude that MLIIIVPD is a LIIIVPD because it is load-independent and 
correlates with conventional IVPD parameters. Further validation of MLIIIVPD in selected 
pathophysiologic settings is warranted.
9:30 a.m.
1015-189 Genetic Deletion of IL-6 Attenuates Pressure Overload-
Induced Left Ventricular Hypertrophy and Dysfunction
Santosh K. Sanganalmath, Christine R. James, Hisham Taher, Greg Hunt, Robert J. 
Vincent, Rui Wu, Qianhong Li, Michael P. Flaherty, Roberto Bolli, Buddhadeb Dawn, 
Institute of Molecular Cardiology, University of Louisville, Louisville, KY
Background: Although interleukin (IL)-6 has been implicated in ischemic heart disease, 
its role in pressure overload-induced LV hypertrophy and dysfunction remains unclear.
Methods: We subjected IL-6-/- (IL-6-B, n=8) and age-matched wild-type (WT) (WT-B, 
n=6) mice to suprarenal aortic banding. Sham-operated (nonbanded) WT (WT-NB, n=6) 
and IL-6-/- (IL-6-NB, n=6) mice served as controls. Echocardiography was performed 
before (BSL) and at 6 wks after banding before euthanasia.
Results: Compared with sham controls, aortic banding increased LV end-diastolic 
volume (LVEDV) and LV mass, and decreased LVEF in WT mice (Fig). Compared with 
aortic-banded WT mice, the increase in LVEDV (61±1.7 μL vs. 50±3.4 μL in WT-B and 
IL-6-B, respectively, P<0.05) and LV mass (140±11 mg vs. 119±7 mg in WT-B and IL-6-B, 
respectively, P<0.05), and the decrease in LVEF (49.7±3.3% vs. 58.6±2.2% in WT-B and 
IL-6-B, respectively, P<0.05) were signiﬁcantly attenuated in aortic-banded IL-6-/- mice 
(Fig). Compared with sham controls, the myocardial levels of COX-2 protein, which exerts 
potent antiﬁbrotic effects, was reduced by 25% in WT-B mice. This reduction in myocardial 
COX-2 protein expression was attenuated in IL-6-B mice (Fig).
Conclusions: The absence of IL-6 signaling protects against LV hypertrophy and 
dysfunction during pressure overload possibly by preventing the downregulation of COX-
2 expression. Thus, inhibition of IL-6 may potentially ameliorate LV hypertrophy and 
dysfunction in hypertensive patients.
9:30 a.m.
1015-190 A High Fat Diet Inhibits the Cardioprotective Effects of W-3 
Polyunsaturated Fatty Acids on Ventricular Hypertrophy
Keyur B. Shah, Monika K. Duda, David J. Chess, Karen M. O’Shea, Ramzi J. Khairallah, 
Isabelle Frayne-Robillard, Christine des Rosiers, Willem J. Kop, William C. Stanley, 
University of Maryland School of Medicine, Baltimore, MD
Background: The GISSI-HF study showed that dietary supplementation with W-3
polyunsaturated fatty acids from ﬁsh (eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA)), improves survival in patients with chronic congestive heart failure. EPA 
and DHA are incorporated into the cardiac membrane phospholipids where they exert 
metabolic and anti-inﬂammatory effects. It is unknown whether high dietary fat intake 
competitively displaces W-3 PUFA in myocyte membranes, consequently inhibiting 
downstream beneﬁcial effects.
Methods: We assessed the development of LV hypertrophy and pathology in rats 
subjected to aortic banding randomized to a diets consisting of (1) standard diet [14% 
of energy from fat] (2) standard diet + W-3 PUFA [2.3% of energy intake as EPA+DHA], 
(3) high fat [60% fat]; or (4) high fat + EPA+DHA. Echocardiography was performed at 7 
weeks, and tissue harvested at 8 weeks.
Results: Aortic banding increased LV mass in both diets without EPA+DHA (standard diet: 
40%, P < 0.001; high fat diet: 43%, P <0.001). Treatment with EPA+DHA limited left ventricular 
hypertrophy in animals on the high in carbohydrate diet (4% increase), but not in those receiving 
diets high in fat (36% increase). Banding up-regulated expression of the fetal gene MHCB (P < 
0.001) and ANF (P < 0.001), which was signiﬁcantly blunted by treatment with EPA+DHA (P = 
0.003 and 0.033, respectively) in animals receiving diets high in carbohydrates, but increased 
expression MHCB (P = 0.009) and ANF (P = 0.003) in animals consuming diets high in fat. 
Regardless of diet composition or surgical banding, supplementation increased EPA and 
DHA and decreased arachidonic acid in cardiac membrane phospholipids (all P’s <0.001).
Conclusion: The cardioprotective effects of EPA+DHA on ventricular hypertrophy and 
expression of MHCB and ANF are limited in rats fed diets high in fat, despite incorporation 
of EPA and DHA into the cardiac cell membranes.
9:30 a.m.
1015-191 Cardiorenal Actions of New Designer Natriuretic 
Peptide CD-NP in Experimental Heart Failure
Ondrej J. Lisy, Horng H. Chen, John C. Burnett, Jr., Mayo Clinic and Mayo Clinic College 
of Medicine, Rochester, MN
Background: Our aim was to deﬁne for the ﬁrst time biological actions of a new designer 
natriuretic peptide CD-NP in a model of experimental heart failure (HF). We recently 
reported design, synthesis and potent biological actions of a designer peptide CD-
NP which combines vascular and antiproliferative actions of C-type natriuretic peptide 
(CNP) with natriuretic, diuretic and cardiac unloading properties of newly discovered 
Dendroaspis natriuretic peptide (DNP).
Methods: Hemodynamic, renal, and hormonal parameters were obtained prior (Baseline), 
during and after (Recovery) intravenous infusion of 100 ng/kg/min of CD-NP in a canine 
model of chronic HF produced by rapid ventricular pacing (n=6). * p<0.05 vs. Baseline.
Results: CD-NP decreased right atrial pressure (from Baseline 2.9±0.7 to 2.1±0.9* and 
Recovery 3.5±0.9* mmHg), wedge pressure (from 11±1 to 9±1*and Recovery 12±1 mmHg) 
with a mild decrease in MAP (from Baseline 109±9 to 100±8* and Recovery 105±8 mmHg). 
CD-NP increased GFR (from 30±3 to 54±7* and Recovery 37±4 ml/min) and RBF (from 
185±13 to 226±20* and Recovery 203±23 ml/min) and also produced signiﬁcant natriuresis 
(UNaV from 5±2 to 96±35* and Recovery 60±17 μEq/min) and diuresis (UV from 0.1±0.0 to 
1.3±0.6* and Recovery 0.6±0.2 ml/min). Distal fractional reabsorption of sodium decreased 
(DFRNa from 99±0 to 96±1* and Recovery 96±1* %) localizing the tubular actions of CD-
NP to the distal nephron. These actions were associated with increase in plasma cGMP 
(from 15.8±2.6 to 36.1±4.3* and Recovery 26.1±5.3* pmol/ml) and urinary cGMP. CD-
NP infusion was also associated with a marked decrease in plasma renin activity (from 
16.6±3.4 to 4.8±2.1* and Recovery 8.4±3.1 ng/ml/hr).
Conclusions: Our study demonstrates that the new designer peptide CD-NP has cardiac 
unloading, natriuretic, diuretic and GFR enhancing properties together with a suppression 
of renin release with mild effects on blood pressure in an experimental model of HF. These 
beneﬁcial properties warrant further evaluation of this designer peptide in a human HF.
9:30 a.m.
1015-192 Left Ventricular Torsion and Untwisting Are Correlated 
With Left Ventricular End-Diastolic Pressure: A 
Simultaneous Catheterization and Two-Dimensional STE
Sung-Ji Park, Rick A. Nishimura, Paul Sorajja, Barry A. Borlaug, GyeongSang National 
University Hospital, Jinju, South Korea, Mayo Clinic, Rochester, MN
Background: Left ventricular torsion (LVtor) and untwisting have been shown to be integral in 
systolic and diastolic mechanics of the heart.Our earlier study showed that LVtor surprisingly 
increases in patients with mild diastolic dysfunction and normal systolic function before 
decreases with worsening of diastolic function. We hypothesized that, LV torsion is dependent 
on ﬁlling pressure. However, there is limited information about relationship between LVtor 
and invasive hemodynamic parameters. The aim of this study was to evaluate the correlation 
between LVtor-derived parameters and invasive high-ﬁdelity LV hemodynamic parameters.
Methods: Forty-three consecutive patients (age: 61.6±14.6 years, female 20) underwent 
simultaneous echocardiographic imaging (Toshiba Apolio XG) and LV pressure 
measurements (7F Millar catheters). All had normal ejection fraction (62.7±10.2%).
Results: Peak LV torsion was signiﬁcantly correlated with LV end-diastolic pressure 
(LVEDP: r =-0.474, P=0.0013). Twisting rate and untwisting rate were signiﬁcantly 
correlated with LVEDP (r =-0.426, P=0.0044, r =0.4562, P=0.0021, respectively). Close 
correlation were found between peak negative dp/dt and LVtor (r =-0.365, P=0.0161).
Conclusions: Higher LV torsion, TR and UTR are signiﬁcantly correlated with lower LVEDP. 
LVtor-derived parameters are good correlated with LVEDP than conventional Doppler 
parameters. This ﬁnding gives additional hemodynamic insight in LV torsion and untwisting. 
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1015-193 Does Adverse Cardiac Remodelling Contribute to 
Clozapine-Induced Cardiac Injury?
Rachel Denver, Bing Wang, Jennifer Cooke, Gary Gordon, Paul Katz, Gishel New, 
Henry Krum, Box Hill Hospital, Box Hill, Australia, Monash University, Alfred Hospital, 
Prahran, Australia
Background: Clozapine is an atypical antipsychotic used for treatment-refractory 
schizophrenia. Despite its favourable side effect proﬁle, clozapine may be associated with 
fatal cardiac sequelae. Myocarditis and dilated cardiomyopathy are estimated to occur 
in up to 8.5% and 0.1% of clozapine patients respectively. The mechanisms of cardiac 
injury are largely unknown. We examined the effect of clozapine on markers of cardiac 
remodelling in our in vitro model of human cardiac ﬁbroblasts (VFs).
Methods: VFs were isolated from the left ventricle of explanted human hearts. Cells at 
passage 3-5 were seeded at medium density in 6- or 12-well plates for mRNA and proline 
analyses respectively, and rested for 24 hours. VFs were serum deprived for 48 hours then 
stimulated with clozapine (10nM to 10μM) or olanzapine (1nM to 1μM), a similar atypical 
antipsychotic not associated with cardiac injury. In separate experiments, the effect of 
clozapine on TGFB1 (60pM) stimulated collagen production by VFs was also assessed. 
Cells were harvested at 6-48 hours. Exogenous collagen production was estimated by 
incorporation of [3H]-proline. Real-time PCR was used to quantitate A1(I)-procollagen
mRNA, CTGF mRNA and 18S rRNA. Unstimulated cells served as controls.
Results: Clozapine reduced basal collagen synthesis by VFs in a dose-dependant 
manner (p<0.001), maximal at 10μM with a 47% reduction in [3H]-proline incorporation 
(p<0.001). TGFB1 stimulated collagen synthesis (195% of controls, p<0.001) was reduced 
to unstimulated levels with 10μM clozapine (p<0.001). Olanzapine had no effect on 
basal or stimulated collagen synthesis. A1(I)-procollagen mRNA was reduced in a time 
dependent manner with clozapine treatment, maximal at 48 hours (48% of controls, 
p<0.001). CTGF mRNA was reduced by 38% at 6 hours (p<0.005) and 60% at 12 hours 
(p<0.001). VF viability was not affected by either antipsychotic.
Conclusion: Clozapine reduces basal and stimulated collagen synthesis and transcription 
in human VFs. Reduced production of ﬁbrillar collagen with clozapine treatment may 
disrupt the myocardial collagen network, leading to slippage of cardiac myocytes and 
subsequent chamber dilation and systolic dysfunction.
9:30 a.m.
1015-194 Donepezil: An Acetylcholinesterase Inhibitor Against 
Alzheimer’s Dementia, Prevents Remodeling and 
Improves Survival in Volume Overload Heart Failure Mice
Takemi Handa, Takayuki Sato, Yoshihiko Kakinuma, Mikihiko Arikawa, Shiro Sasaguri, 
Kochi Medical School, Nankoku, Kochi, Japan
Background: We previously reported that chronic Vagal nerve stimulation (VNS) 
markedly improved long-term survival after large myocardial infarction in rats through 
cardioprotective effects of Ach, a neurotransmitter at cardiac nerve endings. However, 
such an approach is invasive and its safety is unknown in clinical settings. To develop 
an alternative therapy with a clinical available drug, we examined the chronic effect of 
oral donepezil (DNP) on cardiac remodeling and survival with a mouse model of volume-
overload heart failure (CHF).
Methods: The care and use of the animals were in strict accordance with the guiding 
principles of the Physiological Society of Japan. Four weeks after the surgery of aortocaval 
shunt, CHF mice were randomly assigned to untreated and DNP-treated groups. DNP 
was given at a dosage of 5 mg/kg/day. The dosage was selected without the bradycardiac 
effect. At the end of 4-week treatment, we evaluated left-ventricular (LV) pressure-volume 
relationships of Langendorff perfused hearts and LV function of in-situ hearts.
Results: When compared to the untreated group (n=20), the DNP-treated group (n=20) 
had signiﬁcantly low LV end-diastolic pressures (EDP) and high end-systolic pressures 
in the operating range of in situ LV volumes (Ees: 0.98±0.03 vs 1.12±0.05 mmHg/μL, 
p<0.05). DNP signiﬁcantly reduced the volume intercept of ESPVR (V0: 3.22±0.28 vs 
1.44±0.33 μL, p<0.05), and heart weight (6.14±0.16 vs 5.68±0.17mg/g, p<0.05). And 
EDP was signiﬁcantly lower (10.2±1.6 vs 14.9±0.8 mmHg, p<0.05), dp/dt max was 
signiﬁcantly higher (5961±562 vs 4506±997 mmHg/s, p<0.05) in in-situ hearts. There 
were 13 survivors among 24 untreated mice, 22 survivors among 27 treated mice during 
100-day treatment (54% vs 81%, p<0.05). In CHF mice, donepezil augmented ANP 
(1.85±0.11 vs 2.93±0.12, p<0.05), lowered BNP (5.55±0.83 vs 3.66±0.57, p<0.05). In 
vitro study, DNP upregulated ANP in HL-1 cells.
Conclusions: Our ﬁndings suggest that the upregulatory effect of DNP on ANP 
terminates the vicious circle of maladaptation in CHF through the natriuretic actions and 
that the hemodynamic improvement suppressed an increase in ventricular BNP mRNA. 
DNP improved cardiac remodeling and survival.
9:30 a.m.
1015-195 Alpha-Adrenergic Stimulation Increases Myocardial 
Distensibility Through PKC Activation in Health and 
Disease
Ana Patrícia Fontes-Sousa, Carmen Brás-Silva, Vera Monteiro-Cardoso, Nádia Pereira-
Gonçalves, Luisa Lopes-Conceição, Adelino F. Leite-Moreira, Department of Physiology, 
Faculty of Medicine, Porto, Portugal
Bachground: Alpha1-adrenoceptor (AR) stimulation has an important role in the 
regulation of cardiac function. Some neurohumoral agents acutely decrease myocardial 
stiffness, effect that could be altered in heart failure (HF). The present study was designed 
to determine the, yet unknown, acute effects of phenylephrine (FE), an alpha1-AR
agonist, on the diastolic properties of the myocardium in healthy rabbits and in the model 
of doxorubicin-induced HF.
Methods: Effects of increasing doses of FE (3*10-7-10-4M) were studied in papillary 
muscles of normal rabbits with (i) intact endocardial endothelium (control group), and in 
the presence of (ii) damaged endocardial endothelium (EE) (iii) NO synthase inhibitor, 
NG-Nitro-L-Arginine (L-NNA; 10-5 M) and (iv) PKC inhibitor, chelerythrine (CHE; 10-5M). 
Papillary muscles from rabbits injected with doxorubicin were also evaluated (HF group). 
Calculated parameters: passive tension (PT), active tension (AT), maximum velocity of 
tension rise and decline (dT/dt
max
 and dT/dt
min, respectively) and muscle length. Results 
presented as mean±SEM (p<0.05).
Results: FE induced concentration-dependent positive inotropic and lusitropic effects, with 
10-4M promoting an increase of 117.5±25.3% AT, 142.4±28.7% dT/dt
max
, and 96.6±22.5% 
dT/dt
min. The same concentration of FE induced a signiﬁcant increase on muscular length 
of 1.013±0.003 L/L
max
, which corresponds to a 28±6% decrease of PT and represents a 
decrease of myocardial stiffness. This later effect was abolished by the inhibitor of PKC, 
while the other experimental protocols did not change any of the myocardial effects. 
Additionally, all the effects induced by FE were maintained in HF group.
Conclusion: The present study demonstrated that alpha1-adrenergic stimulation 
promotes an increase of myocardial distensibility, modulated by the activation of PKC. 
On the other hand, this effect occurs even after EE removal, is independent of nitric oxide 
release and is preserved in HF, which might have important pathophysiologic implications 
in this syndrome where EE dysfunction occurs.
9:30 a.m.
1015-196 Eplerenone Attenuates Atrial Remodeling and 
Abolishes the Vulnerability to Induced Atrial Fibrillation 
in Experimental Heart Failure
Gordon W. Moe, Andrea Konig, George O. Naik, Andrew Ramadeen, Paul Dorian, St. 
Michael’s Hospital, Toronto, ON, Canada
Background: Structural remodeling is a substrate for abnormal atrial mechanical 
function and the development of atrial ﬁbrillation (AF) in the setting of heart failure (HF). 
Aldosterone is a key player in vascular pathology but its role in atrial remodeling and AF 
has not been elucidated. We therefore tested the hypothesis that aldosterone played a 
role in the development of atrial remodeling and AF by studying the effect of aldosterone 
inhibition in a novel dog model of atrial remodeling and AF in the setting of HF.
Methods: Mongrel dogs were randomized to 1) controls without pacing (CTRL, n=5), 2) 
simultaneous atrioventricular pacing (SAVP) for 2 weeks (SAVP, n=9) and 3) SAVP and 
treatment with eplerenone 10 mg/kg twice daily orally (SAVP-Epl, n=9).
Results: Data for LA pressure (LAP); LA area and shortening fraction from ultrasound 
(LA area and LAFS); measures of vulnerability to AF from rapid atrial stimulation; tissue 
collagen area fraction (CAF) (Picrosirius stain) and matrix metalloproteinase-9 (MMP-9) 
activity (gelatin zymography) are shown in the table. 
CTRL SAVP SAVP-Epl
LAP (mm Hg) 10±1 21±3* 16±2*†
LAA (cm2/kg body weight) 0.35±0.01 0.59±0.04* 0.55±0.03*†
LASF (%) 25±3 12±2* 18±2*†
Burst attempts leading to AF (%) 3.2 ± 1.8 20 ± 5* 3.2 ± 1.2†
Median AF duration (s) 191 1932* 504†
Collagen area fraction (%) 7±1 13±1* 10±1*†
MMP-9 (% of controls) - 452±43 249±23†
* p <0.05 vs. CTRL; † p <0.05 vs. SAVP
Eplerenone attenuated the LA chamber dilatation and partially restored the impaired 
function while abolishing the AF induced by SAVP. This was accompanied by a marked 
reduction in ﬁbrosis and MMP activation in the LA.
Conclusion: Aldosterone plays a key role in mediating atrial remodeling and AF and may 
provide a novel therapeutic target against heart failure related arrhythmias.
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1015-197 The Salutary Paracrine Effects of Antiinﬂammatory 
Cytokines May Play a Role in Cellular Cardiomyoplasty 
Using Mesenchymal Stem Cells
Guangyong Chen, Madhur Nayan, Minh Duong, Juan-Francisco Asenjo, Yin Ge, Ray 
C-J Chiu, Dominique Shum-Tim, McGill University Health Centre, Montreal, Canada
Background: Mesenchymal stem cells (MSCs) have been explored to treat myocardial 
infarction (MI) and heart failure, but the mechanism remains controversial. We hypothesized 
that changes in the pro-/anti-inﬂammatory cytokine ratio after MSCs therapy may improve 
cardiac function following MI.
Methods: 88 rats with coronary artery ligations were injected with culture media (Grp M) 
or MSCs (Grp C). All rats underwent echocardiography to assess left ventricular ejection 
fraction (LVEF). Gene expression of IL-1B, IL-6, IL-8 (pro-inﬂammatory) and IL-10 (anti-
inﬂammatory) was quantiﬁed by Real-time PCR. Extra-cellular matrix (ECM) deposition, 
inﬂammatory cell inﬁltration and the ratio of matrix metallopeptidase 2 (MMP2) to 
metallopeptidase inhibitor 1 (TIMP1) were also analyzed.
Results: The ratio of pro-/anti-inﬂammatory cytokine gene expression (ﬁg1) was 
signiﬁcantly decreased in Grp C with times. In Grp C, LVEF improved signiﬁcantly 
(M=57% vs C=75% at 1 wk*, M=52% vs C=70% at 2 wks*, *p<0.01); ECM deposition 
was signiﬁcantly lower (M=19.3% vs C=9.3% at 1 wk*, M=24.4% vs C=7.5% at 2 wks*, 
*p<0.01); Inﬂammatory cell inﬁltration decreased after 24 hrs (C=1.7 vs M=2.1 at 1 wk, 
and C=0.9 vs M=1.7 at 2 wks, p<0.05); MMP2/TIMP1 ratio was lower at 12 and 24 hrs, 
and 2 wks (0.40-, 0.51- and 0.39-fold, p< 0.05).
Conclusions: Our data showed that MSCs therapy decreases the pro-/anti-inﬂammatory 
cytokine ratio in the infarct microenvironment. This may explain the early functional 
improvement after MI.
9:30 a.m.
1015-198 Different Mechanisms of Myocardial Insulin Resistance 
in the Diabetic and Failing Heart
Christina Kleinert, Stuart A. Cook, Anabel Varela-Carver, Takashi Matsui, Saumya Das, 
Ornella E. Rimoldi, Anthony Rosenzweig, Paolo G. Camici, Medical Research Council, 
Clinical Sciences Centre, London, United Kingdom, Division of Cardiology, Beth Israel 
Deaconess Medical Center, Boston, MA
Background: Whole body and myocardial insulin resistance are features of type 2 diabetes 
mellitus (T2DM) and left ventricular dysfunction (LVD) in non-diabetic patients. The aim of 
the study was to determine whether abnormalities of insulin receptor substrate-1 (IRS1), 
different members of the PI3 kinase (PI3K) pathway and glucose transporter 4 (GLUT4) 
contribute to myocardial insulin resistance in these two disease states.
Methods: In patients awaiting cardiac surgery whole body and myocardial glucose 
uptake was measured using positron emission tomography and euglycemic-
hyperinsulinemic clamp. Myocardial biopsies were used to examine IRS1-PI3K activity 
and protein expression levels of different members of the PI3K pathway. Additionally, 
GLUT4 expression was studied in cytosolic, intracellular vesicular pools and sarcolemmal 
fractions by sucrose gradient puriﬁcation. In parallel, we examined the same parameters 
in leptin-deﬁcient, insulin resistant ob/ob mouse hearts and a mouse model of LVD.
Results: Patients with T2DM or LVD had lower whole body and myocardial glucose 
utilization compared to controls. Myocardial IRS1-PI3K activity was signiﬁcantly increased 
in both groups, while an increase in Akt activity was only seen in T2DM. Additionally, 
both PTEN and GLUT4 expression was decreased in T2DM (45.19%±26.29% for PTEN 
and 71.8±5.13%, P=0.012 for GLUT4, n=3) compared to controls. However, a signiﬁcant 
increase in GLUT4 expression in patients with LVD (42.78±13.16%, P=0.01, n=4) 
compared to controls was observed. In the ob/ob mouse heart GLUT4 expression at 
the sarcolemma was also signiﬁcantly reduced compared to controls but increased in 
the LVD model.
Conclusions: We observed a strong activation of IRS1-PI3K, elevated Akt and PTEN 
activity and diminished expression of GLUT4 at the sarcolemma in T2DM patients and 
diabetic mouse. However, in patients with LVD as well as in the mouse model of LV 
dysfunction, intermediate IRS1-PI3K activity, no increase in Akt activity but an increase in 
PTEN expression and GLUT4 at the sarcolemma under basal conditions was observed. 
Thus, we conclude that the mechanism underlying myocardial insulin resistance is 
different between T2DM and LVD.
9:30 a.m.
1015-199 Endogenous Interleukin-1 Receptor Antagonist 
Protects Against Severe Adverse Cardiac Remodeling 
After Acute Myocardial Infarction
Fadi N. Salloum, Nicholas N. Hoke, Amit Varma, Benjamin Van Tassell, Stefano Toldo, 
Vinh Q. Chau, Elena Vecile, Aldo Dobrina, Antonio Abbate, Virginia Commonwealth 
University Pauley Heart Center, Richmond, VA
Background: Interleukin-1 receptor antagonist (IL-1Ra) is a naturally occurring anti-
inﬂammatory protein with anti-apoptotic activity. We hypothesized that knock-out (KO) mice 
lacking the IL-1Ra gene (IL-1RN -/-) may be at increased risk for adverse cardiac remodeling 
after acute myocardial infarction (AMI) due to lack of the protective effects of IL-1Ra.
Methods: Seven IL-1RN -/- mice and 8 age-matched wild-type (WT) mice with the 
same genetic background underwent surgical coronary artery ligation. All animals 
underwent transthoracic echocardiography before surgery and at day 7. Infarct size and 
cardiomyocyte apoptosis were measured using collagen staining and in situ detection of 
DNA fragmentation, respectively.
Results: Seven days after AMI, KO mice showed increased left ventricular (LV) end-
diastolic diameter and LV end-systolic diameter with reduced fractional shortening vs WT 
mice [Figure]. An average of 5 aneurysmatic segments were seen in the KO mice vs 1 
segment in the WT mouse (p=0.010). KO mice also had a signiﬁcantly larger area of scar 
(35±2% vs 23±2%,p=0.009) and signiﬁcantly greater cardiomyocyte apoptosis both in 
the peri-infarct myocardium (9.5±2.2% vs 1.9±0.1%, p=0.022) and remote myocardium 
(0.3±0.2% vs 0%, p=0.014) compared to WT mice.
Conclusions: IL-1Ra plays a protective role in the myocardium during AMI by preventing 
cell death, ensuing adverse cardiac remodeling and aneurysm formation. 
9:30 a.m.
1015-200 Intracoronary Injection of Autologous Bone Marrow 
Mononuclear Cells Plus Granulocyte Colony 
Stimulating Factor Therapy or Granulocyte Colony 
Stimulating Factor Alone Improve Chagas’ Chronic 
Heart Failure
Valeria B. Carvalho, Ricardo R. Santos, Carlos Eduardo S. Silva, Silvano Wendel Neto, 
Antonio Esteves Filho, Milton Godoy, Enis D. Silva, Vicente Amato Neto, Gilson S. 
Feitosa, Radi Macruz, Antonio Carlos C. Carvalho, Hospital Sirio Libanes, Sao Paulo, 
Brazil, FIOCRUZ, Bahia, Brazil
Background: Autologous bone marrow mononuclear cells (ABMMC) transplantation 
followed by Granulocyte Colony Stimulating Factor (G-CSF) therapy has been effective 
in Chagas` heart failure, but effects of G-CSF alone remain unknown. We sought to 
compare both therapies, after etiological and optimized medical treatment.
Methods: In a Double Blind study, 14 patients with New York Heart Association (NYHA) 
class III-IV and left ventricular ejection fraction (LVEF) < 35% were randomly assigned 
to intracoronary injection of ABMMC (10 8 cells) followed by G-CSF, 5mcg/kg/day, for 5 
days (G1) Versus G-CSF alone, in the same dose (G2). Effects were assessed up to one 
year on LVEF (Simpson’s formula), myocardial performance index (MPI) and velocity-time 
integral of LV outﬂow tract (VTI) in echocardiogram, also on NYHA class, quality of life, time 
walked and maximal physical work in treadmill test, arrhythmias in Holter (24 hours) and 
biochemical parameters. Friedman and Mann-Whitney non-parametric tests were used for 
statistics.
Results: LVEF changed from 24.9±3.8 to 29±9.3% (p>0.05) in G1 and from 26.4±7.6 to 
37.4±5.0 (p=0.019) in G2; MPI and VTI changes were not signiﬁcantly different in either 
group, but improvement was greater in G2 Versus G1 (p<0.05); 86% of the patients went 
to NYHA class I-II in G1, and 100% to class I in G2 (p>0.05). Minnesota Life Quality score, 
time walked and maximal physical work in treadmill test had prominent improvement in G1 
and G2 (p<0.05). No signiﬁcant differences were seen in arrhythmias, serum Na or BNP 
in either group, but BNP tended to increase in G1 and to decrease in G2. Overall data 
presented no differences in G1 Versus G2, except in MPI and VTI improvement in G2.
Conclusions: Clinical beneﬁts of the therapies, within the regimens used, were similar, 
although signiﬁcant cardiac function improvement was shown with G-CSF alone. Given 
its easy employment, G-CSF offers great potential use for cardiac repair in Chagas’ 
disease.
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1015-201 Prospective Study of the Inﬂuence of Fasting Glucose 
Level on Mortality of Patients With Heart Failure
Victor S. Issa, Alexandre Amaral, Fatima D. Cruz, Guilherme V. Guimarães, Silvia MA 
Ferreira, Edimar A. Bocchi, Heart Institute (InCor) University of São Paulo Medical 
School, São Paulo, Brazil
Background: glucose level is associated with cardiovascular events in patients with
diabetes. However, recent ﬁndings have identiﬁed a harmful effect of intensive glucose 
lowering. As conﬂicting data report on the role of glucose level in heart failure (HF) we 
tested the association between glucose level and mortality in HF patients.
Methods: 457 patients were prospectively followed from September 1999 through 
December 2007; ages ranged from 18 to 83 (50.3±11.5) years, 322 (70.5%) patients 
were male and 135 (29.5%) female; 142 (31%) were in NYHA III-IV, mean left-ventricle 
ejection fraction was 0.36±0.1, and 78 (17.1%) were diabetic.
Results: Death occurred in 202 (44.2%) patients and 27 (5.9%) were submitted to heart 
transplantation. Mean glucose was 110±7 mg/dL, and 254 (55.6%) had glucose > 100. 
In diabetic patients, glucose level > 100 was associated better survival free from death/
transplant(LogRank 0.0006). In Cox Regression model including age, sodium, creatinine, 
ejection fraction and NYHA status, presence of glucose > 100 was associated with better 
survival (p<0.001). No association between glucose and mortality was found in non-
diabetic patients
Conclusions: hyperglycemia was frequent in HF patients, and lower glucose levels 
in diabetic patients were associated with increased mortality. Our ﬁndings identify a 
previously unknown association between glucose and mortality in diabetic patients with 
HF, and suggest that current treatment targets in this setting should be reviewed.
9:30 a.m.
1015-202 Anthracycline Chemotherapy Impairs Left Ventricular 
Diastolic Function in Lung Cancer Survivors
Dan Radulescu, Sorin Pripon, Elena Buzdugan, Sorin Dudea, Valer Donca, Laurentiu 
Stoicescu, Maria L. Radulescu, Andreea Parv, Gavril Saplacan, Gheorghe Sebestyen, 
Marian Mihaiu, Constantin Cosma, University of Medicine and Pharmacy “Iuliu 
Hatieganu”, Cluj-Napoca, Romania, Cardiology Department, 5th Medical Clinic, 
Municipal Hospital, Cluj-Napoca, Romania
Background: Anthracycline-induced alteration of the left ventricular (LV) performance is 
a serious consequence of chemotherapy in cancer patients. Epirubicin, a less cardiotoxic 
anthracycline isomer was less studied in this respect.
Methods: Forty-six patients with lung cancer, treated with a chemotherapy protocol 
containing epirubicin in low doses (mean cumulative dose 450 mg/m2), associated with 
cyclophosphamide and vincristine (study group) and a gender and age-matched control 
group of 46 lung cancer patients who had not started oncologic treatment yet, were 
assessed by Doppler echocardiography. LV diastolic function was evaluated by measuring 
the transmitral inﬂow indices: maximal velocity of the E and A waves, E/A ratio, E wave 
pressure half time (PHT) and isovolumic relaxation time (IVRT). LV ejection fraction 
(LVEF) was also assessed. Analysis of data included between-group comparison of LV 
performance variations at baseline and at 6 months after treatment completion.
Results: No signiﬁcant differences between the 2 groups were found at baseline. At 6 
months after treatment, an alteration of LV diastolic performance was found in the study 
group: signiﬁcant increase of A
max
 with a decrease of E
max
, prolonged PHT and IVRT. The 
LVEF was within normal limits in both groups.
Conclusions: Epirubicin chemotherapy, even in low doses in lung cancer patients, alters 
diastolic ﬁlling parameters, impairment due to poor LV compliance, representing an early 
marker of infraclinical cardiotoxicity.
Echocardiographic parameters in the study and control group 
(mean ± standard deviation)
Parameter Study group Control group p-value
Amax (cm/s) 56.02±4.66 36.76±8.44 <0.001
Emax (cm/s) 48.24±3.44 68.42±10.88 <0.001
PHT (ms) 67.01±12.44 53.68±12.64 <0.001
IVRT (ms) 97.21±12.20 85.68±12.16 <0.001
LVEF 59.44 ± 6.12 60.14 ± 6.18 NS
9:30 a.m.
1015-203 Low-Dose B Blocker Therapy Improves Cardiac Function 
in Patients With Acute Heart Failure Partly Through 
Correction of Abnormal Intracellular Ca2+ Handling
Shigeki Kobayshi, Takeo Tanaka, Takehisa Susa, Takeshi Suetomi, Makoto Ono, 
Hitoshi Uchinoumi, Shinichi Okuda, Masahiro Doi, Syuji Kawamura, Takeshi Yamamoto, 
Masafumi Yano, Masunori Matsuzaki, Yamaguchi University Graduate School of 
Medicine, Department of Medicine and Clinical Science, Ube, Japan
Background:Altough B blocker is considered to be inappropriate for the treatment of 
patients with acute heart failure (AHF), low-dose of B blocker, which has modest negative 
chronotropic (but less inotropic) effect, may improve myocardial performance in these 
patients. Here, we investigated whether low-dose of B blocker improves cardiac function 
in human AHF (Protocol 1), and if so, we clariﬁed the cardiprotective mechanism using 
isolated canine failing cardiomyocytes (Protocol 2).
Methods and Results:In 15 AHF patients (Killip’s classiﬁcation;III(n=2) and IV(n=13), 
heart rate; 115±15 bpm, LVEF; 23 ±5%, Cardiac index(CI); 2.6±0.5 l/min/m2, PCWP; 
26±8mmHg), who ﬁrst underwent conventional therapy by milrinon(<0.5 μg/kg/min) or 
dopamine(<3.0 μg/kg/min), vasodilators, and diuretics, we added landiolol (1.5-6.0 μg/kg/
min;i.v., an ultra-short acting B1-selective blocker) to study the effect on hemodynamics. 
Low-dose of landiolol (1.5-3.0 μg/kg/min) signiﬁcantly reduced heart rate by11-15% and 
rate pressure product without changing blood pressure (BP), CI and PCWP, whereas 
its higher dose (>3.0μg/kg/min) decreased BP and CI, suggesting that optimal (safety) 
dose of landiolol is 1.5-3.0 μg/kg/min. After the treatment with landiolol (3.0 μg/kg/min),
hemodynamic parameters such as transmitral ﬂow pattern, ﬁlling time/RR, E/Ea and Tei 
index were all improved (p<0.01), and interestingly, pulsus alternans, which had been 
observed in 4 patients, disappeared. For protocol 2, cardiomyocytes were isolated from 
the LV of canine HF model by 4-week’s rapid RV pacing (250 bpm, LVEF 27±5%, n=6). 
Then, we investigated the effect of landiolol on the intracellular Ca2+ transient (CaT) and 
cell shortening. In the failing cardiomyocytes, both CaT and cell shortening were markedly 
impaired as compared with normal cardiomyocytes (p<0.01). After an incubation with 
low-dose landiolol (10 nM) for 4 hours, both CaT and cell shortening in the failing 
cardiomyocytes were substantially improved (p<0.01).
Conclusions: Low-dose of B blocker, by suppressing tachycardia and correcting 
abnormal Ca2+ handling, improves cardiac function in patients with AHF with severe LV 
systolic dysfunction.
9:30 a.m.
1015-204 Relationship of Left Ventricular Systolic Function to 
Persistence or Development of Electrocardiographic 
Strain Pattern in Hypertensive Patients: Implications for 
the Development of New Heart Failure
Peter M. Okin, Kristian Wachtell, Eva Gerdts, Kurt Boman, Markku S. Nieminen, Björn 
Dahlöf, Richard B. Devereux, Weill Cornell Medical College, New York, NY
Background: Persistence or development of ECG strain are associated with an 
increased risk of new heart failure (HF) compared with regression or continued absence 
of ECG strain. We postulated that this relationship might be in part mediated via worse left 
ventricular (LV) systolic function in patients with new and persistent ECG strain.
Methods: Baseline and year-1 ECG strain and LV midwall shortening (MWS) were 
examined in 725 patients in the LIFE echocardiographic substudy without HF. MWS 
<14.2% and stress-corrected MWS (scMWS) <89.2% were considered abnormal.
Results: Baseline mean MWS and scMWS were signiﬁcantly lower in patients with 
persistent or new strain. Although both MWS and scMWS improved in all groups after 
1 year of antihypertensive treatment, persistence or development of ECG strain were 
associated with signiﬁcantly lower year-1 mean MWS and scMWS and with higher 
prevalence and odds of abnormal MWS and scMWS than absence of ECG strain, even 
after controlling for age, gender, race, treatment, diabetes, history of ischemic heart 
disease or MI, baseline and change from baseline to year-1 of systolic and diastolic 
pressure and ECG LVH by Cornell product and Sokolow-Lyon voltage.
Conclusions: Persistence or development of ECG strain during antihypertensive therapy 
are associated with increased risk of LV systolic dysfunction at baseline and after 1 year 
follow-up. These ﬁndings provide insight into a possible mechanism by which changes in 
ECG strain are associated with changing risk of HF. 
Variable
No Strain 
Baseline/No
Strain Year 1
Absence of 
Strain
(n=603)
Strain 
Baseline/
No Strain 
Year 1
Regression of 
Strain
(n=32)
No Strain 
Baseline/Strain 
Year 1
Development of 
New Strain
(n=21)
Strain Baseline/
Strain Year 1
Persistence of 
Strain
(n=73)
p value
Baseline MWS (%) 15.8±2.0 15.5±1.8 14.0±1.6 14.3±2.3 <0.001
Year-1 MWS (%) 16.8±1.8 16.4±2.3 15.7±1.7 15.6±2.2 <0.001
Year-1 MWS< 14.2% (%) 6.6 18.8 23.8 27.4 <0.001
Year-1 univariate odds ratio 
of MWS<14.2% (95% CI) 1
3.3
(1.3-8.4)
4.4
(1.5-12.6)
5.3
(2.9-9.7) <0.001
Year-1 multivariate odds 
ratio of MWS<14.2% 
(95% CI)
1 2.8(1.1-7.5)
4.0
(1.4-11.6)
3.7
(1.9-7.2) <0.001
Baseline scMWS (%) 98.5±12.3 97.3±10.7 88.0±10.3 91.6±16.0 <0.001
Year-1 scMWS (%) 103.5±10.6 103.0±14.2 98.7±10.9 97.6±14.6 <0.001
Year-1 scMWS< 89.2% (%) 7.9 13.8 26.3 29.4 <0.001
Year-1 univariate odds ratio 
of scMWS<89.2% (95% CI) 1
1.9
(0.6-5.6)
4.2
(1.4-12.1)
4.9
(2.7-8.9) <0.001
Year-1 multivariate odds ratio 
of scMWS<89.2% (95% CI) 1
1.4
(0.4-4.4)
3.1
(1.0-9.5)
3.7
(1.9-7.2) 0.001
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1015-205 Occurrence of Hopitalization in Relation to Time of 
Follow-Up in Older Patients With Advanced Systolic 
Heart Failure Treated With Rosuvastatin: Experiences 
From the CORONA Trial
Finn Waagstein, Peter Dunselman, Ake Hjalmarson, John Kjekshus, John JV McMurray, 
Hans Wedel, John Wikstrand, Wallenberg Laboratory, Gothenburg, Sweden
Background The CORONA trial in ischemic systolic heart failure with rosuvastatin 
(R) versus placebo (P) included only patients without statin indication. We analyzed if 
baseline NT-proBNP could predict effect.
Methods Table shows numbers of hospitalizations for cardivoascular and worsening 
heart failure reasons.Primary composite endpoint (PCE) of nonfatal myocardial infarction 
or stroke or CV death (time to ﬁrst event) was analyzed after 12 and 24 months of FU.
Results After 12 months 297 patients in the P group had suffered a PCE compared to 265 
Pts in the R group (HR 0.88 CI 0.75-1.04 p=0.13); after 24 months was 544 vs. 487 Pts (HR 
0.88 CI 0.78-0.99 p=0.034); end of study data 732 vs. 692 Pts (HR 0.92 p= 0.12). 
Follow-up 
time
Total n of CV 
hospitaizations
Total n of WHF 
hospitalizations
Placebo/Rosuvastastin Difference Placebo/Rosuvastastin Difference
6 months 486/414 -72 219/233 +14
12 months 953/849 -104 455/452 -3
18 months 1399/1220 -179 697/635 -32
24 months 1856/1619 -237 931/834 -97
30 months 2243/1924 -319 1116/978 -138
36 months 2489/2117 -372 1254/1070 -184
The effect on both variables was strongest among patients in the lowest baseline tertile 
for NT-proBNP CV-H -33 %, p=0.009 and WHF-H -55%, p=0.0002. Less percentage 
effects but no harm were seen in upper two tertiles.
Conclusion Data suggest de NOVO use of R in pts with ischemic systolic heart failure. 
Selection of heart failure patients for therapy may be based on biochemical baseline 
variables such as NTproBNP.
ACC.POSTER CONTRIBUTIONS
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1024-165 Risk of Heart Failure and Peripheral Edema in Patients 
With Pre-Diabetes and Type 2 Diabetes With Use of 
Thiazolidinediones (TZD): A Systematic Review and 
Meta-Analysis of Placebo-Controlled Randomized 
Clinical Trials
Anitha Rajamanickam, Ali Usmani, Amir Moheet, Abdul Rashid, Christina Heckathorn, 
Adrian V. Hernandez, Cleveland Clinic, Cleveland, OH
Background: A recent meta-analysis of randomized trials demonstrated a higher risk 
of heart failure (HF) with >12 month use of thiazolidinediones (TZDs) in comparison to 
an active control or placebo in patients with pre-diabetes and type 2 diabetes (DM-2). 
However, this effect may have been diluted by including active comparators, and the 
consistency of the risks was not explored with different methods. We quantiﬁed the risks 
of HF and peripheral edema with TZD usage in placebo-controlled trials of adult patients 
with pre-diabetes and DM-2.
Methods: We performed a systematic review and meta-analysis of published double-
blind, placebo-controlled randomized trials that evaluated the effect of TZDs (roziglitazone 
[RSG] or pioglitazone [PIO]) on investigator-reported HF and edema. We included 
English language trials with q100 patients, and q2 months of follow-up. We quantiﬁed 
the effect of TZDs on HF and edema by using the Mantel-Haenzel (MH) ﬁxed effects 
model. Heterogeneity of effects across trials was evaluated with Chi Square test, and 
the associations were shown as Odds Ratios (OR) and 95% conﬁdence intervals (CIs). 
To evaluate the consistency of the risks we also used the Peto ﬁxed effects and the MH 
random effects models.
Results: A total of 35 trials (n=22950) were evaluated. TZDs were signiﬁcantly associated 
with both HF (TZD 328/6785 (4.8%) vs. placebo 207/6413 (3.2%), ORMH 1.62; 95% CI, 
1.35-1.94; p<0.00001), and edema (1457/12856 (11.3%) vs. 688/9597 (7.2%), ORMH 2.04; 
1.85-2.26; p<0.00001). There was no evidence of heterogeneity of HF risks across trials 
(p=0.6), but heterogeneity of edema risks was signiﬁcant (p=0.0007). Both RSG and PIO 
were independently associated with HF and edema: the risk of HF was higher with RSG 
than with PIO (ORMH 3.40; 1.94-5.94 vs. 1.49; 1.24-1.80, p=0.006), but the risk of edema 
was similar between PSG and PIO. HF and edema risks from the Peto and MH random 
effects models were consistent with the ones from the MH ﬁxed effects model.
Conclusion: TZD therapy in adult patients with pre-diabetes and DM-2 is signiﬁcantly 
associated with higher risk of HF and edema. The risk of HF is higher with RSG than with 
PIO, although the risk of edema was similar between these drugs.
3:30 p.m.
1024-166 Intravenous Iron Is Safe and Equally as Efﬁcient as 
Darbepoetin Alpha for the Treatment of Anemia in 
Advanced Heart Failure
Elisabeth Kaldara, John Terrovitis, John Kanakakis, Stavros Drakos, Argyris Ntalianis, 
Evangelos Repasos, Vasiliki Kontopidi, Despoina Barmparousi, John Nanas, 3rd 
Department of Cardiology, University of Athens School of Medicine, Athens, Greece
Background. Anemia is as a frequent and important co-morbidity in heart failure, 
associated with worse prognosis. Suppression of hematopoiesis, due to cytokine excess, 
has been considered as the main etiologic factor, however recently the prevalence of 
iron deﬁciency has been increasingly recognized. It is not known if the bone marrow of 
severely sick patients will demonstrate normal response to iron supplementation alone or 
concomitant use of erythropoietin stimulating agents (ESA) is needed.
Purpose. To investigate the optimal treatment strategy in patients with advanced heart 
failure, anemia and iron deﬁciency.
Methods. Twenty four patients, 56±1 yrs with advanced heart failure (NYHA class III or IV, 
EF<35%), anemia (hemoglobin-Hb-<12g/dl for men and <11.5g/dl for women) and iron 
deﬁciency (diagnosed by bone marrow aspiration and absence of iron in the erythroblasts) 
were randomized in two groups: Group A (n=12), was treated with IV intravenous iron 
sucrose alone (300mg) and Group B (n=12), treated with darbepoetin alpha (50μg 
weekly) and intravenous iron for 6 weeks. Patients were followed for 3 months.
Results. There were no differences in patients’ baseline characteristics, between the 
two groups (NYHA: 3.5±0.5 vs 3.6±0.5, p=0.698, EF:25.8±9.4 vs 22.6±7.2, p=0.354, 
Hb:10.5±1.1vs10.5±0.7, p=0.88, creatinine:1.4±0.7 vs 1.7±0.9, p=0.459, for Group A 
and B, respectively). At 3 months, there was no difference in patients’ functional class 
(2±0.6 vs 2.4±0.8, p=0.308) and EF (31.5±12.9 vs 28.9±7.5, p=0.64, for Group A and 
B respectively). Erythropoietic response started as early as two weeks from treatment 
initiation in both groups. At completion of treatment, Hb increased to 12.5±0.9.in Group A 
(p=0.001) and to 12.7±1.6 in Group B (p=0.001). The increase in Hb was similar in both 
groups (2.1±0.9 vs 2.3±1.4, p=0.822, for group A and B).
Conclusion. Iron supplementation alone is effective for patients with advanced heart 
failure, anemia and iron deﬁciency. In patients with severe heart failure and well 
documented iron deﬁciency, the bone marrow response to intravenously administered 
iron remains adequate and there is no need for additional ESA treatment
3:30 p.m.
1024-167 Long-Term Adherence to Evidence-Based Care and 
Outcomes of Black and Whites With Heart Failure: A 
Review of the UT Southwestern Heart Failure Database, 
1996-2005
Faris Araj, David W. Markham, Lynn Fernandez, Brenda S. Thompson, Colby R. 
Ayers, Parag C. Patel, Pradeep PA Mammen, Mark H. Drazner, Clyde W. Yancy, UT 
Southwestern Medical Center, Dallas, TX, Baylor University Medical Center, Dallas, TX
Background: Racial disparities in heart failure (HF) include differences in prevalence, 
morbidity, and mortality. However, data are currently limited regarding the racial differences 
in quality of care and long-term outcomes in tertiary care HF management programs. We 
sought to evaluate adherence to evidence-based therapy (EBT) and outcomes in a single 
center tertiary care disease management program as a function of race.
Methods: We identiﬁed 405 patients referred to our HF disease management program 
between April 1996 and August 2005. Inclusion criteria required a minimum of two 
outpatient visits and one year follow up. Analyses were performed based on self-reported 
racial classiﬁcation. Adherence to EBT was stratiﬁed by race, and the use of ISDN-
hydralazine was examined before and after November 2004 (release of the A-Heft trial 
results). All-cause mortality was obtained by a search of the National Death Index.
Results: 109 African American (AA) and 227 white subjects were identiﬁed. Mean follow 
up was 4.8 years. In univariable analysis of the entire database, AA and whites had similar 
high rates of long term adherence of certain EBT: beta blockers (84% vs. 80%; p=0.4) and 
ACE-inhibitors (92% vs. 90%; p=0.6); prior to 2004, ISDN-hydralazine in AA vs. whites 
was 24% vs. 4% (p<0.01). Quality of care improved in both groups over time with excellent 
rates of long term adherence, especially for AA after 11/2004: beta blockers (82% to 
100%), ACE-inhibitors (91% to 100%), and ISDN-hydralazine (24% to 64%, respectively). 
Multivariable analysis demonstrated that race was not a signiﬁcant predictor of survival. 
Long term survival was not signiﬁcantly different for AA or whites at ﬁve year follow up 
(76% and 75%, respectively; p=0.9).
Conclusions: In a tertiary care HF program, adherence to evidence-based care improved 
substantially for AA with HF. These data conﬁrm that high rates of adherence with EBT 
and similar outcomes can be achieved in all patients with HF.
3:30 p.m.
1024-168 Changes in Ventricular Systolic and Diastolic Function 
Over Time: Relationship to Incident Heart Failure in the 
Community
Garvan C. Kane, Barry L. Karon, Doug W. Mahoney, Steven J. Jacobsen, Margaret M. 
Redﬁeld, Richard J. Rodeheffer, Mayo Clinic, Rochester, MN
Background - Heart failure (HF) is a progressive disease that becomes increasingly 
prevalent as the population ages, with over half of patients having a normal left ventricular 
ejection fraction. Yet longitudinal changes in LV systolic and diastolic function and their 
relation to incident HF in population-based cohorts is unknown.
Methods - Subjects enrolled in the Olmsted County HF Study (1997-2001), an extensively 
characterized randomly selected population-based cohort of persons >45 years old, were 
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Clinical Trial/
BB studied # pts
Total ACM 
Results
& HR
Actual # US 
Deaths/total
(Rel. Risk)
Actual # ROW 
Deaths/total
(Rel. Risk)
US 
HR’s, 
(C.I.)
ROW 
HR’s
(C.I.)
COPERNICUS/
carvedilol
2289
(US=482)
191/1133 P
132/1156 C
0.65
(0.52-0.81)
(p=0.0014)
50/233 P
44/249 C
(0.82)
141/900 P
88/907 C
(0.62)
0.80 0.60
MERIT-HF/
metoprolol
3991
(US 
=1071)
217/2001 P
145/1990 M
0.66
(0.53-0.81)
(p=0.00009)
49/539 P
51/532 M
(1.05)
168/1462 P
94/1458 M
(0.56)
1.05
(0.71-
1.56)
0.55
(0.43-
0.70)
CIBIS-II/
bisoprolol
2647
(US=0)
228/1320 P
156/1327 B
0.66
(0.54-0.81)
(p<0.0001)
No U.S. pts
228/1320
156/1327
(0.68)
No U.S. 
Pts
0.66
(0.54-
0.81)
BEST/
bucindolol
2708
(US=2645)
439/1354 P
402/1354 B
0.87
(0.76-1.0)
(p=0.053)
428/1322 P
391/1323 B
(0.91)
11/32 P
11/31 B
(1.03)
0.87
(0.76-
1.00)
1.53
(0.55-
4.30)
All Studies
(Relative Risk) 11,635
1075/5808
(19%) P
835/5827
(14%) B-b Tx
(0.774)
527/2094 
(25.2%) P
486/2104
(23.1%) B-b Tx
(0.918)
548/3714
(14.8%) P
349/3755
(9.3%) B-b Tx
(0.635)
Conclusions: The magnitude of beta-blocker (BB) survival effect was either reduced 
(HR 0.80) or non-existent (HR 1.05) in large US populations included in COPERNICUS 
and MERIT-HF, respectively. These effects are more comparative to BEST trial results 
with bucindolol in US patients. Such ﬁndings suggest that differences in BB survival 
beneﬁt observed in clinical trials may be signiﬁcantly inﬂuenced by inclusion of varying 
geopraphic populations (US vs. ROW).
3:30 p.m.
1024-171 Sleep Apnea Incidence and Outcomes in Heart 
Failure Patients: A Retrospective Study of Medicare 
Beneﬁciaries
William T. Abraham, Shahrokh Javaheri, The Ohio State University, Columbus, OH
Background:Previous studies showed a high prevalence (40%-60%) of sleep apnea 
(SA) in patients with heart failure (HF) and that SA has adverse effects on the progression 
of HF, leading to higher mortality and higher healthcare utilization (HCU). We investigated 
the incidence, treatment, and outcomes of SA in new onset HF.
Methods:This retrospective cohort study used the 2003-2005 Medicare Standard Analytical 
Files (SAFs) that contain a 5 percent sample of randomly selected Medicare beneﬁciaries. 
The study population included newly diagnosed HF patients in the ﬁrst quarter of 2004 
without prior diagnosis of SA, stratiﬁed by SA diagnosis and SA testing status.
Results:Among a ﬁnal study population of 30,719 newly diagnosed HF patients, only 
1,263 (4%) were diagnosed with SA. Of these, 553 (only 2% of the total cohort) received 
SA testing. Among subjects diagnosed with SA, those tested and diagnosed had higher 
rates of treatment compared with those not tested and diagnosed (52.4% vs. 15.5%, 
P<0.001), lower overall mean payment ($42,859 vs. $63,747), and lower all cause 
mortality (7.8% vs. 26.3%, P<0.001).
Conclusions:SA was under-tested and therefore under-diagnosed in Medicare HF 
patients during 2004 and 2005. Newly diagnosed HF patients who were diagnosed with 
SA after testing had higher rates of treatment, lower mortality, and lower overall Medicare 
costs than HF patients diagnosed with SA without testing and those not diagnosed with 
SA. These results support SA testing for HF patients. 
invited to participate in a follow-up evaluation. A total of 1,402 (69%) subjects returned for 
clinical and Doppler echo assessment of systolic and diastolic function 4 ± 0.3 years after 
their initial evaluation. An incident HF diagnosis was identiﬁed through medical record 
review and validated HF with Framingham criteria.
Results - At follow-up, there was a modest increase in mean LVEF, from 63.9 ± 6.6% to 
65.9 ± 7.5% (p<0.001). The rates of systolic dysfunction (EF < 50%) remained low and 
unchanged. By contrast, the prevalence of any diastolic dysfunction increased over time, 
rising from 25.1% to 40.8% (p<0.001) and the prevalence of moderate-severe diastolic 
dysfunction increased from 9.1% to 18.3% (p<0.001). The prevalence of increased left 
ventricular ﬁlling pressures (E/e’q10) increased from 25.7% to 56.2% (p<0.001). Factors 
associated with worsening diastolic function over time included age (p<0.01), female sex 
(p=0.08) and systemic hypertension (p=0.01). The annual incidence of new validated HF 
was 0.21% (95% CI, 0.1%-0.4%). 9/12 incident HF cases had an EF > 50% at the 2nd
exam. All 12 HF cases had E/e’ >10 at the 2nd evaluation with a mean E/e’ of 15 ± 6. 
Factors associated with the development of incident HF included age (p<0.001 - with 
an incident annual HF rate of 0.73% in those > 75 years of age), incident myocardial 
infarction (2/12, p<0.05) and diabetes mellitus (4/12, p < 0.01).
Conclusions - Middle aged and elderly community subjects demonstrate signiﬁcant 
progression of rates and severity of diastolic dysfunction while rates of systolic dysfunction 
remaining stable and relatively low. Incident HF occurs predominantly in the setting of 
normal LVEF and increases with age.
3:30 p.m.
1024-169 Erythropoiesis Stimulating Agents In Heart Failure: A 
Meta-Analysis Of Clinical Trials
Eiran Z. Gorodeski, Dharam J. Kumbhani, Daniel J. Cantillon, Mazen A. Hanna, 
Cleveland Clinic, Cleveland, OH
Background: Anemia predicts poor outcomes in heart failure (HF). It is unknown if 
treatment with erythropoiesis stimulating agents (ESAs) reduces HF hospitalizations, 
increases thrombotic risks, or improves survival. Prior clinical trials did not primarily 
examine these end points.
Methods: We performed a pooled analysis of clinical trials that randomized HF patients to 
ESAs or placebo. We contacted authors where data was unavailable. Efﬁcacy estimates 
were pooled using ﬁxed effects models.
Results: We included 7 trials, of which 367 patients were randomized to ESAs and 303 
to placebo. Ninety-two percent were NYHA class II or higher. Mean baseline hemoglobin 
was 11 g/dL. The weighted mean duration of follow-up was 9.5 months. There was a 
signiﬁcant increase in hemoglobin after treatment with ESAs (Mean change 1.65 g/dL, 
95% CI [1.47-1.83], p<.01). The incidence of HF hospitalizations was lower in the ESA 
group (20.3% vs. 29.7%, RR 0.74, 95% CI [0.58-0.94], p=.02). There was no signiﬁcant 
difference in the incidence of death or transplantation (6.5% vs. 6.6%, RR 1.02, 95% [CI 
0.6-1.73], p=.95), myocardial infarction (RR 0.86, 95% CI [0.29-2.54], p=.79), or venous 
thrombosis (RR 0.17, 95% CI [0.03-1.03], p=.054) between the two groups.
Conclusions: ESAs are efﬁcacious (increase hemoglobin, reduce HF hospitalizations) and 
safe (no increase in mortality, MI, or thrombosis) in HF. Their use in treatment of anemia in 
HF should be studied in appropriately powered long-term randomized clinical trials. 
3:30 p.m.
1024-170 All-Cause Mortality Endpoint Comparison in Large 
Beta-Blocker Heart Failure Trials: United States (US) 
Versus Rest of World (ROW)
Christopher M. O’Connor, Bruce Koch, Mona Fiuzat, Gordon Davis, Michael R. Bristow, 
Duke University Medical Center, Durham, NC, ARCA biopharma, Broomﬁeld, CO
Background: Large randomized, controlled trials have shown that B-blockers reduce 
mortality by 34-35% in moderate to severe systolic dysfunction heart failure patients 
(COPERNICUS, MERIT-HF, and CIBIS-II). However, the majority of patients enrolled in 
these trials were from outside the US (i.e. Rest of World, ROW). BEST, the only intention-
to-treat mortality trial which enrolled almost exclusively US patients, showed only a 
13% reduction in mortality. We investigated whether or not improvement in survival was 
different due to enrollment of ROW populations.
Methods: We compared the primary endpoint of all cause mortality and annual placebo 
mortality rate for the 4 trials.
Results: Table 1. 
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aromatization of androgens, so that abnormal estrogen metabolism would be anticipated 
in CHF. We sought to examine the relation between the serum concentration of estradiol 
(E2) and mortality in men with CHF.
Methods: Serum concentrations of E2 and androgens (total testosterone [TT], 
dehydroepiandrosterone sulfate [DHEAS]) were measured using immunoassays in 501 
men with stable systolic CHF (age: 58±12 [mean±SD] years, LVEF [left ventricular ejection 
fraction]: 28±8%, NYHA [New York Heart Association] class [I/II/III/IV]: 52/231/181/37, 
ischemic CHF etiology: 71%).
Results: During follow-up (mean: 32±18 months), there were 194 (39%) deaths. In 
stepwise multivariable regression models, serum E2 predicted mortality in men with CHF 
(P<0.0001), independently of low serum TT and DHEAS, reduced LVEF, high plasma 
N-terminal pro-B type natriuretic peptide and high NYHA class. In multivariable models, 
men in the lowest and highest quintiles for serum E2 had an increased mortality as 
compared to the middle quintile (adjusted hazard risk: 3.33 (95% conﬁdence interval 
[CI]: 2.05-5.40) and 2.62 (95% CI 1.57-4.38), both P<0.001, respectively). These two 
quintiles had different clinical characteristics. Men in the lowest quintile for serum E2 
had increased serum TT, reduced serum DHEAS, advanced NYHA class, more prevalent 
ischemic etiology of CHF, lower hemoglobin concentration, reduced estimated glomerular 
ﬁltration rate and lower total fat tissue mass as compared to a middle quintile (all P<0.05). 
Men in the highest quintile for serum E2 demonstrated a deterioration of liver function 
(increased serum bilirubin, increased serum activity of aminotransferases) as compared 
to a middle quintile (all P<0.05).
Conclusions: In men with systolic CHF, both high and low concentrations of serum E2 are 
related to an increased mortality. The mechanisms for the U-shaped outcome in relation 
to serum E2 concentrations require further studies. Modulation of steroid metabolism is a 
potential therapeutic target in selected male patients with CHF.
3:30 p.m.
1024-175 Biomarker Guided Therapy in Chronic Heart Failure: A 
Meta-Analysis of Randomized Controlled Trials
Gary Michael Felker, Victor Hasselblad, Christopher M. O’Connor, Duke Clinical 
Research Institute, Durham, NC
Background: Measurement of circulating natriuretic peptides (NP) has been shown to 
play an important role in diagnosis and prognosis in patients with chronic heart failure 
(HF). Whether using serial NP measurements to guide titration of therapy would improve 
HF outcomes remains uncertain.
Methods: We performed a meta-analysis of published or presented randomized 
controlled trials (RCTs) of NP guided therapy for chronic HF. A Medline search combining 
“natriuretic peptide”, “BNP”, “NTproBNP”, and “heart failure” was used to identify potential 
studies. We searched proceedings of major cardiovascular meetings to identify studies 
not yet published. We included studies which randomized patients with chronic HF to 
a control group or a strategy of adjusting medical therapy that incorporated NP levels, 
and which reported mortality. For each study, we estimated the hazard ratio (HR) for 
all-cause mortality, and studies were combined using an empirical Bayes random-effects 
estimator.
Results: Four RCTs were identiﬁed which met criteria for inclusion, randomizing a total of 
918 patients. HRs and 95% conﬁdence intervals (CI) for each study are shown (Figure). 
The combined HR was 0.61, 95% CI = 0.43-0.86. There was no quantitative evidence of 
heterogeneity between studies (p=0.31).
Conclusions: Analysis of completed RCTs suggests that a strategy incorporating NP 
levels to guide therapy is associated with a signiﬁcant reduction in all cause mortality 
compared to usual care in patients with chronic HF. 
3:30 p.m.
1024-176 Glucagon-Like Peptide-1 Increases Blood Pressure and 
Heart Rate in Heart Failure Patients
Mads Halbirk, Helene Nørelund, Niels Møller, Jens Juul Holst, Ole Schmitz, Jens Erik 
Nielsen-Kudsk, Søren Steen Nielsen, Torsten Toftegaard Nielsen, Hans Eiskjær, Hans 
Erik Bøtker, Henrik Wiggers, Aarhus University Hospital, Skejby, Aarhus, Denmark, 
Aarhus University Hospital, Aarhus Hospital, Aarhus, Denmark
Objectives: The incretin hormone glucagon-like peptide 1 (GLP-1) and its analogues are 
currently emerging as anti-diabetic medications. GLP-1 improves left ventricular ejection 
fraction (LVEF) in dogs with heart failure and in patients with acute myocardial infarction. 
The inﬂuence of GLP-1 on blood pressure and heart rate (HR) is conﬂicting. We studied 
the effect of 48-hour GLP-1 infusion on hemodynamics in patients with congestive heart 
failure (CHF).
3:30 p.m.
1024-172 How Does Exercise Affect Natriuretic Peptides in Heart 
Failure With Preserved Ejection Fraction?
Barry A. Borlaug, Carolyn S.P. Lam, Thomas P. Olson, Kelly S. Flood, Bruce D. Johnson, 
Margaret M. Redﬁeld, Mayo Clinic, Rochester, MN
Background Atrial (ANP) and B-type Natriuretic Peptides (BNP) are released in response 
to cardiac wall distention, stimulating synthesis of cyclic guanosine monophosphate (cGMP). 
Elevated BNP is common in Heart Failure with preserved Ejection Fraction (HFpEF), yet little 
is known regarding acute effects of exercise on natriuretic peptide (NP) signaling in HFpEF.
Objectives To compare basal and exercise (Ex) changes in NP and cGMP levels in 
patients with HFpEF and hypertensive (HTN) controls.
Methods Age/gender matched subjects with HFpEF (n=21) and HTN (n=19) underwent 
metabolic Ex testing. ANP, BNP and cGMP levels were measured prior to Ex and at peak. 
The ratio of A/BNP to cGMP was examined as a surrogate for NP resistance.
Results Exercise performance was impaired in HFpEF (p<0.0001, Table). ANP, BNP and 
cGMP rose with Ex, while NP/cGMP ratios fell. NP levels were higher in HFpEF at rest 
and Ex, but there were no differences in the change in ANP, BNP or cGMP between 
groups, and peak VO2 was not associated with $ANP, $BNP or $cGMP (p=NS). BNP/
cGMP was higher in HFpEF, while ANP/cGMP was not.
Conclusions ANP, BNP and cGMP levels increase with exercise, while NP/cGMP ratios 
decrease, suggesting enhanced NP sensitivity and/or alternative sources of cGMP are 
activated. While HFpEF display elevated resting NP levels compared with HTN, acute 
changes with exercise are similar and do not predict exercise performance. The ratio of 
BNP to cGMP is elevated in HFpEF, suggesting BNP resistance is present.
*p<0.05 vs base; †p<0.05 vs HTN; ‡p=0.09 vs HTN
Overall HTN (n=19) HFpEF (n=21)
Base Ex Base Ex Base Ex
BNP(pg/ml) 98±84 126±111* 60±50 73±67* 143±94† 204±120†
ANP(pg/ml) 980±690 1110±720* 790±530 850±550 1210±810‡ 1590±800*†
cGMP(nmol/L) 8.5±3.9 13.1±5.6* 7.8±2.4 12.0±4.9* 9.3±5.0 14.5±6.3*
BNP/cGMP 10.8±7.6 8.6±6.3* 7.5±5.6 6.0±5.1* 14.6±8.0† 12.6±5.9*†
ANP/cGMP 119±67 85±42* 110±66 78±45* 130±70 100±32*
Peak VO2(ml/
min*kg) 18.6±3.7 12.7±3.0†
3:30 p.m.
1024-173 Gender of Physicians and Patients: Risk Factor for 
Patients With Chronic Heart Failure?
Magnus Baumhäkel, Ulrike Müller, Michael Böhm, University Hospital of the Saarland, 
Homburg, Germany
Background: To determine possible effects of patients’ and physicians’ gender on 
medical treatment of chronic heart failure (CHF).
Methods: Consecutive patients (n=1857) with CHF were evaluated regarding co-
morbidities, NYHA-classiﬁcation and current medical treatment as well as dosage of ACE-
inhibitors and beta-receptor-blockers. Gender of treating physicians were documented. 
Multivariable regression analysis to determine association of patients and physicians 
gender (independent variables) and use of ACE-I and beta-blockers was adjusted to 
hypertension, coronary heart disease, NYHA-classiﬁcation, ACE-I/ARB or beta-blocker 
use, specialization of physicians, age of patient, time since medical board examination 
and left ventricular ejection fraction as confounding variables.
Results: Baseline characteristics of patients were comparable in males and females. 
In female and male physicians, specialization (63.2% male vs. 68.0% female general 
practitioners, 29.0% male vs. 25.7% female internists, 7.8% male vs. 6.2% female 
cardiologists, p=0.105) and duration since medical examination (male: 23.9±9.1 years, 
female 23.5±8.8 years, n.s.) were not different. Female patients were less frequently 
treated with an ACE-inhibitor or an ARB (p=0.021) and tended to with beta-blockers 
(p=0.054). Achieved doses were smaller in female compared to male patients (ACE-I 
p=0.058, beta-blockers p=0.021). Drug use and achieved doses tended to be better in 
patients treated by female physicians. There was no different treatment of male or female 
patients by female physicians (n.s.), whereas male physicians signiﬁcantly used less 
medication and lower doses in female patients (p<0.05). In multivariable linear regression, 
physicians’ gender was an independent risk factor for using beta-blockers (p=0.029, 
95%CI -1.000_0.055), but not ACE-I (n.s.).
Conclusions: Treatment of chronic heart failure is inﬂuenced by patients’, but also 
physicians’ gender with regard to evidenced based drugs and their dosage. Physicians 
should be aware of this problem, to avoid gender dependent medical treatment.
3:30 p.m.
1024-174 Circulating Estradiol and Mortality in Men With Systolic 
Chronic Heart Failure
Ewa A. Jankowska, Piotr Rozentryt, Waldemar Banasiak, Philip A. Poole-Wilson, Piotr 
Ponikowski, Cardiology Department, Military Hospital, Wroclaw, Poland, National Heart 
& Lung Institute, Imperial College London, London, United Kingdom
Background: Androgen deﬁciency is common in men with chronic heart failure (CHF), 
and is associated with increased morbidity and mortality. Estrogens are formed by the 
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3:30 p.m.
1024-179 NT-proBNP Keeps Its Predictive Ability During Several 
Years of Follow-Up Experiences from CORONA
Hans Wedel, John McMurray, John Wikstrand, John Cleland, Peter Dunselman, Ake 
Hjalmarson, John Kjekshus, Nodic School fo Public Health, Gothenburg, Sweden
Background To analyze the importance of the biomarker NT-proBNP (BNP) by time 
of follow up after adjustment for other well-known risk factors in patients with stable 
advanced systolic heart failure.
Methods Patients in CORONA with BNP available from baseline (n= 3366) were analyzed. 
The hazard function of death from heart failure (and of other events) was estimated by 
Poisson models as a continuous function of time in study and BNP together with other 
risk variables. The event hazard was of the form exp(B0+B1·x1+Bk·xk), where B0, B1, etc, 
were constants and x1, x2, etc, were the values of the variables. More precisely the time 
in study was modeled by connected linear pieces in speciﬁed intervals and interaction 
between logBNP and time in order to investigate whether the predictive power changed 
(decreased) with time. Endpoints were all-cause mortality (n= 940 deaths) and for death 
due to worsening of heart failure (n= 230 deaths).
The HR for a difference in logBNP of one standard deviation was calculated by time of 
follow up. The HR for EF is given for a difference of 5%. The following variables at baseline 
have been used in the model: logBNP, ejection fraction (EF), diabetes mellitus (DM), age, 
sex, New York Heart Association (NYHA) class, hypertension and MI. Median follow up 
time was 32.8 months
Results InBNP was the strongest predictor of outcome both early and later during follow 
up. In the ﬁrst six months of follow the HR for all cause mortality was 2.3 decreasing to 1.6 
after 3 years with both p<0.001, for EF the ﬁgures were 1.2 p=0.003 and n.s at 3 years. 
Corresponding ﬁgures for death due to worsening of heart failure was 3.6 and 2.0 with 
both p<0.001, and 1.3 p=0.007 and 1.1 at 3 years p=0.04, respectively.
Conclusions Adding the biomarkers NT-pro-BNP to routine clinical variables can improve 
estimating the cardiovascular risk in older patients with advanced systolic heart failure. 
NT-proBNP added substantial information as regards risk estimation both in the short and 
longer term prediction. Interestingly, even a three year old BNP carries a stronger risk for 
death than a recent measurement of EF.
3:30 p.m.
1024-180 Impact of Age on the Levels and Utility of Novel Cardiac 
Biomarkers in Diagnosing Acute Heart Failure: Results 
From the BACH Multinational Study
Lori B. Daniels, Kimberly Tran, Paul Clopton, Stefan D. Anker, Inder Anand, Robert 
Christenson, Salvatore DiSomma, Gerasimos Filippatos, Christopher Hogan, Michael 
Hudson, James McCord, Martin Möckel, Christian Müller, Sean-Xavier Neath, Leong 
Ng, Richard Nowak, W. Franklin Peacock, Piotr Ponikowski, Mihael Potocki, A. Mark 
Richards, Alan Wu, Alan S. Maisel, University of California, San Diego, San Diego, CA, 
Veterans Affairs San Diego Healthcare System, La Jolla, CA
Background: B-type natriuretic peptide (BNP) levels are useful in the diagnosis of heart 
failure (HF) in patients with acute dyspnea, but their diagnostic value is confounded by 
age. We examined the impact of age on the levels and utility of novel cardiac biomarkers 
in a secondary analysis of the Biomarkers in ACute Heart Failure (BACH) study.
Methods: The BACH study was a multinational 15-center prospective study of the use of 
novel cardiovascular prohormone fragments in diagnosing HF among dyspneic patients 
presenting to the ED. HF diagnosis was determined by 2 independent cardiologists who 
were blinded to the ED physicians’ diagnoses and to the biomarker levels being examined 
in this study.
Results: The mean age of the 1641 subjects was 64±17 years; the 568 (35%) patients 
with a ﬁnal diagnosis of HF were older than those with alternate diagnoses (71 vs. 60 
years, p <0.001). In patients without acute HF, median levels of all BACH markers (CT-
proET, MR-proADM, MR-proANP, CT-proAVP) increased signiﬁcantly with increasing age 
group (p <0.001), as did levels of MR-proADM (p=0.001) and MR-proANP (p=0.025) in 
subjects with HF. The area under the ROC curve was largest in the youngest age group 
and decreased with age, suggesting that the BACH markers were stronger predictors in 
younger patients (Figure).
Methods: We included 20 non-diabetic ischemic CHF patients, LVEF 33% ±2%, NYHA II 
and III (n=14 and 6). Patients were hospitalized during infusions and blood samples were 
drawn regularly. On two separate occasions patients received native GLP-1 (0.7 pmol·kg-
1
·min-1 intravenously) and placebo-infusion for 48 hours in a double-blind randomized 
cross-over design. Each infusion was separated by a time period of at least 14 days. 
At 0 and 48 hours LVEF was determined by echocardiography and cardiac index was 
measured using an inert gas rebreathing method. Blood pressure and HR was recorded 
every 4 hours.
Results: Fifteen (13 males) completed the protocol, 5 dropped out (side effects 1, cancer 
1, withdrawal of consent 3). Two suffered side effects (hypoglycemia 1, nausea 1). HR 
(67 ± 2 beats/min vs. 65 ± 2 beats/min; p=0.016) and diastolic blood pressure (71 ± 2 
mmHg vs. 68 ± 2 mmHg; p=0.008) increased during GLP-1 treatment. Systolic and mean 
arterial pressure remained unaffected. Cardiac index (1.5 ± 0.1 L·min-1·m-2 and 1.7 ± 0.2 
L·min-1·m-2; p=0.55) and LVEF (33 ± 2 % and 33 ± 3 %; p=0.95) were unchanged. Insulin 
levels were higher during GLP-1 infusion than during placebo (90 ± 17 pmol/L vs. 69 ± 
12 pmol/L; p=0.025) and blood glucose concentration were lower (5.0 ± 0.1 mmol/L vs. 
5.7 ± 0.2 mmol/L; p=0.005).
Conclusion: GLP-1 increases HR and diastolic blood pressure in CHF patients without 
altering LVEF or cardiac index. GLP-1 had blood glucose lowering effects in this non-
diabetic population. The mechanisms and potential clinical consequences of the observed 
increases in HR and diastolic blood pressure require further studies.
3:30 p.m.
1024-177 Liver Failure Is Mainly Related to Increased Central 
Venous Pressure in Patients With Heart Failure
Kevin Damman, Vincent M. Van Deursen, Hans L. Hillege, Dirk J. van Veldhuisen, 
Adiraan A. Voors, University Medical Center Groningen, Groningen, The Netherlands
Introduction. Heart failure is often accompanied by liver failure. However, the relation 
between liver failure, cardiac output (cardiac forward failure) and central venous pressure 
(cardiac backward failure) has not been well established. We assessed the hypothesis 
that liver failure in patients with heart failure is dependent of both reduced perfusion and 
increased congestion, and is associated with poor prognosis.
Methods. We evaluated central venous pressure (CVP), cardiac output (CO) and clinical 
outcome in 340 patients with heart failure that underwent right heart catheterization 
between 1989 and 2006. Chart review was done to investigate follow up and 
demographics and laboratory liver function tests. These included aspartate and alanine 
aminotransferase (AST and ALT), alkaline phosphatise (ALP), G-glutamyl transpeptidase 
(GGT), lactate dehydrogenase (LDH), direct and total bilirubin (Bili dir, and Bili tot). Liver 
failure was deﬁned as values above the upper limit of normal.
Results. Mean age was 53±14 years, amd 61% were male. Abnormal liver function 
tests were prevalent: 19% ALP, 24% AST, 28% Bili tot, 37% GGT, 51% ALT, 68% LDH 
and 69% Bili dir. In univariate regression analysis, almost all liver function tests were 
associated with higher CVP and lower CO. However, in multivariate analysis, only AST 
remained associated with both CVP and CO, while all other were only related to CVP. 
Especially GGT (r=0.341), Bili tot (r=0.334) and Bili dir(r=0.369) (all P <0.001) were 
strongly associated with CVP. In univariate analysis, GGT, ALP, AST and LDH were 
signiﬁcant predictors of all cause mortality. However, after adjustment for CO and CVP, 
none remained independently associated with prognosis.
Conclusion. Liver failure in patients with heart failure is mainly dependent of increased 
CVP. Liver failure is associated with reduced survival, but this is attributable to impaired 
hemodynamics, suggesting that liver failure in heart failure is a reﬂection of poor 
hemodynamic status.
3:30 p.m.
1024-178 Chronic Obstructive Pulmonary Disease Is 
Independently Associated With Adverse Clinical 
Outcome in Patients With Heart Failure: A Substudy of 
the COACH Study
Kevin Damman, Hans L. Hillege, Adriaan A. Voors, Dirk J. van Veldhuisen, Tiny Jaarsma, 
University Medical Center Groningen, Groningen, The Netherlands
Background. Comorbidities in heart failure are prevalent and increase the risk for 
adverse clinical outcome in heart disease such as mortality and high medical costs. 
There is however surprisingly little information on the association between the presence 
of Chronic Obstructive Pulmonary Disease (COPD) and adverse clinical outcome in 
patients with heart failure.
Methods. The Coordinating Study Evaluating Outcome of Advising and Counseling 
in Heart Failure (COACH) included 1023 HF patients. Presence of COPD and other 
comorbidities, were assessed at baseline. Primary outcome was a composite of all-cause 
mortality and heart failure admissions after discharge.
Results. Mean age was 71±11 years and 62% were male. Mean LVEF was 33±14%, 
and 50% were in NYHA III/IV. In total 268 (27%) had coexisting COPD at admission. 
Patients with COPD were older, more often men, had lower renal function and more likely 
coexisting atrial ﬁbrillation. In univariate analysis, the presence of COPD was associated 
with worse outcome: Hazard ratio (HR): 1.39 (95% conﬁdence interval (CI) 1.13 - 1.71), 
P = 0.002. COPD especially predisposed to increased heart failure admissions: HR 1.42 
(95% CI 1.09 - 1.84), P = 0.008). In multivariate analysis, the presence of COPD remained 
independently associated with on the composite end point of death and hospitalization: 
HR 1.29 (95% CI 1.01 - 1.65), P = 0.043 (Figure).
Conclusion. COPD is highly prevalent in patients with HF and independently associated 
with adverse clinical outcome. 
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Conclusions: In patients with refractory angina or post-ischemic heart failure, treatment 
with G-CSF appears to improve symptoms, possibly through improvements of stress-
induced ischemia.
3:30 p.m.
1024-183 Depression in Men With Chronic Heart Failure: 
Prevalence, Hormone Determinants, Detrimental Impact 
on Exercise Capacity and Survival
Ewa A. Jankowska, Beata Ponikowska, Anna Drohomirecka, Jolanta Maj, Bartosz Biel, 
Waldemar Banasiak, Philip A. Poole-Wilson, Piotr Ponikowski, Cardiology Department, 
Military Hospital, Wroclaw, Poland, Physiology Department, Wroclaw Medical University, 
Wroclaw, Poland
Background: Men with androgen deﬁciencies (testosterone, dehydroepiandrosterone 
sulfate [DHEAS]) are prone to development of late-onset depression. We investigated 
links between circulating androgens and depressive symptoms, and their combined 
impact on prognosis in men with chronic heart failure (CHF).
Methods: We examined 203 men with stable systolic CHF (age: 60±10 years [y], NYHA 
class [I/II/III/IV]: 36/101/60/6; LVEF: 31±9%) and 328 healthy men aged 35-80 living in 
the same area.
Results: The prevalence of Beck Depression Inventory (BDI) score above 15 points (at 
least moderate depression) was higher in CHF men as compared to healthy peers in all 
age groups (35-45 y: 22% vs 3%, p<0.01, 46-55 y: 36% vs 3%, p<0.0001, 56-65 y: 26% vs 
9%, p=0.01, 66-80 y: 48% vs 26%, p<0.05). In a multivariable regression, in men with CHF 
severe affective-cognitive depressive symptoms were related to advanced NYHA class, high 
serum high sensitivity C-reactive protein, low hemoglobin, reduced serum total testosterone 
[TT] and DHEAS, marked somato-wegetative depressive symptoms correlated with 
reduced glomerular ﬁltration rate and high plasma N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) (all p<0.05). During follow-up (mean: 24±12 months), there were 74 (47%) 
cardiovascular deaths and unplanned hospitalizations. There were the following independent 
predictors of unfavorable outcome in men with CHF: TT deﬁciency and DHEAS deﬁciencies 
(below the 10th percentile of healthy peers), high plasma NT-proBNP (above 3242 pg/mL, 
median), BDI above 15 points (all p<0.05). The higher the number of risk factors, the worse 
prognosis (HR [95% CI] for 1, 2, 3, 4 vs. 0 risk factors, respectively: 1.01 [0.50-2.04], p=0.99, 
3.41 [1.69-6.88], p<0.001, 8.05 [3.90-16.63], p<0.0001, 15.27 [6.03-38.67], p<0.0001).
Conclusions: Depression in common in men with CHF, and reduced serum TT and 
DHEAS are accompanied by more severe depressive symptoms. Depression together 
with neuro-hormonal activation and androgen deﬁciencies are related to poor outcome in 
these patients. Whether androgen therapy would ameliorate depressive symptoms and 
improve prognosis in CHF men, requires further studies.
3:30 p.m.
1024-184 Beta-Blocker Evaluation of Survival Trial (BEST) 
Findings Show Beneﬁt of Bucindolol in Moderate 
to Severe HF Patients, According to Prespeciﬁed 
Statistical Analysis Plan
Michael Bristow, Eric Eichhorn, Hector Ventura, Bruce Koch, Mona Fiuzat, Gordon 
Davis, A. Douglas Robertson, University of Colorado Health Sciences Center, Denver, 
CO, Dallas Heart Group, Dallas, TX
Background: Preliminary results from the Beta-Blocker Evaluation of Survival Trial 
(BEST) were reported in 2001, following early termination of the study for loss of 
investigator equipoise. However, results analyzed according to the FDA-negotiated pre-
speciﬁed statistical analysis plan (SAP) have never been reported. This paper presents 
results from that analysis.
Methods: A total of 2708 patients with heart failure (HF) designated as New York Heart 
Association (NYHA) functional class III (92%) or IV ( 8%) and a left ventricular ejection 
fraction a35% were randomly assigned to double-blind treatment with either bucindolol 
(1354 patients) or placebo (1354 patients) and followed for the primary endpoint of death 
from any cause, and the highest ranking secondary endpoint of HF progression.
Results: Analysis of study results according to the pre-speciﬁed SAP indicated a near 
signiﬁcant reduction in all cause mortality with bucindolol compared to placebo (HR 0.87, 
p=0.053), despite the availability of only 92% of the projected number of primary endpoints 
based on the pre-trial sample size calculations. Analysis of the composite endpoint of HF 
progression indicated that bucindolol was signiﬁcantly superior to placebo for slowing 
progression of HF (HR 0.80, p=0.00003), and its components of HF-related mortality 
(HR 0.85, p=0.042), HF-related hospital admission (HR 0.77, p=0.00002), and HF-related 
ER visit (HF 0.74, p=0.024). Bucindolol also demonstrated signiﬁcant superiority over 
placebo for eight secondary endpoints.
Conclusions: In a demographically diverse group of primarily U.S. patients with NYHA 
class III and IV heart failure, bucindolol resulted in near signiﬁcant overall survival beneﬁt 
as well as signiﬁcant beneﬁt in slowing progression of HF, despite premature termination 
of the study. These ﬁndings are contrary to the common belief that BEST was terminated 
early due to futility.
Conclusions: The utility of the studied prohormone biomarkers for diagnosing acute HF 
varies by age. The BACH biomarkers proved to be a powerful adjunct to the diagnosis of 
HF, especially in younger patients.
3:30 p.m.
1024-181 The Effect of Pioglitazone on Sympathetic and 
Baroreﬂex Function in Type Two Diabetes Mellitus After 
Myocardial Infarction
Hiroshi Yokoe, Fumio Yuasa, Masue Yo, Reisuke Yuyama, Tetsuro Sugiura, Toshiji 
Iwasaka, Kansai Medical Univercity Hospital, Osaka, Japan, Kochi Univercity Hospital, 
Kochi, Japan
Background:Pioglitazone has been shown to reduce the occurrence of fatal and nonfatal 
cardiovascular events in type2 diabetes mellitus (DM) after myocardial infarction (MI). 
However the mechanisms of such favorable effects remain speculative. The aim of this 
study was to investigate the effect of pioglitazone on the sympathetic and baroreﬂex 
function in the type2 DM patient after MI.
Methods:Thirty patients with type2 DM after MI were assigned to a pioglitazone group 
(n=15) or control group (n=15). Baroreﬂex sensitivity(BRS) and muscle sympathetic 
nerve activity (MSNA) (microneurography at peroneal nerve) were measured at 
rest and during baroreceptor stimulation (phenylephirine infusion) and baroreceptor 
deactivation(nitroglycerin infusion). Insulin resistance and plasma adiponectin were 
measured. Insulin resistance was evaluated using the homeostasis model assessment 
insulin resistance (HOMA-IR). These measurement were performed at baseline and after 
3 months.
Results:Resting MSNA reduced signiﬁcantly (from 37±7 to 25±8 burst/min ; p=0.007) 
and BRS improved signiﬁcantly (from 6.7±3.0 to 9.9±3.2 msec/mmHg ;p=0.01) after 
pioglitazone. MSNA response to baroreceptor activation (change of integrated MSNA from 
-26±13 to-45±11%;p=0.001) and baroreceptor deactivation (change of integrated MSNA 
from 115±14 to 153±23%;p=0.01) improved signiﬁcantly after pioglitazone. Adiponectin 
(6.9±3.3 to 12.2±7.1μg/ml ; p=0.01)and HOMA-IR (4.0±2.7 to 2.1±0.9; p=0.006) improved 
signiﬁcantly after pioglitazone. The change in resting MSNA was related signiﬁcantly to 
the changes in HOMA-IR (r=0.6 ;p<0.05)and plasma adiponectin (r=0.7 ;p<0.05) after 
pioglitazone. However, there were no signiﬁcant changes in measured variables in the 
control group.
Conclusions:Pioglitazone treatment increased arterial BRS and decreased sympathetic 
nerve trafﬁc through the improvement of insulin resistance and adiponectin in the patients 
with type2DM after MI, which indicate that the sympathoinhibitory effects of this agent 
may contribute to the beneﬁcal effects of pioglitazone in type 2 DM after MI.
3:30 p.m.
1024-182 Safety and Usefulness of G-CSF in Patients 
With Ischemic Heart Failure: The Cell Option 
for Recovery in the Non-eligible Patients for 
Revascularization(CORNER) Study
Antonio Maria Leone, Maria Benedetta Giannico, Isabella Bruno, Matteo Perfetti, 
Alessandro Giordano, Giampaolo Niccoli, Italo Porto, Luigi Marzio Biasucci, Filippo Crea, 
Department of Cardiovascular Medicine, Rome, Italy, Nuclear Medicine, Rome, Italy
Background: Despite recent advances in pharmacological and mechanical treatment of 
post-infarction heart failure, mortality and morbidity remain high. After the demonstration 
that the heart is not a post-mitotic organ but can be regenerated from cardiac and non-
cardiac cells, several clinical trials have been accomplished aimed to obtain myocardial 
repair even in patients with ischemic congestive heart failure. Aim of the study: To evaluate 
the cytokine-induced cell mobilization, in particular using granulocyte colony-stimulating 
factor (G-CSF) , as a less invasive method for promoting cardiac repair. Methods: We 
enrolled 13 patients with ischemic heart disease (IHD) and stable refractory angina and/
or stable severe heart failure (NYHA III or IV) for at least 1 month, in spite of optimal 
medical therapy and we added G-CSF at a dose of 10μg/Kg/die, evaluating changes in 
cardiac perfusion and function at Gated SPECT. Quality of life was assessed by Seattle 
Angina Questionnaire (SAQ), Minnesota Living with Heart Failure Questionnaire (MLHF) 
and visual scale of Quality of Life (QoL). Results: G-CSF was well tolerated. At SAQ we 
found improvement of physical limitation (from 39.25+ 30.69% to 64.34+29.45%, p=0.03), 
angina stability (from 41.67+ 28.87% to 64.09+28.44%, p=0.05), angina frequency (from 
53.33+ 33.12% to 72.73+25.73%, p=0.04), treatment satisfaction (from 67.28+ 29.23% 
to 82.87+20.66%, p=0.07), disease perception (from 36.80+ 29.17% to 66.39+26.50%, 
p=0.01). MLHF improved from 52.58+ 27.02 to 39.36+26.24, p=0.15, QoL improved 
from 32.82+ 23.99 mm to 64.55+20.55 mm, p=0.003. Segmental stress and differential 
perfusion signiﬁcantly improved at follow up (respectively from 1.78+ 1.38 to 1.66+1.38, 
p=0.05 and from 0.35+ 0.68 to 0.23+0.53, p=0.02).
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1024-187 Physiogenomic Comparison of Edema and BMI in 
Patients Receiving Rosiglitazone or Pioglitazone
Gualberto Ruano, James Bernene, Andreas Windemuth, Bruce Bower, Detlef Wencker, 
Richard L. Seip, Mohan Kocherla, Theodore R. Holford, Steven Hanks, Genomas, Inc., 
Hartford, CT, The Hospital of Central Connecticut, New Britain, CT
Background: The thiazolidinediones (TZDs) improve tissue sensitivity to insulin in patients 
with type II diabetes, resulting in reduced levels of fasting blood glucose and glycated 
hemoglobin. However, TZDs unpredictably demonstrate adverse effects of increased 
body weight, ﬂuid retention, and edema. The balance of efﬁcacy and safety of TZD varies 
widely from patient to patient. Genetic variability may reveal pathophysiological pathways 
underlying weight gain associated with TZD therapy and due to adiposity and/or edema.
Methods: We analyzed 384 single nucleotide polymorphisms (SNPs) from 222 
cardiovascular and metabolic genes in 87 outpatients with type 2 diabetes receiving 
thiazolidinedione therapy. Physiogenomic analysis was used to discover associations with 
body mass index (BMI) and edema.
Results: The ﬁve most signiﬁcant gene associations found between BMI and SNPs were 
ADORA1, adenosine A1 receptor (rs903361, p<0.0003), PKM2, pyruvate kinase-muscle 
(rs2856929, p<0.002); ADIPOR2, adiponectin receptor 2 (rs7975375, p<0.007); UCP2,
uncoupling protein 2 (rs660339, p<0.008); and APOH, apolipoprotein H (rs8178847, 
p<0.010). For edema, the ﬁve most signiﬁcant gene associations were NPY, neuropeptide 
Y (rs1468271, p<0.006); GYS1, glycogen synthase 1-muscle (rs2287754, p<0.013); 
CCL2, chemokine C-C motif ligand 2 (rs3760396, p<0.015); OLR1, oxidized LDL receptor 
1 (rs2742115, p<0.015); and GHRH, growth hormone releasing hormone (rs6032470, 
p<0.023). After accounting for multiple comparisons, ADORA1 was signiﬁcantly 
associated with BMI at a false discovery rate (FDR) of < 10%.
Conclusions: Physiogenomic associations were discovered suggesting mechanistic 
links between adenosine signaling and BMI, and between vascular permeability and 
drug-induced edema.
3:30 p.m.
1024-188 Inﬂuence of Body Mass Index on Patients Presenting 
Characteristics, Treatment Practices, and Mortality 
in Patients Hospitalized With Decompensated Heart 
Failure: A Communitywide Perspective
Armen A. Chalian, Timothy P. Fitzgibbons, Olga T. Hardy, Darleen Lessard, Joel M. Gore, 
Jorge Yarzebski, Robert J. Goldberg, UMASS Medical School, Worcester, MA
Background: Obesity is associated with an increased risk of mortality and cardiovascular 
disease, including heart failure (HF). The effect of body weight on clinical characteristics, 
treatment regimens, and prognosis in acute HF patients is largely unknown, however, 
particularly from a community - wide perspective. Methods: 3,722 patients admitted with 
acute HF to all 11 greater Worcester, MA, hospitals were categorized as being of either 
normal weight, overweight, or obese based on their body mass index (BMI). Results: 
The average patient age was 76 years. 55% of patients were overweight or obese. Obese 
patients were younger, and more likely to have diabetes and a history of PCI (Table 1). 
Obese patients were more likely to have received lifestyle recommendations during 
hospitalization and be treated with an ACE inhibitor. They were less likely to receive 
Digoxin (Table 1). Although normal weight patients had a higher hospital death rate than 
obese patients, this effect was not signiﬁcant in multivariate analyses (OR 0.88, 95% CI 
0.60-1.31). Conclusion: In this community based study of patients with acute HF, there 
were important differences in treatment practices among HF patients of different body 
weight. Although normal BMI patients have a greater mortality rate than obese patients, 
this effect is not signiﬁcant after controlling for confounding factors. Our results suggest 
that an “obesity paradox” in acute HF does exist, and that it may be related to older age 
and cachexia in the normal weight HF group. 
BMI <25
(n=1,681)
BMI25-29.9
(n=1,007)
BMI >30
(n=1,034) P Value
AGE (%) < 65 years old 8.2 13.6 28 <0.001
65-74 years old 17.7 27.1 28
> 74 years old 74.1 59.3 44.1
GENDER (%) Male sex 40.6 50.7 38.5 0.74
MEDICAL Coronary HD 58.2 58.1 54.6 0.08
HISTORY (%) PCI 5.6 9.0 10.3 <0.001
CABG 19.0 22.7 17.3 0.48
Hypertension 62.9 67.9 68.9 <0.01
Diabetes 30.2 43.6 54.8 <0.001
Atrial ﬁbrillation 39.9 33.9 29.0 <0.001
MEDICATIONS ACE inhibitors 51.3 52.4 55.3 <0.05
(%) Beta blockers 39.7 45.1 40.6 0.41
Diuretics 97.9 97.9 98.7 0.15
Nitrates 65.9 68.2 65.2 0.84
Digoxin 57.5 51.5 41.6 <0.001
LIFESTYLE Low fat diet 55.7 61.7 65.5 <0.001
ADVICE (%) Fluid restriction 21.7 20.8 26.3 <0.05
Reduce salt intake 80.4 82.1 86.0 <0.01
MORTALITY (%) Hospital case-fatality rate 7.2 6.0 4.2 <0.01
3:30 p.m.
1024-185 Human Umbilical Cord Blood Stem Cells Decrease 
Fibrosis and Increase Cardiac Function in 
Cardiomyopathy
Robert J. Henning, Darrell Sawmiller, Masood Shariff, Jeffrey Aufman, Vincent DeLostia, 
Holly Hayden, Michael Morgan, James A. Haley Hospital/University of South Florida, 
Tampa, FL
BACKGROUND: We have reported that human umbilical cord blood stem cells (HUCBC) 
decrease LV infarct size and increase wall thickening and ejection fraction (EF) after LV 
infarction in rats. We hypothesize that HUCBC would be beneﬁcial in treating the dilated 
cardiomyopathy due to progressive ventricular ﬁbrosis in TO2 hamsters. METHODS: In
Group I we compared the effects of 4X106 HUCBC injected into the LV myocardium at 
1 month of age in 22 TO2s with 17 TO2s injected with only Isolyte and 16 F1B normal 
hamsters. In Group II in 4 month old hamsters, we compared the effects of 4X106
HUCBC injected into the myocardium of 8 TO2s with 8 TO2s treated with Isolyte and 
16 normal F1B hamsters. Immunosuppression therapy was not given to any hamster. 
Echocardiograms for EF and fractional shortening (FS) were done prior to and after 
treatment at 1 to 3 months in Group I and at 4 to 6 months in II then LV dP/dtmax was 
determined by catheterization. LVs were then examined for ﬁbrosis and myocyte loss 
with H&E, trichrome and dystrophin stains. RESULTS: In Group I between 1 and 3 
months the control F1B EF and FS were 90.5 + 0.6% and 55.7 + 1.0%. The Isolyte TO2s 
decreased their EF from 89.5 + 1.4 to 66.7 + 2.2% and FS from 55.2 + 1.4% to 32.3+
1.5% (p<0.0001). In contrast, the HUCBC TO2s decreased their EF from 90.8 + 0.6 to 
only 76.0 + 2.5 and FS from 56.2 + 0.8 to 39.4 + 2.6 which were larger than Isolyte treated 
TO2s (p<0.05). In Group II between 4 and 6 months the F1B EF and FS were 86.0 +
1.5% and 49.7 + 1.8%. Isolyte TO2s decreased their EF from 66.8 + 2.7 to 37.8 + 5.1% 
and their FS from 33.4 + 2.2% to 15.7 + 2.4% (p<0.0002). In contrast, the EF in HUCBC 
TO2s decreased only slightly from 64.3 + 2.7 to 57.6.0 + 2.4 and the FS from 30. 7 + 1.9 
to 26.2 + 1.5 which were larger than Isolyte TO2s (p<0.05). HUCBC TO2s had greater LV 
dP/dtmax (3990 + 258 vs. 3389 + 423 mmHg/sec) and 51% less ﬁbrosis and LV myocyte 
loss between 3 and 6 months compared with Isolyte TO2s which showed progressive 
LV ﬁbrosis (p<0.02). The changes in LV ﬁbrosis correlated inversely with the EF, FS, 
and dP/dtmax. CONCLUSION: HUCBC can limit LV ﬁbrosis and myocyte loss and LV 
dysfunction, without requirements for immunosuppressive therapy, when administered 
early in course of dilated cardiomyopathy.
3:30 p.m.
1024-186 Oral Iron Chelation Therapy Prevents Diastolic 
Dysfunction in Chronic Iron Overload: Two-Year Follow-
Up in Patients With Aplastic Anemia
Woo-Baek Chung, Ho-Joong Youn, Eun-Ju Hong, Youn-Seok Choi, Yong-Seog Oh, 
Wook-Sung Chung, Jae-Hyung Kim, Jong-Wook Lee, St. Mary’s Hospital, The Catholic 
University of Korea, Seoul, South Korea
Purpose: In patients (pts) with aplastic anemia (AA), chronic iron overload due to 
multiple transfusions can lead to cardiac hemochromatosis. The aim of this study was to 
elucidate whether deferasirox (Exjade®), an oral iron-chelating agent, can prevent cardiac 
dysfunction in chronic iron overloading conditions.
Methods: Twenty-one AA pts (age 31±8 years, M:F=12:9) were recruited and divided 
into two groups [Deferasirox responder (DR) group, serum ferritin level <1500 mg after 
treatment; Deferasirox non-responder (DnR) group, serum ferritin level q1500 mg after 
treatment]. The serum ferritin level was measured regularly, and the deferasirox dosage 
was adjusted. Transthoracic echocardiography was performed during the 1st, 25th, 50th,
and 100th weeks, and parameters including left ventricular ejection fraction (LVEF), LV 
mass, left atrial (LA) volume, and LV ﬁlling indices were measured. Results: 1. The serum 
ferritin level did not correlate with E/E’ before treatment, but it was positively correlated 
with E/E’ after treatment (Figure) 2. E/E’ changed from 7.3±1.6 to 6.9±1.1 in the DR group 
and from 6.9±1.1 to 8.6±2.1 in the DnR group (p=0.041) 3. LA volume changed from 
46.2±16.6 mL to 47.8 ±11.6 mL in the DR group and from 61.3±17.9 mL to 68.3±15.4 mL 
in the DnR group (p=0.004). Conclusion: The iron-chelating agent deferasirox prevents 
deterioration of diastolic function in patients with chronic iron overload. 
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1024-191 Do Patients With Advanced Heart Failure Beneﬁt From 
Deﬁbrillation Threshold Testing at the Time of CRT 
Implantation?
Grace Lin, Nandan Anavekar, Daniel Couri, Robert F. Rea, David L. Hayes, Peter A. 
Brady, Mayo Clinic, Rochester, MN
Background: Deﬁbrillation threshold (DFT) testing is routinely performed at the time of 
implantable cardioverter deﬁbrillator implantation to determine adequate safety margin. 
Cardiac resynchronization therapy deﬁbrillator (CRT-D) has established beneﬁt in patients 
(Pts) with advanced heart failure (AHF), however in some cases DFT testing cannot be 
performed due to hemodynamic instability.
Methods: To determine the likelihood of achieving adequate DFT in Pts with AHF, we 
reviewed clinical and follow up data of all Pts who underwent implantation of a CRT-D 
device at Mayo Clinic between 1999 and 2005. High DFT was deﬁned as DFT >15 J. 
Results: A total of 413 Pts (mean age 68 ± 11 years; 337 males, 82%) underwent 
implantation of a CRT-D device during the study period. Baseline ejection fraction was 
21% ± 7%, and etiology of AHF was ischemic in 270 (65%) Pts. Indication for deﬁbrillator 
placement was for primary prevention of sudden cardiac arrest in 315 (76%) patients. The 
CRT-D device was implanted on the left side in 377 (91%) Pts and on the right side in 36 
(9%) Pts. In 3 Pts, the deﬁbrillator lead was placed in the right ventricular (RV) outﬂow 
tract; in the remaining 410 (99%) Pts the lead was placed in the RV apex. DFT testing was 
performed at implant in 315 (76%) Pts and was successful at the initial RV lead location in 
98% of Pts. Mean DFT was 15 ± 4J, with high DFT in 60 (19%) Pts. Although right sided 
CRT-D implant was not associated with high DFT, DFT of the 3 Pts with RV outﬂow tract 
leads was 24 J (p<0.01). Subsequent RV lead revision was not required in any Pts to 
improve DFT. Clinical characteristics (age, etiology and severity of AHF, ejection fraction, 
hemoglobin, serum sodium, estimated GFR) of Pts with high DFT were similar to Pts with 
DFT a 15 J (p>0.05 for all). One year survival of Pts with high DFT was 76% compared 
with 85% in Pts with DFT a 15 (p> 0.05).
Conclusions: Adequate DFT was achieved in 98% of patients undergoing CRT-D without 
need for RV lead revision either at the time of implantation or subsequently. This suggests 
a high likelihood for adequate safety margin in Pts with AHF in whom DFT testing is 
deferred due to hemodynamic instability or other concerns.
3:30 p.m.
1024-192 Restrictive Cardiomyopathy With Preserved Ejection 
Fraction: Outcomes of Inotropic Support
Aisling J. Carroll, Barry A. Boilson, John A. Schirger, Sudhir S. Kushwaha, Alfredo 
L. Clavell, Krishnaswamy Chandrasekaran, Robert P. Frantz, Richard J. Rodeheffer, 
Brooks S. Edwards, Naveen L. Pereira, Mayo Clinic, Rochester, MN
Background: Cardiac inotropes have traditionally been used in patients with severe 
systolic dysfunction as a bridge to cardiac transplantation. Occasionally patients with 
preserved ejection fraction (EF) demonstrate low cardiac output states and are determined 
to be inotrope dependent. We sought to investigate the clinical response of patients with 
heart failure preserved EF to inotropes while awaiting cardiac transplantation.
Methods: We identiﬁed 145 consecutive patients with a diagnosis of restrictive 
cardiomyopathy referred for transplant evaluation between January 1,1988 and August 29, 
2008. 21 patients met inclusion criteria: EF >50%, intravenous inotrope use as a bridge 
to transplantation. Hemodynamics pre and 24 hours post treatment were documented. 
Metabolic parameters, adverse cardiac and non-cardiac outcomes were reviewed.
Results: All patients were admitted for monitoring and initiation of milrinone, dopamine or 
dobutamine with mean duration of inotrope use 74 days. Average age at start of treatment 
was 50 years with 7 patients discharged for ambulatory therapy.
PCWP improved from 24.9 ± 1.3 to 17.7 ± 2.1 mmHg 24 hours after inotrope initiation 
(p=0.01). There was no signiﬁcant difference between cardiac output, pulmonary artery 
pressure, BUN, serum creatinine or bilirubin.
There was a subjective improvement in symptoms in all patients. There were no deaths in the 
sub-group of patients maintained on outpatient treatment; 4/7 had implantable cardioverter 
deﬁbrillators and no shocks or anti-tachycardia pacing therapies were administered.
In the severely ill group of patients who remained in hospital awaiting transplantation, 
there were 4 deaths and one episode of clinically signiﬁcant VT requiring electrical 
therapy. Only one patient required mechanical assist device support. There was no new 
requirement for renal replacement therapy following inotrope initiation.
Conclusion: Cardiac inotropes can improve symptoms and hemodynamics in patients 
with preserved EF awaiting cardiac transplantation. The majority of patients can be 
bridged successfully to transplantation. Further study is needed to elucidate the role of 
inotropes in heart failure with preserved EF.
3:30 p.m.
1024-193 Predictors of the Improvement in Left Ventricular 
Ejection Fraction in Nonischemic Dilated 
Cardiomyopathy During Beta-Blocker Therapy
Yoko Masukata, Kazuhiko Hashimura, Masataka Watanabe, Makoto Amaki, 
Takahiro Ohara, Takuya Hasegawa, Hideaki Kanzaki, Masafumi Kitakaze, National 
Cardiovascular Center, Suita, Japan
Background: Although beta-blocker therapy results in a signiﬁcant improvement in left 
ventricular ejection fraction (EF) and prognosis in patients with chronic heart failure, little 
information is available to predict which patients will be responder or non-responder. 
Therefore, we sought to clarify speciﬁc predictor(s) for improvement in EF in patients with 
non-ischemic dilated cardiomyopathy, who are treated with standard pharmacotherapy 
and subsequent beta-blocker (carvedilol) therapy.
3:30 p.m.
1024-189 Red Cell Distribution Width and One-Year Mortality in 
Acute Heart Failure
Asim A. Mohammed, Roland RJ van Kimmenade, Shanmugam Uthamalingam, Peter 
van der Meer, Michael Felker, James L. Januzzi, Jr., Massachusetts General Hospital, 
Boston, MA, University Hospital Maastricht, Maastricht, The Netherlands
Background: Red blood cell distribution width (RDW) predicts mortality in chronic heart 
failure (HF). The prognostic value of RDW in acute HF, and its relative prognostic value 
compared to established measures such as amino-terminal pro-B type natriuretic peptide 
(NT-proBNP) is unknown.
Methods: In 206 patients with acute HF, independent predictors of RDW were identiﬁed 
using linear regression analysis. The association between RDW and 1 year survival in 
the context of other known predictors was assessed using Cox proportional hazards 
analysis.
Results: RDW was elevated in 116 (56%) patients (ﬁgure - cumulative hazard curves 
showing rates of mortality by 1 year as associated with quartiles of RDW); RDW was 
independently associated with hemoglobin (T-score= 9.97; P<.001), loop diuretic 
(T-score=2.77; P=.006) and B-blocker (T-score=2.46; P=.015) on presentation, but not to 
nutritional deﬁciencies, recent transfusion or inﬂammatory parameters. log-transformed 
RDW values independently predicted mortality in multivariable Cox proportional hazards 
analysis (HR 1.03, 1.00-1.06 95% CI; P=.04); when stratiﬁed on the basis of RDW and NT-
proBNP status, the combination of markers provided additional prognostic information.
Conclusions: RDW is frequently high in patients with acute HF and was not associated 
with folate or iron deﬁciencies or inﬂammation. RDW independently predicts 1 year 
mortality in acute HFand appears to be additive to established prognostic variables like 
NT-proBNP.
3:30 p.m.
1024-190 The Effects of Sildenaﬁl on Hemodynamic Parameters 
and Exercise Capacity in Patients With Chronic Lung 
Disease and Secondary Pulmonary Hypertension
Hye-Sun Seo, Tae Soo Kang, Jon Suh, Yoon Haeng Cho, Nae-hee Lee, Soonchunhyang 
university hospital, Bucheon, South Korea
Background: Sildenaﬁl is a selective phosphodiesterase type 5 inhibitor which leads to 
nitric oxide-mediated vasodilatation decreases pulmonary vascular resistance. Sildenaﬁl 
also signiﬁcantly improves exercise tolerance and hemodynamic parameters in patients 
with idiopathic pulmonary hypertension (PAH), chronic congestive heart failure and 
consequent pulmonary hypertension. We hypothesized that sildenaﬁl would improve 
pulmonary vascular resistance in patients with secondary pulmonary hypertension by 
chronic lung disease and could augment exercise capacity by improving right ventricular 
(RV) function. Methods: Fifteen patients who had chronic lung disease and pulmonary 
hypertension (peak pulmonary artery pressure (PAP) > 40 mmHg & mean PAP > 
25mmHg by echocardiography) without other left heart problem were included. Thirteen 
patients (mean age: 68.6 years, 9 men) tolerable to drug were given sildenaﬁl 25mg tid 
everyday during 4weeks. BNP, hs-CRP, ABG, pulmonary function test and 6M walk test 
were also performed before and after treatment.
Results: Pulmonary vascular resistance index was reduced by sildenaﬁl (-21.3%, 5.02 
to 3.32 Wood units, p=0.075). Peak PAP (-20.4%, 57.9 to 46.1 mmHg, p=0.043) and 
mean PAP (-8.7%, 39.3 to 35.9 mmHg, p=0.042) were all reduced after treatment. 
Exercise capacity measured by 6M walk test was also improved by sildenaﬁl. (+10.5%, 
190m to 210m, p=0.066). However RV fractional area change and RV diastolic, systolic 
function measured by tissue Doppler image (TDI) were not different. The hs-CRP level 
had tendency to be lower after treatment and concentration of O2, CO2 levels were not 
signiﬁcantly changed during sildenaﬁl administration. There were no adverse events.
Conclusion: Sildenaﬁl improves pulmonary vascular resistance, decreases pulmonary 
artery pressure and improves exercise tolerance in patients with chronic lung disease and 
secondary pulmonary hypertension.
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1024-196 The Selective Cardiac Myosin Activator, CK-1827452, 
Increases Systolic Function in a Concentration-
Dependent Manner in Patients with Stable Heart Failure
Roxy Senior, Fady Malik, Khalil G. Saikali, Jacqueline Lee, Gerrit Brand, Andrew A. 
Wolff, CK-1827452 in Heart Failure Investigators, Northwick Park Hospital, Harrow, 
United Kingdom, Cytokinetics Inc., South San Francisco, CA
Background: CK-1827452 (CK-452) increases systolic function by activating cardiac 
myosin. In healthy subjects CK-452 increases systolic ejection time (SET), stroke volume 
(SV), fractional shortening (FS), and ejection fraction (EF).
Methods: This ﬁrst Phase II trial of CK-452 is a multi-center, double-blind, randomized, 
placebo-controlled study in patients with EF < 40% and treated with stable HF medication. In 
Cohorts 1 - 4, patients received 3 escalating i.v. doses of CK-452 and 1 placebo treatment. 
Infusions were 2 h in Cohorts 1 & 2 and 24 h in Cohorts 3 & 4, and 72 h in Cohort 5.
Results: For 28 completed patients in Cohorts 1 to 4, echocardiographic data were 
paired with coincident plasma concentrations of CK-452. 
Placebo Corrected Changes from Baseline
[CK-452] (ng/
mL) 1-100
>100-
200
>200-
300
>300-
400
>400-
500
>500-
883
(n per bin) (69) (50) (32) (19) (30) (20)
Baseline Correlation
vs[CK-452]
SET (ms) 318 3 ± 4 24 ± 5‡ 54 ± 5‡ 65 ± 7‡ 72 ± 8‡ 98 ± 7‡ ‡
LVOT SV 
(mL) 68 1 ± 2 1 ± 2 6 ± 2* 12 ± 3‡ 14 ± 3‡ 14 ± 3‡ ‡
FS (%) 17 1 ± 1 2 ± 1* 3 ± 1† 4 ± 1† 3 ± 1# 4 ± 1‡ ‡
EF (%)A 32 0 ± 1 0 ± 1 1 ± 1 1 ± 1 1 ± 1 2 ± 1 #
EF (%)B 30 1 ± 1 1 ± 1 1 ± 2 7 ± 2† 8 ± 2† 5 ± 2# ‡
± SEM; # p < 0.05 * p a 0.01 † p<0.001 ‡p<0.0001
AEF = ([LVEDV-LVESV]/LVEDV)*100 (Bipl MOD)
BEF = (LVOT SV/LVEDV)*100 (Doppler, Bipl MOD)
Increases in SET, SV, and FS were statistically signiﬁcant. The signiﬁcance of increases 
in EF differed between methods of calculation. Statistically signiﬁcant concentration 
dependence was observed for increases in EF and for decreases in heart rate and left 
ventricular end systolic volume. Treatments were well tolerated at pre-speciﬁed dosages. 
Results from the completed trial will be available at the time of presentation.
Conclusions: CK-452 increases systolic function in stable HF patients during intravenous 
administration. Data from this ﬁrst Phase II trial supports translation of this mechanism 
into populations with more advanced heart failure.
3:30 p.m.
1024-197 Use of High Dose Carvedilol in Chronic Heart Failure 
With Chronic Obstructive Pulmonary Disease: CIM-HF 
Registry Analysis
Michelle M. Harris, Linda Houston-Feenstra, Jun R. Chiong, Loma Linda University, 
Loma Linda, CA
Background: Use of Beta-blocker (BB) in Chronic Obstructive Pulmonary Disease 
(COPD) is controversial, associated with the belief that BB will exacerbate dyspnea. BB 
has been shown to reduce mortality in CHF. Our experience, using newer generations 
of BB, has shown that with carefully managed titration, in a dedicated CHF program, 
patients with both COPD and CHF beneﬁt from this therapy. However, limited data exist on 
the long-term use of high dose BB therapy in patients with CHF and COPD.
Methods: This study evaluated the use of non-selective BB therapy in patients with both 
CHF and COPD as part of the Clinical Information Manager for Heart Failure (CIM-HF) 
registry. Designed as a prospective observational study, the proportion of BB use in 
patients with different degrees of COPD was evaluated.
Results: Data from 880 patients were reviewed, 312 patients had pulmonary function 
tests (PFT) as part of their dyspnea workup and 249 (80%) were on carvedilol. Mean 
duration of follow up was 4.4 years. Figure 1 demonstrates the well tolerated use of BB 
following long term, upward titration. Figure 2 shows poor correlation between carvedilol 
dosage and FEV1 (% predicted). Mean and median daily carvedilol dosages were 40.25 
mg and 50 mg, respectively.
Methods: 154 patients with non-ischemic dilated cardiomyopathy (EFa30%), who were 
under carvedilol therapy for one year, were retrospectively analyzed. Echocardiographic 
parameters, including end-diastolic dimension (Dd), end-systolic dimension (Ds), EF, 
wall thickness (Th), and wall stress (Dd/Th) and brain natriuretic peptide (BNP), and 
maintenance carvedilol dose were followed up. Responder was deﬁned as an absolute 
improvement of 10% or more in EF (Group A: responder 76 patients, group B: non-
responder 78 patients).
Results: Although there were no differences in age, gender, New York Heart Association 
functional class, and EF at baseline, group A was associated with lower BNP (142.6±286.9 
vs. 358.5±362.7 pg/ml, p<0.001), higher carvedilol maintenance dose (15.3±8.0 vs. 
10.4±6.8 mg/day, p<0.001), thicker wall thickness (8.5±1.7 vs. 8.0±1.6 mm, p=0.05), 
and lower wall stress ( 8.4±2.1 vs. 9.6±2.6, p=0.002). In multivariate analysis, wall stress 
(HR 1.17; 95%CI 1.02-1.34, p=0.03) and carvedilol dose (HR 0.92; 95%CI 0.87-0.97, 
p<0.01) independently predicted cardiac events after adjusting age, gender, EF and BNP. 
In addition, Kaplan-Meier analysis showed that the group A had better prognosis than 
group B (cardiac death, re-hospitalization due to heart failure, left ventricular assist device 
implantation, and cardiac transplantation).
Conclusion: Wall stress and carvedilol dose used are strong predictors of the 
improvement in left ventricular EF and prognosis during beta-blocker therapy in patients 
with non-ischemic dilated cardiomyopathy.
3:30 p.m.
1024-194 Reduced Renal Function Is Associated With Increases 
in Arterial Stiffness and Left Ventricular Contractility in 
Patients With Coronary Artery Disease: A Ventricular 
Arterial Coupling Pattern Similar to Heart Failure With 
Normal Ejection Fraction
Hidekatsu Fukuta, Nobuyuki Ohte, Seiji Mukai, Kaoru Asada, Kazuaki Wakami, 
Toshihiko Goto, Genjiro Kimura, Nagoya City University Graduate School of Medical 
Sciences, Nagoya, Japan
Background: Although reduced renal function is associated with increased risk for heart 
failure (HF) in various populations, including patients with coronary artery disease (CAD), 
mechanisms underlying the association remain to be fully elucidated. We tested the 
hypothesis that altered arterial and left ventricular (LV) function and their interaction may 
contribute to HF risk associated with reduced renal function.
Methods: We examined the relation of estimated glomerular ﬁltration rate (eGFR) with 
augmentation index (AI) of ascending aortic pressure, effective arterial elastance (a ratio 
of LV systolic pressure to stroke volume index, Ea), an estimate of LV contractility (a ratio 
of LV systolic pressure to end-systolic volume index, Ees), and indices of LV diastolic 
function (time constant of decrease in LV pressure [Tau] and end-diastolic pressure 
[EDP]) in 147 consecutive patients without prior myocardial infarction undergoing cardiac 
catheterization for coronary artery disease (CAD; age, 66±9 years; males, 67%; eGFR, 
65.5±17.4 ml/min/1.73m2; ejection fraction [EF], 0.72±0.08).
Results: AI, Ea, and Ees increased with reducing eGFR (All P<0.001). Ea/Ees, EF, Tau, 
or EDP did not correlate with eGFR (All P>0.1). Findings were similar after considering 
potential confounders, including age, gender, other cardiovascular risk factors, and the 
severity of CAD.
Conclusions: Reduced renal function is associated with increases in arterial stiffness 
and LV contractility in CAD patients. This ventricular-arterial coupling pattern is similar 
to that seen in HF with normal EF and may provide a mechanistic link between reduced 
renal function and increased risk for HF in this population.
3:30 p.m.
1024-195 How Should Dyspnea Be Measured in Acute Heart 
Failure?: A Comparison of Visual Analog and Likert 
Scales in an International Clinical Trial
Marco Metra, John R. Teerlink, Adriaan A. Voors, G. Michael Felker, Elaine Unemori, 
Beth Weatherley, Sam L. Teichman, Gad Cotter, Section of Cardiovascular Diseases, 
Department of Experimental And Applied Medicine, Univ of Brescia, Brescia, Italy, 
Section of Cardiology, Veterans Affairs Medical Center, University of California, San 
Francisco, CA
Relief of dyspnea is an important therapeutic goal in acute heart failure (AHF), and 
patient reported dyspnea is a key endpoint in AHF clinical trials. However, there has been 
little comparison of methods that quantify dyspnea.
Methods: In PreRELAX-AHF, the vasodilator relaxin was given for 48 h to 234 patients 
hospitalized for dyspnea due to AHF. The 7-pt Likert and 100-mm VAS were used to 
assess dyspnea at baseline (VAS only), 6, 12, 24, 48 h, and days 3, 4, 5, 6, 7 and 14. 
We compared mean change from baseline in VAS to the proportion of patients reporting 
moderate or marked improvement by Likert.
Results: There was moderately good overall correlation between the two scales (r=0.69). 
The coefﬁcients of variation (CV, 100 x SD/mean), an indication of the discriminatory 
power of each scale, were larger for the VAS at later time points, suggesting more 
discriminatory ability later, while the Likert tended to be more discriminatory at earlier 
time points (See ﬁgure).
Conclusion: Although they correlate moderately well overall, these results suggest that 
the Likert may be preferable for earlier assessments of dyspnea, while the VAS may be 
better for later assessments. This may be due to the frequent early report of the maximum 
categorical Likert scores of +2 and +3 (moderate or marked improvement), leaving no 
possibility for measuring subsequent improvement, while the VAS continuous scale offers 
a wider range over a longer period. These data are important for the choice of end-points 
related to symptoms in future AHF trials. 
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Results Si was lower in CHF vs controls (2.53±0.26 vs 3.58±0.34, p<0.01) and decreased 
stepwise with NYHA class (I/II/III/IV 5.02±1.8 / 2.49±0.26 / 2.24±0.35 / 1.61±0.38, ANOVA 
p=0.0007). Si correlated with body mass index (BMI) (r=0.34, p<0.001) and total (r=0.28) 
and central (r=0.31, both p<0.01) Fat mass (DEXA scan) and with peakVO2 (r=0.23, 
p=0.02). Si was a prognostic marker in multivariate analysis independent of age, NYHA 
class, peak VO2, BMI, and LVEF (RR 0.38 [95%CI 0.21-0.67]; p=0.001). Si by minimal 
modelling correlated moderately with indices of HOMA, FIRI (both r=0.31, p=0.0003) 
and QUICKI (r=0.29, p=0.0008). HOMA identiﬁed impaired insulin sensitivity in CHF vs 
controls (3.45±0.29 vs 1.39±0.19) as did FIRI (3.10 vs 0.26) and QUICKI (0.34±0.01 vs 
0.39±0.004, all p<0.0001). All three indices related to BMI and total and regional fat tissue 
in CHF (all p<0.01) but did not discriminate between NYHA classes, did not relate to peak 
VO2 and did not predict prognosis.
Conclusion: HOMA, FIRI and QUICKI are surrogate estimates of Si with poor discriminatory 
power in pathophysiologic studies in patients with CHF. Indices based on single time 
point estimates of Si are inferior to the physiological proﬁle-derived assessment of insulin 
sensitivity by minimal modelling.
3:30 p.m.
1024-200 Asymptomatic Left Ventricular Dysfunction in Idiopathic 
Dilated Cardiomyopathy: Long-Term Prognosis and 
Comparison Between Subgroups of Patients
Marco Merlo, Andrea Di Lenarda, Giulia Barbati, Alberto Pivetta, Elisabetta Dalefffe, 
Gastone Sabbadini, Biancamaria D’Agata, Gianfranco Sinagra, Cardiovascular 
Department, “Ospedali Riuniti” and University of Trieste, Trieste, Italy
Background: Few data are available regarding characteristics and prognosis in patients 
(pts) with asymptomatic idiopathic dilated cardiomyopathy (AIDC).
Methods and Results: 744 pts with idiopathic dilated cardiomyopathy (IDC) have been 
enrolled in the Trieste Heart Muscle Disease Registry from 1978 to 2007: males were 75%, 
mean age 45±14 years; 68% were symptomatic for heart failure (HF): 307(41%) in II NYHA 
class, 198(27%) in III-IV NYHA class. 239 pts(32%) were asymptomatic despite impaired 
LV ejection fraction (LVEF<50%): 134 (56% Group A) had no previous symptoms of HF, 
105 (44%, Group B) had previous symptoms of HF. In all pts without controindications 
treatment with ACE-inhibitors and beta-blockers were chronically used. Compared to 
Group B, at ﬁrst evaluation Group A presented younger age (37±14 vs 42±14 years, 
p= 0.045), more frequent familial disease (39% vs 18%, p<0.001), less advanced heart 
disease (LVEF 39±7% vs 33±9%, p<0.001; LV end-diastolic diameter 62±7 vs 66±9mm, 
p=0.011; moderate-to-severe mitral regurgitation 7 vs 28%, p<0.001); LVEFa30% 10 vs 
43%, p<0.001). ACE inhibitors were used in 75 vs 87%, p=0.002, Beta-blockers 65 vs 79%, 
p=0.02. Data on medical treatment are signiﬁcantly worse if compared with our symptomatic 
patients. During a mean follow-up of 112±63 months, 46 pts (21%) out of 239 pts with AIDC, 
experienced death/heart transplantation (D/HTx): 16 pts (7%) were transplanted, 7 pts (3%) 
died for refractory HF, 13 (6%) for unexpected sudden death/major ventricular arrhythmias 
(SD/MVA). At Cox analysis LVEFa30% predicted both D/HTx (HR 3.15, 95% CI 1.5-6.7, 
p=0.003) and SD/MVA (HR 3.9, 95% CI 1.7-9.3, p=0.002). Kaplan-Meier analysis showed a 
non signifcant trend between Group A and B concerning D/HTx (at 120 months 7 vs 16%, 
p=0.06) and SD/MVA (17 vs 23%, p=NS).
Conclusions: in our experience the proportion of pts with AIDC at ﬁrst evaluation is 
noteworthy. Severe LV dysfunction, present in 29% of AIDC pts, independently predicted a 
worse prognosis. AIDC pts demonstrated less advanced disease with respect to those who 
previously experienced symptoms of HF but similar prognosis on optimal medical treatment.
3:30 p.m.
1024-201 Optimal Beta-Blocker Therapy and Lower Achieved 
Heart Rate Are Independently Associated With Better 
Survival in Heart Failure Patients That Are in Sinus 
Rhythm
Damien Cullington, Kevin M. Goode, Thanjavur K. Bragadeesh, Ahmed A. Tageldien, 
Andrew L. Clark, John G F Cleland, University of Hull, Kingston-Upon-Hull, United Kingdom
Background: Randomised controlled trials show that treatment with beta blockers (BB) 
reduces morbidity and mortality in patients with heart failure (HF). Whether these beneﬁts 
are mediated primarily by adrenergic blockade or heart rate reduction remains uncertain. 
To investigate this further, we assessed the hypothesis that lower heart rate is associated 
with improved survival and whether this was independent of BB use in non-trial heart 
failure patients with left ventricular systolic dysfunction and in sinus rhythm.
Methods: Patients attending a HF clinic (Hull, UK) were recruited to a prospective cohort study. 
Heart rate was evaluated at 4 months following attempted optimisation of HF treatments to target 
doses. BB therapy was expressed as % of maximal target dose and split into those receiving 
no BB (0%), low target dose (0-33%) and moderate to target dose (>33%). Cox-regression 
models were used to determine the independent association of BB and heart rate with all cause 
mortality after adjusting for age, sex, and other co-morbidities commonly associated with HF.
Results: Of 937 patients, 689 (74%) patients were treated with BBs (60% carvedilol, 31% 
bisoprolol). Of those on BB, 272 (39%) were on low dose and 417 (61%) on moderate-to-
target dose. Median age 72 (IQR 65-78), 72% male, 47% LVEF <35% and median follow-
up 50 (IQR 38-60) months with 233 (25%) deaths. On adjusted Cox-regression, higher 
achieved heart rate (HR 1.16 per 10 bpm increase, p=0.005) and no-to-low target dose 
of BB therapy (HR 1.80, p=0.001) were independently associated with worse survival. 
Achieved heart rate was higher in the no-to-low BB group compared to the moderate-to-
target BB group (median (IQR) 68 (59-80) vs 62 (56-70) bpm, p=0.0001).
Conclusions: Lower achieved heart rate and optimal BB therapy are both independently 
associated with better survival in HF patients in sinus rhythm. Reaching target BB therapy 
improves outcome independently of achieved heart rate, conﬁrming that beneﬁt is 
mediated through mechanisms other than just heart rate control.
Conclusion: CHF Patients with COPD tolerated long-term use of high dose BB with out 
exacerbation of symptoms. This study suggests that the severity of COPD should not 
dictate the initiation and dose titration of BB therapy. 
3:30 p.m.
1024-198 Very Early Initiation (<24 Hours) of Carvedilol Shortens 
Length of Stay Compared to Pre-discharge Initiation in 
Acute Decompensated Heart Failure
Jun R. Chiong, Jasmine Putnam, Christopher Hauschild, Loma Linda University, Loma 
Linda, CA
Background: The latest heart failure (HF) guidelines recommend delaying beta-blockade 
(BB) in acute setting. A gap exists regarding the timing of carvedilol. This may be due in 
part to persisting perceptions, despite recent evidence to the contrary, that BB worsens 
acute HF symptoms by bronchoconstriction.
Carvedilol use at the time of hospital discharge has been repeatedly shown to be well 
tolerated, and is associated with an early survival beneﬁt. The aim of this study is to 
evaluate the strategy of early (<24 hours) vs. pre discharge (DC) initiation of carvedilol 
and the length of stay in acute decompensated HF.
Methods: There were 756 patient with systolic dysfunction (EF < 40%) who had 
carvedilol during hospitalization in 2007. We divided patients into 2 groups: Group A: 
Carvedilol initiated within 24 hours of admission. Group B: carvedilol given anytime prior 
to discharge. Patients who were already on carvedilol prior to admission and during 
hospitalization were excluded.
Results: Both groups have similar ejection fraction, age and discharge dose of carvedilol. 
Despite the similarities, early carvedilol initiation resulted in a shorter length of stay.
Conclusion: This study demonstrated that very early (<24 hours) initiation of carvedilol is 
associated with shorter length of stay. This ﬁnding is of signiﬁcant clinical importance as 
it provides patients the protective beneﬁts of therapy sooner and reduces the cost of care 
by shortening the length of the hospitalization. 
3:30 p.m.
1024-199 Inferiority of Insulin Sensitivity Indices From Single 
Time Point Assessment in Metabolic Studies in 
Patients With Chronic Heart Failure
Wolfram Doehner, Stephan von Haehling, Mathias Rauchhaus, Mitja Lainscak, Dirk 
Habedank, Anja Sandek, Tibor Szabo, Stefan D. Anker, Charite University Medical 
School, Berlin, Germany
Background: Impaired insulin sensitivity (Si) indicates abnormal energy metabolism in 
chronic heart failure (CHF) and contributes to symptomatic status and mortality. Several 
indices of Si are based on mere single time assessment of fasting glucose and insulin. 
We aimed to assess the discriminatory power of such indices in comparison to more 
physiologic assessments of Si using dynamic glucose and insulin proﬁles.
Methods: In 105 CHF patients (NYHA I/II/III/IV 10/40/43/12, age 62±1y, peak VO2 18.2±0.7ml/
kg/min, LVEF 28±2%, all mean±SEM). Si was assessed by minimal modelling using glucose 
and insulin proﬁles of a 3h intravenous glucose tolerance test. The Si indices HOmeostasis 
Model Assessment (HOMA: Insulin x Glucose /22,5), Fasting Insulin Resistance Index (FIRI: 
Insulin x Glucose / 25), and QUick Insulin ChecK Index (QUICKI: 1/ (log insulin log Glucose) 
were calculated from single time fasting glucose and insulin assessment.
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1024-204 Improved Mortality Associated With ACE-I and Beta 
Blocker Treatment in Heart Failure With Preserved 
Ejection Fraction: An Exploratory Analysis of the 
Biomarkers in ACute Heart Failure (BACH) Trial
Niraj Parekh, Kabir Singh, Daniel Jones, Paul Clopton, Inder Anand, Robert 
Christenson, Lori B. Daniels, Salvatore DiSomma, Gerasimos Filippatos, Christopher 
Hogan, Martin Möckel, Michael Hudson, Christian Müller, Sean-Xavier Neath, Leong 
Ng, Richard Nowak, W. Franklin Peacock, Piotr Ponikowski, A. Mark Richards, Mihael 
Potocki, Alan Wu, Stefan D. Anker, Alan Maisel, Veterans Affairs San Diego Health Care 
System, San Diego, CA, University of California San Diego, San Diego, CA
Background: There is limited evidence on the optimal management of preserved 
ejection fraction (EF) heart failure (HF). We compared outcomes of patients hospitalized 
with acute HF based on their systolic function and discharge medications.
Methods: This study was an exploratory analysis of the Biomarkers in ACute Heart 
Failure (BACH) trial, a multi-center study assessing novel biomarkers in dyspneic patients 
presenting to emergency department. Enrolled patients who were admitted to the hospital 
were followed for 90-days for all-cause mortality.
Results: Of 1641 enrolled patients, 429 had a primary diagnosis of HF and EF data, and 
50 of these patients died during follow-up. 162 of these patients had preserved EF with an 
EF q 50%. In both reduced and preserved EF groups, patients discharged on either ACE-I 
or beta blocker had better survival (see ﬁgure containing Kaplan-Meier survival curves). 
Survival beneﬁt was greatest in patients discharged on dual therapy, and this persisted 
after adjusting for age, gender, history of HF, diabetes and chronic renal insufﬁciency.
Conclusions: After hospitalization for acute HF, discharge on ACE-I and beta blockers is 
associated with substantial survival beneﬁt in patients with preserved ejection fraction. This 
strongly suggests a new therapeutic approach for acute HF patients with preserved EF. 
3:30 p.m.
1024-205 Inferior Vena Cava Inspiratory Collapsibility as 
a Predictor of Change in Renal Function During 
Hospitalization for Acute Decompensated Heart Failure
Jeffrey Testani, Lee Goldberg, Julio A. Chirinos, Amit Khera, James N. Kirkpatrick, 
University of Pennsylvania, Philadelphia, PA
Background: The presumed pathophysiology of cardiac renal interactions traditionally 
assumed that reduced cardiac output lead to a reduction in renal perfusion with a cause 
and effect relationship. These assumptions have recently been challenged and the 
possibility of multiple distinct mechanisms of the cardiorenal syndrome have been raised. 
Animal models support renal venous hypertension as one of the candidate mechanisms 
for the syndrome.
Methods: We reviewed consecutive admissions to the general cardiology or medicine 
services with a primary discharge diagnosis of congestive heart failure. Inclusion required 
an echocardiogram day 1 or 2 of the hospitalization, a B-type natriuretic peptide (BNP) 
level >400 pg/ml, intravenous diuretic use > 50% of the hospitalization, length of stay 
3 to 10 days, and the non-use of inotropes. The degree of inspiratory collapse of the 
inferior vena cava (IVC) was used as a noninvasive surrogate of renal venous pressure 
and was evaluated for its association with changes in renal function. IVC collapse was 
classiﬁed into groups as no collapse (G1), <50% collapse (G2), >50% collapse (G3), and 
full collapse (G4).
Results: 130 patients met the entry criteria with 18 patients in G1, 47 in G2, 40 in G3, 
and 25 in G4. Between groups there were no statistically signiﬁcant differences in BNP, 
serum sodium, volume overload on chest X-ray, length of stay, systolic blood pressure 
(SBP), ejection fraction, hemoglobin, or maximum diuretic dose. By the time of discharge 
mean glomerular ﬁltration rate (GFR) increased by 26.7% in G1 but had decreased by 
2.7% in G2, 0.1% in G3, and 7.3% in G4 (p=0.0004). Worsening renal function, deﬁned 
as a decrease in GFR by 25%, did not occur in any patients in G1 but occurred in 17.9% 
of non-G1 patients (p=0.04). Adjusting for SBP, blood urea nitrogen, BNP, baseline GFR, 
hemoglobin, and maximum diuretic dose IVC collapse remained a signiﬁcant predictor 
of change in GFR.
Conclusion: IVC non-collapsibility predicts improvement in renal function during treatment 
of acute decompensated heart failure despite otherwise similar patient characteristics. 
These data suggest a role of renal venous hypertension in the pathogenesis of the 
cardiorenal syndrome.
3:30 p.m.
1024-202 Tubular Damage Is Common and Associated With 
Reduced Survival in Patients With Chronic Heart 
Failure
Kevin Damman, Dirk J. van Veldhuisen, Gerjan Navis, Vishal S. Vaidya, Tom D. Smilde, 
Daan B. Westenbrink, Joseph V. Bonventre, Adriaan A. Voors, Hans L. Hillege, University 
Medical Center Groningen, Groningen, The Netherlands
Background. Reduced glomerular ﬁltration rate (GFR) is common in chronic heart failure 
(CHF). However, there is little information on the prevalence of tubular damage, and the 
association with renal function and prognosis in patients with CHF.
Methods. Ninety patients with CHF underwent GFR measurement by Iothalamate clearance. 
In addition, we studied 20 age and gender balanced controls. Kidney Injury Molecule 1 (KIM-
1), Neutrophil gelatinase associated lipocalin (NGAL) and N-acetyl-B-D-glucosaminidase (NAG) 
were determined as selective markers of tubular damage in 24 hours urine collection. The primary 
endpoint consisted of the ﬁrst occurrence of either all cause mortality, HTx or admission for CHF.
Results. Mean age was 58 ± 11 yr, 78% was male. Mean GFR was 78 ± 26 ml/min/1.73m2.
Urinary KIM-1 (277 (188-537) vs 136 (63-195) ng/gCr), NGAL (175 (70-346) vs 37 (6-58) 
μg/gCr) and NAG (12 (6-17) vs 1.6 (0.7-2.2) U/gCr) levels were highly elevated compared 
to controls (all P < 0.001). NAG but not NGAL and KIM-1 was related to GFR (r =-0.34). 
Both urinary NAG and KIM-1 were strong predictors of outcome, even independent of 
GFR: NAG HR 1.42 (1.02-1.94) per 5 U/gCr, P=0.039 and KIM-1 HR 1.15 (1.02-1.30) per 
100ng/gCr, P = 0.025 (FIGURE).
Conclusion. Tubular damage is prevalent in patients with CHF. Both increased urinary 
NAG and KIM-1 levels are associated with reduced survival, independent of GFR. 
3:30 p.m.
1024-203 Quality of Care for Atrial Fibrillation Among Patients 
Hospitalized for Heart Failure
Jonathan P. Piccini, Adrian F. Hernandez, Xin Zhao, Manesh R. Patel, William R. Lewis, 
Eric D. Peterson, Gregg C. Fonarow, Duke Clinical Research Institute, Durham, NC
Background: Atrial ﬁbrillation (AF) is common in heart failure (HF) and guidelines 
recommend discharge on warfarin for stroke prophylaxis. However, the frequency and 
factors associated with the guideline adherence are poorly described.
Methods: We analyzed 72,534 HF admissions at 255 hospitals participating in the AHA 
Get With the GuidelinesSM HF program. Multivariable logistic regression was used to 
identify independent factors associated with warfarin use at discharge.
Results: In this HF population, 20.5% (n=14,901) had AF on admission; while another 
13.7% (9918) had a prior history of AF but were in a regular rhythm at admission. 
Contraindications to warfarin therapy were documented in 9.2%. Among eligible HF 
patients without contraindications, the median prevalence of warfarin therapy at discharge 
was 64.9% (IQR 55.5 - 73.4) and did not improve during the 3.5 years of study. After 
adjustment, major factors associated with lower odds of warfarin use at discharge included 
increasing age, non-white race, anemia, and treatment in the south (Table). Warfarin use 
also varied inversely with CHADS2 risk (70.9% to 59.5% for CHADS2 1-6, p<.0001).
Conclusions: Guideline recommended warfarin use in patients with AF and HF is 
suboptimal, has not improved over time, and varies signiﬁcantly according to age, race, 
risk proﬁle, region, and hospital site.
Table. Independent predictors of warfarin use at discharge.
Odds ratio (95% CI) P Value
Age (per 10 years increase) 0.83 (0.80-0.88) <.001
Female (vs male) 0.93 (0.87-1.00) 0.067
Race (Non-white vs white) 0.68 (0.60-0.78) <.001
Renal insufﬁciency 0.8 (0.73-0.88) <.001
Anemia 0.70 (0.63-0.78) <.001
Prior stroke or transient ischemic attack 1.17 (1.04-1.31) 0.008
Hospital size (per 100 beds increase) 1.06 (1.03-1.10) <.001
Geographic Region 0.047
Midwest vs Northeast 0.92 (0.75-1.13
South vs Northeast 0.77 (0.64-0.93)
West vs Northeast 0.82 (0.63-1.07)
*Eligible patients without documented contraindications or other reason for not 
prescribing
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3:30 p.m.
1024-208 Does Endothelial Dysfunction Contribute to Exercise 
Limitation in Heart Failure With Preserved Ejection 
Fraction?
Barry A. Borlaug, Thomas P. Olson, Carolyn S.P. Lam, Kelly S. Flood, Bruce D. Johnson, 
Margaret M. Redﬁeld, Amir Lerman, Mayo Clinic, Rochester, MN
Background Arterial stiffening and impaired vasodilation with exercise are frequently 
observed in Heart Failure (HF) with preserved Ejection Fraction (HFpEF). While 
endothelial dysfunction is common in systolic HF, its role in HFpEF remains uncertain.
Objectives To compare endothelial function and vascular stiffening in patients with 
HFpEF and hypertension (HTN) and determine relationships with exercise performance.
Methods Age/gender matched subjects with HFpEF (n=21) and HTN (n=19) underwent 
baseline assessment of peripheral reactive hyperemia index (RHI), a measure of 
endothelium-dependent vasodilation, and central aortic pulse pressure (PP), an index 
of vascular stiffness, followed by metabolic exercise testing (Ex). Systemic vascular 
resistance (SVR) was determined from echo-Doppler at rest and Ex.
Results RHI and PP were similar in HFpEF and HTN, while Ex capacity was reduced 
in HFpEF (*p<0.0001; Table). In combined analysis, $SVR with Ex was associated with 
peak VO2 (r= -0.55, p<0.05). $SVR was lower in HFpEF than HTN (†p=0.003). In HFpEF, 
peak VO2 was directly related to resting RHI (r= 0.50, p<0.05) and inversely to aortic PP 
(r= -0.51, p<0.05), but neither of the latter was associated with $SVR.
Conclusions While patients with HFpEF display abnormal vasodilation with exercise, 
resting indices of endothelial function are similar to HTN. Endothelial dysfunction and 
vascular stiffening contribute to exercise limitation in HFpEF and may serve as novel 
therapeutic targets. 
HTN (n=19) HFpEF (n=21)
Aortic Systolic Blood pressure (mmHg) 130±12 125±19
Aortic Pulse Pressure (mmHg) 54±12 59±22
Reactive Hyperemia Index 2.31±0.66 2.18±0.69
Percent with Endothelial Dysfunction (RHI<2) 28 42
Peak VO2 (ml/min*kg) 18.6±3.7 12.7±3.0*
Baseline SVR(DSC) 1780±400 1600±500
$SVR with Exercise(DSC) -980±300 -620±350†
ACC.ORAL CONTRIBUTIONS
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0901-3 Predictors of Stroke on Heartmate II Left Ventricular 
Assist Device
Biswajit Kar, Sukhdeep S. Basra, Pranav Loyalka, Igor D. Gregoric, Reynolds Delgado, 
Andrew Civitello, Roberta Bogaev, William Cohn, Antonius Attallah, Rohan Wagle, O. H. 
Frazier, Texas Heart Institute, Houston, TX, University of Texas at Houston, Houston, TX
Background: The Heartmate II is an effective treatment alternative for patients with end 
stage heart failure refractory to medical therapy. However, a relatively large proportion of 
patients on Heartmate II develop stroke. We aimed to determine the predictors of stroke 
in this patient population.
Methods and Materials: All patients (n=71) implanted with Heartmate II at our institute 
were included in the study. Patients developing a stroke were classiﬁed as cases (n 
= 18) with the remaining as controls (n=53). We speciﬁcally assessed the following 
predictors of stroke: Non-Pulsatile ﬂow, Anticoagulation, Mean Arterial Pressure (MAP) 
and Infections.
Results: The mean duration of support for cases and controls was 429.06 and 304.92 
days respectively, with a median implant-stroke interval of 174 days. On statistical 
analysis, Non Pulsatile Flow (O.R: 4.68, 72.2% vs. 37.7% in cases and controls; p = 
0.039) and Bacteremia (O.R: 9.59, 88.9% vs. 51% in cases and controls ; p = 0.045) 
were found to be signiﬁcantly associated with an increased risk of developing stroke. This 
remained signiﬁcant even after adjusting for potential confounders like duration of support, 
MAP, anticoagulation status, gender, and atrial ﬁbrillation using logistic regression in a 
multivariate analysis. However, Anticoagulation (Median INR 1.3 vs. 1.55 in cases and 
controls, p = 0.181) and MAP (Median 85.5 vs. 78.6 mm Hg in cases and controls; p = 
0.123) were not signiﬁcantly associated with stroke. 53.8% of the cases suffered from 
acute peristroke infections (positive cultures 15 days before upto 5 days after stroke).
Conclusions: Traditional risk factors of stroke like Diabetes, Hypertension, Hyperlipidemia, 
Age, Smoking and Atrial Fibrillation are not associated with stroke in patients on Heartmate 
II LVAD. Instead, Non-pulsatile ﬂow and Bacteremia are the important predictors of stroke 
in patients on Heartmate II.
3:30 p.m.
1024-206 Effects of the Selective PPAR Gamma Modulating 
Angiotensin Receptor Blocker Irbesartan on Impaired 
Insulin Sensitivity in Patients With Chronic Heart 
Failure IRIS-HF: A Placebo-Controlled, Double Blinded, 
Randomized Study
Wolfram Doehner, Cornelia Kenneke, Johanna Todorovic, Mathias Rauchhaus, Stephan 
von Haehling, Stefan D. Anker, Charite University Medical School, Berlin, Germany
Background: Impaired insulin sensitivity (Si) is common in chronic heart failure (CHF), 
contributes to symptomatic status and independently predicts prognosis. It has been 
suggested that the angiotensin II-receptor antagonist irbesartan can improve insulin 
sensitivity via selective activation of the peroxisome proliferator-activated receptor 
gamma (PPAR gamma). We aimed to assess the effect of irbesartan on impaired insulin 
sensitivity in patients with CHF.
Methods: In a prospective, placebo-controlled, double-blinded, randomized single center 
study we included 36 non-diabetic patients with stable ischemic CHF (age 63±9y, BMI 
28.2±3.9kg/m2, peakVO2 16.6±4.8mL/kg/min all mean ±SD). Irbesartan (target dose 
300mg/d) or placebo was given on top of standard optimum CHF therapy including ACE 
inhibitor and beta-blockers for 16 weeks. Change of insulin sensitivity from baseline to 
week 16 (primary endpoint) was assessed using the minimal modelling technique from 
glucose and insulin proﬁles of a frequently sampled intravenous glucose tolerance test.
Results: At baseline both groups were similar for age, NYHA class, peak VO2, BMI, body 
composition (DEXA scan), Si (p=0.2), and main clinical characteristics. Si was 2.51±1.58 
min-1.μU.mL-1.104 in the study population, which is 30% lower than in healthy controls 
of similar age (P<0.05). In the irbesartan treated group SI increased by 26% (p<0.001 
within group), but it decreased by 15% in the placebo group (p=0.17 within group). 
Change in SI from baseline was signiﬁcantly different between groups (mean difference 
1.044 min-1.μU.mL-1.104; 95%CI 0.45 to 1.64, p=0.001). Treatment with irbesartan was 
well tolerated. NYHA class, peak VO2 and body composition did not change but blood 
pressure signiﬁcantly decreased on irbesartan (-5±2 mmHg, p<0.002).
Conclusion: Our study shows that 16 weeks of added therapy with irbesartan compared 
to placebo signiﬁcantly improves impaired insulin sensitivity in non-diabetic patients with 
chronic heart failure. Whether this metabolic effect of irbesartan translates into additional 
clinical beneﬁts for heart failure patients should be tested in larger studies.
3:30 p.m.
1024-207 Relaxin, A Novel, Multiple Mechanism Vasodilator, for 
the Treatment of Acute Heart Failure - The PreRELAX-
AHF Study
John R. Teerlink, Marco Metra, G. Michael Felker, Adriaan A. Voors, Beth Weatherley, 
Elaine Unemori, Sam L. Teichman, Gad Cotter, Section of Cardiology, Veterans Affairs 
Medical Center, University of California, San Francisco, CA, Section of Cardiovascular 
Diseases, Department of Experimental And Applied Medicine, Univ of Brescia, Brescia, 
Italy
Relaxin is a naturally-occurring peptide that is known to affect multiple vascular control 
pathways. In preliminary studies, it reduced wedge pressure and increased cardiac 
output.
Objective: PreRELAX-AHF is the pilot for a phase 3 trial evaluating safety and dose-
response to 48h of IV relaxin in patients with acute heart failure (AHF) and normal to high 
systolic blood pressure (SBP).
Methods: Eligible patients were hospitalized for AHF with dyspnea, congestion on 
chest X-ray, NTproBNP >1,400 pg/ml, SBP >125 mmHg and eGFR 30-75 mL/min. 
Randomization (double-blind) was <16 h from presentation to placebo (PBO) or relaxin 
10, 30, 100 or 250 mcg/kg/d. Endpoints of interest were dyspnea (by 7-pt Likert and 
Visual Analog Scales [VAS]), clinical outcomes and renal function.
Results: In this interim analysis, 209 patients in 8 countries were followed for >14 days. 
Baseline characteristics were balanced across groups. Improvement in dyspnea was 
greater in the relaxin arms vs PBO, with greater efﬁcacy seen at 10, 30 and 100 mcg/kg/d 
at all time points from 6h to Day 14. The largest effects were seen at 30 mcg/kg/d. Dyspnea 
improvement by VAS was 96% greater in the 30 mcg group than placebo at 6h. The VAS 
change from baseline over time was signiﬁcant (P=0.03 for 30 mcg vs PBO, for 6h to Day 
14). Time to ﬁrst moderate or marked improvement by Likert was 2.7, 2.4, 1.8, 2.4 and 
2.2 days in PBO, 10, 30, 100 and 250 dose groups (P<0.05, relaxin 30 vs PBO). Similar 
trends were seen in measures of HF including greater weight loss (up to 1 kg difference), 
lower IV loop diuretic use and lower incidence of in hospital worsening HF. Mean length of 
stay was shorter in the active arms by 1-2.5 days, most pronounced at 30 mcg/kg/d. There 
were no safety or tolerability issues, including the absence of symptomatic hypotension or 
worsening of renal function. Follow-up to Day 180 will be presented.
Conclusion: In patients with AHF and normal to high SBP (>75% of AHF patients), early 
IV relaxin administration for 48 hours may produce rapid and sustained improvement in 
dyspnea and other heart failure measures, without evidence of symptomatic hypotension 
or adverse effects on renal function. Larger studies are planned with relaxin to conﬁrm 
these effects.
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0901-6 Predictors of Improvement in Right Ventricular Function 
After Placement of a Left Ventricular Assist Device
Barry A. Boilson, John A. Schirger, Basar Sareyyupoglu, Sudhir S. Kushwaha, Irina 
Penev, Christopher GA McGregor, Richard C. Daly, Lucian A. Durham, III, Brooks S. 
Edwards, Soon J. Park, Mayo Clinic, Rochester, MN
Background:End stage heart failure is increasing in prevalence and left ventricular assist 
device (LVAD) technology being used increasingly as a bridge to transplantation and also 
as destination therapy. Although LVAD placement is followed by left ventricular ofﬂoading 
and increase in systemic cardiac output, persistent right ventricular (RV) dysfunction 
is common.The aim of this study was to investigate the baseline characteristics which 
contribute most to improvement in right ventricular dysfunction after LVAD placement.
Methods:All patients who underwent LVAD implantation at our institution between May 
2003 and July 2008 were evaluated. The primary endpoint was improvement in RV 
function measured by echo. Secondary endpoints were improvement in measures of 
pulmonary hypertension by right heart catheterization and echo. Both bridge to transplant 
and destination therapy patients were included. Both continuous ﬂow and pulsatile 
devices were included.
Results:A total of 57 patients were studied. Mean duration of followup was 230.5 days. 
Mean age was 58.4±12.3 years. Baseline mean peak VO2 was 10.3±2.1 ml/kg/min, 
mean serum creatinine 1.5±0.5 mg/dl, and mean BNP 1688±1195 pg/ml. The most 
powerful predictors of improvement in right ventricular function at last followup were 
baseline severity of mitral valve regurgitation (MR) (p=0.0006, R=-0.51), tricuspid valve 
regurgitation (TR) (p=0.01, R=0.39) and pulmonary vascular resistance (PVR) (p=0.006, 
R=0.42). Similarly, improvement in pulmonary hypertension was predicted by baseline 
MR (p=0.005, R=0.4), PCWP (p=0.002, R=0.44) and PVR (p<0.0001, R=0.53). Predictors 
of change in PVR were baseline PA pressure (p=0.0002, R=0.5), MR severity (p=0.05, 
R=0.28 )and PVR at baseline (p<0.0001, R=0.9)
Conclusions:Improvement in RV function improves most after LVAD implantation when it 
occurs in the setting of severe MR. Dramatic ofﬂoading of the left ventricle and reduction in 
MR severity in these patients post LVAD placement results in a signiﬁcant drop in RV afterload 
and PVR which facilitates recovery of RV function. RV dysfunction present at baseline in the 
absence of signiﬁcant MR may not improve to the same degree post LVAD placement.
9:00 a.m.
0901-7 Ventricular Assist Device Removal After Cardiac 
Recovery: Main Predictors for Long-Term Outcome 
Without Transplantation or Assist Device Re-
Implantation
Michael Dandel, Yuguo Weng, Henryk Siniawski, Hans B. Lehmkuhl, Thorsten Drews, 
Evgenij Potapov, Thomas Krabatsch, Christoph Knosalla, Roland Hetzer, Deutsches 
Herzzentrum Berlin, Berlin, Germany
Background: There is increasing evidence for cardiac recovery which allows ventricular 
assist device (VAD) removal. However, few chronic heart failure (HF) patients have been 
weaned from VADs, most of them only recently. Thus, long-term (> 5 years) outcome data 
after VAD removal are few. Now that our patient cohort with post-weaning stability for > 5 
years has become larger, we focused on these patients, in order to obtain new information 
for future weaning decisions.
Methods: Among 84 patients weaned from VADs since 3/1995 we selected only patients 
(n = 36) who were weaned q 5 years ago, before 9/2003. We evaluated echocardiogtaphic 
(ECHO) data recorded before VAD implantation and during pre-explantation “off-pump” 
trials, HF duration before VAD implantation, duration of mechanical support, and stability 
of unloading-induced recovery before and early after VAD removal.
Results: Of 36 evaluated patients, 33 (91.7%) had non-ischemic, and the other 3 ischemic 
cardiomyopathy. Only 2 had BVADs; the other 34 had LVADs. Post-weaning 5- and 10-year 
survival with native hearts was 76.5% and 70.6.%, respectively. Post-weaning survival for q
13 years was reached by 3 patients. During the ﬁrst 5 post-weaning years, HF recurred in 13 
(36.1%) patients (9 underwent HTx, one received another LVAD and 3 died). Patients with q
5 years stability were younger, their history of HF and recovery time during unloading were 
shorter and pre-weaning LV assessment revealed lower diameters, less altered geometry 
and higher LVEF. For LVEF q 45% at end-diastolic diameter a 55mm the predictive value for 
q 5 year was 88.9%. Early post-wening time course of LVEF also appeared predictive for 
long-term stability. History of HF > 5 years and pre-weaning instability of unloading-induced 
recovery appeared predictive for HF recurrence.
Conclusions: Long-term successful weaning from VADs is possible even in patients 
with chronic HF and incomplete cardiac recovery. Pre-explantation off pump ECHO-data, 
stability of recovery, duration of HF before VAD insertion and duration of VAD support 
allow identiﬁcation of patients with the potential to remain stable for > 5 years. LVEF time 
course early after-weaning facilitates prognostic assessment.
8:15 a.m.
0901-4 Validation of the Model for End-Stage Liver Disease in 
Predicting Left Ventricular Assist Device Mortality
Jennifer Cowger Matthews, Todd F. Dardas, Jonathan W. Haft, Francis D. Pagani, Keith 
D. Aaronson, University of Michigan Health System, Ann Arbor, MI
Background: Preoperative Model for End-Stage Liver Disease (MELD) scores have 
previously been shown to predict mortality in LVAD recipients at our center. Our aim was 
to validate the prior ﬁndings using a national LVAD database.
Methods: Preoperative MELD scores were calculated for subjects undergoing LVAD 
support enrolled into the INTERMACS registry between 2006-2008. MELD score= 
9.57(logeCreatinine) + 3.78(logeBilirubin) + 11.2(logeINR) + 6.43, with minimums for all 
variables set at 1.0. Complete data for MELD score calculations were available on 324 
(87%) of 372 subjects.
The primary outcome of interest was the relationship between preoperative MELD score 
and operative death (death within 30 days of LVAD operation). Student’s t tests were 
used to compare mean MELD scores amongst operative deaths and survivors with odds 
ratios (OR, 95% CI) generated from logistic regression. MELD scores were dichotomized 
at the previously published threshold of 17. Secondary outcomes included survival and 
the hazard ratio for death at 6 months in high (MELD q17) versus low (MELD <17) strata, 
calculated with Kaplan-Meier and Cox regression analyses, respectively.
Results: The mean±standard deviation preoperative MELD score for the entire cohort 
was 15.2±5.8, with mean creatinine, bilirubin, and INRs of 1.6 ±0.9 mg/dL, 1.7±0.1 mg/
dL, and 1.4±0.02 sec., respectively. Operative deaths (n=19, 6%) had higher mean (95% 
CI) MELD scores [17.9(14.2,21.6)] than survivors [15.0(14.4,15.7); p=0.036)], such that 
the odds of operative death increased 50% [OR 1.5(1.1,2.1)] for each 5-unit increase in 
MELD. At 6 months, survival for subjects with MELD scores q17 (n=120) was 67±5% 
compared with 82±3% in subjects with lower scores (p=0.032). At 6 months, the hazard 
ratio for death (n=56) in subjects with MELD scores q17 was 1.76 (1.04,2.98) times that 
of those with lower scores (p=0.035).
Conclusion: Preoperative MELD scores, a marker of multisystem dysfunction, are 
predictive of operative and 6-month LVAD mortality in INTERMACS and may serve as an 
important preoperative tool in assessing LVAD risk.
8:30 a.m.
0901-5 Early Decrease in Platelet Counts Following Left 
Ventricular Assist Devices Implantation Is Part of the 
Systemic Inﬂammatory Response Syndrome and a 
Marker of Poor Long-Term Outcome.
Andrea Mignatti, Daniel B. Sims, Nir Uriel, Basil Ramlawi, Steve Holleran, Yoshifumi 
Naka, Ulrich P. Jorde, Columbia University, New York, NY
Background: Alterations of platelet (plt) count have been described as part of the 
systemic inﬂammatory response syndrome (SIRS) following open heart surgery. Several 
studies suggest that SIRS can be modulated using perioperative steroid and/or statin 
therapy. Plt behavior has not been studied after implantation of left ventricular assist 
devices (LVADS).
Methods and results: Retrospective single center study of 114 consecutive HM I & II 
implants performed at our institution for BTT or DT since 04/2004. For the purposes of this 
study, success was deﬁned as being alive and/or transplanted 180 days post-op. Mean 
plt count on day 3 (123 vs 91, p 0.009) and day 7 (196 vs 130 p 0.001) were signiﬁcantly 
higher in success (n=87) compared to failure (n=27) pts. Overall success was 77 %. 
However, success rate was 59% in pts whose plt count averaged < 100 between day 3 
and 7 and 90% in those who averaged > 100 (Fig 1).Decrease in plt was weakly correlated 
with pump time (R= 0.3 p 0.01) and pump time was not different between success and 
failure pts (105 vs 111 min P=NS). Decrease in platelet count was signiﬁcantly correlated 
with increase in WBC (median correlation coeff = -0.45 p<0.01) (Fig. 2).
Conclusion: Early plt count decrease following LVAD implant at least in part reﬂects 
SIRS and the degree of plt decrease is a marker of long term outcome. Pharmacological 
modulation of SIRS occurring in the early postoperative period should be investigated and 
may improve long term outcomes of pts undergoing LVAD implantation. 
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lower BUN 26.8 ± 16.4 (p=0.06), shorter stay in the CCU (p=0.06) and most importantly 
lower readmission rate at 30 days (p=0.028)
Conclusions: Continuous Infusion of Furosemide in addition to Low Dose Dopamine is 
safe, effective and less nephrotoxic than intermittent boluses in patients admitted with acute 
decompensated heart failure and carries shorter ccu stay and lower readmission at 30-days.
9:30 a.m.
1033-167 Prediction of Incident Heart Failure in the Elderly: 
Validation of the Health ABC HF Model in the 
Cardiovascular Health Study
Andreas P. Kalogeropoulos, Vasiliki V. Georgiopoulou, Tamara B. Harris, Ramachandran 
S. Vasan, Andrew L. Smith, Nicholas L. Smith, Stephen B. Kritchevsky, Anne Newman, 
Peter WF Wilson, Bruce M. Psaty, Javed Butler, Emory University, Atlanta, GA
Background: The published Health ABC Heart Failure (HF) model uses nine routinely 
available clinical variables (age, history of coronary heart disease, smoking, ECG 
left ventricular hypertrophy, blood pressure, heart rate, and plasma levels of glucose, 
creatinine, and albumin) to estimate 5-yr incident HF risk in the elderly. We evaluated the 
external validity of the model in the Cardiovascular Health Study (CHS).
Methods: Observed HF incidence rates in 5335 CHS participants (median age 71 
yr, 57.6% female, 84.7% white) without baseline HF were compared with 5-yr HF risk 
estimates derived from the model. Goodness-of-ﬁt, calibration, and discrimination of the 
model were evaluated.
Results: Over 5 years of follow-up, there were 400 (7.5%) new HF events (16.2/1000 
person-years). Observed HF rates in CHS closely followed the model-predicted rates 
across deciles of risk (Fig. 1), suggesting adequate model ﬁt. The weighted sum of 
risk factors of the model had a B=0.95 (95% CI, 0.85-1.05, p=0.316 vs. optimal B=1),
suggesting adequate calibration. Results were consistent across gender and race. The 
C-index was 0.74 (95% CI 0.72-0.76) as compared to optimism-corrected 0.72 in the 
derivation cohort, indicating acceptable discrimination.
Conclusions: The Health ABC HF model predicted the 5-yr incident HF risk in the 
community-based CHS sample, supporting the model’s external validity and suggesting 
that the model may be used to identify high-risk individuals in the community who could 
be targeted to prevent HF.
9:30 a.m.
1033-168 Interpreting the Follow-Up NT-ProBNP Concentration 
and Symptoms After Hospitalization for Acute Dyspnea
Keyur B. Shah, Willem J. Kop, Robert H. Christenson, Deborah B. Diercks, Dick Kuo, 
Sue Henderson, Christopher R. deFilippi, University of Maryland School of Medicine, 
Baltimore, MD, Baltimore Veterans Affairs Medical Center, Baltimore, MD
Background: Elevated NTproBNP levels in acute dyspnea patients (pts) identiﬁes 
increased mortality irrespective of diagnosis. The signiﬁcance of a change in level 
compared to symptoms on outpatient follow-up is uncertain.
Methods: 262 pts (58±14 yrs, 40% female) presenting with dyspnea were prospectively 
enrolled and had 30 day follow-up. Clinical data, Minnesota Living with Heart Failure Score 
(MLHFS), and NTproBNP levels were obtained. A change in NTproBNP and MLHFS was 
considered 25% and 5 points. The predictive value of changes in NTproBNP and MLHFS 
for 1-year mortality were evaluated by Cox proportional hazards and KM analysis.
Results: At 30 day follow-up, we observed signiﬁcant decreases of NTproBNP levels 
(median [IQR]; 312 [37-2299] vs 289 [79-1439]; P=0.03, 109 (48%) decreasing by > 
25%), and MLHFS (55±24 vs 43±29; P<0.001, 164(62%) decreasing > 5). 251 (96%) At 1 
year, 23 (9%) had died. Compared to pts with baseline NTproBNP < 300 pg/mL (n=132): 
elevated NTproBNP pts that didn’t decrease were at higher risk of death (RR=2.69, 
95% CI=1.07-6.80) vs pts that did decrease (RR=0.75, 95% CI=0.23-2.44). When 
combining NTproBNP and symptoms, pts who had both no decrease in either NTproBNP 
and MLHFS at follow-up were at highest risk of death (RR=4.14, 95% CI=1.31-13.07). 
Decrease of either variable identiﬁed intermediate risk (ﬁgure).
Conclusions: Outpatient follow-up for change in both NTproBNP and symptoms in acute 
dyspnea pts with elevated NTproBNP is important for long-term risk stratiﬁcation.
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9:30 a.m.
1033-165 Intermittent Claudication as a New Predictor of 
Outcome in Heart Failure: Evidence From the 
Controlled Rosuvastatin Multinational Trial in Heart 
Failure (CORONA)
John J. V. McMurray, Peter Dunselman, John Wikstrand, Magnus Lindberg, Hans Wedel, 
Finn Waagstein, John Kjekshus, Ake Hjalmarson, University of Glasgow, Glasgow, 
United Kingdom
Background: Patients q60 years with NYHA class II-IV, low ejection fraction (EF) heart failure 
(HF) of ischemic etiology were enrolled in CORONA. Rosuvastatin did not reduce mortality. 
Intermittent claudication (IC) is an important predictor of clinical outcome in patients with 
coronary heart disease but its prognostic importance in HF has not been studied.
Methods: To determine whether IC is an independent predictor of mortality in ischemic, 
systolic, HF we built a multivariable model, ﬁrst using demographic/clinical variables (step 
1), then adding biochemical measures (step 2) and ﬁnally incorporating high-sensitivity 
C-reactive protein (hsCRP) and N-terminal pro B-type natriuretic-peptide (NT-BNP) - 
3342 patients had all variables measured.
Results: 637 patients in CORONA had IC. 38% of patients with IC died compared to 28% of 
those without, p<0.00001 (934 deaths overall). The table shows the top ten predictors of death 
at step 1, ranked according to the Wald C2 (total model C2343). Creatinine was most predictive at 
step 2 (C2 440). Log NT-BNP was the most powerful of the 14 independently predictive variables 
at step 3 (C2 600). IC remained an independent predictor of mortality at all three steps.
Conclusion: IC is a previously unrecognized independent predictor of outcome in HF.
Table: Multiple Cox regression: all-cause mortality 
Variable Hazard(95% CI) C
2 p-value
Age/10 1.44 (1.31,1.58) 56 <0.0001
Ejection fraction *100 0.97 (0.96,0.98) 44 <0.0001
BMI 0.95 (0.93,0.96) 42 <0.0001
Diabetes Mellitus 1.44 (1.25,1.66) 25 <0.0001
Sex 0.67 (0.57,0.80) 22 <0.0001
NYHA 1.40 (1.21,1.62) 20 <0.0001
Intermittent claudi. 1.40 (1.18,1.67) 14 0.0002
Heart rate/10 1.11 (1.05,1.17) 12 0.0005
SBP/10 0.94 (0.90,0.98) 10 0.0020
9:30 a.m.
1033-166 Continuous Infusion of Furosemide Combined With 
Low Dose Dopamine Compared to Intermittent Boluses 
in Acutely Decompensated Heart Failure Patients is 
Less Nephrotoxic and Carries a Lower Readmission at 
30 Days
Emad F. Aziz, Eyal Herzog, Amjad Nader, Manpreet Singh Sabharwal, Dan Musat, 
Ajay Shah, Rishi Malhan, Divyajot Sandhu, Raja Singh, Sahil Jaiswal, Deborah Tormey, 
Suzanne Karl, Amanda Schneider, Marrick Kukin, St. Luke’s-Roosevelt Hospital Center, 
New York City, NY
Background: Furosemide is a potent loop diuretic that is widely used in management of 
heart failure. Several reports have suggested that continuous intravenous administration 
of loop diuretics may be superior to intermittent administration. In addition the effect of low 
dose dopamine might be of beneﬁt to this patient cohort.
Methods: To test this hypothesis we retrospectively evaluated 45 consecutive Cardiac Care 
unit patients, who admitted with acute decompensated heart failure (ADHF) and compared 
the effect of low dose dopamine and Continuous Furosemide infusion (Group A) to the 
standard of care with IV Furosemide boluses (Group B). Furosemide infusion was started 
at 0.2-0.4 mg/kg/hr and Dopamine infusion was at 1-2 mcg/kg/min; primarily used in ‘sicker’ 
patients with creatinine higher than 2.1. Group B was managed according to our novel 
heart failure pathway by which outpatient total oral daily Furosemide dose is converted into 
intravenous route. The effect on renal function and readmission rate was recorded.
Results: Among 45 patients (55% males, average age 74, range 46 - 96 years) 35% had 
ischemic cardiomyopathy, NYHA functional Class was 2.9 ± 1.2 and average EF was 27 
± 15%. Average admission Sodium was 138 ± 5.4 mEq/L, Potassium 4.6 ± 0.8mEq/L, 
Blood Urea Nitrogen (BUN) 39 ± 25 mg/dL, Creatinine (Cr) 1.9 ± 1 mg/dL and B-type 
Natriuretic Peptide (BNP) 1135 ± 894 pg/mL. Furosemide and dopamine infusions were 
used in 21 patients and IV Furosemide bolus was used in 24 patients. Patients in Group 
A had Cr 2.1 ± 0.6, BUN level of 47 ± 26 and BNP level of 1464 ± 1086 compared to 
group B patients with Cr 1.7 ± 0.8, BUN of 32 ± 21 and BNP of 846 ± 562. The average 
Furosemide infusion dose in group A was 6.9 mg/hr compared to 7.6 mg/hr for group B 
(P=NS). At the end of the study, patients in group A had lower Cr 1.5 ± 0.5 (p=0.0025), 
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outpatient heart failure clinics and prior to optimization of drug therapy. This may reﬂect the 
perceived beneﬁt of early referral to heart failure clinics by these referring physicians.
9:30 a.m.
1033-171 Deleterious Effects on Ejection Fraction Upon 
Withdrawal of ACE Inhibitors and Beta-Adrenergic 
Blockers in Patients With Anthracycline Associated 
Cardiomyopathy
Ashish Shukla, Wamique Yusuf, Iyad Daher, Xiao Zhou, Cezar Illiescu, Daniel Lenihan, 
Jean-Bernard Durand, MD Anderson Cancer Center, Houston, TX, SUNY, Buffalo, NY
Background: Left ventricular (LV) function is the most common assessment of cardiac 
performance in cancer patients. Although Beta Adrenergic blockers and ACE inhibitors 
(A+B) are used for treatment of left ventricular (LV) dysfunction in patients with 
anthracycline-associated cardiomyopathy (ACM), the effect of their withdrawal after an 
improvement of LV function is unknown. We report a retrospective cohort study of patients 
with ACM on A+B who underwent withdrawal from these medications and their follow up 
LV ejection fraction (LVEF).
Methods: From a cohort of patients with ACM stabilized on A+B, sixteen patients were 
identiﬁed to have been withdrawn from therapy. These patients were restarted on A+B 
and LVEF changes compared using paired t test and t test using a matched control 
population.
Results: A total of 48 patients (case =16 and matched control =32) were studied. The 
mean LVEF of the sixteen patients at presentation with ACM was 28.68%, down from a 
mean EF of 54% at baseline (p<0.0001). Once on maximal doses of A+B, the patients’ EF 
improved to a mean of 49.62% (p<0.0001). Upon withdrawal of the treatment with A+B, 
the mean EF decreased to 30.62% (p<0.0001). Upon reinstitution of A+B therapy, the 
patients’ LVEF improved to a mean of 45% (p<0.0001).
Conclusions: The initial fall in LVEF with ACM is reversible and is then maintained on 
continuous treatment with A+B. Withdrawal of treatment is associated with a signiﬁcant 
reduction in LVEF. We conclude that patients with ACM should remain on A+B 
indeﬁnitely.
9:30 a.m.
1033-172 Vitamin D Deﬁciency Is Common in Chronic Heart 
Failure Patients and Relates to the Severity of the Heart 
Failure
Klaus K. Witte, Richard M. Cubbon, Christopher P. Gale, Lorraine C. Kearney, Rachel E. 
Klawiter, Mark T. Kearney, University of Leeds, Leeds, United Kingdom
Background: Chronic heart failure (CHF) is a syndrome of exercise intolerance in 
the presence of left ventricular dysfunction. A further feature is deﬁciency of essential 
micronutrients. Vitamin D deﬁciency leads to imapired skeletal and cardiac muscle and 
immune function, hence deﬁciency might also be an aetiological factor. We examined the 
prevalence of vitamin D deﬁciency in CHF patients and whether vitamin D levels were 
related to CHF severity.
Methods: Serum 25(OH)D3 levels were measured in 55 stable CHF patients, (40 men) 
mean age 70 (11) years. CHF was deﬁned as current or previous symptoms of fatigue 
or breathlessness and left ventricular ejection fraction <45%. Patients taking vitamin D 
supplementation were excluded from the analysis. Vitamin D levels were categorised 
as deﬁciency (serum level <25nmol/l), insufﬁciency (<50nmol/l), and hypovitaminosis D 
(<75nmol/l). Patients with levels q75nmol/l were classed as sufﬁcient.
Results: Patients were taking appropriate medical therapy (80% on beta-blockers, 90% 
ACE inhibitors). Calcium levels were normal (2.32 (0.1)mmol/l). Only three patients had 
sufﬁcient vitamin D. Patients with NYHA class II and III CHF had lower levels of vitamin 
D than those in class I (29.0 (16.2) v 45.2 (32.5); p=0.03). There was no difference in 
vitamin D levels between class II and III, although there was an interaction between 
NYHA class and vitamin D category (C2-value 15.0; p=0.02). There was an inverse 
relationship between furosemide dose and vitamin D (r=0.40; p=0.005). Patients taking 
spironolactone had lower levels than those not taking this agent (25.8 (13.8) v 43.1 (22.6); 
p=0.002). There was no relationship between vitamin D and age, left ventricular function, 
calcium or creatinine or CRP, and no differences between those patients taking and those 
not taking beta-blockers and angiotensin-converting enzyme inhibitors.
Conclusions: CHF patients are frequently deﬁcient of vitamin D, related to the severity 
of the condition. Whether vitamin D deﬁciency contributes to CHF or is merely a result 
of lifestyle constraints in these patients requires further investigation with a randomised, 
placebo-controlled trial of high dose vitamin D supplementation.
9:30 a.m.
1033-169 Short-Term Treatment With Rosuvastatin Increases the 
Number of Endothelial Progenitor Cells in Patients With 
Heart Failure
Dimitris Tousoulis, Ioannis Andreou, Meletios-Athanasios Dimopoulos, Nikos 
Papageorgiou, Panagiota Gounari, Charalambos Antoniades, Gerasimos Siasos, 
Costas Tentolouris, Christodoulos Stefanadis, 1st Cardiology Department, Hippokration 
Hospital, Athens Medical School, Athens, Greece
Background: Current evidence suggests that HMG-CoA reductase inhibitors (statins) 
modify the number of endothelial progenitor cells (EPCs) in patients with atherosclerosis. 
However their effect on EPC mobilization in patients with heart failure (HF) remains 
unknown. We evaluated the impact of rosuvastatin on EPC number in patients with HF.
Methods: Forty two clinically stable patients with systolic HF (NYHA II-III, mean 
age 65±11 years, mean LVEF 28±8%, 76% ischemic) who were already on optimal 
conventional cardiovascular treatment were randomized to receive rosuvastatin 10 mg/
day (n=21), or placebo (n=21) and followed up for 4 weeks. The number of EPCs in 
whole blood was measured as CD34/KDR and CD34/AC133/KDR positive cells using 
ﬂuorescence-activated cell sorting. Endothelial function was evaluated by estimating the 
brachial artery ﬂow mediated dilation (FMD). All measurements were made before and 
after 4-week treatment.
Results: CD34+/KDR+ and CD34+/AC133+/KDR+ cells were signiﬁcantly increased after 
rosuvastatin treatment (from 0.023 (0.017-0.038) and 0.001 (0.0008-0.0024) to 0.039 
(0.023-0.052) cells/100 peripheral blood mononuclear cells (PBMNCs) and 0.0019 
(0.0008-0.0033) cells/100 PBMNCs respectively, p=0.004 and p=0.008), whereas they 
remained unchanged in the placebo group. FMD was signiﬁcantly increased in the 
rosuvastatin group (from 2.9±1.5 to 3.5±1.6%, p<0.05), while it remained unchanged in 
the placebo group. There was no correlation between baseline EPC number and FMD 
(r=-0.09, p=0.87). Moreover, the change in EPC levels after rosuvastatin treatment was 
not correlated with the change in FMD (p=0.24).
Conclusions: Short-term treatment with rosuvastatin signiﬁcantly increases endothelial 
progenitor cells number in patients with heart failure. This ﬁnding provides further insights 
into the role on the pleiotropic effects of statins in patients with chronic heart failure.
9:30 a.m.
1033-170 Changes in Drug Utilization in Patients Referred to 
Outpatient Heart Failure Clinics in Canada Between 
1999 and 2007
J. Malcolm O. Arnold, Andrew Ignazweski, Jonathan Howlett, Marie-Helene LeBlanc, 
Peter Liu, Rosa Guiterrez, Gordon Marchiori, University of Western Ontario, London, 
ON, Canada
Background:The Canadian Heart Failure Network (CHFN) links 26 clinics across Canada 
which share a common longitudinal database and a common philosophy that a specialized 
heart failure physician(s) and nurse(s) can optimize care in patients referred from hospital 
or community physicians. The Network supports the Canadian Cardiovascular Society 
National Guidelines for the diagnosis and management of heart failure but allows each 
clinic to practice within those guidelines according to local resources which may differ 
across the country.
Methods: We describe here the referral patterns of heart failure drug use at the time of 
ﬁrst referral for the years from January 1999 to December 2007 to determine if evidence 
based guidelines have resulted in an increase in the community use of guideline 
recommended drugs.
Results: Over that period of time 10,449 patients were referred to active CHFN clinics 
who recorded data at the ﬁrst clinic visit. These data reﬂect selected heart failure and other 
medications used in the referral community at the time that referral to a specialized clinic 
was considered necessary or desirable. From January 1999 to December 2007, referral 
drug use of angiotensin receptor blockers, beta-blocker and statins remained unchanged 
(means 10.8%, 58.5%, 34.8%).. The use of angiotensin converting enzyme inhibitors 
decreased from a high of 86.6% in 1999 to low of 15.5% in 2005, spironolactone decreased 
from 38.0% in 2001 to 20.9% in 2007, frusemide decreased from 82,2% in 2000 to 38.9% 
in 2005, digoxin decreased from 49.5% in 1999 to 10,5% in 2006, coumadin from 38.3% in 
2000 to 22.5% in 2007, and aspirin from 46.5% in 2001 to 22.% in 2007.
Conclusions: These data suggest that, between January 1999 and December 2007, 
physicians referred patients on fewer rather than more drugs related to their heart failure 
condition. This suggests that, over the last 9 years, patients are being referred earlier to 
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AL(n=64) SSA(n=14) ATTR(n=37) p value
Low QRS voltage, n/N (%) 33/62 (53) 5/12 (42) 9/33 (27) 0.052
Left bundle branch block, n/N (%) 3/62 (5) 4/12 (33) 1/33 (3) 0.001
Voltage/mass ratio 0.9 ± 0.5 1.0 ± 0.5 1.2 ± 0.5 0.017
Diastolic interventricular septum 
thickness (mm) 15.8 ± 2.8 19.5 ± 4.2 16.2 ± 3.8 0.001
Left atrial diameter (mm) 46.0 ± 6.6 49.8 ± 6.7 41.1 ± 6.7 0.0001
LV ejection fraction (%) 50.6 ± 13.9 44.5 ± 15.9 59.5 ± 14.7 0.001
E-wave deceleration time (msec) 153.8 ± 40.7 168.2 ± 20.8 190.0 ± 70.6 0.004
Atrioventricular valve thickening, 
n (%) 25 (39) 7 (50) 25 (68) 0.022
Mean RA pressure (mm Hg) 9.4 ± 5.7 (n=38)
6 ± 4.5 
(n=11)
5.0 ± 4.8 (n 
=22) 0.006
Mean PCWP (mm Hg) 17.9 ± 8.2 (n 
=38)
15.3 ± 6.1 (n 
=11)
11.2 ± 7.1 (n 
=22) 0.006
Cardiac index (L/min/m2) 2.4 ± 0.6 (n 
=38)
2.3 ± 0.4 (n 
=11)
2.8 ± 0.7 (n 
=22) 0.027
ATTR and SSA patients had better outcomes than AL patients in terms of both overall 
survival (at 2 yrs 48% for AL, 92% for ATTR, 69% for SSA; p <0.001) and freedom from 
major cardiac events (at 2 yrs 38.18% for AL, 83% for ATTR, 100% for SSA; p <0.001). At 
Cox proportional hazards analysis, ATTR was a strongly favorable predictor of survival, 
and SSA predicted freedom from major cardiac events.
Conclusions: AL, ATTR and SSA should be considered three different cardiac diseases, 
characterized by different pathophysiological substrates and courses.
9:30 a.m.
1033-176 Impact of Renin-Angiotension System Polymorphisms 
on Occurrence of Atrial Fibrillation Associated With 
Heart Failure in Hypertrophic Cardiomyopathy: Results 
From Clinical and Gene Analyses of Genotyped 
Patients
Akira Funada, Hidekazu Ino, Noboru Fujino, Kenshi Hayashi, Katsuharu Uchiyama, 
Eiichi Masuta, Yuuichirou Sakamoto, Toshinari Tsubokawa, Akihiko Muramoto, 
Masakazu Yamagishi, Kanazawa University, Kanazawa, Japan
Background: Atrial ﬁbrillation (AF) and heart failure due to systolic dysfunction are 
major complications of hypertrophic cardiomyopathy (HCM). Since HCM with identical 
sarcomere gene mutation show various clinical courses, other modiﬁer genes such 
as renin-angiotensin system (RAS) may play important roles in clinical deterioration. 
However, few data exist regarding the relationship between RAS polymorphisms and 
these cardiac events. Therefore, we determined impact of RAS polymorphisms on clinical 
manifestations of genotyped HCM.
Methods and Results: In 134 carriers of HCM-causing sarcomere gene mutations such 
as MYH7, MYBPC3, TNNT2, and TNNI3 (age 50±21 years, 70 males), we examined 
relationship between RAS polymorphisms (angiotensin-converting enzyme insertion/
deletion (ACE I/D) and angiotensin II type 1 receptor A/C1166 (AT1 A/C1166)), 
echocardiographic parameters and occurrence of AF. Thirty-two patients (24%) had AF 
which was closely related to dilated left ventricular end-diastolic dimension, decreased 
fractional shortening (FS) and dilated left atrial dimension (p<0.05, respectively). As for 
polymorphisms and AF, Kaplan-Meier analysis demonstrated that the ﬁrst onset of AF was 
signiﬁcantly earlier in carriers with AT1 C allele than in those with A/A homozygotes (log-
rank test, p<0.05). As for polymorphisms and heart failure associated with decreased FS 
(<25%), ACE D allele (D/D and D/I) exhibited signiﬁcantly lower FS than I/I homozygotes 
(p<0.05). Interestingly, simultaneous presence of AT1 C allele and ACE D allele was 
signiﬁcant risk factor of occurrence of AF associated with heart failure (p<0.05).
Conclusion: These results demonstrate that in genotyped HCM, subjects with both AT1 
C allele and ACE D allele may develop systolic dysfunction and show early onset of AF, 
and could be at high-risk compared with other groups. We suggest the usefulness of 
detecting RAS polymorphisms for risk stratiﬁcation in genotyped HCM.
9:30 a.m.
1033-177 Pathologic Changes to the Heart Induced by Chronic 
Exposure to Air Pollutants Generated in Trafﬁc and the 
Wildﬁres of Southern California in October 2007
Boris Z. Simkhovich, Glenn Gookin, Dianne Meacher, Paul Willert, Michael T. Kleinman, 
Robert A. Kloner, Good Samaritan Hospital, Los Angeles, CA, University of California - 
Irvine, Irvine, CA
Background: Air pollutants (AP) affect cardiovascular indices. We sought to characterize 
pathophysiological changes in the cardiovascular system using controlled exposure to 
particulate AP.
Methods: In the ﬁrst experiment, Sprague Dawley rats were exposed for 9 months to 
ﬁltered air (FA) vs. AP of different aerodynamic diameter (AD); i.e. coarse (CP, median 
AD 4.0 microns ), ﬁne (FP, median AD 0.7 micron) and ultraﬁne (UFP, median AD 0.06 
micron) in a mobile trailer located near a busy Southern California freeway. In the second 
experiment, SHR and WKY rats were exposed for 3 months to UFP, including the period 
of October 2007 California wildﬁres. Animals in this set had implanted wireless sensors 
for continuous arterial blood pressure (ABP) monitoring.
Results: In the 9 month experiment, hearts exposed to UFP demonstrated signiﬁcant 
degenerative changes within the cardiomyocytes including intracellular edema and 
intensive vacuolization. In addition, UFP caused myocardial inﬂammation and vascular 
congestion. CP caused a trend towards increased accumulation of collagen (assessed 
by picrosirius red staining, p=0.065). Bronchoalveolar lavage demonstrated 3.5 fold 
9:30 a.m.
1033-173 Relationships of Late Enhancements in Myocardium 
by Multislice CT With Ventricular Late Potentials in 
Subjects With Hypertrophic Cardiomyopathy
Marehiko Ueda, Nobusada Funabashi, Masae Uehara, Hiroyuki Takaoka, Michiko 
Daimon, Yoko Mikami, Taichi Murayama, Issei Komuro, Chiba University, Chiba, Japan
Background: Late enhancement (LE) in the left ventricular myocardium (LVM) detected 
by magnetic resonance imaging (MRI) or multislice computed tomography (MSCT) is 
believed to identify non-ischemic cardiomyopathy patients at risk for sustained ventricular
tachycardia and sudden death. Meanwhile, the usefulness and signiﬁcance of ventricular 
late potentials by signal averaged electrocardiography is unconﬁrmed in subjects with 
hypertrophic cardiomyopathy (HCM). We evaluated the relationship of LE in the LVM by 
MRI or MSCT with ventricular late potentials in HCM.
Methods: 49 subjects with HCM (34 male, 15 female, mean age: 63±14 years) underwent 
signal averaged electrocardiography and enhanced MSCT (Light Speed Ultra 16, GE). 
According to the method by Simpson, three leads of signal-averaged electrocardiograms 
were obtained. An average of 250 beats was recorded after ﬁltering with a band-pass ﬁlter 
between 40 and 250 Hz.
Results: LE in the LVM was detected in 32 of 49 subjects (65.3%) in whom the presence 
and distribution of LE in the LVM in MSCT. There were no signiﬁcant differences in the 
duration of ﬁltered QRS (132 ± 25 ms vs. 120 ± 21 ms), the root-mean-square voltage of 
the terminal 40 ms of the ﬁltered QRS complex (54 ± 43 μV vs. 47 ± 34 μV), or duration 
of the terminal ﬁltered QRS complex that remains <40 μV (29 ± 16 ms vs. 34 ±14 ms, p 
<0.05) between the groups. All 14 subjects with a QRS complex that remained <40 μV
shorter than 22 ms had LE. Conversely only 15 of 35 subjects (43%) with a QRS complex 
that remained <40 μV equal or longer than 22 ms had LE.
Conclusions: In HCM subjects, interaction between ﬁbrosis, represented by LE in 
the LVM by MRI or MSCT, and hypertrophy or heterogeneity of myocardial ﬁbers, may 
prevent detection of slow conduction developing independently on signal averaged 
electrocardiography. The signiﬁcance of ventricular late potentials by signal averaged 
electrocardiography in subjects with HCM may be inﬂuenced by the presence of LE in 
the LVM by MRI or MSCT.
9:30 a.m.
1033-174 Abnormal Response to Mental Stress in Patients With 
Takotsubo Cardiomyopathy Evaluated Using Gated 
Single-Photon Emission Computed Tomography
Guido Parodi, Roberto Sciagrà, Stefano Del Pace, Sabrina Genovese, Linda Zampini, 
Benedetta Bellandi, Nazario Carrabba, Gentian Memisha, Gian Franco Gensini, Alberto 
Pupi, David Antoniucci, Department of Cardiology, Careggi Hospital, Florence, Italy
Background: Beyond the acute phase, no persistent abnormality is detected in patients with 
Takotsubo cardiomyopathy (TTC). Since sympathetically-mediated myocardial damage has 
been proposed as the causative mechanism of TTC, we veriﬁed whether mental stress, which 
acts also through sympathetic activation, could evoke abnormalities in these patients.
Methods and results: At least one month after the acute event, 21 patients fulﬁlling all 
TTC diagnostic criteria (Mayo Clinic) underwent resting and mental stress gated single-
photon emission computed tomography (SPECT). Perfusion and wall motion were blindly 
scored, and transient ischemic dilation (TID) and left ventricular (LV) ejection fraction 
(EF) measured using an automated program. In 3 patients (all with signiﬁcantly higher 
enzyme release during acute event) resting perfusion defects suggested the diagnosis 
of prior myocardial infarction instead of TTC. In the remaining 18 subjects, mental stress 
evoked 3 patterns of response: 1) regional changes (perfusion defects and/or wall motion 
abnormality) in 12 cases; 2) global abnormalities (LVEF fall > 5% and/or TID > 1.10) in 11 
patients; and 3) completely negative response in 2 patients. During 6-month follow up, 3 
patients of those with normal resting gated SPECT and mental-stress-induced changes 
(1 regional and 2 global) experienced new cardiac events (angina and/or heart failure).
Conclusion: Mental stress is able to evoke regional and/or global abnormalities in most 
TTC patients; soft clinical event may occur during follow up in patients with abnormal 
response.
9:30 a.m.
1033-175 Analogies and Differences Between the Three Main 
Types of Systemic Cardiac Amyloidosis
Cristina C. Quarta, Letizia Riva, Paolo Ciliberti, Simone Longhi, Fabrizio Salvi, 
Francesca Pastorelli, Giuseppe Galati, Elena Biagini, Michele Cavo, Angelo Branzi, 
Claudio Rapezzi, University of Bologna and S.Orsola-Malpighi Hospital, Bologna, Italy, 
Bellaria Hospital, Bologna, Italy
Background: Most studies of amyloidotic cardiomyopathy consider as a single entity 
the three main systemic cardiac amyloidoses: 1) primary amyloidosis (AL), 2) hereditary, 
transthyretin-related amyloidosis (ATTR), 3) systemic “senile” amyloidosis (SSA). Our aim 
was to assess and compare the diagnostic and clinical proﬁles of the three main types of 
systemic cardiac amyloidosis.
Methods: We conducted a longitudinal study of 115 cardiac amyloidosis patients with clear-
cut etiological diagnosis seen at our institutional network for diagnosis/treatment of systemic 
amyloidosis since 1994 (minimum follow-up, 6 months). In addition to diagnostic ECG and 
echocardiographic ﬁndings, hemodynamic data were available for most patients (n = 71).
Results: Average age at diagnosis was higher in AL than in ATTR; all but one of the 
SSA patients were elderly men. Table summarizes patients’ baseline instrumental 
characteristics according to etiology. 
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features in an Italian setting.
Methods. Our institution provides a coordinated ATTR diagnosis/treatment network with a 
dedicated database (all patients receive echocardiography). We deﬁned cardiac phenotype 
as echocardiographically diagnosed amyloidotic cardiomyopathy accompanied by 
subclinical (mild/absent) neurologic signs not constituting the primum movens for referral.
Results. 16/134 (12%) patients (all Caucasian) had cardiac phenotype (65/118 patients 
with predominantly neurologic phenotype also presented amyloidotic cardiomyopathy). 
Median value of follow-up was 30 months.
Table. Patients’ characteristics according to cardiologic/neurologic phenotype.
Cardiac
(n=16)
Neurologic
(n=118) p value
Men, n (%) 14(87%) 61 (51%) 0.02
Age at diagnosis, years (mean ± SD) 61±10 48±14 < 0.001
Diastolic interventricular septum thickness, mm 
(mean ± SD) 18 ± 3
16 ± 4
(n = 65) 0.06
Restrictive ﬁlling pattern, n (%) 8 (50%) 19/65 (29%) 0.2
Left ventricular ejection fraction, % (mean ± SD) 49 ± 11 59 ± 13(n = 65) <0.01
TTR mutation, n (%)
- Val30Met 
- Ile68Leu
- Glu89Gln
- Other
0 (0%)
10
(62%)
1 (7%)
5 (31%)
41 (35%)
5 (4%)
24 (21%)
48 (40%)
0.01
0.001
0.3
n.a.
Orthotopic liver transplantation, n (%) 1 (6%) 17 (14%) 0.6
Heart and liver transplantation, n (%) 2 (12%) 5 (4 %) 0.4
Annual mortality rate (100 pts/year) 0 15 0.01
Conclusion. Over 10% of our patients presented with cardiac phenotype, highlighting the 
need for cardiologists to consider the possibility of ATTR, even in the absence of overt 
neurologic manifestations. The majority of the patients with cardiac phenotype carried the 
Ile68Leu mutation (and tended to be elderly men); timely recognition of Ile68Leu could be 
relevant for clinical management.
9:30 a.m.
1033-181 Left Ventricular Rotational Mechanics: Differences 
Between Acute Myocardial Infarction and Chronic 
Ischemic and Nonischemic Heart Failure Patients
Matteo Bertini, Gaetano Nucifora, Nina Ajmone Marsan, Victoria Delgado, Rutger J. van 
Bommel, Giuseppe Boriani, Edward R. Holman, Ernst E. van der Wall, Martin J. Schalij, 
Jeroen J. Bax, Leiden University Medical Center, Leiden, The Netherlands
Background: Left ventricular (LV) twist and untwisting rate are emerging as global and 
thorough parameters for the assessment of LV function. Aim of the study was to assess
the differences of LV twist and untwisting rate between acute myocardial infarction (AMI) 
patients and ischemic (IHF) and non-ischemic (NIHF) chronic heart failure patients.
Methods: A total of 50 AMI patients, 49 IHF and 38 NIHF patients were studied. As a 
control group, 28 normal subjects were included. Speckle tracking analysis was applied to 
LV short-axis images at basal and apical level. LV twist was deﬁned as the net difference 
of apical and basal rotation at isochronal time points. The ﬁrst time derivative of LV untwist 
was deﬁned as LV untwisting rate.
Results: Peak LV twist was reduced in AMI patients and extremely reduced in IHF/NIHF 
patients. Furthermore, peak LV twist occurred earlier in patients with worse systolic 
function. In addition, LV untwisting rate was reduced in AMI patients and a trend towards 
a lower value was observed in IHF/NIHF as compared to AMI patients (Table). In the 
overall population, an excellent correlation between peak LV twist and LV ejection fraction 
(r = 0.85, p <0.001) was found and a good correlation between peak LV untwisting rate 
and grade of diastolic dysfunction (r = 0.56, p <0.001) was observed.
Conclusions: LV twist and untwisting rate are strongly related with LV function. An 
impairment of LV function is associated with a reduction of LV twist and untwisting rate 
and with an earlier peak of LV twist.
increase in polymorphonuclear leukocytes in the UFP- vs. FA-exposed rats (p<0.05). In 
the 3 month experiment, SHR rats (both FA- and UFP-exposed) demonstrated increases 
in heart/body weight ratio (p<0.05 vs. WKY), wall thickness of blood vessels and amount 
of collagen in their hearts. Exposure to UFP caused inﬂammation in both SHR and WKY 
rat hearts including a characteristic linear stacking of mononuclear cells within intra-
myocardial vessels. This phenomenon has not been seen in cardiac inﬂammation induced 
by trafﬁc-generated AP and might be speciﬁc to ﬁre-generated AP. In the SHR group UFP 
increased the mean ABP by ~26 mmHg as compared to the SHR group exposed to FA.
Conclusions: Our results indicate that chronic exposure to AP caused degenerative 
changes within the cardiomycytes and inﬂammation within the cardiac muscle and 
vasculature which had an unusual pattern in the ﬁre-generated pollution group. Chronic 
exposure to AP exacerbated hypertension in SHR.
9:30 a.m.
1033-178 Relationship of Left Ventricular Non-compaction With 
Papillary Muscle Insertion Site and Partition
Mitra Sahebazamani, Ijaz Ahmad, Geetha Bhumireddy, Igor Klem, Joshua A. Socolow, 
Sorin J. Brener, Terrence Sacchi, John F. Heitner, New York Methodist Hosptial, 
Brooklyn, NY, Duke Univ Medical Center, Durham, NC
Background: Left ventricular non-compaction (LVNC) is a rare congenital morphogenetic 
abnormality and occurs as a result of an arrest in the compaction of the embryonic 
myocardium during development resulting in excessive trabeculations in the left ventricle 
(LV). The relationship of the papillary muscle (PM) development and LVNC has not been 
previously described.
Methods: We enrolled 297 consecutive patients referred to our cardiac magnetic resonance 
(CMR) center for cardiac evaluation. We assessed the non-compacted (trabecular region) 
and compacted myocardium by drawing diameters of each at the left ventricular apex and 
averaging from two long axis cine views. LVNC was deﬁned as non-compacted to compacted 
ratio 2.3. The PM insertion site was determined by dividing the long axis of the LV into 3 equal 
regions and determining in which region (mid or apical) the papillary muscle inserted into the 
LV. The number of partitions of the PM was determined by counting the number of separate 
PM visualized 10mm apical from the mid plane of the LV on short axis cine view.
Results: The mean age of the patients was 58.1 years, 60% were males. The patients were 
referred to CMR for the following reasons: evaluation of left ventricular function (37%), viability 
(30%), valvular diseases (21%), and other (12%). The average LVEF was 51.2 ± 14.6%. 
The mean number of PM partition in the LVNC group was 5, and in the normal group was 
6(p=0.41). The LVNC group had a signiﬁcantly higher apical insertion of the PM compared to 
the normal group, 87% (67 of 77 patients) vs 67.3 % (148 of 220 patients, p<0.001).
Conclusions: Patients with LVNC have a higher incidence of apical insertion of the 
papillary muscle into the myocardium, without a higher number of partitions.
9:30 a.m.
1033-179 A Case-Control Study of Cellular and Humoral 
Autoimmunity to Cardiac Troponin-I in Patients With 
Idiopathic Dilated Cardiomyopathy
Jason M. Lappe, Clara M. Pelfrey, Anne Cotleur, WH Wilson Tang, Cleveland Clinic, 
Cleveland, OH
Background: The presence of autoantibodies (AAbs) speciﬁc to cardiac troponin I (cTnI) 
has been associated with deleterious outcomes in the post-infarction setting. However, 
the mechanistic role of active cellular autoimmunity in patients with idiopathic dilated 
cardiomyopathy (iDCM) remains unclear.
Methods:  Serum samples and peripheral blood monocytes (PBMCs) were obtained from 
stable ambulatory iDCM patients and healthy controls. A cellular response was identiﬁed by 
staining PBMCs with CFSE dye and culturing for 7 days with 10 μg/mL of cTnI. Proliferation 
was measured using ﬂow cytometry, and a positive response was deﬁned as a ratio between 
the test and the background of >/= 2.0 and an absolute increase of at least 1.0%. AAbs 
against cTnI were detected by ELISA, and a positive response deﬁned as a titer >/= 1:1000. 
Speciﬁcity of anti-cTnI AAbs binding was conﬁrmed by competitive inhibition studies.
Results: Forty-four patients with iDCM (mean age 52±12 years, 46% male, LVEF 23±7%, 
54% on statin) and 35 healthy controls (mean age 47±14years, 63% male) were enrolled. A 
positive cellular proliferative response to cTnI was identiﬁed in 21% (9/44) patients with iDCM 
and 6% (2/35) of healthy controls (p<0.05). Positive anti-cTnI AAbs were identiﬁed in 14% 
(6/44) of iDCM patients and 20% (7/35) of healthy controls (p = NS). The presence of anti-cTnI 
AAbs did not correlate with a positive cellular proliferative response to cTnI. Interestingly, iDCM 
patients who had an AAb response to cTnI were less likely to be taking a statin (p<0.05).
Conclusions: Active cellular autoimmune response to cTnI has been identiﬁed in one-ﬁfth 
of patients with iDCM. The presence of a cellular response was not correlated with the 
presence of AAbs to the same antigen; however this may be confounded by statin use.
9:30 a.m.
1033-180 Hereditary Transthyretin-Related Amyloidosis With 
Predominant or Exclusive Cardiac Phenotype in a 
White Caucasian Population
Paolo Ciliberti, Candida Cristina Quarta, Letizia Riva, Simone Longhi, Fabrizio Salvi, 
Elena Biagini, Giuseppe Galati, Angelo Branzi, Claudio Rapezzi, University of Bologna 
and S.Orsola-Malpighi Hospital, Bologna, Italy
Background. In hereditary transthyretin-related amyloidosis (ATTR), cardiac involvement 
usually occurs after neurologic signs (except among Afro-Americans carrying Val122Ile). 
When neurological manifestations are mild or absent, diagnosis of amyloidotic 
cardiomyopathy may be delayed or missed. Since little is known about the frequency of 
cardiac phenotype in Caucasian ATTR patients, we assessed its prevalence and clinical 
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predictors of outcome in children with AMC.
Methods: Study population consisted of 21 consecutive patients (pts) (age 18d-17y 
median 11 y) who underwent MRI for a clinical diagnosis of myocarditis. The cardiac 
MRI included cine-bright-blood True FISP and delayed contrast-enhanced T1-weighted 
inversion recovery (IR) segmented fast gradient recalled echo imaging. Outcomes 
measured by echo normalization of LV size (end diastolic dimension z score a 2) and 
function (EF q 50%) on follow up (1- 45m median 7m) divided the patients in complete, 
partial and no recovery groups deﬁned as resolution of both, either or none respectively.
Results: Subepicardial enhancement (SEE) was present in 100% and transmural 
enhancement (TME) in 67% of pts. Only 50% of pts with TME had recovery compared 
to 100% of pts without TME. Pts who had SEE associated with normal wall motion, LV 
size and EF had complete recovery. However, pts with TME in combination with segmental 
akinesia, global hypokinesia and LV dilation had 0%, 43% and 22% recovery respectively.
Conclusions: AMC in children is characterized predominantly by subepicardial 
enhancement on cardiac MRI. MRI characteristics such as transmural enhancement, wall 
motion abnormality, LV dilation and EF may be predictors of outcomes.
9:30 a.m.
1033-185 Outpatients With Heart Failure and Low Baseline BNP 
Levels (<200 pg/mL) Have the Greatest Magnitude of 
Change When Undergoing Clinical Decompensation
Pam R. Taub, Ellen Fitzpatrick, Kimberly Tran, Kevin Shaw, Kevin Jiang, Paul Clopton, 
Mitchell Saltzberg, Robert Fitzgerald, Alan Maisel, UCSD Medical Center, San Diego, 
CA
Background: B-type natriuretic peptide (BNP) has become mainstay in the diagnosis 
or exclusion of acute heart failure (HF). However, criteria for interpreting BNP changes 
in the outpatient setting and in detecting early subclinical congestion prior to clinical 
decompensation have not been established.
Methods: 194 patients with HF and at least 5 BNP measurements over 6 month to 2 year 
period were recruited and over 2000 clinical visits with BNP levels were reviewed. Clinical 
determination of decompensation was made by a cardiologist blinded to BNP levels and 
based on Framingham criteria. For this subanalysis, only patients with hospitalizations 
(n=75) were included and were divided into low (<200 pg/mL) and high baseline BNP 
(>200 pg/mL) groups. Baseline BNP was deﬁned as the ﬁrst BNP value upon study 
enrollment not corresponding to hospitalization.
Results: 16 patients in the low baseline BNP group and 59 patients in the high baseline 
BNP group had hospital admissions. Patients in the low baseline BNP group had 564% 
increase (SEM 175) while those in the high baseline BNP group had a 60% increase 
(SEM 16)) prior to hospitalization for decompensated HF (ﬁgure 1, p<.0001).
Conclusions: Patients with low baseline BNP have signiﬁcantly larger changes in BNP 
levels prior to decompensation than those with higher baseline BNP levels. Understanding 
the clinical signiﬁcance of changes in BNP levels prior to decompensation maybe useful 
in diagnosing subclinical congestion and preventing hospitalization.
9:30 a.m.
1033-182 Uric Acid as a Predictor of Mortality in Congestive 
Heart Failure: A Meta-Analysis
Leonardo Tamariz, Arash Harzand, Sameer Verma, John Jones, Joshua Hare, 
University of Miami, Miami
Background: Serum uric acid (SUA) is a product of xanthine oxidase (XO). Apoptosis leads 
to increased purine catabolism increasing XO activity and SUA levels.The purpose of this 
study is to evaluate the evidence supporting SUA as a predictor of all cause mortality in 
patients with heart failure (HF) and to determine the SUA cut-off for the increase in risk.
Methods: We selected all cohort studies in the English literature in which SUA was 
measured and mortality was reported in patients with HF. We calculated the pooled relative 
risk (RR) with the corresponding 95% conﬁdence interval (CI) for all cause mortality 
using the ﬁxed effects method. We evaluated the effects of SUA on all cause mortality 
at different cut-offs >6.5, 6.0-6.5 and 5.0-6.0 mg/dl. Results: Our search strategy yielded 
333 studies; however, only 6 studies met our eligibility criteria. We found no heterogeneity 
(p=0.73). The studies included 4,996 patients with heart failure with a median age of 63 
(range 18-67) and a median ejection fraction of 32% (range 11-37). The RR of all cause 
mortality was 2.48; 95% CI (2.06 - 2.98) for SUA >6.5 mg/dl compared with < 6.5 mg/dl 
SUA level (ﬁgure). The RR of all cause mortality for SUA of 6.0-6.5 mg/dl was 1.69; 95% 
CI (1.35 - 2.12) compared with SUA <6.0 mg/dl. The RR of all cause mortality was 1.42; 
95% CI (1.05-1.93) for SUA of 5.0-6.0 mg/dl compared to SUA <5.0 mg/dl.
Conclusions: Uric acid is an important prognostic marker for all cause mortality in HF. SUA 
has a dose-dependent effect on all cause mortality. 
9:30 a.m.
1033-183 The Prevalence of Effusive Constrictive Pericarditis in 
Patients With Conﬁrmed Tuberculous Pericarditis
Mpiko Ntsekhe, Faisal S. Syed, James Russell, Phillip Usim, Bongani M. Mayosi, 
Department of Medicine, University of Capetown, Capetown, South Africa
Background: Effusive constrictive pericarditis (ECP) occurs when pericardial effusion 
and visceral pericardial constriction coexist and is thought to be a precursor to constrictive 
pericarditis. In the largest study reported to date <10% of the 190 patients undergoing 
pericardiocentesis had evidence of ECP. A small minority in the study had tuberculosis 
pericarditis where ECP may be more common.Using the Initiative for the Investigation 
and Management of Pericarditis In Africa (IMPI Africa) registry we set out to determine 
the prevalence of ECP in patients with TB pericarditis.
Methods: Between Jan ‘06 and May ‘08 consecutive patients with symptomatic 
pericardial effusions referred for therapeutic or diagnostic pericardiocentesis were 
recruited. Simultaneous right atrial and intra-pericardial pressures were measured pre 
and post pericardiocentesis in all who met entry criteria. Tuberculosis was conﬁrmed by 
pericardial ﬂuid microbiology and or chemistry. ECP was deﬁned as failure of the right 
atrial pressure to fall by 50% or to a new level of a12mmHg after the intra-pericardial 
pressure was normalized. Tamponade was deﬁned as equalization of the intra-pericardial 
and mean right atrial pressure.
Results: In the period under review, of 148 consecutive patients referred with symptomatic 
pericardial effusions, 60 had a tuberculous etiology conﬁrmed and had complete hemodynamic 
data for analysis. 38% met criteria for ECP. 52% met criteria for cardiac tamponade. By 
univariate analysis the hemodynamic predictors of ECP were RAP q 20mmHg OR 24.08 
[p=,006]) and pericardial pressure q 20mmHg OR 10.93[p=.004]). Cardiac tamponade was 
not associated with ECP (OR 0.87)[p=.673] By multivariate analysis only RAP q 20mmHg 
remained signiﬁcantly [.001] associated with ECP (OR 18 [p=.001])
Conclusions: We show, in this ﬁrst and largest study of its kind anywhere, that effusive 
constrictive pericarditis is relatively common (38% prevalence) in tuberculous pericardial 
effusions.
9:30 a.m.
1033-184 MRI Characteristics of Acute Myocarditis in Pediatric 
Patients: Patterns and Predictors of Outcomes
Sudhir Vashist, Pamela Woodard, Mark Grady, Gautam Singh, Washington University 
School of Medicine, St. Louis, MO
Background: Acute myocarditis (AMC) often presents a diagnostic dilemma. AMC 
in adults exhibits speciﬁc MRI characteristics, which have not been well described in 
children with AMC. The purpose of the study is to investigate MRI characteristics and 
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were on enzyme replacement therapy (ERT). Structural cardiac abnormalities included at 
least moderate valvular regurgitation in 53%, obstructive hypertrophy in 27% and severe 
CAD in 20%. In addition, clinically signiﬁcant bradycardia was present in 33%, palpitations 
in 59%, atrial ﬁbrillation in 20% and documented non-sustained VT in 13%. Forty-six 
percent (7/15) of patients had implanted devices; 6 were ICDs, and 1 was a dual chamber 
pacemaker. Indications for implantation were symptomatic bradycardia in 3 patients, 
NSVT in 1 patient, hypertrophic cardiomyopathy in 1 patient, syncope in 1 patient and 
palpitations in 1 patient. There was only one detected ventricular tachyarrhythmia over 
a mean follow-up of 30 ± 18 months (range:14-63 months). This episode occurred 63 
months after placement in the setting of profound gastrointestinal bleed, hemorrhagic 
shock, lactic acidosis and hypoxemic respiratory failure as a terminal event during the 
attempted resuscitation.
Moreover, patients were paced in the atrium 84 +/- 23% of the time and in the ventricle 42 
+/- 52% of the time. Three patients in the ICD group and the patient with the pacemaker 
were paced over 95% of the time and likely pacemaker-dependant. Patients with an ICD 
had lower heart rates prior to ICD implant (57+/- 11 BPM vs 81 +/- 12 BPM, p<0.01) 
than the group that did not have devices implanted. There was a trend towards higher 
LV mass in the patients with devices, especially in the subgroup of patients being paced 
over 95% of the time.
Conclusions: Ventricular arrhythmias are less common than previously described in 
patients with FC who are on ERT. However, utilization of pacing is high, and patients may 
become pacemaker dependent as the disease progresses. Sinus bradycardia may be an 
indicator of disease severity and should be considered for device therapy.
9:30 a.m.
1033-189 Relapsing Pericarditis Is Not a Benign Disease in Terms 
of Complications
Kye Hun Kim, Dali Feng, James Glockner, Matthew Martinez, Imran S Syed, Philip 
Aroaz, Paul R Julsurud, Jerome F Breen, Eric Williamson, Jae K Oh, Mayo Clinic, 
Rochester, MN
Background: Although the impairment of quality of life may be severe, it has been generally 
accepted that relapsing pericarditis has excellent life prognosis with exceedingly rare 
severe complications. The aim of this study was to investigate clinical outcomes according 
to the types of initial clinical presentation in patients with relapsing pericarditis.
Methods: A total of 52 patients with relapsing pericarditis were divided into two groups 
and analyzed the development of complications; intermittent type (group I, 36 patients, 
40.0±13.6 years, 21 males), incessant type (group II, 46.5±23.0 years, 9 males).
Results: The frequency of the recurrence in group I was 5.0±2.4. Clinically signiﬁcant 
ventricular dysfunction, arrhythmias, and valvular heart diseases were not developed. 
However, cardiac tamponade requiring pericardiocentesis in 20 patients (38.5%), pleural 
effusion requiring thoracentesis in 16 patients (30.8%), intractable symptoms requiring 
pericardiectomy in 13 patients (25.0%), constrictive pericarditis in 5 patients (1 persistent, 
4 transient) (9.6%), treatment-related complications in 2 patients (1 iatrogenic Cushing, 
1 renal failure) were developed during the clinical courses in patients with relapsing 
pericarditis. Among these complications, the development of cardiac tamponade was 
signiﬁcantly higher in group II (11 patients, 68.8%) than in group I (9 patients, 25.0%) 
(p=0.003). Fourteen patients (38.9%) in group I had developed steroid dependency and 
thus changed into incessant type during clinical courses. Improvement of pericarditis 
without recurrence following pericardiectomy was observed in only 2 patients (15.4%) and 
the remainders were still symptomatic or showed recurrence of pericarditis. Conclusion: 
The present study demonstrated that relapsing pericarditis is not a benign disease in 
terms of complications. Clinically signiﬁcant cardiac tamponade are not uncommon, 
especially in incessant type, and constrictive pericarditis either persistent or transient 
may be developed.
9:30 a.m.
1033-190 Impact of Anti-B1 and Anti-B2 Antibodies on the 
Genesis of Ventricular Arrhythmias
Juan A. Marques, Alfredo Mijares, Nancy Linares, Rodolfo Fernandez-Gomez, Johan 
Hoebeke, Ivan Mendoza, Ariel L. Escobar, Ivan Mendoza-Britto, IVIC, Caracas, 
Venezuela, Central University of Venezuela, Caracas, Venezuela
Background: Ventricular arrhythmias in ischaemic heart disease, congestive heart 
disease, idiopatic dilated cardiomiopathies and Chagas disease have been related with 
autoantibodies against beta-receptors
Objective: To evaluate the impact of autoantibodies against beta-receptors in a mouse 
whole heart Langendorff’s preparation that allows the assessment of calcium currents 
and action potentials.
Methods: Hearts from 5-7 weeks old Balb/c mice were perfused in a whole heart 
Langendorff’s preparation. Calcium currents were evaluated by local-ﬁeld ﬂuorescence 
microscopy. Action potentials were recorded through 2-mm electrodes. Monoclonal anti 
beta-2 antibodies against H19C peptide in the second extracellular loop of human beta-2 
receptor and anti beta-1 against H26R peptide were used.
Results: Calcium currents in different heart areas were obtained (ﬁg 1). Monoclonal 
beta-2 antibodies on calcium currents in right atrium and right ventricle produce AV 
conduction block (ﬁg 2-B), that dissappers with the washout (ﬁg 2-C).Anti-B1 antibodies 
produce produce a positive chronotropic effect (ﬁg 3-B), disappearing with washout and 
propranolol (ﬁg 3-C). Conclusions: Anti beta-1 antibodies show a positive chronotropic 
effect, while anti beta-2 antibodies affect AV conduction. The presence of both could 
contribute to the appearance of ventricular arrhythmias in whole hearts. 
9:30 a.m.
1033-186 Echocardiographic Two-Dimensional Speckle Tracking 
Radial Strain for Detection of Severe Heart Iron 
Overload in Transfusion-Dependent Thalassemia Major: 
Validation With Magnetic Resonance Heart T2*
Thu-Thao Le, Yacui Gu, Ru-San Tan, National Heart Centre, Singapore, Singapore
Background. Siderotic cardiomyopathy in transfusion-dependent thalassemia major 
(TM) often exhibits normal echocardiographic ﬁndings. T2* magnetic resonance (MR) 
imaging allows early detection - heart T2*<10ms indicates severe heart iron overload 
with high risk of heart failure - but is not widely available. We studied echo radial strain in 
severe heart iron overload.
Methods. 24 beta TM patients underwent MR scans and were stratiﬁed by heart T2* results: 
<10ms (severe iron loading) and q10ms (no or mild iron loading). From same-day echo scans, 
we measured left ventricular (LV) ejection fraction, mitral E and A velocities, deceleration time, 
myocardial septal velocity E’. From 2D speckle tracking analysis of 12 segments in the mid 
and apical LV short-axis views, we determined average peak radial strain (S), average (t) and 
maximum time lag (t
max
) between aortic valve closure and peak radial strain.
Results. See table. There was no signiﬁcant difference in all variables except t (p=0.022) 
and t
max
 (p=0.008) at mid LV level. t
max
 has higher area under curve (AUC=0.82) compared 
to t (AUC=0.77) for diagnosis of T2*<10ms. Cutoff value t
max
 = 77ms predicts severe heart 
iron overload (NPV 76.5, PPV 83.3).
Conclusion. In TM, severe heart iron overload signiﬁcantly delays peak radial strain 
development in the mid LV, without signiﬁcant decrease in amplitude of myocardial radial 
strain. Prolonged t
max
 >77ms at mid LV may be used to triage TM patients for MR imaging 
and intensiﬁed iron chelation therapy.
Echocardiographic parameters by heart T2* status (values expressed 
as mean ± SD)
T2*<10ms (n = 10) T2*q10ms (n = 14) p value
Age (years) 19.6 ± 5.8 19.3 ± 8.6 ns
Gender (M:F) 8:2 10:4 ns
Mitral deceleration time (ms) 149 ± 20 142 ± 24 ns
Mitral E/A 2.31 ± 0.70 2.43 ± 0.57 ns
Mitral E/septal E’ 10.21 ± 3.73 7.99 ± 1.27 ns
Ejection fraction (%) 59.2 ± 4.3 59.7 ± 5.3 ns
Mid S (%) 48.8 ± 14.9 57.4 ± 10.5 ns
Mid t (ms) 49 ± 34 22 ± 19 0.022
Mid t_max (ms) 77 ± 38 33 ± 34 0.008
Apical S (%) 31.9 ± 11.7 57.4 ± 10.5 ns
Apical t (ms) 59 ± 48 38 ± 36 ns
Apical t_max (ms) 68 ± 53 51 ± 49 ns
9:30 a.m.
1033-187 Impact of Race on Prevalence of Hypertrophic 
Cardiomyopathy in Healthy Teenagers Undergoing 
Screening Echocardiography
Mohammad Reza Movahed, Sudhakar Sattur, Sharon Bates, The Southern Arizona VA 
Health Care System and Sarver Heart Center, Tucson, AZ
Background: The prevalence of Hypertrophic Cardiomyopathy (HCM) in the population 
has been thought to be less than 1%. The goal of this study was to evaluate the prevalence 
of HCM in a population of teenage high school students who underwent screening 
echocardiography for the detection of HCM based on race across the United States
Method: The Anthony Bates Foundation has been performing screening echocardiography 
in high schools across the United States for the prevention of sudden death since 2002. A 
total of 2066 students were identiﬁed between the ages of 13 to 19 years who underwent 
screening echocardiography with documented wall thickness. Suspected HCM was 
deﬁned as any wall thickness q 15 mm.
Results: The total prevalence of suspected HCM, deﬁned by a cut off value of 15 mm or 
more, was 1.3% (7/551). The incidence of suspected HCM was markedly higher in the 
African American teenagers [6% (3/50) of African American teenagers, vs. 0.8 % (4/501) of 
other races, OR 7.93, CI 1.72-36.49, p=0.002]. Using multivariate analysis adjusting for age, 
gender, BMI and HTN (systolic BP >140 and diastolic BP of > 90), African American race 
remained independently associated with suspected HCM (OR 4.89, CI 1.24-39.62, p= 0.02).
Conclusion: The prevalence of suspected HCM in young African American teenagers is 
markedly higher in comparison to other races. The cause of this difference is not known 
warranting further investigations.
9:30 a.m.
1033-188 Arrhythmias and Implantable Cardioverter-Deﬁbrillators 
in Fabry Cardiomyopathy
Peter G. Robertson, G. Neal Kay, David Warnock, Leslie Jackson, Jose Tallaj, University 
of Alabama at Birmingham, Birmingham, AL
Background: Arrhythmias have been reported in patients with Fabry cardiomyopathy (FC). 
Methods: Retrospective chart review and analysis of the ICD interrogation strip in patients 
with known FC to determine the observed arrhythmias.
Results: Fifteen patients (10 male, 5 female) with FC were followed in our clinic; all patients 
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of the 35 ICP patients (both p<0.0001). In PSCP patients, pulmonary capillary wedge 
pressure (20±6 vs. 15±4 mmHg; p<0.01) and left ventricular end-diastolic pressure 
(22±4 vs. 17±4 mmHg; p<0.01) were signiﬁcantly higher, and the difference between left 
ventricular end-diastolic pressure and right ventricular end-diastolic pressure (6.7±1.8 
vs. 1.5±2.1 mmHg; p<0.0001) was signiﬁcantly greater than in ICP patients, indicating 
a left heart-dominant constrictive physiology for PSCP. Tagged cine MRI distinguished 
the pericardial adhesions that predominantly covered the left heart in PSCP from those 
uniformly covering both the left and right heart in ICP.
Conclusions: The classic hemodynamic criteria and dynamic respiratory variations for 
CP, which are based on the assumption of uniform pericardial constriction, may not be 
applicable to PSCP patients who have left heart-dominant pericardial constriction. Tagged 
cine MRI is useful for detecting left heart-dominant pericardial adhesions in PSCP.
9:30 a.m.
1033-193 Reversal of Heart Iron Overload Following Intensiﬁed 
Chelation Therapy in Tranfusion-Dependent 
Thalassemia Major: Assessment Using Magnetic 
Resonance Heart T2*
Thu-Thao Le, Ru-San Tan, National Heart Centre, Singapore, Singapore
Background. Siderotic cardiomyopathy is the commonest cause of premature death in 
thalassemia major (TM). The degree of heart iron overload is inversely proportional to 
the magnetic resonance (MR) relaxation parameter T2*. We studied the time course of 
heart iron load reversal, expressed as improvement in heart T2*, following iron chelation 
therapy.
Methods. We retrospectively analyzed the initial and serial MR T2* scans (performed 
every 6 to 12 months) in 19 beta TM patients, who had been detected to have heart 
iron overload on MR scans (T2*<20ms) and were treated thereafter with intensiﬁed iron 
chelation regimen.
Results. 14 patients had severe (T2*<10ms, Group A), and 5 had mild to moderate 
(T2* 10ms to 20ms, Group B) heart iron overload (table). On survival analysis, median 
durations for heart T2* values to increase by 10% were 20 and 12 months in Groups A 
and B, respectively.
Conclusion. Despite intensive chelation therapy, heart T2* improved very slowly, 
especially in severe heart iron overload. This implies that intensive chelation therapy must 
be prolonged in patients with heart iron overload. MR T2* scans should be performed to 
document resolution of heart iron deposition before withdrawal of intensive chelation. 
Transfusion history and chelation treatment of patients in both 
groups
Group A, 
T2*<10ms
(n = 14)
Group B, T2* 10ms 
to 20ms
(n = 5)
p
value
Age (years) 23 ± 5 24 ± 8 ns
Transfusion duration (years) 23 ± 5 23 ± 8 ns
Transfusion units per transfusion 2.3 ± 0.6 2.4 ± 0.5 ns
Interval between transfusions (weeks) 3.6 ± 0.5 3.9 ± 0.5 ns
Chelation duration (years) 12 ± 5 15 ± 5 ns
Chelation therapy: deferoxamine : 
deferiprone : combination (%) 60:0:40 26.3:5.3:68.4 ns
Serum ferritin level (mg/dl) 5621 ± 5646 2400 ± 1920 ns
9:30 a.m.
1033-194 Factors Determining Clinical Outcomes of Patients With 
Stress-Induced Cardiomyopathy in a Tertiary Referral 
Hospital
Pil Hyung Lee, Byung Joo Sun, Hyung Oh Choi, Ji Hye Yim, Jong-Min Song, Duk-Hyun 
Kang, Jae-Kwan Song, Seong-Wook Park, Department of Internal Medicine, Asan 
Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Background: Stress-induced cardiomyopathy (SCMP) is an increasingly recognized 
disease entity and clinical features and outcomes of SCMP in a tertiary referral hospital 
are not known.
Methods: Inclusion criterion was newly developed wall motion abnormalities on 
echocardiography beyond a single epicardial coronary distribution without clinical 
evidence of coronary artery disease.
Results: A total of 60 patients (median 63 years) were enrolled from Jan 2000 to June 
2008. Women comprised 78% of total patients. The triggering events were acute medical 
illness (sepsis, hypoxemia, bleeding, etc) in 31 patients (52%, group I), in-hospital surgery 
or procedure (endoscopy, bronchoscopy, elective surgery, etc) in 17 (29%, group II) 
and emotional stress in 12 (19%, group III). Chest pain was more frequently observed 
in group III, whereas dyspnea was more frequent in group I and II. Age and sex ratio 
were not different among groups. Median ejection fraction was 34% and peak troponin 
I level was only mildly elevated (median 3.2 ng/mL). QT prolongation was the most 
freqent ECG abnormality (88%) and T wave inversion was present in 73%. Typical apical 
ballooning was present in 45 patients (75%) and right ventricular involvement in 12 (20%). 
Tachyarrhythmia (atrial ﬁbrillation [n=7], atrial ﬂutter [n=2], and ventricular tachycardia 
[n=3]) was observed in 12 patients (20%). Laboratory ﬁndings were not signiﬁcantly 
different among groups. Admission to the intensive care unit (ICU) was needed in 48 
patients (81%), largely due to pulmonary edema (n = 30, 51%) or shock (n =21, 35%). 
Although the frequency of ICU admission was not different, endotracheal intubation was 
9:30 a.m.
1033-191 Trastuzumab Cardiotoxicity: Not as Benign as It Looks?
Christopher C. Reynolds, Gregory Hartlage, Vinod Patel, Ren Chen, Maya Guglin, 
University of South Florida, Tampa, FL, H. Lee Mofﬁtt Cancer Center, Tampa, FL
Background: Trastuzumab (TZB) reduces mortality and recurrence in breast cancer. 
Cardiotoxicity (CTX) is a major side effect often resulting in early cessation of treatment 
(TX). The full extent of the problem in a “real life” situation is not well studied. Our objective 
is to determine the incidence of TZB-induced CTX and the rate of discontinuation of TZB 
in patients.
Methods: We retrospectively reviewed the records of 187 women with breast cancer 
who received TZB as an adjuvant (ADV) TX (118) or TX of metastatic (MET) cancer (69) 
between 2004 and 2006. CTX was deﬁned as a decrease of ejection fraction (EF) to 
a50%, or q10% from the baseline, or symptoms of heart failure. Statistical analysis was 
done with Chi-square test and Fisher exact test.
Results: After excluding 25 patients with no follow-up EF, 161 patients, all women ranging 
from 29 to 86 years, mean 51.4±10.9, were analyzed. CTX developed in 56 patients 
(34.8%), including 33.1% of ADV patients and 39.5% of MET patients.
In the ADV group, 19.5% of patients discontinued TZB due to CTX. CTX accounted for 
75.5% of premature discontinuation of TZB. In both groups, EF decreased in 3 months in 
patients with CTX and remained below baseline for the 12 months of TX. In 3 of 5 patients 
with follow-up beyond 12 months, EF remained <50%. In patients with either hypertension 
or diabetes, risk of CTX was higher (56.4% vs 32.9%, p<0.05).
Conclusions: CTX occurred in 1/3 of breast cancer patients treated with TZB and was 
the reason for premature discontinuation of TX in 20% of the ADV group.
Ejection Fraction in Patients With Breast Cancer Treated with 
Trastuzumab
Baseline (%) 3 Months (%) 6 Months (%) 9-12 Months (%)
Adjuvant
No Cardiotoxicity 59.2+4.9 59.9+5.3 59.2+5.0 59.2+4.7
Cardiotoxicity 61.3+7.0 54.4+7.6 54.2+7.9 53.1+6.5
Metastatic
No Cardiotoxicity 59.3+7.2 59.1+7.3 59.8+6.8 59.6+6.7
Cardiotoxicity 59.4+6.8 56.7+5.7 55.6+5.0 54.2+7.0
Total
No Cardiotoxicity 59.3+5.5 59.7+5.6 59.3+5.2 59.3+5.2
Cardiotoxicity 60.7+6.9 54.9+7.2 54.5+7.3 53.5+6.9
9:30 a.m.
1033-192 Diagnosis of Post-surgical Constrictive Pericarditis: 
Demonstration of Left Heart-Dominant Pericardial 
Adhesion
Teruo Noguchi, Sunao Kojima, Naoaki Yamada, Yoichi Goto, National Cardiovascular 
Center, Suita, Japan
Background: We sought to identify the distinctive clinical and hemodynamic features of 
post-surgical constrictive pericarditis (PSCP) in comparison with idiopathic CP (ICP) and 
to assess the utility of magnetic resonance imaging (MRI) in PSCP diagnosis.
Methods: High-ﬁdelity intracardiac pressure waveforms from 51 consecutive patients with 
surgically proven CP (16 PSCP patients and 35 ICP patients) were examined. Tagged 
cine MRI was performed in 10 PSCP and 10 ICP patients using a 1.5T MR system.
Results: Only 6% and 25% of the 16 PSCP patients fulﬁlled the classic hemodynamic 
criteria or had dynamic respiratory variations, respectively, in contrast to 77% and 86% 
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9:30 a.m.
1033-197 Immunological Correlates of Tuberculous Effusive 
Constrictive Pericarditis
Bongani M. Mayosi, Kerryn van Veen, Faisal Syed, James Russell, Kemilembe 
Tibazarwa, Okechukwu Usim, Mpiko Ntsekhe, Robert J. Wilkinson, Katalin A. Wilkinson, 
University of Cape Town, Cape town, South Africa
Background: Effusive constrictive pericarditis is present when there is evidence of 
clinical and haemodynamic constriction following pericardiocentesis in a patient with a 
pericardial effusion. It is not known whether effusive constrictive physiology is associated 
with speciﬁc immunological changes compared to pure effusive disease in tuberculous 
pericarditis.
Methods: The expression of inﬂammatory, anti-inﬂammatory, and ﬁbrotic response 
genes were analysed using quantitative RT-PCR of RNA extracted from pericardial 
ﬂuid and blood of 23 patients with tuberculous pericardial effusion. Gene expression 
was normalized to human beta-actin in the same sample. Blood and pericardial ﬂuid 
was compared in all patients, after which patients were stratiﬁed according to disease 
outcomes of either pure effusive or effusive-constrictive pericarditis according to invasive 
haemodynamic monitoring of the pericardium and right side of the heart..
Results: There was abundant expression of the proﬁbrotic TGF-beta, inﬂammatory IL-1 
beta, SPARC (a ﬁbrotic response gene with a regulatory role) and Timp1 (the natural 
inhibitor of matrix metalloproteinase 2 and 9) in both blood and pericardial ﬂuid. There 
was clear evidence of compartmentalized gene expression as RNA levels of genes 
associated with ﬁbrosis Col1a1, Col1a2, Col4a1 and Col4a2 (encoding procollagen 
molecules) and regulatory FOXP3 were signiﬁcantly upregulated in the pericardial ﬂuid 
compared to the blood. We next stratiﬁed the data according to disease status and found 
that TGF-beta (p=0.016) and IFN-gamma (p=0.014) were signiﬁcantly down regulated in 
the pericardial ﬂuid of patients with effusive constrictive pericarditis compared to those 
with purely effusive pericardial disease.
Conclusion: We show for the ﬁrst time that effusive constrictive pericarditis is associated 
with a speciﬁc pattern of cytokine expression in tuberculosis. These ﬁndings may assist in 
the development of predictive biomarkers for ﬁbrosis in pericardial tuberculosis.
9:30 a.m.
1033-198 Sudden Death Due to Concentric Left Ventricular 
Hypertrophy in the Absence of Myoﬁbrillary Disarray in 
African-Americans
Laudino M. Castillo-Rojas, David A. Appel, Jennifer A. McNear, Lena Avedissian, John 
E. Atwood, Lisa A. Pearse, Robert N. Potter, Allen P. Burke, Ladd Tremaine, Eric A. 
Shry, Philip J. Gentlesk, Stephen S. Reich, Robert E. Eckart, Department of Defense 
Cardiovascular Death Registry Group, Brooke Army Medical Center, San Antonio, TX, 
Armed Forces Institute of Pathology, Washington, DC
Background: Sudden death in young African-Americans is frequently under-reported 
and limited to case series of athletes. We sought to describe a cohort of patients to deﬁne 
differences in cause of death as a function of race.
Methods: Clinical and pathologic records from the Ofﬁce of the Armed Forces Medical 
Examiner from 1998 to 2008 were reviewed.
Results: There were 838 deaths identiﬁed that serve as the basis for the cohort (mean 
age 38±11 years). Reported race included Caucasian (n=589, 70.3%), African-American 
(n=213, 25.4%), Paciﬁc Islander (n=19, 2.3%), and Asian (n=17, 2.0%). There was no 
difference in ﬁnding of idiopathic sudden death as a function of race (Caucasians - 
20.2%, African-Americans - 22.5%, p=0.54). Fatal coronary disease was most common in 
Caucasians (n=381, 64.7%), while signiﬁcantly lower in African-Americans (n=97, 45.5%, 
p<0.001). Concentric left ventricular hypertrophy without myoﬁbrillary disarray was more 
common in African-Americans than Caucasians (16.9% vs. 3.7%, p<0.001), but there 
was no difference in hypertrophic CM (3.7% vs. 2.0%, p=0.17) as a function of race. There 
was no clinical difference in LV thickness or cardiac mass between African-Americans 
and Caucasians (1.7±0.4cm vs. 1.6±0.4cm, p=0.022; and 454±88gm vs. 451±86gm, 
p=0.69).
Conclusion: Idiopathic concentric left ventricular hypertrophy without myoﬁbrillary 
disarray, but not hypertrophic cardiomyopathy, is more commonly noted in African-
Americans than Caucasians and represents a common cause of sudden cardiac death.
9:30 a.m.
1033-199 Clinical Signiﬁcance of Plasma Brain Natriuretic 
Peptide Level in Cardiac Sarcoidosis Patients Treated 
With Corticosteroids
Yoshikazu Yazaki, Mitsuaki Horigome, Ayako Takahashi, Uichi Ikeda, Noriyuki Sekimura, 
Division of Cardiology, Matsumoto Medical Center, Matsumoto, Japan, Department of 
Cardiovascular Medicine, Shinshu University, Matsumoto, Japan
Background:Corticosteroid treatment is generally indicated in patients with cardiac 
sarcoidosis (CS). A reliable heart-speciﬁc marker for the monitoring of steroid treatment 
remains to be established in CS. Although plasma brain natriuretic peptide (BNP) level is 
related to the severity of heart failure, clinical utility of BNP measurement on the follow-up 
of CS patients treated with corticosteroids is unknown.
Methods:We studied 30 CS patients who measured plasma BNP levels, and compared 
the values to clinical ﬁndings and outcome. Serial measurements were also performed 
before and during steroid treatment.
Results:At the time of BNP measurement, 8 patients showed abnormal gallium-67 
uptake in the myocardium. BNP levels of the 8 patients were signiﬁcantly higher than 
those of the other patients with negative results (549±515pg/ml versus 104±122pg/ml, 
p<0.05), although left ventricular ejection fraction was similar between the two groups. 
more frequently needed in group I and II. Fifteen patients (25%) died and mortality was 
not different among groups. Multivariate analysis showed that APACHE II score, a clinical 
index representing the severity of systemic illness, (HR 1.233, 95% CI 1.116 - 1.362, 
p<0.001) and right ventricular involvement (HR 6.187, 95% CI 1.727 - 22.158, p = 0.005) 
were independently associated with death.
Conclusions: Clinical features of SCMP in a tertiary referral hospital are quite different 
with grave prognosis depending on the severity of underlying disease.
9:30 a.m.
1033-195 Patterns of Septal Hypertrophy in Hypertrophic 
Cardiomyopathy Are Associated With Differences 
in Clinical and Functional Characteristics by 
Echocardiography and Cardiac MRI
Aslan T. Turer, Zainab Samad, Anne M. Valente, Michele A. Parker, Brenda Hayes, 
Raymond J. Kim, Joseph Kisslo, Andrew Wang, Duke University, Durham, NC
Background: Hypertrophic cardiomyopathy (HCM) has a wide spectrum of anatomic 
and clinical expression, yet septal hypertrophy is a typical ﬁnding.. Classiﬁcation of septal 
morphology in HCM has been proposed, yet its clinical signiﬁcance is undeﬁned.
Methods: 75 patients with HCM were prospectively enrolled. Septal morphology was 
categorized based on the echocardiographic parasternal long-axis (LAX) and apical 
4-chamber (Ap) views into 5 subtypes:
Simple sigmoid: maximal septal wall thickness at the basal septum in both LAX and Ap 
views. Complex sigmoid: maximal septal wall thickness at the basal septum in LAX view 
(i.e. subaortic) and an additional prominent mid-septal wall thickness q basal septum in 
Ap view. Catenoid: maximal septal wall thickness at the mid-septum in Ap view. Neutral: 
uniformly thickened septum, with a ratio of each septal segment:maximal septal wall 
thickness q0.8 in Ap view. Apical: maximal septal wall thickness in the apical septum 
in Ap view. All patients underwent delayed-enhanced cardiac MRI (DE-CMR) imaging. 
Hyperenhancement (HE) was measured by 2 investigators blinded to the clinical and 
echocardiography results.
Results: Catenoid septum was the most common morphologic subtype (31/75, 41%), 
followed by simple sigmoid (22/75, 29%), complex sigmoid (15/75, 20%), neutral (4/75, 
5%), and apical (3/75, 4%). The age at symptom onset was youngest among catenoid 
and complex sigmoid groups (p=0.008). Provocable LV outﬂow obstruction by Doppler 
velocity was highest among simple and complex sigmoid septal subtypes. Diastolic 
function differed between groups, with catenoid or complex sigmoid septal morphologies 
more strongly associated with restrictive ﬁlling pattern (grade 3) by tissue Doppler. By DE-
CMR, the presence of HE also differed signiﬁcantly between the subtypes [apical (100%), 
catenoid (77%), complex sigmoid (67%), simple sigmoid (27%), neutral (25%), p=0.002].
Conclusions: A simple classiﬁcation of 5 septal hypertrophy patterns in HCM demonstrates 
signiﬁcant differences in clinical and functional characteristics, as well as the amount of 
hyperenhancement by CMR, among the septal subtypes. 
9:30 a.m.
1033-196 Effect of Corticosteroid Dose in Relapsing Pericarditis
Masud H. Khandaker, Raul E. Espinosa, Nandan S. Anavekar, Steven I. Robinson, 
Rowlens M. Melduni, Sharonne N. Hayes, Jae K. Oh, Mayo Clinic, Rochester, MN
Background: A recent retrospective study has suggested that high dose but not low dose 
corticosteroids are associated with a higher recurrence rate and morbidity in patients with 
relapsing pericarditis. The purpose of this study was to validate this concept further.
Methods: Retrospective review of 244 patients who presented to the Mayo Clinic, 
Rochester, between 1994 to 2005 with a diagnosis of relapsing pericarditis yielded 108 
patients who were treated with prednisone. Patients were divided into high dose (q 40 mg; 
n = 26), intermediate dose (20 - 39 mg; n = 40) and low dose (< 20 mg; n = 42) prednisone 
groups. The primary endpoint was the time to recurrence, cardiac tamponade, constrictive 
pericarditis or pericardiectomy.
Results: No signiﬁcant differences in mean age and gender were found in the high 
(48.7 ± 17.4 years, 58% female), intermediate (49.3 ± 14.4 years, 63% female) and 
low dose (45.6 ± 14.1 years, 64 % female) prednisone groups. In addition, baseline 
clinical and demographic characteristics were similar across the groups. Mean highest 
prednisone dose was 54 ± 22 mg/day vs 23 ± 4.4 mg/day vs 8.9 ± 3.6 mg/day for the 
high, intermediate and low dose groups respectively. Kaplan Meier analysis was used 
to analyze event free survival over 5 years (Figure) and revealed no differences in any 
corticosteroid group (p = 0.784).
Conclusion: While this study is limited by sample size and its retrospective design, 
corticosteroid dosage does not appear to affect outcome in patients with multiple relapses 
of pericarditis. 
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1033-202 Left Ventricular Dysfunction in Patients Receiving 
Cardiotoxic Cancer Therapies: Are Clinicians 
Responding Appropriately?
Geoffrey Yoon, Melinda Telli, David Kao, Kelly Matsuda, Ronald Witteles, Stanford 
University, Stanford, CA
Background: Cancer survivors treated with anthracyclines and/or trastuzumab are at risk 
for cardiotoxicity. Left ventricular (LV) systolic dysfunction, symptomatic or asymptomatic, 
represents a Class I indication for therapy with beta-blockers and angiotensin-converting 
enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) according to ACC/AHA 
guidelines. We designed this study to examine treatment practices for patients with cancer 
therapy-associated LV dysfunction, and the real-world adoption of treatment guidelines.
Methods: After IRB approval, we reviewed all patients who received anthracycline and/
or trastuzumab cancer therapy at Stanford University from October 1, 2005 to October 
31, 2007. Out of 6,530 total cycles of chemotherapy administered, we identiﬁed all unique 
patients who had at least one echocardiogram performed before and after the start of 
chemotherapy. Detailed chart review was then conducted for these patients, examining 
chemotherapy regimens, cardiac risk factors, cardiac imaging results, concomitant 
medications, and patient referrals/consultations.
Results: A total of 88 patients met inclusion criteria. Ninety-two percent were treated with 
anthracyclines, 25% with trastuzumab in combination with anthracyclines, and 8% with 
trastuzumab alone. Mean baseline EF was 60%, with 13% of patients having a baseline EF 
below normal. A total of 41% had LV dysfunction (EF less than 55%) during or after cancer 
therapy. Of these patients, 56% received beta-blocker therapy, 47% received ACE-I or ARB 
therapy, and 50% received Cardiology consultation. Of the patients with asymptomatic LV 
dysfunction (75% of the LV dysfunction cohort), 41% received beta-blocker therapy, 33% 
received ACE-I or ARB therapy, and 37% received Cardiology consultation.
Conclusions: In real-world clinical practice, many cancer survivors with cardiotoxicity are 
not adequately evaluated and treated from a cardiovascular standpoint. Multidisciplinary 
collaboration between oncologists and cardiologists is vitally needed to improve the 
quality of care for these patients.
9:30 a.m.
1033-203 Cardiac MRI Study of Duchenne Cardiac Dysfunction: Is 
It a Dilated Cardiomyopathy?
William M. Gottliebson, Joshua T. Germann, Robert J. Fleck, Linda H. Cripe, Wojciech 
Mazur, Janaka P. Wansapura, Erik C. Michelfelder, D. Woodrow Benson, Kan N. Hor, 
Cincinnati Childrens Hospital Medical Center, Cincinnati, OH
Background: The cardiac ﬁndings in Duchenne muscular dystrophy (DMD) are 
considered a progressive dilated cardiomyopathy. Our experience with cardiac MRI (CMR) 
surveillance of DMD patients, however, has not shown consistent elevation of LV volume. 
We hypothesized that DMD cardiomyopathy has geometric features distinguishing it from 
the classic dilated cardiomyopathies.
Methods: Clinical and research CMR data was reviewed from DMD patients with cardiac 
dysfunction (LV EF < 55%), and from normal controls. Age, LV EF, and indexed LV 
mass (LVMi) and LV end-diastolic volume (EDVi) were tabulated for each individual. LV 
geometry was quantiﬁed by the Mass/Volume Ratio (MVR). MVR between groups was 
compared via Student’s t-test.
Results: LVMi and EDVi were normal in both the controls (n=61, age 6.87 - 34.2 years) 
and DMD patients (n=56, age 5.57 - 34.4 years). EF ranged from 7 - 54% in DMD patients; 
EF was normal (> 55%) in all controls. Mean MVR values for controls (0.67 ± 0.17) and 
DMD patients (0.72 ±0.17) were not statistically different (p=0.092).Figure 1a (boxplot) 
demonstrates the similarity in the MVR values, while Figures 1b-c conﬁrm the absence of 
a signiﬁcant relationship between MVR and either age or EF.
Conclusion: MVR of DMD patients is normal, in distinction to published MVR values of 
classic dilated cardiomyopathies. This suggests that DMD LV myocardium responds with 
a unique pattern of remodeling, and thus requires consideration of alternative therapeutic 
strategies for this disease. 
9:30 a.m.
1033-204 Variable Wall Motion Abnormalities Seen With Stress 
Mediated Cardiomyopathy
Khadija Siddiqui, Matthew Weinberg, Ronald Siegel, Medical College of Wisconsin, 
Milwaukee, WI
Background: Takotsubos cardiomyopathy (TC) has been reported as an apical ballooning 
(“typical”) or midventricular (“atypical”) dysfunction. However, transient global wall motion 
abnormality in the absence of obstructive epicardial disease has not been described. 
Plasma BNP levels of 16 patients requiring device therapies were signiﬁcantly higher 
than those of the other 14 patients (342±459pg/ml versus 43±35pg/ml, p<0.05). All 
patients received oral prednisone with an initial dose of 30mg/day and a maintenance 
dose of 5 to 10mg/day. Plasma BNP concentrations were unchanged within 6 months 
after starting corticosteroids (221±144pg/ml to 188±124pg/ml, not signiﬁcant), but 
signiﬁcantly decreased until 12 months (221±144pg/ml to 118±136pg/ml, p<0.05). 
During a mean follow-up of 3 years, we clinically detected relapse of cardiac lesions 
in 8 patients presenting with recurrence of abnormal myocardial gallium-67 uptake, 
conduction disturbance or arrhythmias, or rapid worsening left ventricular ejection 
fraction (LVEF) after the long-term stable clinical course. The 8 showed a signiﬁcantly 
increased BNP level when the relapse occurred (58±53pg/ml to 125±116pg/ml, p<0.05). 
After an increase in corticosteroid dose or addition of methotrexate, the BNP levels were 
signiﬁcantly decreased (125±116pg/ml to 58±68pg/ml, p<0.05).
Conclusions:Plasma BNP levels may be related to the disease activity in CS. Serial 
measurements of BNP are helpful for the management of CS patients treated with 
corticosteroids.
9:30 a.m.
1033-200 Early Diastolic Myocardial Tissue Doppler Velocities 
Are Not Reduced in Asymptomatic Carriers of MYBPC3 
Gene Mutation for Hypertrophic Cardiomyopathy
Sabe De, Heng Wang, Leah Nye, Baozhong Xin, W.H. Wilson Tang, Cleveland Clinic 
Foundation, Cleveland, OH, Das Deutsch Center (DDC) Clinic for Special Needs 
Children, Middleﬁeld, OH
Background: Prior studies have suggested that early diastolic myocardial tissue Doppler 
(TD) velocities (Ea) may be reduced in mutation positive patients without left ventricular 
hypertrophy (LVH). We examined echocardiographic characteristics of asymptomatic 
carriers for a known MYBPC3 gene mutation for hypertrophic cardiomyopathy (HCM)
Methods: We prospectively evaluated 15 consecutive subjects with a known myosin 
binding protein C 3 (MYBPC3) mutation (c.3330+2T>G) identiﬁed by familial screening. All 
subjects underwent anthropometric measurements, electrocardiogram, and transthoracic 
echocardiography.
Results: In our study cohort (mean age 33±12 years, 47% male), 26% had evidence of 
LVH, and one had asymmetric septal hypertrophy without evidence of obstruction. All 
patients had preserved left ventricular ejection fraction with no evidence of signiﬁcant 
valvular diseases. Of the 14 phenotype-negative patients, 3 (27%) had evidence of
diastolic dysfunction (all with Stage 1). Mean Ea were 11.1 ±3.2 cm/s
for the septal annulus and 16.4 ±5.3 cm/s for the lateral annulus, both higher
than expected (from normal controls or prior reports).
Conclusions: In our cohort of symptomatic, phenotype-negative carriers of MYBPC3 gene 
mutation for HCM, TD-derived Ea levels were not reduced as previously reported. These 
results challenge the ability of TD imaging for early screening in HCM gene mutation 
carriers.
9:30 a.m.
1033-201 Cardiac MRI Findings in Patients With Relapsing 
Pericarditis: Comparison With Acute Idiopathic 
Pericarditis
Kye Hun Kim, Dali Feng, James Glockner, Matthew Martinez, Imran S Syed, Philip 
Aroaz, Paul R Julsrud, Jerome F Breen, Eric Williamson, Jae K Oh, Mayo Clinic, 
Rochester, MN
Background: Cardiac MRI (CMR) is a useful imaging method for identifying inﬂammation 
of the pericardium, using delayed enhancement (DE) of Gadolinium. However, CMR’s 
ﬁndings of relapsing pericarditis are not well known.
Methods: Fifty two patients with relapsing pericarditis (group I), 11 patients with acute 
pericarditis (group II), and 10 controls (group III) who had CMR were analyzed.
Results: Pericardial, myocardial, or pleural DE, thickened pericardium, pericardial or 
pleural effusion, dilation of IVC (inferior vena cava), septal bouncing motion were not 
found in control group. The ﬁndings of CMR between group I and II were summarized in 
table. The prevalence of DE of the pericardium and pleura were not different, but DE of the 
myocardium was signiﬁcantly prevalent in group II than in group I (p<0.001). Pericardial 
thickness measured by pre-enhancement CMR was signiﬁcantly thicker in group I than 
in group II (p<0.001), but the pericardial thickness measured by fast imaging employing 
steady state acquisition (FIESTA) sequence and DE CMR were not different. Septal 
bouncing motion was observed in 12 patients and constrictive physiology was observed 
in 5 patients (1 persistent, 4 transient) in group I, but not in group II.
Conclusions: CMR in this study demonstrated that the pericardial thickening and 
pleuropericarditis are not uncommon, the development of constrictive pericarditis may be 
seen, and the myocardial involvement is not a feature in patients with relapsing pericarditis.
CMR ﬁndings of the patients
Group I (n=52) Group II (n=11) P value
DE of pericardium (%) 42 (80.8) 11 (100.0) 0.119
DE of pleura (%) 10 (19.2) 2 (18.2) 0.936
DE of myocardium (%) 0 (0.0) 5 (45.5) <0.001
Pericardial thickness by pre-enhance CMR 
(mm) 2.66±1.15 1.88±0.31 <0.001
Pericardial thickness by FIESTA (mm) 2.32±2.01 2.01±0.47 0.193
Pericardial thickness by DE CMR (mm) 2.55±1.49 2.18±1.26 0.458
Septal bouncing motion (%) 12 (23.1) 0 (0.0) 0.077
Constrictive physiology (%) 5 (9.6) 0 (0.0) 0.284
Dilation of IVC (%) 4 (7.7) 0 (0.0) 0.342
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Results. Semiquantitative measures of late (3 h) DPD uptake were ~2-fold higher in 
TTR (table). Heart/body retention ratio correlated with LV mass in TTR (R=0.37; P=0.04 
at linear regression analysis) but not in AL (P=0.9). In a multivariate model (adjusting 
for age, sex, LV mass/vol, LV mean wall thickness and renal failure), TTR predicted 
increasing DPD uptake (COEF -3.5998; 95%CI, -4.898 to -2.301; P=0.0001). Sensitivity 
of visual score 0-1 for diagnosis of AL was 93% (95%CI, 83%-100%), speciﬁcity 100% 
[reference standard: immunohistochemistry/DNA analysis]. 
TTR-related (n=35) AL (n=28) p value
Age, yr 62±14 61±9 0.7
Left Ventricular Mass, g 423±167 297±101 0.0001
Heart tracer retention: median (iqr) 7.9% (6.5%-8.9%) 3.5% (3.2%-5.9%) 0.0001
Heart/body retention ratio: median (iqr) 10.3 (8.2-11.6) 5.2 (4.5-6.6) 0.0001
Visual cardiac score: 0.0001
0 (no uptake) 0 (0%) 20 (72%)
1 (mild uptake) 0 (0%) 6 (21%)
2 (moderate uptake) 12 (34%) 2 (7%)
3 (strong uptake) 23 (66%) 0 (0%)
Conclusions. In TTR CA, myocardial DPD uptake is strong and correlates with LV mass, 
whereas in AL CA it is weak and not correlated with LV mass. The visual score may be a 
useful non-invasive tool for etiologic diagnosis of AL vs TTR, particularly when the score 
is clear-cut (ie “no” or “strong” uptake).
9:30 a.m.
1033-207 Clinical and Pathologic Characteristics of Myocarditis 
as a Cause of Sudden Death
Lena Avedissian, Jennifer A. McNear, David A. Appel, Laudino M. Castillo-Rojas, John 
E. Atwood, Lisa A. Pearse, Robert N. Potter, Allen P. Burke, Ladd Tremaine, Philip J. 
Gentlesk, Eric A. Shry, Stephen S. Reich, Robert E. Eckart, Department of Defense 
Cardiovascular Death Registry Group, Brooke Army Medical Center, San Antonio, TX, 
Armed Forces Institute of Pathology, Washington, DC
Background: Myocarditis has been a signiﬁcant cause of death in prior studies of young 
military personnel.
Methods: Clinical and pathologic records from the Ofﬁce of the Armed Forces Medical 
Examiner from 1998 to 2008 were reviewed.
Results: We identiﬁed 739 patients with an autopsy with sudden cardiac or idiopathic 
death. There were 30 cases (4.1%) of pathology-deﬁned myocarditis on autopsy that 
serve as the basis for the cohort. The mean age was 31±10 years (range 18-45 years, 
86.7% male). In contrast to other cardiac causes of death, most cases were non-
exertional (80.0%). A clinical prodrome was reported in 69.6% of cases where information 
was available. The most common antemortem symptoms were a constellation of fever, 
myalgias, nausea and vomiting in 52.2% of cases. Chest pain was less common, reported 
in only 3 (10%) cases. Out of hospital arrest, with survival to hospital admission was 
seen in 22.2% of cases. Of those cases in which there was discrimination as to location 
of ﬁbrosis and/or necrosis, the ﬁndings were most commonly biventricular (43.8%), and 
isolated right ventricular (31.3%). While the ﬁnding of atherosclerosis was noted in 27.6%, 
there was disease with >70% occlusion in only 3.5%, and there was no evidence of 
plaque rupture or coronary thrombosis in any of the cases identiﬁed.
Conclusion: Myocarditis represents a unique cause of sudden death with characteristic 
prodrome in some that may allow for earlier recognition before the fatal event and 
improved treatment.
9:30 a.m.
1033-208 Mortality due to Cardiomyopathy and Heart Failure in a 
Population of 41 654,020 Habitants
Edimar A. Bocchi, Guilherme Guimarães, Sandrigo Mangini, Heart Institute (InCor) of 
the São Paulo University Medical School, São Paulo, Brazil
Background: Continued assessment of temporal trends in mortality and epidemiology 
of speciﬁc cardiovascular diseases is needed to provide a scientiﬁc basis for rational 
allocation of the limited health care resources, and strategies to reduce risk and predict 
the future burden of cardiovascular disease. Speciﬁc data about speciﬁc cardiomyopathies 
(CMP) and heart failure (HF) is not well reported.
Methods: Causes of deaths due to CMP, HF or etiologies associated with HF based 
on the SEADE data Foundation from São Paulo State (Brazil) during 2006 according 
International Classiﬁcation of Diseases (ICD)-10 in an estimated 41 654,020 habitants
Results: From 242,832 deaths 15336 (6.3%) were due to CMP or HF. Chagas´disease 
(acute or chronic with heart involvement were responsible by 1197 deaths (7.8% of HF 
deaths) being acute in one case and chronic in 1196; amyloidosis by 23 deaths (0.15%); 
hypertensive diseases by 2128 (13.88%); ischemic cardiomyopathy by 1404 (9.16%); 
chronic constrictive pericarditis by 7 (0.046%); dilated cardiomyopathy by 2638 (17.2%); 
endomyocardial disease (endomyocardial ﬁbrosis, Löfﬂer´s endocarditis) by 6 (0.039%); 
endocardial ﬁbroelastose by 24 (0.16%); other restrictive cardiomyopathy by 3 (0.02%); 
alcoholic cardiomyopathy by 69 (0.45%); drugs and other external agents 2 (0.013%); 
other cardiomyopathies by 8 (0.052%); unspeciﬁed cardiomyopathy by 821 (5.3%); 
HF by 6468 (42.18%); cardiomegaly by 458 (2.99%) ; and cardiogenic shock as main 
manifestation 79 (0.52%) .
Conclusion: Restrictive CMP, pericarditis,drugs, and alcoholic were rare causes of HF. 
Chagas´disease, hypertensive, and ischemic etiologies remain as important preventable 
causes of HF deaths. These ﬁndings have important public health implications because 
the allocation of health care resources, and strategies to reduce risk of HF, CMP and 
Chagas´disease.
In addition, information regarding recurrent ventricular dysfunction also appears to be 
limited.
Methods: 38 cases of cardiac catheterization conﬁrmed TC were reviewed. Assessment 
of patient population included demographic, clinical, serial echocardiographic, and 
angiographic data. Also reviewed, were the variable presentations in this group; these 
were then categorized by apical, midventricular, or global wall motion abnormalities. 
Clinical management and outcomes was assessed, and subsequent recurrent 
presentations were recorded.
Results: Of the 38 patients, 32 (84%) were females, and 6 (16%) were males. 11 (29%) 
patients had evidence of apical ballooning, 20 (53%) had midventricular dysfunction, and 
3 (8%) were found to have global hypokinesis. Of the patient population, 4 (11%) had 
recurrent episodes. Speciﬁcally, in the patients with recurrences, 2 (50%) of the 4 had 
similar midventricular wall motion abnormality on both occasions. 1 (25%) of the 4 initially 
presented with apical ballooning, and then subsequently with midventricular involvement; 
while the other patient (25%) had midventricular dysfunction on initial presentation, but 
global hypokinesis with the recurrent episode. All recurrences occurred within 1 month to 
a year of initial presentation.
Conclusions: While most literature notes only the apical ballooning form of TC, recent 
reports also recognize the midventricular dysfunction as a less frequent presentation of 
this syndrome. However, based on our data, we suggest midventricular ballooning as a 
more common abnormality of stress induced cardiomyopathy than has been reported. 
Furthermore, we also propose global hypokinesis as another variable presentation of TC. 
Finally, it is also important to note, that patients with recurrences may not have the same 
wall motion abnormalities as seen on the initial presentation.
9:30 a.m.
1033-205 Variability of the Left Ventricular Outﬂow Tract 
Gradient in Hypertrophic Cardiomyopathy: A Cardiac 
Catheterization-Echocardiographic Study
Jeffrey B. Geske, Paul Sorajja, Rick A. Nishimura, Steve R. Ommen, Mayo Clinic College 
of Medicine, Rochester, MN
Background: The presence of severe left ventricular outﬂow tract (LVOT) obstruction 
directs the management algorithm in patients with hypertrophic cardiomyopathy (HCM). 
There are few data on the variability of the LVOT gradient and the potential impact of this 
variability on clinical practice.
Methods: One hundred HCM patients (age 58±13 years, 47% male) underwent 
comprehensive two-dimensional and Doppler transthoracic echocardiography and 
cardiac catheterization with transseptal measurement of left-sided pressures. All studies 
were performed within 48 hours of one another.
Results: LVOT gradients from both methods correlated (r=0.59, p<0.0001, see ﬁgure); 
however, wide scatter was present with 95% conﬁdence limits of agreement ±84 mmHg. 
For classifying patients as having severe LVOT obstruction on the basis of either method 
(<30 vs. q30 mmHg), discrepant results occurred in 21% of patients. Eighteen studies were 
performed with simultaneous measurement of the LVOT gradient, in whom there was a very 
strong correlation (r=0.99, p<0.0001) with 95% conﬁdence limits of agreement ±11 mmHg.
Conclusions: In patients with HCM, LVOT gradient measurements are routinely obtained 
to characterize the severity of obstruction. These data demonstrate the marked variability 
of the LVOT obstruction, which must be considered when determining both appropriate 
therapy and their efﬁcacy.
9:30 a.m.
1033-206 Diagnostic Accuracy of Differential 99Tc-DPD Myocardial 
Uptake in Transthyretin-Related and Primary Systemic 
Cardiac Amyloidosis
Cristina C. Quarta, Paolo Ciliberti, Simone Longhi, Letizia Riva, Elena Biagini, Pier Luigi 
Guidalotti, Cinzia Pettinato, Giuseppe Galati, Angelo Branzi, Claudio Rapezzi, University 
of Bologna and S.Orsola-Malpighi Hospital, Bologna, Italy
Background. We previously reported that 99Tc-DPD scintigraphy tests positive in 
transtyretin-related (TTR) but not primary (AL) cardiac amyloidosis (CA). We reassessed 
diagnostic accuracy of DPD scintigraphy for distinguishing TTR from AL in an extended 
population of CA patients.
Methods. We evaluated 35 TTR (23 mutant; 12 wild-type) and 28 AL patients, all with 
echocardiographically diagnosed CA. Myocardial uptake of DPD was semiquantitatively/
visually assessed by experts 3 h (and 5 min) after 99Tc-DPD (740 MBq iv).
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1042-167 Plasma Natriuretic Peptide Levels Between 
Asymptomatic Carriers and Non-carriers of MYBPC3 
Gene Mutation for Hypertrophic Cardiomyopathy
Wai Hong Wilson Tang, Baozhong Xin, Leah Nye, Stanley L. Hazen, Heng Wang, 
Cleveland Clinic, Cleveland, OH, Das Deutsch Center (DDC) Clinic for Special Needs 
Children, Middleﬁeld, OH
Background: Several sarcomeric gene mutations have been identiﬁed in the 
pathogenesis of hypertrophic cardiomyopathy (HCM). The potential for cardiac 
biomarker screening such as B-type natriuretic peptide (BNP) to identify carriers 
for such mutations has not been examined in a prospective manner.
Methods: From a large cohort of families with a speciﬁc MYBPC3 gene mutation 
(c.3330+2T>G), we measured plasma BNP levels (Abbott Architect) and compared 
levels between asymptomatic carriers and non-carriers.
Results: A total of 125 consecutive subjects were enrolled and genotyped, including 
3 homozygous carriers (all phenotype-positive), 54 heterozygous carriers, and 
68 non-carriers. Overall, homozygous carriers have signiﬁcantly higher BNP 
levels than asymptomatic individuals (median BNP 2,994 pg/mL vs 15.8 pg/dL, 
respectively), but the mean and median levels were similar between asymptomatic 
carriers and non-carriers (mean BNP 27 ±40 vs 19 ±17 pg/mL, p=0.17; median 15.8 
vs 15.8 pg/mL, p=0.96).
Conclusion: Plasma BNP levels were similar between asymptomatic carriers 
versus non-carriers of MYBPC3 mutation, challenging the utility of BNP testing in 
asymptomatic non-carriers of sarcomeric gene mutations.
3:30 p.m.
1042-168 Predictors of Survival for More Than OneYear in 
Primary Cardiac Amyloidosis
Ahmad M. Alqaqa’a, Hussam Suradi, Kamran Asl Hamidi, Mithilesh K. Das, Merrill 
Benson, Krannert Institute of Cardiology, Indiana University, Indianapolis, IN
Background: Cardiac involvement in 1º amyloidosis (AL) is associated with poor 
prognosis. We postulated that prognosis of 1º cardiac amyloidosis (CA) is better than 
reported.
Methods: Clinical, ECG,echo and mortality data of 172 patients with histologically proven 
1º amyloidosis were studied.
Results: 121 patients (age: 60+13.7 yrs; male, 66%) had CA (57 patients had positive 
cardiac biopsy or autopsy, and 64 patients had CA by clinical criteria [CHF with LVH or 
low voltage ECG]). The median survival was 15.9+3.2 months and 55% patients survived 
>1 year. CHF was present in 81(72%) patients. Low voltage ECG, Q wave, and LVH were 
present in 39.9%, 43%, and 13% respectively. Echo showed LVH, mitral regurgitation 
(MR), left atrial enlargement and speckled appearance in 85%, 13%, 14% and 14.5% 
patients, respectively. Univariate predictors of survival for >1year were absence of CHF 
(class II-IV), MR and pericardial effusion, as well as presence of interventricular septum 
<1.5 cm (all p <0.05). Absence of CHF (p=0.028, RR 1.86[95% CI: 1.1-3.25]) was the 
only multivariate predictor of survival. Multiorgan involvement, low voltage ECG, speckled 
appearance, LVEF and pulmonary HTN were not predictors for survival. Median survival 
with CHF was 8.9 +2.1months compared to 31+6.3 months without CHF (P<0.001).
Conclusion: 1-Contrary to previous reports, the median survival of patients with 1º CA 
is 15.6 months and 55% patients survive >12 months. 2-CHF is the only multivariate 
predictor of mortality in these patients. 
3:30 p.m.
1042-169 Amino-Terminal Pro-B-Type Natriuretic Peptide 
(NTproBNP) Levels Predict Deterioration of Left 
Ventricular Function in Chronic Heart Failure
Leandro Perez, Denise Petersen, Jun Chiong, Loma Linda University Medical Center, 
Loma Linda, CA
Background: Left ventricular (LV) remodeling leads to loss of myocytes, increased 
interstitial ﬁbrosis; its negative impact in chronic heart failure (HF) is evidenced by 
chamber enlargement, contractile dysfunction and dyssynchrony. Response to HF 
therapy is largely deﬁned in terms of changes on LV size, shape and contractility. 
Natriuretic peptides are prognostic markers in patients with HF and are useful in their risk 
stratiﬁcation; it is unknown whether they correlate with LV remodeling.
Methods: NTproBNP levels and ejection fraction (EF) were measured in 515 ambulatory 
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1042-165 Incidence of Adequate ICD Interventions in Patients 
With Hypertrophic Cardiomyopathy Supposed to Be at 
High-Risk for Sudden Cardiac Death
Christian Prinz, Juergen Vogt, Bogdan G. Muntean, Johannes Heintze, Detlef Hering, 
Dieter Horstkotte, Lothar Faber, Department of Cardiology, Heart and Diabetes Center 
North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
Background: In patients (pts.) with hypertrophic cardiomyopathy (HCM) risk assessment 
for sudden cardiac death (SD) is currently based on presence or absence of risk markers 
(RM) like non-sustained ventricular tachycardia (nsVT) on Holter ECG, excessive left 
ventricular hypertrophy (LVH) of >30 mm on imaging, abnormal blood pressure response 
(aBPR) during exercise, family history of SD, and recurrent syncope. Recently, detection 
of myocardial ﬁbrosis by gadolinium-enhanced magnetic resonance imaging (GE-MRI) 
has been suggested as an additional RM.
Methods: In a cohort of 1291 clinically characterized HCM-pts. 50 individuals (33 men, 17 
women; mean age: 44±13 years, NYHA class: 2.0±0.9) were identiﬁed who had more than 
1 (2-4) RM and a GE-MRI before their ICD implantation. ICD implantation was performed 
for secondary SD prophylaxis in 2, and for primary prophylaxis in 48 pts.. Outﬂow 
obstruction was present in 25 pts., the other 25, including 1 pt. after septal ablation and 1 
pt. after myectomy, were non-obstructive. With GE-MRI maximum wall thickness and LV 
mass were measured, and the presence of ﬁbrosis was scored semiquantitatively (from 
0=absent, 1=point-shaped, 2=limited to 1 LV segment, 3=involving q2 segments). During 
follow-up device-related problems were noted, and the ICD memories were analyzed for 
adequate ICD interventions or other arrhythmic events.
Results: The number of RM per pt. was 1.7±0.8. Evidence of myocardial ﬁbrosis q2 was 
present in 39 pts. with a mean score of 2.2±0.9. During follow up (1.5±1.5 [0.2-6.0]) years, 
adequate ICD interventions (9 episodes) were documented in 3 pts., 11 pts. had at least 
1 episode of atrial ﬁbrillation. Inadequate ICD interventions were noted in 3 cases. The 
only difference among pts. without vs. with event was a longer follow-up duration (2.3±2.0 
vs. 1.2±2.3 years, p=0.03) in the latter group.
Conclusions: The incidence of appropriate ICD discharges in our cohort of 50 pts. with 
HCM who received ICD implantation for SD prevention was 4%/pt.-year, supporting the 
proposed risk stratiﬁcation. However, no single RM nor additional GE-MRI was predictive 
for future arrhythmic events.
3:30 p.m.
1042-166 Association Between Circulating Neuregulin-1B and 
Clinical Outcomes in Heart Failure
Bonnie Ky, Stephen E. Kimmel, Radwan Safa, Mary E. Putt, Nancy K. Sweitzer, James 
C. Fang, Douglas B. Sawyer, Thomas P. Cappola, University of Pennsylvania School of 
Medicine, Philadelphia, PA, Vanderbilt University Medical Center, Nashville, TN
Background: Basic research has demonstrated that the neuregulin/ErbB pathway is 
necessary for fetal cardiac development and cardioprotection in the adult heart. Cardiac 
stress leads to increased NRG-1/ErbB signaling, and loss of this pathway results 
in decreased survival in animal models. However, whether these ﬁndings translate to 
humans is unknown. Our objective was to establish the relationship between circulating 
NRG-1B levels and incident adverse clinical outcomes in a diverse heart failure cohort.
Methods: Serum NRG-1B was quantiﬁed in 899 outpatients in the Penn Heart Failure 
Study, a prospective cohort of patients with primarily systolic heart failure. At time of study 
entry, detailed clinical data regarding cardiac history were obtained and two-dimensional 
transthoracic echocardiography was performed. The primary outcomes were all-cause 
mortality and cardiac transplantation. Univariate and multivariable associations between 
NRG-1B and the combined endpoint death or transplant were determined using Cox 
proportional hazards models.
Results: The mean±sd ejection fraction in this cohort was 31.6±16.5%, and 72.9% had 
NYHA Class II/III heart failure. Over a median follow-up time of 2.4 years, 195 patients 
reached the composite endpoint. In univariate models, higher circulating NRG-1B was 
associated with an increased risk of death or transplant [HR 1.20 per log increase (1.008-
1.433, p=0.04)]. After multivariable adjustment, this remained signiﬁcant [HR 1.24 (1.03-
1.49, p=0.02)]. This relationship was modiﬁed by cardiomyopathy etiology, with higher 
NRG-1B levels associated with worse outcomes in ischemics, but a decreased risk in 
hypertensive cardiomyopathy patients (interaction p=0.003).
Conclusions: This study demonstrates an independent association between NRG-1B
levels and risk of all-cause death or cardiac transplant, supporting a role for NRG-1/
ErbB signaling in human heart failure. Our data suggest that NRG-1B is a marker of 
heart failure severity and provide insight into the differing functions of NRG-1B in various 
cardiomyopathy etiologies. Further study of NRG-1B will help deﬁne its utility as a novel 
prognostic biomarker in heart failure.
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1042-172 Cytokine Gene Polymorphisms Are Associated With 
Disease Severity and Prognosis in Patients With 
Idiopathic Dilated Cardiomyopathy
Stamatis Adamopoulos, Fotis Kolokathis, Angeliki Gkouziouta, Panagiota Georgiadou, 
Antigoni Chaidaroglou, Alexandros Kouloubinis, George Karavolias, Dimitrios Degiannis, 
Vassilis Voudris, Dimitrios Th Kremastinos, Onassis Cardiac Surgery Center, Athens, 
Greece
Background: Speciﬁc genes coding for cytokines involved in the pathophysiological 
process of heart failure may promote the progression and contribute to the severity of 
idiopathic dilated cardiomyopathy (IDC). We investigated the potential associations of 6 
gene polymorphisms with markers of disease severity and prognosis in patients (pts) 
with IDC.
Methods: Polymorphisms investigated in 80 clinically stable pts with IDC were the T10C 
and C25G of the transforming growth factor beta1 (TGF-B1) gene, the G-174C of the 
interleukin-6 (IL-6) gene, the A-592C of the inteleukin-10 (IL-10) gene, the G-308A of the 
tumor necrosis factor-alpha (TNF-A) gene and the T874A of the interferon-gamma (IFN-G)
gene. Potential associations were sought between genotypes and the disease severity 
as expressed by symptoms, measures of exercise capacity, echocardiographic indices 
and speciﬁc biomarkers. Pts were stratiﬁed during their ﬁrst admission according to the 
disease severity and followed-up for 79±21 months.
Results: A positive correlation was observed between T carriers of the T10C 
polymorphism of the TGF-B1 gene and the peak oxygen consumption (p=0.04), which 
remained signiﬁcant only for pts younger than 39 years old after adjusting for age and 
sex (p=0.009). C carriers for C25G TGF-B1 were 4.2 times more likely to present worse 
symptoms of heart failure than non C carriers (OR: 4.2, 95%CI 1.43- 12.34, p=0.009). 
Pts GG homozygous for G-174C IL-6 polymorphism presented with greater left ventricle 
end-systolic (p=0.002) and end-diastolic (p=0.02) diameters in comparison to the CC 
homozygous. A carriers of the G-308A TNF-A polymorphism were associated with 
higher levels of IP-10 (p=0.05) whereas T carriers of the 4874A IFN-G polymorphism 
were associated with lower levels of MCP-1 (p=0.06). C carriers of the C25G TGF-B1
polymorphism were associated with worse prognosis (p=0.0423) whereas T carriers of 
the T874A IFN-G polymorphism were associated with better survival (p=0.0163).
Conclusions: Polymorphisms in genes coding for cytokines seem to be associated with 
measures of disease severity and prognosis in IDC. These associations may identify 
genes in pathways important for IDC pathogenesis and therapy.
3:30 p.m.
1042-173 Left Atrial Remodeling Is Common and Associated 
With High Risk Markers in Patients With Cardiac AL 
Amyloidosis
Jennifer E. Liu, Teimuraz Apridonidze, Richard Steingart, Ray Comenzo, James 
Hoffman, Yuliya Goldsmith, Memorial Sloan Kettering Cancer Center, New York, NY
Background: AL amyloidosis is known to affect all cardiac chambers. Although changes 
in LV structure and function are well known, the effect of amyloidosis on the left atrium 
is less well deﬁned.
Methods: We examined eight-six patients with cardiac AL amyloidosis who had an 
echocardiogram at the time of diagnosis between March 1997 - May 2008. The patients 
were divided into Group I: left atrial volume indexed to body surface area (LAVI) a 32 ml/
m2 ( n= 38) or Group II: LAVI >32 ml/m2 (n=48)
Results: Fifty-six percent of the patients had LAVI>32 ml/m2. The two groups were similar 
in age, gender and body surface area (BSA). Group II had a signiﬁcantly higher BNP 
than Group I with no signiﬁcant difference in creatinine clearance or troponin. Higher 
prevalence of clinical congestive heart failure (CHF) at baseline was noted in Group II 
than Group I. Group II had higher interventricular septal thickness, LV mass and mitral 
E/A ratio with lower ejection fraction and stroke volume than Group I. Left atrial systolic 
force (LASF), an index of left atrial systolic function was signiﬁcantly lower in Group II 
than Group I. 
Group I Group II P
Age (y) 59 60 0.3
Gender, male 17 (35%) 31 (65%) 0.5
BSA m2 1.82 1.86 0.5
BNP 809 1291 0.0004*
Creatinine Clearance (ml/min) 65 54 0.1
troponin 0.128 0.184 0.14 *
Clinical CHF 7 (32%) 15 (68%) 0.04*
Interventricular septum (cm) 1.40 1.50 0.002*
Ejection fraction % 61 69 0.045*
LV mass (gm) 201 227 0.0014*
LASF (kdynes) 14.02 9.14 0.007*
Stroke volume (ml) 65 52 0.008*
E/A ratio 1.42 2.39 0.006*
*adjusted for age,gender and creatinine clearance
Conclusion:
Left atrial remodeling is common in patients with cardiac AL amyloidosis and is associated 
with worse LV structure, systolic and diastolic function and atrial function. Left atrial 
volume is highly correlated with BNP level and provides an index of overall cardiovascular 
disease burden in the amyloid heart.
HF patients before and during optimal medical therapy. The initial and ﬁnal EF were 
compared and subjects were subdivided into 3 groups based on EF changes: Group A, 
EF > 20% improvement; Group B, EF a 20% change; Group C, EF >20% reduction.
Results: The mean NTproBNP levels among the 3 groups were: Group A, 2987pg/dL; 
Group B, 3536pg/dL and Group C, 8101pg/dL. Patients in group C had signiﬁcantly higher 
NTproBNP (ﬁgure) when compared to Groups A (p=0.028) and B (p=0.038).
Conclusions: Elevated plasma NTproBNP levels predict deterioration of ejection fraction 
in heart failure individuals; they are helpful in the identiﬁcation of high-risk patients who 
warrant closer outpatient follow-up.
3:30 p.m.
1042-170 Renal Dysfunction in Heart Failure Results From 
Congestion but Not Poor Perfusion
Maya E. Guglin, Marcos Garcia, Abel Rivero, Fadi Matar, University of South Florida, 
Tampa, FL
Background: Renal dysfunction in heart failure is thought to be due to poor perfusion 
of the kidney. We tested the hypothesis that passive congestion is more important than 
poor perfusion.
Methods: We retrospectively studied 223 sequential patients who underwent right heart 
catheterization. In 178 of them, serum creatinine was checked before the procedure. In 
156, echocardiograms were performed within six months of the procedure. We divided 
the subset based on cardiac index (CIa2.4L/min/m2 and >2.4 L/min/m2), based on wedge 
pressure (wedgea12 mm Hg and >12 mm Hg), and based on ejection fraction (EFq50%
and <50%). Student’s t test and Pearson’s correlation coefﬁcient were used for analysis.
Results: There was a progressing increase in serum creatinine with increase in wedge 
pressure, from 0.99±0.3 mg/dL in wedge pressure 0-12 mm Hg, to 1.04±0.4 mg/dL (p=NS) 
in wedge pressure 13-21 mm Hg, and to 1.17 ±0.5 mg/dL (p2.4 L/min/m2) creatinine 
even was worse (1.13±0.5 mg/dL) than in patients with CI a2.4 L/min/m2 (1±0.3 mg/
dL, p<0.05). In the whole dataset, serum creatinine correlated with invasively measured 
pulmonary artery systolic and diastolic pressure (r=0.29, p<0.01, and r=0.17, p<0.05, 
respectively), and with the end diastolic velocity of pulmonary regurgitation and tricuspid 
regurgitation velocity by echo (r=0.46, p<0.0001, and r=0.17, p<0.05) and with the wedge 
pressure (r=0.19, p<0.05), but not with cardiac index, cardiac output, or EF.
Conclusions: Renal dysfunction in heart failure is determined more by passive congestion 
than by low perfusion.
3:30 p.m.
1042-171 Detection of Constrictive Pericarditis: A Single-Centre 
Experience of 523 Surgically Conﬁrmed Cases
Lieng H. Ling, Hartzell V. Schaff, Jacob dal-Bianco, Marion E. Barnes, Brian D. Lahr, 
Thoralf M. Sundt, III, Jae K. Oh, Mayo Clinic, Rochester, MN, National University of 
Singapore, Singapore, Singapore
Background: Constrictive pericarditis (CP) often eludes detection because presentation 
is nonspeciﬁc. We aimed to determine the means by which CP was detected over a 
2-decade period.
Methods: We reviewed clinical data and use of diagnostic tests in 523 pts (mean 
age±SD 57±15 yrs; 70% male) with a surgically conﬁrmed diagnosis of CP at Mayo Clinic 
Rochester from 1985-2006. Data were tested for a temporal trend using C2 tests.
Results: Etiologies of CP were prior cardiac surgery (n=154, 29%), idiopathic (n=117, 
22%), acute pericarditis (n=89, 17%), mediastinal irradiation (n=64, 12%), arthritides 
(n=29, 6%), non-viral infection (n=22, 4%), neoplasm (n=7, 1%) and miscellaneous 
(n=41, 8%). Procedures done elsewhere while investigating CP symptoms included liver 
biopsy (n=28, 5%), pleurodesis (n=17, 3%), thoracoscopy/mediastinoscopy (n=16, 3%), 
gastrointestinal endoscopy (n=16, 3%), bronchoscopy (n=15, 3%), pleural biopsy (n=10, 
2%), laparotomy (n=5, 1%), cholecystectomy (n=5, 1%), lung biopsy (n=6, 1%) and bone 
marrow biopsy (n=3, 1%). Two pts had unneeded valve replacement. Among 292 pts 
undiagnosed at presentation, CP was diagnosed preoperatively in 279 pts - clinically in 
174 pts (60% of undiagnosed cases), by echocardiography in 81 (28%) and by radiologic 
or hemodynamic studies in 24 (8%). Echocardiography performed in 496 pts was initially 
diagnostic in 72% of cases. Compared to 1985-1995, there was a 2.4 fold increase 
(n=156 vs 367) in pericardiectomies for CP from 1996-2006. During this period, the only 
signiﬁcant trend in attributable causes was an increase in postoperative CP (19% vs 34%, 
P=0.001). Between the 2 decades, no signiﬁcant differences in utilization of diagnostic 
tests or clinical or echocardiographic detection of CP were observed; however pts more 
frequently had an outside diagnosis of CP (33% vs 49%, P<0.001) from 1996-2006.
Conclusions: Cardiac surgery is the contemporary leading cause of CP and accounts 
partly for the increasing volume of pericardiectomies. While the increase in referred cases 
suggests a growing recognition of CP, the frequency of noncardiac procedures conducted 
before diagnosis indicates that its detection remains challenging.
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1042-176 Adiponectin Serum Levels, Hemodynamics and 
Inﬂammatory Markers in Patients With Inﬂammatory 
Cardiomyopathy
Peter Bobbert, Uwe Kuehl, Ursula Rauch, Carmen Scheibenbogen, Heinz Peter 
Schultheiss, Carsten Skurk, Department of Cardiology and Pneumology, Charite 
Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany
Background: Adiponectin (APN) is an adipocytokine present in the systemic circulation 
in different isoforms exerting anti-inﬂammatory, anti-apoptotic and pro-angiogenic effects. 
The adipocytokine has recently been shown to prevent remodeling after cardiac injury. 
Adiponectin is also synthesized within the heart and cardiac expression is downregulated 
in patients with inﬂammatory cardiomyopathy (DCMi) indicating the cytokine as a potential 
new therapeutic target. However, systemic expression of the cytokine, i.e. plasma levels 
of APN and its isoforms, have not been studied in DCMi. Therefore, we determined the 
systemic expression and its correlation with hemodynamic and inﬂammatory parameters 
in patients with DCMi.
Results: Plasma APN concentrations (total, high, medium, low molecular weight) were 
signiﬁcantly higher in patients with DCMi (n=140, EF<50%, LVEDD>55mm, positive 
inﬂammatory score) when compared with controls (n=30, EF>65%, LVEDD<55mm, no 
inﬂammation), i.e. 4.8±0.4 vs 6.0±0.4 μg/ml for APN (p<0.02). Furthermore, plasma 
levels of the cytokine in DCMi were not signiﬁcantly different from patients with dilative 
cardiomyopathy (DCM) (n=52, EF<50%, LVEDD>55mm, negative inﬂammatory score). 
APN concentrations in patients with DCMi but not DCM strongly correlated with LV-EF 
(r= -0.44, p<0.01), LVEDP (r=0.51, p<0.001), mean PAP (r=0.39, p<0.002 ), and PCPW 
(r=0.39, p<0.002 ) after normalization for BMI. Similar correlations were found with 
HMW-adiponectin, while MMW and LMW isoforms did not correlate with hemodynamic 
parameters. For further analysis, serum inﬂammatory cytokine concentrations were 
measured. However, only IL-8 serum concentrations signiﬁcantly correlated with APN 
concentrations (r=0.37, p<0.015). During follow-up, DCMi patients in the upper quartile 
of APN basal levels showed increased LVEF and decreased LVEDD, that was signiﬁcant 
after 6-12 months (p<0.05).
Conclusion: Our results indicate a dissociation of systemic and local cardiac APN 
expression in DCMi that is associated with increased IL-8 expression. High serum HMW/
APN levels might be beneﬁcial in the progression of DCMi.
3:30 p.m.
1042-177 Septal Morphology and Late Gadolinium Enhancement 
Predict Genetic Test Status in Patients With 
Hypertrophic Cardiomyopathy
J. Martijn Bos, Ronen Rubinshtein, Melissa L. Will, Uma Valeti, James Glockner, Phillip 
A. Araoz, A. Jamil Tajik, Rick A. Nishimura, Bernard J. Gersh, Steve R. Ommen, Michael 
J. Ackerman, Mayo Clinic, Rochester, MN
Background: Contrast enhanced cardiac magnetic resonance imaging (CE-MRI) 
is a useful tool to deﬁne cardiac morphology and the presence of late gadolinium 
enhancement (LGE) indicating myocardial ﬁbrosis. Previous studies have shown a strong 
correlation between reverse-curve hypertrophic cardiomyopathy (HCM) and a positive 
HCM genetic test, but ﬁbrosis cannot be assessed. We therefore sought to evaluate MRI-
derived septal contour and LGE in a large cohort of patients who also had genetic testing 
for sarcomeric HCM.
Methods: A genotype-phenotype subset analysis of 230 HCM patients (148 male, 
mean age 56 ± 17yrs) who underwent both CE-MRI and genetic testing for mutations 
in 9 myoﬁlament-encoding, HCM-susceptibility genes was performed. Patients with prior 
history of septal ablation/myectomy were excluded. Septal shape was assessed from a 
3-chamber standard steady state free precession pulse sequence. The presence of LGE 
was traced from a dynamic post contrast inversion recovery pulse sequence.
Results: Overall, only 44/230 patients (19%) had a positive HCM genetic test. Among the 
mutation positive subset, 47% had mutations in myosin binding protein C, 39% had thick 
myoﬁlament mutations, and 9% had mutations involving the thin myoﬁlaments. By MRI, 
the distribution of septal morphologies were sigmoidal in 144 (63%), reverse curve in 37 
(16%), and apical in 15 (7%). Over half of the patients with reverse curve-HCM by MRI 
had a positive genetic test compared to only 15% for sigmoidal-HCM and 13% for apical-
HCM (p < 0.001). There were no signiﬁcant differences between the particular HCM gene 
involved and septal morphology. LGE was present in 75% of patients with a positive 
genetic test compared to 53% with a negative genetic test (p < 0.001). In a multivariate 
analysis, adjusting for age, gender, LV morphology and function, and presence of LGE, 
reverse curve morphology was the only independent predictor of a positive genetic test 
(p<0.001).
Conclusion: Comparable to echocardiography, reverse septal curvature on CE-MRI is a 
strong and independent indicator of myoﬁlament-HCM. Furthermore, ﬁbrosis as indicated 
by LGE is more common in patients with a positive genetic test.
3:30 p.m.
1042-178 In-Hospital Prognostic Factors in Patients With Acute 
Myocarditis
Jong Pil Park, Jong-Min Song, Sung-Hwan Kim, Sung Sik Kim, Jae-Joong Kim, Duk-
Hyun Kang, Jae-Kwan Song, Asan Medical Center, Seoul, South Korea
Background: The initial prognostic predictors of acute or fulminant myocarditis remain 
to be clearly established.
Methods: In a total of 73 consecutive patients diagnosed as acute myocarditis, initial 
presentations and short-term outcomes were analyzed.
Results: Of 73 patients, mechanical ventilation, extracorporeal membrane oxygenation 
3:30 p.m.
1042-174 Primitive Microorganisms (Archaea) in Idiopathic 
Dilated Cardiomyopathy: A New Etiological Frontier
Maria L. Higuchi, Marcia M. Reis, Nadia V. Sambiase, Renata N. Ikegami, Sandrigo 
Mangini, Victor S. Issa, Alfredo Fiorelli, Edimar A. Bocchi, Noedir Stolf, São Paulo, Brazil
Background: The occurrence of DNA and antigens from viruses in the myocardium of 
patients with idiopathic dilated cardiomyopathy (IDCM) has been reported. However the 
presence of primitive microorganisms as archaea has not been well demonstrated.
Objective : The primary objective was to test endomyocardial biopsies (EMB) samples 
for the presence of archeal forms. Additionally we sought for the presence of Mycoplasma
pneumoniae, Chlamydia pneumoniae and viruses.
Material and Methods: EMB fragments from four patients with myocarditis (acute and 
subacute) and from four patients with IDCM were studied by in situ hybridization (ISH), 
immunohistochemistry and electron microscopy (EM)techniques.
Results: Generic archaeal DNA was present in all cases, as well as M. pneumoniae
antigens. Antigens for Hepatitis B viral surface were present in 3 myocarditis cases; 
antigens for Parvovirus B19 were present in four IDCM cases and in one myocarditis case, 
with negative ISH. EM of positive cases for Epstein-Barr virus revealed viral-like particles 
in regions of myocytolysis, with 30-35 nm diameter in complete virus or 16nm when only 
nucleocapsides. The Parvovirus B19 cases revealed icosahedric particles with less than 
16 nm, non-encapsulated. These viral particles have lower diameters than those found in 
human viruses, were in round vesicles with double lipidic envoltory membrane containing 
clear thin cytoplasm and intracellular vacuole, compatible with archaea. There were also 
other procaryont forms at the interstitium or inside macrophages. Viral-like tailed particles 
were present in macrophages or among the ﬁbrosis.C. pneumoniae bodies were found 
inside macrophages in two positive cases for Parvovirus B19.
Conclusion : Archeal forms are frequent ﬁndings in patients with myocardial diseases.
To the extent of our knowledge this is the ﬁrst report to suggest that archaea forms are 
present in the myocardium in association with bacteria and viruses. Our ﬁndings open 
new frontiers for the diagnosis and treatment of patients in this setting.
3:30 p.m.
1042-175 Neurohormonal Features of Stress Cardiomyopathy 
Triggered by Acute Central Neurologic Injury
Jacob Abraham, Hunter C. Champion, Navin K. Kapur, James O. Mudd, Ilan S. Wittstein, 
Johns Hopkins University School of Medicine, Baltimore, MD, Tufts Medical Center, 
Boston, MA
Background: Stress cardiomyopathy (SCM) is triggered by acute emotional and 
physiologic stressors, but the clinical and neurohormonal features of SCM following 
neurologic injury remain poorly deﬁned.
Methods: We identiﬁed 30 patients who developed left ventricular (LV) ballooning 
following central neurologic injury. Serial electrocardiography and echocardiography 
were performed in all patients, and 18 patients underwent coronary angiography. Plasma 
catecholamine (CA) and neuropeptide (NP) levels were measured in 27 SCM patients and 
compared to 32 patients with acute myocardial infarction (AMI) and 9 healthy controls.
Results: The mean age of SCM patients was 63 ± 16 years and 83% were women. 
Neurologic triggers included intracranial hemorrhage, seizure, migraine, carotid 
thrombosis, and brain contusion. Hypotension, heart failure, and shock were common. 
Troponin-I levels were elevated on admission (4.7± 6.2 ng/ml), and no patients undergoing 
angiography had obstructive coronary disease. LV function was severely reduced on 
admission (EF 25 ± 12%) and signiﬁcantly improved (EF 52 ± 9%, p<0.0001) at follow-
up (mean 16 ± 7 days). All 3 patterns of LV ballooning (apical, mid-ventricular, basal) 
previously described in SCM were observed. Plasma CA and NP levels were signiﬁcantly 
elevated in SCM compared to both AMI and controls (Table).
Conclusions: SCM can be precipitated by diverse central neurologic insults. Excessive 
sympathetic stimulation is strongly implicated in its pathogenesis. 
Plasma Catecholamines and Neuropeptides in SCM Following 
Neurologic Injury
SCM AMI Control
Dihydroxyphenylalanine 1857 ± 240 * 1376 ± 252 1229 ± 243
Epinephrine 676 ± 149 * 231 ± 144 92 ± 30
Norepinephrine 1952 ± 458 * 563 ± 392 213 ± 44
Dopamine 94 ± 15 * 45 ± 16 † 21 ± 7
Dihydroxyphenylglycol 2183 ± 448 * 1225 ± 299 914 ± 172
Dihyroxyphenlacetic acid 2164 ± 399 * 1528 ± 190 † 984 ± 360
Metanephrine 156 ± 19 * 94 ± 19 79 ± 24
Normetanephrine 162 ± 22 * 116 ± 32 † 75 ± 29
Neuropeptide Y 108 ± 51 * 61 ± 18 65 ± 22
Brain natriuretic peptide 1012 ± 242 * 160 ± 177 22 ± 9
5-Hydroxytryptamine 1994 ± 359 * 1094 ± 247 1092 ± 434
All values are expressed as mean ± standard deviation.
All units are pg/ml.
* P<0.001 versus AMI and Control.
† P<0.001 versus SCM and Control.
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in the carriers (63.2±3.2% vs. 59.7±2.8%, p=0.02). Peak apical rotation and peak torsion 
were signiﬁcantly larger in the carriers (14.6±3.2 º vs. 10.3±3.3º, p=0.01, and 10.2±2.3 º 
vs. 7.1±1.0 º, p=0.001, resp.), while peak basal rotation was signiﬁcantly smaller (-2.5±2.2 
º vs. -4.6±1.7 º, p=0.03).
Conclusion: HCM mutation carriers with normal wall thickness demonstrate increased LV 
torsion. Underlying altered myocardial architecture might be responsible for this ﬁnding.
References:
1. Circ 90, 854-867(1994).
2. Circ115, e610-1(2007).
3. J Cardiovasc Magn Reson 10, 26(2008).
3:30 p.m.
1042-181 Differential Cardiac Autonomic Modulation in Transient 
Left Ventricular Apical and Midventricular Ballooning
Hendrik Bonnemeier, Robert Amschler, Wanda Mäuser, Timothy Krauss, Michael 
Reppel, Heribert Schunkert, Medizinische Klinik II, Universität zu Lübeck, Lübeck, 
Germany
Background: Recently, a new variant of the transient left ventricular apical ballooning 
(AB) syndrome with only midventricular affection was described, suggestive for a shared 
pathophysiologic etiology. As in midventricular ballooning (MB) the apical segment is 
spared, only etiologies not related to an epicardial coronary artery distribution can be 
supported. Thus we hypothesized that differences in regional autonomic modulation may 
play a role in the genesis of these syndromes.
Methods: We prospectively enrolled 37 consecutive patients with transient left ventricular 
dysfunction syndrome. AB was diagnosed in 27 (73%), MB in 10 (27%) patients. Non-
linear indices of heart rate dynamics [Detrended ﬂuctuation analysis (DFA); power-law-
slope (PLS)], traditional time and frequency parameters of heart rate variability (HRV), as 
well as deceleration capacity (DC) were determined from 24-hour-Holter-ECGs, recorded 
on the third day after hospital admission.
Results: There were no signiﬁcant differences in baseline clinical characteristics. Mean 
RR-interval was higher in AB patients (908±118 vs. 835±104ms, p<0.05). There were no 
differences regarding parameters of time domain HRV, except higher values of SDNNi in AB 
patients (46.6±22 vs. 40.8±12ms; p<0.05). In frequency domain, LF and LF/HF-ratio were 
higher in MB patients (LF/HF-ratio 1.28±0.6 vs. 1.69±0.9, p<0.01). MB patients exhibited lower 
values for DC (5.98±1.4 vs. 4.55±1.4, p<0.01) and PLS (-1.13±0.15 vs. -1.27±0.18, p<0.01), 
and higher values for DFA-A1 (0.991±0.12 vs. 1.094±0.07) compared to AB patients.
Conclusions: This is the ﬁrst study to show that there are signiﬁcant differences in 
cardiac autonomic modulation and fractal organization of heart rate dynamics between 
AB and MB syndromes. Patients with MB exhibit stronger fractal correlations of short- and 
long-term heart rate dynamics, and lower levels of tonic parasympathetic nervous activity. 
Thus, the interplay between right and left cardiac autonomic nervous modulation and 
differences in bilateral sympathetic co-activation may be an underlying pathophysiological 
mechanism for AB and MB syndromes.
3:30 p.m.
1042-182 Progressive Left Ventricular Remodeling and Adverse 
Cardiac Events in Hypertrophic Cardiomyopathy 
Associated With Mutations in Cardiac Troponin 
Genes:Longitudinal Ten-Year Follow-Up
Toshinari Tsubokawa, Noboru Fujino, Hidekazu Ino, Kenshi Hayashi, Kastuharu 
Uchiyama, Eiichi Masuta, Yuichiro Sakamoto, Akira Funada, Akihiko Muramoto, Masakazu 
Yamagishi, Kanazawa University Graduate School of Medicine, kanazawa, Japan
Background:Although mutations in cardiac troponin T (TNNT2) and troponin I (TNNI3) 
genes cause hypertrophic cardiomyopathy (HCM), little is known about differences in 
long term clinical course and changes in left ventricular (LV) morphologies .To elucidate 
differences in clinical manifestations between carriers with TNNT2 and TNNI3 genes 
mutations by a 10 years longitudinal evaluation.
Methods:Total 7 carriers with the TNNT2 mutations (Arg92Trp, Val85Leu and Phe110Ile) and 
7 carriers with the TNNI3 mutation (Lys183del) were examined by longitudinal evaluations.
Results:At the initial, there were no differences in echocardiographic parameters 
between 2 groups. During a mean follow-up period of 10±3.2 years, 3/7(43%) carriers 
in both groups and suffered from congestive heart failure (CHF). Interestingly, carriers of 
end-stage HCM in TNNT2 group showed larger LV end-diastolic dimension (74±8.7 mm 
v.s. 53±2.9 mm, p<0.05) compared with those in TNNI3 group at the time of follow-up. In 
addition to the occurrence of CHF, ventricular and/or supraventricular arrhythmias which 
required hospitalization occurred in 5/7 (71%) in TNNT2 group while 3/7 (43%) in TNNI3 
group. Cardiac death occurred in 2/7 (29%) in TNNT2 group while none in TNNI3 group.
Conclusions:There data demonstrate that HCM with TNNT2 rather than TNNI3 mutation 
may have unfavorable clinical course during 10 years follow-up periods, probably due to 
enhanced extent of LV remodeling in TNNT2 mutation.
3:30 p.m.
1042-183 Utility of ECG-Gated MDCT to Differentiate 
Arrhythmogenic Right Ventricular Cardiomyopathy 
Patients From the Ventricular Tachyarrhythmia Patients
Takatomo Nakajima, Fumiko Kimura, Katsuya Kajimoto, Tsuyoshi Sihga, Morio Shouda, 
Hiroshi Kasanuki, Nobuhisa Hagiwara, Tokyo Women’s Medical University, Tokyo, Japan, 
International Medical Center of Saitama Medical University, Saitama, Japan
Background: Cardiac MRI is accepted as a noninvasive method in diagnosis of 
arrhythmogenic right ventricular cardiomyopathy (ARVC). The utility of CT is not assured 
because CT is difﬁcult in evaluating functional abnormality. We propose a comprehensive 
and continuous renal replacement therapy were required in 16 (22%), 8 (11%), 5 (7%) 
patients, respectively. Twenty-ﬁve patients presented with fulminant myocarditis. In-
hospital mortality occurred in 12 patients (16%). All of them presented with fuminant 
myocarditis and showed signiﬁcantly older age (46 ± 11 vs. 36 ± 15 years, p<0.05), lower 
body mass index (21 ± 2 vs. 23 ± 3 kg/m2, p<0.05), higher initial creatinine level (2.0 ± 
1.7 vs. 1.2 ± 0.7 mg/dl, p<0.05) and higher maximal CK-MB level (95 ± 128 vs. 30 ± 42 
ng/ml, p<0.05) than the patients who survived by univariate logistic regression analyses. 
Multivariate logistic regression analysis revealed that maximum CK-MB level (p=0.026, 
OR; 0.018, 95% CI; 0.002 - 0.034) and age (p=0.028, OR; 1.073, 95% CI; 1.008 - 1.143) 
are independent predictors for in-hospital mortality. The maximum CK-MB level q 29.5 ng/
ml predicted in-hospital mortality with a sensitivity of 83% and a speciﬁcity of 73%, and 
age q 44 years did with a sensitivity of 75% and a speciﬁcity of 74% (Figure).
Conclusion: Old age and high maximal CK-MB level are short-term poor prognostic 
factors in patients with acute myocarditis. 
3:30 p.m.
1042-179 A High Prevalence of Brugada Syndrome Among 
Patients With Steinert’s Disease: A New Insight Into the 
Pathophysiology of the Brugada Syndrome
Karim Wahbi, Véronique Fressart, Henri Marc Bécane, Christophe Meune, Arnaud 
Lazarus, Nawal Benamar, Pascale Richard, Bruno Eymard, Denis Duboc, Pitié 
Salpétriêre Hospital, Paris, France, Cochin Hospital, Paris, France
Background: SCN5A is the principal gene currently known to be associated with 
Brugada syndrome, but a mutation is identiﬁed in only 15 to 20% of families, suggesting 
that other genes have to be identiﬁed. Cardiac manifestations in Steinert’s disease - an 
autosomal dominant systemic disease caused by a mutation in the DMPK gene - and in 
patients with SCN5A mutations are very similar, including ventricular and supraventricular 
arrhythmias, atrioventricular block and sudden death. However, Brugada syndrome was 
never reported in patients with Steinert’s disease. We aimed at determining whether it 
could have been previously overlooked.
Methods: The electrocardiograms of 500 patients with genetically proven Steinert’s 
disease were independently reviewed by two electrophysiologists. Patients with a 
type 1 Brugada ECG pattern were screened for mutations in the SCN5A gene and 
underwent resting and 24-hours ambulatory electrocardiogram, echocardiography and 
electrophysiological study.
Results: A type 1 Brugada ECG pattern was identiﬁed in 7 patients (6 males, 37-60 year 
old), representing a prevalence of 1.4%. It was previously unknown in 5 patients and 
paroxysmal in 3. No confounding factor such as fever or medication was identiﬁed. The 
genetic analysis of SCN5A gene was normal in all patients. One patient died suddenly of 
ventricular ﬁbrillation and 4 had severe ventricular arrhythmias.
Conclusion: The 80-fold higher than expected (1.4% vs 5/10.000) prevalence of Brugada 
syndrome in our patients with Steinert’s disease suggests a link between both diseases. In 
addition, SCN5A gene sequencing was normal in all our patients and Steinert’s disease’s 
systemic complications are known to be caused by alterations of the splicing of multiple 
gene mRNAs. This suggests that Steinert’s disease could be the ﬁrst cause of Brugada 
syndrome related to post transcriptional abnormalities of cardiac ion channels.
3:30 p.m.
1042-180 Increased Left Ventricular Torsion in Hypertrophic 
Cardiomyopathy Mutation Carriers With Normal Wall 
Thickness
Iris Rüssel, Wessel Brouwer, Tjeerd Germans, Tim Marcus, Marco Götte, Albert van 
Rossum, VU University Medical Center, Amsterdam, The Netherlands
Objective: To determine the amount of left ventricular (LV) torsion in hypertrophic 
cardiomyopathy (HCM) mutation carriers (carriers) with normal wall thickness.
Background: Increased LV torsion has been observed in HCM and is thought to be caused 
by wall thickening (1). However, structural abnormalities that precede the development of 
hypertrophy in HCM may also cause alterations in LV torsion in carriers with normal wall 
thickness (2).
Methods: Ten carriers with an LV wall thickness <10 mm, and ten age and gender 
matched controls underwent CMR cine imaging and tissue tagging. LV volumes were 
calculated from the cine images. Basal and apical rotations and LV torsion, deﬁned as 
the circumferential-longitudinal shear angle (3), were determined from tissue tagging. 
Counterclockwise rotation as seen from the apex was considered positive. LV volumes, 
peak rotation and torsion were compared between both groups using Student’s T-test. A 
p-value <0.05 was considered signiﬁcant.
Results: LV end-diastolic and end-systolic volumes were not signiﬁcantly different 
between both groups (p=0.79 and p=0.36, resp.), whereas EF was signiﬁcantly larger 
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yrs, 18 male), 7 with previous rejection (57±9 yrs, 4 male ) and 18 healthy controls (46±18 
yrs, 8 male) underwent transthoracic echocardiography. Peak longitudinal, circumferential 
and radial strains (LS, CS and RS), and rotation were averaged from LV apical, mid and 
basal segments using 2D speckle tracking.
Results: Despite a normal LV EF (57±10 %), LS and CS in TXH were signiﬁcantly 
reduced with a loss of the apex-to-base gradient of LV shortening (Table 1). RS was 
spared in mid segment and exaggerated in the apical segments although rotation of LV 
apical segments was reduced. Transplanted hearts with previous rejection showed only 
reduction of the LS at LV apex (Table 1).
Conclusion: Global LV EF in TXH is preserved despite reduction in longitudinal and 
circumferential shortening due to a compensatory increase in radial deformation. 
Knowledge of unique cumulative alterations in myocardial mechanics that evolve 
independent of changes due to transplant rejection may impact clinical assessment of 
long term prognosis in heart transplant recipients.. 
Table 1. Left Ventricular Deformation in Normal and Transplanted 
Hearts
Control Cardiac Transplantation
Deformation Parameter (n=18) No rejection (n=23)
Rejection
(n=7)
Base Longitudinal strain (%) -14.9±5.1 -13.8±3.4 -11.0±7.0
Circumferential strain (%) -18.3±5.2 -12.0±5.5* -14.5±5.8
Radial strain (%) 50.3±20.5 25.0±16.4* 33.7±9.9
Rotation (degree) -3.2±2.3 -3.0±2.0 -2.8±1.2
Mid Longitudinal strain (%) -18.0±3.2‡ -14.8±3.8 -10.6±8.1*
Circumferential strain (%) -21.4±6.0 -14.3±3.9* -10.3±7.3*
Radial strain (%) 38.5±12.5 36.6±18.5‡ 40.0±16.4
Rotation (degree) 3.0±1.1‡ -1.3±0.8* -1.7±0.8*
Apex Longitudinal strain (%) -20.0±3.3‡, ‡‡ -14.8±5.2* -9.8±5.6*,†
Circumferential strain (%) -28.1±11.1‡, ‡‡ -16.8±5.7*,‡ -18.4±6.5
Radial strain (%) 13.4±10.1‡, ‡‡ 27.3±11.5 24.5±13.1
Rotation (degree) 18.5±1.8‡, ‡‡ 4.2±1.3*,‡, ‡‡ 7.1±1.8*
Net twist angle (degree) 23.2±7.5 8.5±3.7* 7.3±4.5*
*, P <0.05 vs. control; †, P<0.05 vs. non-rejection; ‡, P <0.05 vs. basal level; ‡‡, P 
<0.05 vs. mid level
3:30 p.m.
1042-187 Sirolimus Based Immunosuppression Improves 
Coronary Endothelial and Vasomotor Function 
Compared to Calcineurin-Inhibitors in Stable Cardiac 
Transplant Recipients
Eugenia Raichlin, Abhiram Prasad, Walter K. Kremers, Brooks S. S Edwarads, Rihal S. 
Charanjit, Amir Lerman, Sudhir S. Kushwaha, Mayo Clinic, Rochester, MN
Background:The aim of the study was to evaluate and compare coronary endothelial 
and vasomotor function in heart transplant recipients maintained on sirolimus (SRL) or 
cyclosporin (CyA) based immunosuppression.
Methods:Endothelium dependent response to incremental intracoronary acetylcholine 
(Ach) infusion and endothelium independent response to intracoronary nitroglycerin and 
adenosine were assessed in 15 SRL- and 21 CyA- treated cardiac transplant recipients 
with angiographically normal coronary arteries. Three dimensional intravascular 
ultrasound (3D IVUS) was also performed.
Results:Baseline mean aortic blood pressure was signiﬁcantly lower in the SRL group (93.6 
10.2 mm.Hg vs. 105.2 8.7 mm Hg, p=0.002). Although adenosine administration resulted 
in reduced coronary ﬂow reserve (CFR) during SRL treatment compared to CyA treatment 
univariately (2.67 0.64 vs. 3.53 0.72, p=0.0006), after multivariate analysis there was no 
difference between the groups (p=0.34). In 13 SRL treated subjects without angiographic 
and 3-D IVUS evidence of coronary allograft vasculopathy (CAV), Ach administration 
resulted in less epicardial vasoconstriction compared to CyA treated subjects (2.7 17.7% 
vs.-15.6 17.2%, p=0.005). However, two SRL treated subjects with signiﬁcant CAV on 3 
D IVUS (despite normal coronary angiogram) developed coronary spasm in response to 
Ach 10-4. Microvascular endothelial function did not differ between the groups. Nitroglycerin 
administration resulted in signiﬁcant increase in coronary artery diameter (Cad) in the SRL 
group compared to the CyA group (2.79 0.54 vs. 2.57 0.61, p=0.0036).
Conclusions:SRL immunosuppression is associated with less pronounced coronary 
epicardial endothelial dysfunction compared to CyA immunosuppression. Improvement 
of coronary vasomotor function during SRL immunosuppression may be an important 
mechanism for the prevention of CAV.
3:30 p.m.
1042-188 Comparisons of the Acute Effects of Intra-Aortic 
Balloon Counterpulsation Therapy and Continuous 
Aortic Flow Therapy on Plasma Biomarkers in Dogs 
With Chronic Heart Failure
Ramesh C. Gupta, Menjung Wang, Itamar Ilsar, Alice Jiang, Michael S. Sabbah, Hani N. 
Sabbah, Henry Ford Hospital, Detroit, MI
Background: We previously showed that acute aortic ﬂow therapy (AFT) with the Cancion 
system (Orqis Medical, Inc.) is superior to intra-aortic balloon counterpulsation (IABP) in 
unloading the failing canine left ventricle (LV). This study compared the effects of acute 
AFT and IABP on circulating plasma levels of biomarkers of enhanced neurohormonal 
and pro-inﬂammatory activity in dogs with chronic heart failure (HF).
Methods: Seven dogs with coronary microembolization-induced HF were studied one week 
CT scoring system for diagnosing ARVC and clarify CT’s diagnostic ability using the Task 
Force (TF) criteria as a gold standard.
Methods: Forty patients (pts) (mean age: 41.5 years, 24 men) previously diagnosed with 
or suspected of ARVC because of ventricular tachyarrhythmia underwent pre- and post-
contrast enhanced scanning using ECG-gated MDCT to evaluate listed CT criteria (table). 
We measured the maximum AP diameter of RV to evaluate RV enlargement using normal 
diameter in Japanese as 33.7 +/- 4.1mm. Locations of the fatty tissue contain RV outﬂow, 
RV free wall, trabeculation, and modulator band. We assessed minor (1 point) and major 
(2 points) aspects of each criterion and diagnosed ARVC in pts with more than 4 points.
Results: We diagnosed 14 pts with ARVC according to the TF criteria (table). Each CT 
ﬁnding listed was more signiﬁcantly observed in patients with ARVC (P < 0.0001, Fisher’s 
exact probability test) but also seen in those without ARVC and, so, might cause false 
positive diagnosis. Sensitivity and speciﬁcity for diagnosis of ARVC were 100% using 
the scoring system.
Conclusions: Our CT scoring system is optimal in classifying patients with tachyarrhythmia 
and diagnosing ARVC. 
3:30 p.m.
1042-184 Withdrawn
3:30 p.m.
1042-185 The Immunomodulatory Properties of Brain Natriuretic 
Peptide After Cardiac Transplantation
Steven M. Shaw, Mohammed KH Shah, Nizar Yonan, James E. Fildes, Simon G. Williams, 
University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
Background: Several observations about Brain Natriuretic Peptide (BNP) remain 
unexplained and could highlight gaps in our understanding of its physiology. It is currently 
accepted that ventricular myocytes secrete BNP in response to stretch stimuli or increased 
transmural pressure. However, after cardiac transplantation levels remain elevated 
despite replacement of the failing ventricle and restoration of intracardiac hemodynamics. 
Peaks in serum BNP also occur during acute rejection episodes and bacterial sepsis. In 
addition, experimental studies have shown that BNP is released not only from ventricular 
myocytes, but cells of the immune system such as T cells and macrophages. We therefore 
hypothesized that BNP has a discrete role within the immune system and devised a series 
of in vitro cell cultures to explore this.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from the whole 
blood of 60 cardiac transplant recipients. Cells were co-cultured for 72 hours in the 
presence or absence of BNP. Cultures were then immunophenotyped using ﬂow 
cytometry. The supernatants from 20 patients were also analysed in duplicate using a 
multiplex bead immunoassay kit.
Results: Co-culture of PBMCs with BNP dose dependently reduced the standard cell 
count of Monocytes, T helper, T memory, NK, cytotoxic T, B and myeloid dendritic cells 
(all p<0.05). BNP also impaired functional aspects of several immune cells, including the 
reduction of cytotoxicity in NK cells and reduced adhesion of non-classical monocytes 
(via down-regulation of CD11c).
Supernatant analysis showed that BNP reduced the expression of several inﬂammatory 
cytokines including TNF-A (p=0.016), IL- 1A (p=0.017), IL-6 (p=0.038), IL-7 (p=0.033) and 
IL-12 (p=0.001). Interestingly there was preservation of anti-inﬂammatory and regulatory 
cytokines including IL-4, 5, 10 and 13.
Conclusions: Our ﬁndings suggest that BNP immunoregulates multifarious elements of 
the immune system after cardiac transplantation. This may impart signiﬁcant consequences 
on immune mediated disease processes, such as allograft rejection. Further investigation 
is ongoing to see if similar effects are seen in a non transplant setting.
3:30 p.m.
1042-186 Altered Left Ventricular Mechanics in Cardiac 
Allografts: Novel Insights From 2-Dimensional Speckle 
Strain Echocardiography
Eun Joo Cho, Robert L. Scott, D. Eric Steidley, Francisco Arabia, Krishnaswamy 
Chandrasekaran, Marek Belohlavek, Bijoy K. Khandheria, Partho P. Sengupta, Mayo 
Clinic Arizona, Scottsdale, AZ
Background: Transplanted hearts (TXH) show gradual decline in left ventricular (LV) 
compliance and diastolic function, while global LV ejection fraction (EF) typically remains 
preserved. We hypothesized that chronic biomechanical changes in TXH would produce 
unique alterations in LV deformation patterns that are independent of injuries related to 
transplant rejection.
Methods: 30 patients with TXH (314±110 days old): 23 with no previous rejection (58±11 
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decreased from 5.6 +2.4 Wood Units to 2.2 + 1.5 (p=0.003).
The sildenaﬁl group showed a non signiﬁcative trend towards RVP reduction (4.8 +1.5 
vs. 3.29 +1.1; p=0,053) and TPG decrease (21 +4 vs. 19 +6; p=NS). TPG reduction was 
greater with bosentan (10.5 +5 vs. 4.5 +2mmHg, bosentan vs sildenaﬁl; p=0.04).
Treatment was stopped in 1 patient of each group due to intolerance. After treatment, 8 
patients (5 bosentan, 3 sildenaﬁl) were listed for heart transplantation and 6 of them (4 
bosentan, 2 sildenaﬁl) have already been transplanted successfully.
Conclusions: Bosentan and sildenaﬁl reduce PVR in patients considered ineligible for 
heart transplantation due to pulmonary hypertension, allowing them to be transplanted 
with good results. In our study, bosentan showed to be more effective than sildenaﬁl in 
decreasing TPG and PVR.
3:30 p.m.
1042-192 An Analysis of Single Institution Data for a Maximum BMI 
for Heart Transplantation: Comparison With UNOS Data
Mohammed A. Kashem, James T. Fitzpatrick, Lazaros Nikolaidis, James B. McClurken, 
Satoshi Furukawa, Alfred A. Bove, Temple University School of Medicine, Philadelphia, PA
Background:In heart transplantation, body mass index (BMI) is traditionally considered 
a risk factor for orthotopic heart transplantation (OHT). We report results from 10 years of 
OHT and compare them with the United Network for Organ Sharing (UNOS) database, 
which provides more extensive BMI data from all US heart transplanted patients.
Methods: We reviewed our single institute data (T-n=430 total patients between 1992-
2002) and of UNOS data to identify 23,113 initial OHT recipients (U) between years 1996 
and 2006. Primary stratiﬁcation was by BMI at time of transplant. Demographic and clinical 
factors including wait list (WL) times were recorded. Primary endpoint was all cause mortality 
during the study period. Secondary outcomes included length of hospital stay (LOS), need 
for reoperation and postoperative infection. Post transplant survival was estimated by 
Kaplan-Meier methodology and compared using Cox proportional hazard regression. 
Results: Of 23,113 patients with available data, the distribution of BMI was as follows: 
BMI a 25; 9,983 (43.2%), 26-30; 8,480 (36.7%), 31-35; 3,556 (15.4%), 36-40; 891 (3.9%) 
and > 40; 203 (0.9%). BMI was not an independent risk factor for mortality in the study (Hz 
ratio = 0.98, p = 0.17) and no level of BMI led to signiﬁcantly worse survival. Age, donor 
age, female gender, ischemic time, creatinine, hypertension, and diabetes emerged as 
independent predictors of mortality on multivariable analysis. BMI was not associated 
with increases in LOS (r = 0.01, p = 0.4), postoperative infections, or reoperation rate (OR 
ratio = 0.99, p = 0.6 for each) BMI correlated strongly with WL times (p = 0.01). Our single 
institute results were similar (BMI<30; 80%; 31-35;16.5%; and >35;3.5%; p=0.892) and 
there was no signiﬁcant between the groups in K-M survival curve. 
Conclusions: The present study is the largest reported series focusing on obesity in 
OHT. We found BMI to not be a signiﬁcant predictor of mortality, reoperation, or infection 
even to a BMI of 40. Obesity by itself should not be a contraindication to OHT.
3:30 p.m.
1042-193 Effects of the HeartMate II Continuous-Flow Left 
Ventricular Assist Device on RV Function
Sangjin Lee, Forum Kamdar, Richard Madlon-Kay, Ranjit John, University of Minnesota, 
Minneapolis, MN
Background: The effects of the HeartMate II (HMII) Left Ventricular Assist Device (LVAD) 
on RV function and tricuspid regurgitation (TR) have not been evaluated in detail. The 
goal of this study was to assess for the incidence of RV failure, alterations in RV function, 
TR and cardiac hemodynamics in the unloaded heart following HMII implantation.
Methods: Echocardiograms (n=23) and right heart catheterizations (n=40) were 
performed prior to and following 4-6 months of HMII support in 40 bridge-to-transplant 
patients. Right heart failure was deﬁned as the requirement for inotropes post-LVAD 
implantation for > 14 days or the need for right-sided mechanical circulatory support.
Results: The overall incidence of RV failure after HMII implantation was 5% (2/40). 
As shown in the table, there was a signiﬁcant improvement in the cardiac index with 
reductions in right atrial pressure, RV Stroke Work Index (RVSWI), mean pulmonary 
artery pressure and pulmonary vascular resistance following HMII LVAD support. There 
was a trend towards reduction in TR following LVAD support (p=0.075).
Conclusions: The incidence of RV failure following HMII implantation is low. The favorable 
effects of the HMII on cardiac hemodynamics results in improved RV function, improved 
right and left-sided hemodynamic proﬁles and reduction in TR. These ﬁndings may have 
important implications for patients with bi-ventricular failure needing longer-term support.
Parameter Pre-LVAD Post-LVAD p- value
TR (n=23) 2.5±1.1 (Mild-Mod) 2.0±1.1 (Mild) 0.075
RAP (n=40)* 13.7±5.3 7.71±5.6 <0.001
RVSW (n=40)* 15.1±8.5 12.5±6.6 0.03
RVSWI (n=40)* 7.5±3.9 6.3±3.3 0.04
MPAP (n=40)* 37.4±8.0 23.3±7.1 <0.001
PVR (n=40)* 3.7±1.8 2.1±0.8 <0.001
PCWP (n=40)* 24.5±5.7 12.9±6.23 <0.001
CO (n=40)* 3.8±1.24 4.9±1.3 <0.001
CI (n=40)* 1.9±0.5 2.5±0.5 <0.001
apart with both AFT and IABP. The AFT Cancion system was positioned using a dual femoral 
approach with constant pump ﬂow of 250 ml/min. Blood samples obtained at baseline and at 
4 hours after each therapy were used to measure atrial natriuretic peptide (ANP), nt-pro brain 
natriuretic peptide (BNP), norepinephrine (PNE), endothelin-1 (ENDO-1), angiotensin-II (A-
II), tumor-necrosis factor-alpha (TNF), interlukin-6 (IL-6) and C-reactive protein (CRP).
Results: IABP had no signiﬁcant beneﬁts on any of the biomarkers (Table). In contrast, 
AFT elicited signiﬁcant reductions in ANP, BNP, PNE, ENDO-1, TNF, IL-6 and CRP but 
did not affect A-II (Table).
Conclusions: In dogs with chronic HF, AFT is superior to IABP in attenuating plasma 
markers of enhanced neurohumoral and pro-inﬂammatory activity. The results support 
our earlier ﬁndings that AFT is superior to IABP in unloading the failing canine LV.
*=p<0.05 Baseline vs. 4 Hours
AFT IABP
Baseline 4 Hours Baseline 4 Hours
ANP (pmol/ml) 0.56 ± 0.05 0.45 ± 0.04* 0.58 ± 0.03 0.52 ± .02
BNP (fmol/ml) 123 ± 14 95 ± 8* 135 ± 15 138 ± 17
PNE (pg/ml) 663 ± 50 454 ± 23* 699 ± 50 721 ± 45
ENDO-1 (pg/ml) 1.31 ± 0.09 1.06 ± 0.06* 1.31 ± 0.05 1.95 ± 0.12*
A-II (pg/ml) 141 ± 59 141 ± 58 107 ± 135 111 ± 33
TNF (pg/ml) 4.1 ± 0.5 2.9 ± 0.3* 4.1 ± 0.5 4.6 ± 0.6
IL-6 (pg/ml) 34.9 ± 6.8 22.3 ± 5.9* 30.9 ± 5.0 29.2 ± 5.8
CRP (ng/ml) 214 ± 10 151 ± 10* 218 ± 10 202 ± 15
3:30 p.m.
1042-189 Withdrawn
3:30 p.m.
1042-190 The Allomap Test Fails to Distinguish Between Quilty 
Lesions and Acute Allograft Rejection in Heart 
Transplant Patients
Rajesh M. Kabadi, Colleen Flanagan, Barbara Ebert, John L. Farber, Paul J. Mather, 
Thomas Jefferson University Hospital, Philadelphia, PA
Purpose: The Allomap test is a non-invasive alternative to biopsy as a screen for acute 
cellular rejection (AR) in cardiac transplantation patients. Using the polymerase chain 
reaction (PCR), the test measures the expression of 20 genes in peripheral blood 
lymphoctyes. The PCR values are used to generate a 0-40 score that reﬂects immune 
activation and leukocyte trafﬁcking pathways related to AR. A score greater than 30 
indicates a high probability of AR.
Quilty lesions (QL) are nodular endomyocardial aggregates of inﬂammatory cells 
found only in cardiac allografts of patients treated with a calcineurin inhibitor (CNI). QL 
represent ectopic lymphoid tissue formed by an anti-cardiac allograft immune response 
that has been modiﬁed by the CNI. QL are not associated with AR, viral infection, or the 
development of vasculopathy and, as such, are not treated.
Thus, it is of importance to know if the Allomap test distinguishes QL from AR.
Methods and Materials: From 2/1/08 to 9/26/08, 45 heart transplant patients underwent 
endomyocardial biopsy (total of 170 biopsies). Of these, 36 patients were at least 55 days 
post transplantation and, thus, eligible for Allomap testing.
Results: Five of the 36 patients had an Allomap score greater than 30 (32, 34, 34, 35, 
and 37) and a biopsy that showed QL (invasive or non-invasive) without signiﬁcant acute 
rejection (3 with ISHLT grade 0 and 2 with grade IR). Two patients are African American 
females (age 53 and 64), who were 11 and 16 months post transplantation. The other 3 
patients are Caucasian males (age 29, 65, and 67), who were 32, 24, and 13 months post 
transplantation, respectively. None of the 5 patients received any additional treatment 
and were maintained on their current immunosuppressive regimen. Follow-up has been 
uneventful in all 5 patients.
Conclusions: Over a 34 week period, nearly 15 percent of our eligible patients had QL and 
no signiﬁcant AR, despite an Allomap score greater than 30. Thus, the Allomap test fails 
to distinguish between Quilty lesions and acute cellular rejection.
3:30 p.m.
1042-191 Sildenaﬁl or Bosentan in Patients Considered Inelegible 
for Heart Transplantation Because of Severe Pulmonary 
Hypertension
Marta Farrero, Felix Perez Villa, Adrian Arias, Maria Angeles Castel, Alessandro Sionis, 
Eulalia Roig, Hospital Clinic Barcelona, Barcelona, Spain
Background: Elevated pulmonary vascular resistance (PVR) is associated to an 
increase in mortality in the early post-heart transplant period, mainly due to right ventricle 
dysfunction. This study aims to asses the effectiveness of both sildenaﬁl and bosentan 
in decreasing the PVR in a group of patients initially considered ineligible for heart 
transplantation because of severe pulmonary hypertension.
Methods: Sixteen patients with end-stage congestive heart failure and severe pulmonary 
hypertension were prospectively included. These were randomly assigned to receive 
either bosentan 125mg bid (n=8) or sildenaﬁl 80mg tid (n=8). A second right heart 
catheterization was performed after 16 weeks of therapy.
Results: No signiﬁcant differences were observed in the two group’s basal characteristics. 
The bosentan group had a basal transpulmonary gradient (TPG) of 21 +6mmHg that was 
reduced to 10 + 7 (p=0.005) during the treatment. Also the pulmonary vascular resistance 
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1042-196 Extremes of Body Mass Index Do Not Affect Short- and 
Long-Term Survival Outcomes Following Cardiac 
Transplantation
Sangjin Lee, John Connett, Monica Colvin-Adams, University of Minnesota, 
Minneapolis, MN
Background: The association of recipient body mass index (BMI) with heart transplant 
(HTx) outcomes is unclear, though it is generally accepted that BMI extremes negatively 
affect outcome. The goal of this study is to determine the impact of recipient BMI on 
survival and post HTx infections in all transplants performed in the United States.
Methods: From 1/2000 to 4/2008, 15,359 heart transplants were performed in the United 
States. Using data provided by the Organ Procurement and Transplantation Network 
(OPTN), we evaluated 1 month and 1 year survival stratiﬁed by BMI. In addition, we 
assessed infection at one month and one year.
Results: The mean age was 51.7±12.3 years. 76% were male recipients. Survival was 
comparable between the BMI groups at 30 days and 1 year. The highest survival rate at 1 
year was in the morbidly obese group with BMI>40 at 88.2%. The infections rates requiring 
hospitalization for all BMI categories were comparable within 1 year post-transplant.
Conclusions: Recipient BMI extremes at the time of cardiac transplantation have 
acceptable peri-operative mortality, long-term mortality and infection rates requiring 
hospitalization. These ﬁndings may have important implications for the selection of heart 
transplant recipients.
Recipient
BMI
Number of 
transplants
1 month post-
transplant survival 
rate (%) and 95% 
Conf. Limits
12 month post-
transplant survival rate 
(%) and 95% Conf. 
Limits
1 year post-
transplant 
infection rate (%)
<20 1099 94.8 [93.3,96.2] 86.4 [84.2,88.5] 14.8
20-30 10759 94.5 [94.0,94.9] 87.5 [86.8,88.1] 15.7
30-35 2762 93.7 [92.8,94.7] 85.6 [84.3,87.0] 17.3
35-40 575 93.2 [90.9,95.4] 86.4 [83.4,89.4] 18.8
>40 140 93.5 [88.5,98.5] 88.2 [82.0,94.5] 15.3
3:30 p.m.
1042-197 Reduced Left Ventricular Torsion With Two-Dimensional 
Speckle Tracking Echocardiography Would Predict 
Acute Rejection in Heart Transplant Recipients
Takahiro Sato, Tomoko S. Kato, Shuji Hashimoto, Noboru Oda, Masanobu Yanase, Hideaki 
Kanzaki, Kazuhiko Hshimura, Hatsue Ueda, Kazuo Komamura, Toshiaki Shishido, Takeshi 
Nakatani, Masafumi Kitakaze, National Cardiocascular Center, Suita, Japan
Background: Invasive screenings for acute rejection (AR) by endomyocardial biopsy 
(EBM) in heart transplant (HTx) recipients are standard procedures. Abnormal ventricular 
systolic torsion has been reported to associate with AR. Speckle tracking echocardiography 
(STE) provides a powerful means of assessing left ventricular (LV) torsion (LVtor).
Objectives. We investigated the utility of LVtor derived from STE in HTx recipients.
Methods: In 32 HTx recipients, 301 EMBs and hemodynamic studies were obtained 
between 6 month and 7.2 years post-transplant. The echocardiograms were recorded 
within 3 hours from EMB performed. The apical and basal short-axis rotations were 
assessed by STE.The LVtor was deﬁned as the net difference between rotation angles 
in the two short-axis planes normalized for LV longitudinal length. Echocardiographic 
and hemodynamic parameters were compared with EMB results. According to the 
conventional International Society for Heart and Lung Transplantation criteria, EMBs of 
grade 0 to 1b were deﬁned as group AR- and those of grade 2 or higher were diﬁned as 
group AR+. Additionally, we assessed the utility of diachronic observation of changes in 
LVtor in each patient. Baseline LVtor in each patients was deﬁned as mean values of 3 
serial LVtors obtained during initial phase after HTx without evidence of AR.
Results: The LVtor was signiﬁcantly reduced in group AR+ than that in group AR-(9.3 ± 
0.7 vs. 12.2 ±0.2 degree, p<0.001). Conventional echocardiographic parameters were not 
different between the groups. Pulmonary artery wedge pressure and right atrial pressure 
3:30 p.m.
1042-194 A Recombinant Human Neuregulin-1 Peptide Added to 
Celsior Solution Further Improves Preservation of the 
Transplanted Rat Heart After Prolonged Hypothermic 
Storage
Andrew Jabbour, Ling Gao, Jair Kwan, Alasdair Watson, Xifu Liu, MinDong Zhou, Robert 
M. Graham, Mark Hicks, Peter S. Macdonald, Victor Chang Cardiac Research Institute, 
Sydney, Australia
Background: Maintenance of nitric oxide ﬂux and the minimization of intracellular calcium 
levels are important for donor heart preservation. We have shown that modulating these 
processes by supplementing a cardiac storage solution (Celsior; C) with glyceryl trinitrate 
(GTN) and cariporide, improves cardiac preservation after 6 hrs of hypothermic storage. 
Neuregulin-1 also plays a critical role in the adaptation of the heart to injury, promoting 
cell survival via activation of ErbB2/4 receptors. We hypothesized that the addition of a 
recombinant human neuregulin-1 (B2a isoform) (rhNRG-1) to C, in combination with GTN and 
cariporide, would further improve cardiac preservation after prolonged storage (10 hrs).
Methods: Pre-arrest indices of cardiac function were measured in isolated working rat 
hearts. Hearts were arrested and stored for 10 hrs at 4° Celsius in C supplemented 
with either: 1) GTN (0.1mg/ml); 2) cariporide (10μM); 3) rhNRG-1 (14μM) alone or in 
combination (see table). Hearts were remounted on the perfusion apparatus after storage 
and cardiac function reassessed. Hearts were then frozen for western blotting or prepared 
for immunohistochemical analysis.
Results: Functional improvements were accompanied by signiﬁcant activation of Akt, 
ERK 1/2 and GSK-3B.
Conclusions: Polypharmaceutical activation of multiple pro-survival pathways further 
improves preservation of the rat heart and shows promise for increasing the cold ischemic 
‘shelf life’ of donor hearts in transplantation.
Post-storage recovery as percentage of pre-arrest function (mean+- 
SEM). *p<0.02 vs all groups
Supplement Number Heart Rate(beats/min)
Coronary Flow 
(ml/min)
Cardiac Output 
(ml/min)
GTN 5 9.9±9 8.0±1.7 3.0±0.7
Cariporide 6 17.4±10.2 21.0±4.3 5.8±1.2
rhNRG-1 6 47.5±6.3 5.9±3.9 3.8±0.8
GTN + Cariporide 6 54.5±14.7 48.6±12 25.7±10.6
GTN + Cariporide + 
rhNRG-1* 6 84.3±2.4 79.7±4.7 49.2±5.9
3:30 p.m.
1042-195 Allomap and ImmuKnow - Can They Partner for Post 
Cardiac Transplant Management?
Moses Mathur, Colleen P. Flanagan, Barbara A. Ebert, Paul J. Mather, Thomas Jefferson 
University Hospital, Philadelphia, PA, Jefferson Medical College, Philadelphia, PA
We studied the relationship between Allomap(AL), ImmuKnow(IK) and outcomes in post-
cardiac transplant (OHT) patients.
We studied 42 OHT patients from a single center between 3/08 and 8/08. 79 visits were 
recorded. The AL score measures the expression of 20 genes and reﬂects immune 
activation and leukocyte trafﬁcking pathways, whereas IK measures the ATP production 
by activated T-cells. For each visit, the serum AL and IK levels, and biopsy grades were 
collected. The data was sorted by ISHLT grades, and corresponding AL and IK values.
14 out of 79 specimens (18%) had AL>34. Of these 14, 1 patient had grade 2 rejection, 
and 1 had 3A rejection. The IK levels for these patients were 44 and 175 respectively. There 
were 3 grade 3A rejections, and 3 grade 2 rejections. For grade 2 rejections, the AL-IK 
pairings were (28,254), (29,257) and (37,44) respectively. The pairings for 3A rejections 
were (12, 142), (32, 311) and (37, 175). Pearson correlation scores between AL, IK, 
and rejection values 0, 1A, 2 and 3A were found to be 0.069, 0.015, -0.993 and 0.496 
respectively. 4 patients had infections (3 had CMV, 1 had Staphylococcus pneumonia). Their 
corresponding (AL, IK) levels were (39,101), (9,243), (32, 77) and (37,175) respectively.
We found discordance between AL and IK values, whether in the setting of cardiac 
allograph rejection or infections. Given this, further advances are needed before the 
clinician may feel comfortable using AL and IK values as non-invasive surrogates for the 
gold standard: endomyocardial biopsy. 
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1042-200 UNOS Status Escalation and Adverse Clinical Events 
Among Patients Initially Listed as UNOS Status 2
Todd F. Dardas, Jennifer C. Matthews, Keith D. Aaronson, Francis D. Pagani, University 
of Michigan, Ann Arbor, MI
Background: Previous publications have suggested that patients initially listed as UNOS 
status 2 have an event-free survival of 89% at 1 year. However, some patients initially 
listed as UNOS 2 will deteriorate and may transition to a higher UNOS status. Initial 
UNOS status 2 listing may not be an indicator of future survival and may oversimplify 
the transitions that take place during the listing experience. The result may be an 
overestimation of survival for patients initially listed as UNOS status 2.
Methods: The SRTR database was used to identify 7176 unique patients, of which 
3647 (51%) were initially listed as UNOS status 2 from 2004 to 2007. One-year survival 
estimates were created using the Kaplan-Meier method. Different deﬁnitions of events 
and censoring variables were used to estimate the frequency of adverse clinical outcomes 
and transitions to a higher urgency UNOS status.
Results: Of patients initially listed as UNOS status 2 who received a transplant, 48%, 
received a transplant as UNOS status 2, while 52% received a UNOS status 1a or 1b 
transplant. Freedom from death or being too ill to remain listed was 0.87 (95% CI; 0.85, 0.89 
), which agrees with previously published estimates. The freedom from death, being too ill 
to remain listed or having a ﬁrst transition to status 1a or 1b was 0.25 (95% CI; 0.23, 0.27), 
which demonstrates a high cumulative probability of status escalation within 1 year of initial 
listing. Freedom from death or being too ill to remain listed, with censoring of those who 
transition to UNOS status 1a/b, was 0.86 (95% CI; 0.84, 0.88), suggesting a reasonable 
survival among those who remain UNOS status 2 throughout their listing experience.
Conclusions: Patients initially listed as UNOS status 2 have a high probability of transition 
to UNOS status 1a or 1b and subsequent transplantation from that higher urgency status, 
while those who remain status 2 appreciate relatively low risk of death in the subsequent 
year. This relatively favorable prognosis for status 2 patients is dependent upon physician 
identiﬁcation of clinical deterioration and upgrade to higher UNOS status. The perception 
that UNOS 2 status has a favorable prognosis is misleading.
3:30 p.m.
1042-201 Inﬂammatory Burden of Cardiac Allograft Coronary 
Atherosclerotic Plaque Is Associated With Recurrent 
Acute Cellular Rejections and Predicts a Higher Risk of 
Vasculopathy Progression
Eugenia Raichlin, Bae Jung-Ho, Sudhir S. Kushwaha, Ryan J. Lennon, Abhiram Prasad, 
Charanjit S. Rihal, Amir Lerman, Mayo Clinic, Rochester, MN
Background:We investigated tissue characterization of the coronary allograft atherosclerotic 
plaque with virtual histology intravascular ultrasound (VH-IVUS) imaging to assess the 
presence and predictors of vessel wall inﬂammation and its signiﬁcance in CAV progression.
Methods:Eighty six patients with coronary allograft vaculopathy underwent VH-IVUS 
examination of the left anterior descending coronary artery 3.61 3.04 years following 
cardiac transplantation. Based on the VH-IVUS plaque characteristics coronary allograft 
plaque was divided on inﬂammatory (IP necrotic core and dense calcium 30%) and non-
inﬂammatory plaque (NIP, necrotic core and dense calcium < 30%). Total rejection scores 
(TRS) was calculated based on ISHLT R 2004 grading.
Results:In the whole study population, the mean percentage of ﬁbrous, ﬁbrofatty, dense 
calciﬁed and necrotic core plaques in a mean length of 62.3 17.4 mm of the LAD were 50 
17%, 16 11%, 15 11%, 18 9%. Patients with 6 month TRS > 0.3 had signiﬁcantly higher 
incidence of IP as compared to those with TRS 0.3 (69% vs. 33%, p=0.011). The presence of 
IP at baseline was associated with a signiﬁcant increase in plaque volume (2.42 1.78 mm3/
mm vs. -0.11 1.65 mm3/mm, p=0.010), plaque index (7 9% vs. 0 8%, p=0.04) and remodeling 
index (1.24 0.44 vs. 1.09 0.36, p=0.030) during 12 months follow up as compared to NIP.
Conclusions:The presence of IP as assessed by VH-IVUS is associated with early 
recurrent rejections and with higher subsequent progression of CAV.
VH-IVUS assessment may add important information in the evaluation of transplant recipients.
3:30 p.m.
1042-202 Pretreatment of Human Marrow-Derived Mesenchymal 
Stem Cells With Pioglitazone Improved the Efﬁcacy of 
Transplantation on Cardiac Function In Vivo
Daisuke Shinmura, Shinichiro Miyoshi, Hiroko Tsuji, Nobuhiro Nishiyama, Naoko Hida, 
Hikaru Nakamizo, Ikuko Togashi, Kaoru Segawa, Yuiko Tsukada, Akaru Ishida, Makoto 
Handa, Akihiro Umezawa, Satoshi Ogawa, Keio University School of Medicine, Tokyo, 
Japan, National Research Institute for Child Health and Development, Tokyo, Japan
Background: Transplantation of human marrow-derived mesenchymal stem cell (MSC) 
slightly improved the impaired cardiac function but the effect was insufﬁcient. We found 
that the pretreatment of the cells with pioglitazone (PO) dramatically improved the 
cardiomyogenic transdifferentiation efﬁciency of MSCs via peroxisome proliferators-
activated receptor-g (PPAR-g) activation in vitro. The effect on cardiac function of 
engrafted PO-treated MSCs in vivo has not been elucidated.
Methods & Results: LAD was ligated in open-chest anesthetized nude rats to produce 
myocardial infarction (MI). MSCs were cultured with medium containing 1μM of PO for 2 
weeks. Two weeks after MI, MSCs pretreated with PO (P; n=30) or without PO (C; n=17) 
were isolated, and injected into the MI area (1x106 cells). In 15 rats, the culture medium 
was injected (MI). In 14 rats, sham operation was done (SHAM). Four weeks after the 
initial operation, we compared the rate of LV fractional shortening (%LVFS) measured by 
echocardiogram and systolic LV pressure (LVSP) with the rate of MI volume (%MIVOL) 
tended to be higher in group AR+ than those in group AR- (7.84±0.18 vs. 8.93 ± 0.54 mmHg, 
p=0.054, 3.80±0.15 vs. 4.7±0.46 p=0.058, respectively). In a diachronic analysis in each 
patient, a cut-off value of 25% reduction of LVtor could discriminate grade 2 or higher rejection 
with a sensitivity of 73%, speciﬁcity of 94%, and predictive accuracy of 92%. Conclusions: The 
LVtor derived from STE could be of clinical value in non-invasive evaluation for AR. We might 
be able to optimize the timing of routine EMBs by the use of STE.
3:30 p.m.
1042-198 Cardiac Allograft Sizing in Heart Transplant Candidates 
With Pulmonary Hypertension
Murray Kwon, Allison Ankrom, Abbas Ardehali, Matt Kawano, Michelle Kittleson, 
Jignesh Patel, Krista Kiyosaki, Jon Kobashigawa, David Geffen School of Medicine at 
UCLA, Los Angeles, CA
Background: Oversized donor hearts are favored for candidates with mild-moderate 
pulmonary hypertension (PH). This selection bias may exacerbate the donor organ 
shortage by bypassing suitable smaller donor hearts. We hypothesize that undersized 
and oversized donor hearts fare equally well in the setting of perioperative PH.
Methods: 107 patients from 2003-2008 were reviewed and divided into 2 groups: those 
receiving organs from undersized donors (Donor/Recipient Weight0.90, n=37) and those 
receiving organs from oversized donors (Donor/Recipient Weight >/=1.2, n=70). PH was 
deﬁned as systolic pulmonary arterial pressures (PAP) >/=40 mmHg. Hemodynamic data 
and 1-year survival were examined.
Results: Perioperative PH was seen in 49% of undersized and 57% of oversized donors 
(p=NS). 1-month and 1-year survival for undersized donors was 94.7% and 89.5% and 
for oversized donors was 100% and 90%, respectively (p=NS). Left and right ventricular 
ejection fractions were normal in all patients at 6 months after transplant. There was 
no difference between groups in PAP one week-6 months post-transplant. Both groups 
showed reductions in PAP over 6 months after transplant (p<0.001; Figure).
Conclusions: Hearts from undersized and oversized donors did equally well with respect 
to short and long term survival as well as hemodynamic recovery and normalization of 
PAP over time. The selection bias favoring oversized donor hearts for patients with PH 
may be unwarranted and unjustiﬁably decreases the donor pool.
3:30 p.m.
1042-199 Microvascular Dysfunction and Suboptimal Glycemic 
Control Predicts Poor Outcome Following Heart 
Transplantation
Prateeti Khazanie, Francois Haddad, Anna M. Simos, Michael Pham, Dana M. 
Weisshaar, Sapna V. Desai, Maulik G. Shah, Tracey L. McLaughlin, Sharon A. Hunt, 
Hannah A. Valantine, William Fearon, Stanford University Hospital & Clinics, Stanford, 
CA, Kaiser Permanente- Santa Clara, Santa Clara, CA
Background: Microvascular dysfunction is increasingly recognized as a risk factor for 
adverse outcomes following heart transplantation. The objective was to determine whether 
early microvascular dysfunction at one year predicted hemodynamically compromising 
rejection (HCR) or allograft vasculopathy at three years.
Methods: Forty-eight consecutive heart transplant patients who underwent coronary 
physiology measurements at one year at Stanford University were included in the study. 
Microcirculation was assessed invasively at one year using a coronary pressure sensor/ 
thermistor-tipped guidewire, measuring coronary ﬂow reserve (CFR) and the index of 
microcirculation resistance (IMR) in the left anterior descending artery. Diabetes mellitus 
(DM) was deﬁned as fasting blood glucose > 126 mg/dL or random glucose > 200 mg/dL. 
Suboptimal glycemic control was deﬁned as HbA1C > 7.0%. The combined endpoint at 
three years consisted of HCR or early allograft vasculopathy deﬁned as > 50% angiographic 
stenosis or severe diffuse disease. Predictors of outcome were analyzed using univariate 
regression analysis; the three strongest predictors were then entered into a multivariate 
logistic regression analysis to identify independent predictors of poor outcome.
Results: The study population consisted of 8 women (17%) and 40 men (83%). The mean 
age at transplantation was 53 ± 11 years. The majority of patients were transplanted 
for non-ischemic cardiomyopathy (56%). DM was present in 23 patients (48%); seven 
patients had suboptimal glycemic control. Combined outcome occurred in 17 patients 
(35%). Multivariate analysis identiﬁed both evidence of microvascular dysfunction (CFR 
< 2) at one year (O.R. 5.55, 95% CI: 1.07-28.88) and suboptimal diabetes control (O.R. 
8.55, 95% CI: 1.39-52.65) as predictors of adverse outcome.
Conclusions: Early microvascular dysfunction and suboptimal glycemic control is 
associated with an increased risk of HCR and early allograft vasculopathy at three years.
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1042-205 Unrecognized Severe Left Ventricular Dysfunction in 
Patients With Anemia and Chronic Kidney Disease and 
Future Risk of Death and Heart Failure Hospitalization
Sabha Bhatti, Abdul Hakeem, Jeffrey R. Cook, Kathryn S. Dillie, Su Min Chang, 
University of Cincinnati College of Medicine, Cincinnati, OH, Methodist DeBakey Heart 
and Vascular Center, Houston, TX
Background: While anemia and chronic kidney disease (CKD) portend a worse prognosis 
in patients with heart failure, the prevalence and outcomes of unrecognized severe left 
ventricular dysfunction (ULVSD) in patients with anemia and CKD is not known.
Objectives
The objective of this study was to determine whether anemia (Hemoglobin <13 g/l) and 
CKD ( glomerular ﬁltration rate < 60 ml/min/1.73 Kg/m2 as measured by MDRD equation) 
are risk factors for severe ULVSD (deﬁned as EF<35%;no known history of heart failure ) 
and to determine its impact on clinical outcomes .
Methods: 1358 patients (65+10 years,97%male; 40% with history of CAD;35% diabetic) without 
history of HF undergoing gated myocardial perfusion SPECT for evaluation of suspected CAD 
were followed for a mean duration of 2.15+/- 0.8 years. End points were death and heart failure 
hospitalization (HFH).Patients were divided into 4 groups (I: No Anemia/No CKD n=752, II: 
CKD/No anemia n=285, III: Anemia/ No CKD n=153, IV: Anemia+CKD n=168)
Results: Compared to the group I, severe ULVSD was signiﬁcantly more common in 
those with anemia and CKD. [(11.3% vs. 4%; p=0.0009) Odds ratio = 2.77 ( 95% CI 
;1.53-5.0;P=0.0007)]. The annualized death rate and HFH rates were signiﬁcantly higher 
in patients with the anemia+CKD group compared to the normal group ( Death Rate= 
group I :3.5%/yr vs group IV :12%/yr; p<0.0001) (HFH Rate= group I:1.5%/yr vs group IV: 
8%/yr P<0.0001) translating into a relative risk (RR) of 3.45 (95% CI 2.38-5.01) for death 
(P<0.0001) and 5.02 (95%CI 3.05-8.1) for HFH (P<0.0001) compared to the normal 
group. Among patients with EF <35%, presence of anemia+CKD was associated with a 
RR of 2.48 (95% CI 1.13-5.4;p=0.02) for death compared to normal group.
Conclusions: In patients with suspected CAD and no known history of heart failure, 
unrecognized severe LVSD was almost 3 times more common in patients with Anemia+CKD 
compared to those with no CKD nor anemia , and was associated with a signiﬁcantly higher 
risk of future death and HFH .Based on these results it may be beneﬁcial to screen high risk 
patients with anemia and CKD for unrecognized LVSD as early therapy for LVSD including 
ICD therapy may improve outcomes in this high risk cohort.
3:30 p.m.
1042-206 The Inﬂuence of Left Ventricular Ejection Fraction 
on the Extent of Reverse Remodeling by Cardiac 
Resynchronization Therapy in Mild Heart Failure: 
Results From the REsynchronization reVErses 
Remodeling in Systolic left vEntricular Dysfunction 
(REVERSE) Study
Cecilia Linde, Claude Daubert, William T. Abraham, Michael R. Gold, Christian 
Hassager, John M. Herre, Stefano Ghio, Martin St. John Sutton, Genevieve Derumeaux, 
Karolinska University Hospital, Stockholm, Sweden
Background: The REVERSE trial is the ﬁrst prospective randomized double blind parallel 
trial that demonstrated that CRT plus optimal medical therapy (CRT ON) compared to 
CRT OFF could slow disease progression and reverse left ventricular (LV) remodeling in 
patients (pts) with NYHA I-II HF, QRS q 120 ms and LV ejection fraction (LVEF) a 40%. We 
investigated if the extent of reverse remodeling was related to baseline LVEF.
Methods: 610 pts with NYHA II (82%) or I (18%) were randomized in 73 centres in the 
US, Canada and Europe. The mean LVEF at baseline was 27.0 ±6.6 and the mean QRS 
width 153 ± 22 ms. Echocardiograms were obtained in each patient at baseline and at 
12 month post enrollment to measure LVEF and LV end systolic volume index (LVESVi) 
by a core lab.
Results: The mean change in LVESVi over 12 months was -1.3 ± 23.4 ml/m2 in the 
CRT OFF group and -18.4 ± 29.1 ml/m2 in the CRT ON group. The relationship between 
change in LVESVi and baseline LVEF is shown in the graph. CRT ON patients with lower 
baseline LVEF obtained greater improvements in LVESVi over 12 months than patients 
with higher baseline LVEF. An ANOVA concluded that baseline LVEF and randomization 
assignment (CRT ON vs CRT OFF) were signiﬁcant factors (p<0.0001) in the magnitude 
of reverse remodeling.
Conclusions: REVERSE demonstrates that the extent of reverse remodeling after 12 
months of CRT was related to magnitude to LVEF at baseline. No improvement was noted 
in subjects with a baseline LVEF above 36%. 
measured by histological analysis. Data was shown in a table. Pretreatment with PO 
signiﬁcantly improved %LVFS, LVSP, and %MIVOL (*p<0.05 vs C).
Conclusions: Transplantation of PO-pretreated MSCs decreased ﬁbrosis area and 
restored the LV systolic function in the MI-model in vivo. PO-induced PPAR-g activation of 
MSCs can restore the efﬁcacy of present cardiac stem cell therapy in clinical practice.
Improved cardiac function by PPAR-g pretreated hMSC
% LVFS LVSP (mmHg) %MIVOL
SHAM (n=14) 52.4 ± 1.6 116.9 ± 5.9 0.8 ± 0.4
MI (n=15) 29.2 ± 2.0 104.2 ± 4.8 15.7 ± 1.4
C (n=17) 30.3 ± 2.1 108.6 ± 4.3 15.7 ± 1.5
P (n=30) 39.8 ± 1.6 * 124.8 ± 2.3 * 9.4 ± 1.3 * *p<0.05 vs C
3:30 p.m.
1042-203 Tandem Heart pVAD Outcomes Based on the Intention 
to Treat: A Single Institution Experience
Biswajit Kar, Sukhdeep S. Basra, Reynolds Delgado, Andrew Civitello, Igor D. Gregoric, 
Pranav Loyalka, Texas Heart Institute, Houston, TX
Background : The Tandem Heart percutaneous Ventricular Assist Device (pVAD) is a 
novel short term mechanical circulatory device. Though primarily intended as a Bridge 
to Recovery for patients with Severe Refractory Cardiogenic Shock (SRCS), the Tandem 
Heart is now also being used as a Bridge to LVAD, Bridge to Surgery and Bridge to 
Transplant. We aim to review the survival outcomes for each of these indications.
Methods and Materials: A total of 143 patients implanted with the Tandem Heart at our 
institute were included in the study. These included Bridge to Recovery (n=74), Bridge to 
LVAD (n=32), Bridge to Surgery (n=34) and Bridge to Transplant (n=5).
Results: The mean duration of support was 5.174.6 days. Severe Refractory Cardiogenic 
Shock(SRCS) was observed in 74.8% patients. The overall mortality rate for Tandem 
Heart pVAD was 40.6%. This included an overall mortality rate of 56.8% for Bridge to 
Recovery, 12.5% for Bridge to LVAD, 42.6% for Bridge to Surgery and 0% for Bridge 
to Transplant. The mortality rate while on Tandem Heart support and immediately after 
weaning off was 21.7% and 18.9% respectively (overall), 36.5%and 20.3% (Bridge to 
Recovery), 0% and 12.5% (Bridge to LVAD), 25% and 16.7% (Bridge to Surgery)
Conclusions: Tandem Heart pVAD is an effective tool to reverse SRCS in a subset of high 
risk patients who can the be transitioned to recovery, LVAd, surgery , or transplant
Total Bridge to Recovery
Bridge to 
LVAD
Bridge to 
Surgery
Bridge to 
Transplant
Number 143 72 34 34 5
Age(years) 57.5±15.93 58.11±5.07 46.22±15.78
67.41±
11.33 55.6 ±9.01
Duration of support(days) 5.17 ±4.6 5.57± 4.65 6.44±5.33 3.03± 3.27 6.4±3.36
Overall mortality rate 40% 56.8% 12.5% 42.6% 0%
Mortality rate during 
Tandem Heart Support 21.7% 36.5% 0% 25% 0%
Mortality rate after removing 
Tandem Heart support 18.9% 20.3% 12.5% 16.7% 0%
Cardiogenic Shock 74.8% 98.6% 90.6% 94.4% 80%
3:30 p.m.
1042-204 Sustained Improvement in Left Ventricular Strain Two 
Years Following Gastric Bypass Surgery in Severely 
Obese Patients
Ronny S. Jiji, Theophilus E. Owan, Kimberly Morley, Zachary Williams, Nathaniel Hall, 
Richard Gress, Steven Hunt, Sheldon E. Litwin, University of Utah, Salt Lake City, UT
Background: Strain imaging can detect subclinical left ventricular (LV) dysfunction in 
obese patients. It is unclear whether surgically-induced weight loss can produce sustained 
reversal of this abnormality.
Methods: We prospectively studied 62 severely obese patients at baseline and 2 years 
after Roux-en-Y gastric bypass surgery (GBS). Longitudinal strain was measured from 
a four chamber echocardiographic view using Siemens VVI TM software. Peak systolic 
strain and strain rate were taken as the average value from the 6 standard LV segments. 
We investigated the association of various clinical parameters with average strain using 
linear regression models.
Results: Mean body-mass index (BMI) was 45.8±7.4 at baseline and 30±7.3 at 2 year 
follow up after GBS in this selected cohort of 55 females and 7 males. There was a 
signiﬁcant increase in average LV strain from baseline (-18.7±3.8) to 2 year follow up 
(-21.7±4.1; p <0.001). Although there was an increase in average strain rate from baseline 
(-1.15±0.28) to 2 years (-1.25±0.3), this was not statistically signiﬁcant (p=0.07). Midwall 
fractional shortening was an independent predictor of change in LV strain over 2 years 
($LV strain), (t statistic=2.22, p=0.031). There was a positive correlation between $LV 
strain and the difference in BMI over 2 years (t statistic=2.17, p=0.034). This correlation 
between strain and BMI was independent of LV mass, systolic blood pressure, and age.
Conclusion: In this prospective, longitudinal study of severely obese patients, we found 
evidence that GBS produces long term improvement in myocardial function. Although 
there is a signiﬁcant correlation between LV strain and both BMI and mid-wall fractional 
shortening, we were unable to attribute the improved LV function to alterations in traditional 
hemodynamic or metabolic parameters. Nevertheless, we demonstrate the utility of 
echocardiographic strain imaging in the evaluation of LV function in patients at high risk of 
cardiovascular disease, but who pose major challenges to most imaging modalities.
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Innovative Biomarkers: Boon or Bane?
Monday, March 30, 2009, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room W308A
2:00 p.m.
0907-3 Prognostic Utility of Natriuretic Peptides in Preserved 
Ejection Fraction: An Exploratory Analysis of the 
Biomarkers in Acute Heart Failure (BACH) Trial
Kabir J. Singh, Niraj Parekh, Garrett Terracciano, Paul Clopton, Inder Anand, Robert 
Christenson, Lori B. Daniels, Salvatore DiSomma, Gerasimos Filippatos, Christopher 
Hogan, James McCord, Martin Möckel, Christian Müller, Sean-Xavier Neath, Leong 
Ng, Richard Nowak, W. Franklin Peacock, Piotr Ponikowski, Mihael Potocki, Alan Wu, A. 
Mark Richards, Stefan D. Anker, Alan Maisel, Veterans Affairs San Diego Health Care 
System, San Diego, CA, University of California San Diego, San Diego, CA
Background: Natriuretic peptides (NPs) are well-validated in the diagnosis and prognosis 
of acute heart failure (HF). In this study, we compared the prognostic utility of NPs in acute 
systolic versus preserved ejection fraction (EF) HF.
Methods: The study was an exploratory analysis of results from the Biomarkers in ACute 
Heart Failure trial, a multi-center study assessing novel biomarkers in dyspneic patients 
presenting to the emergency department. Of patients diagnosed with acute HF, discharge 
plasma levels of NPs including B-type natriuretic peptide, mid-region pro-A-type natriuretic 
peptide (MRproANP), and amino-terminal pro-BNP were measured. Patients were 
monitored for 90 days post-discharge for readmission for HF or other cardiac admission 
and all-cause mortality. Relationships between log-transformed NP levels and outcomes 
were assessed by Cox regression and receiver-operator curve analysis.
Results: Of 1641 patients, 429 had a primary diagnosis of HF and EF data, and of 
these patients 104 had an event. 162 had an EF q 50%. There were 23 events amongst 
preserved EF patients, and 81 events amongst patients with EF <50%. Amongst all 
patients with acute HF, the NPs were prognostic. This predictive capacity of NPs was 
more robust amongst patients with preserved EF (see table).
Conclusions: Among decompensated HF patients, discharge NP levels, carry prognostic 
information. Importantly, this phenomenon is signiﬁcant and far more pronounced in 
patients with exacerbation of preserved EF HF. 
3:30 p.m.
1042-207 Responders to Biventricular Pacing Who Normalize 
Their Left Ventricular Ejection Fraction Survive as Well 
as the Normal Population
Mahesh Manne, Mina Chung, David Martin, Patrick Tchou, Cleveland Clinic, Cleveland, OH
Background: Patients with reduced Left Ventricular Ejection Fraction (LVEF) of 35% or 
less have reduced survival. We examined the survival of those who responded well to 
Biventricular (BiV) pacing by normalizing their LVEF to 50% or better and compared their 
survival to an age and sex matched set derived from the general population life table.
Methods: Over a nine year period, 750 patients underwent implantation of BiV pacing 
device at the Cleveland Clinic. 88 pts had follow up echocardiograms that showed LVEF 
of 50% or greater (test group). For each patient, an age and sex matched example was 
selected from the Social Security Life Tables. An expected survival plot derived from the 
matched population was then compared to the actual survival of our test group BiV pacing 
population.
Results: In the test group, there were 40 males. Mean age was 65.8±10.5. Pre-implant 
LVEF was 23.8±7.2. Follow up LVEF was 53.6 ± 4.0. The chart shows the survival plot 
comparison. There is no statistically signiﬁcant difference in the survival curves.
Conclusions: Patients with reduced LVEF who respond well to BiV pacing have 
survivals comparable to the general population. This observation favors the concept of 
a cardiomyopathy generated by the conduction abnormality that is mostly reversed by 
BiV pacing. 
3:30 p.m.
1042-208 Scar Burden From Prior Infarction, Not Heart 
Failure Etiology, Predicts Outcomes After Cardiac 
Resynchronization
Evan C. Adelstein, Samir Saba, University of Pittsburgh, Pittsburgh, PA
Background: Pts with ischemic cardiomyopathy (ICM) may derive less beneﬁt from 
cardiac resynchronization (CRT) than non-ischemic cardiomyopathy (NICM) pts.
Methods: 196 CRT pts with ICM (deﬁned as angiographic >70% stenosis or prior 
revascularization) who underwent myocardial perfusion imaging (MPI) were compared 
to 349 NICM CRT pts and 53 pts with unsuccessful LV lead implants. Survival free from 
transplant (OHT) or ventricular assist device (VAD) and echo response were studied. MPI 
studies were read quantitatively, assigning each a summed perfusion score (SPS) from 
0-68. ICM pts were divided into SPS quartiles (a12, 13-21, 22-32, and >32); the highest 
3 quartiles were combined.
Results: Pts with NICM or SPSa12 had signiﬁcantly better OHT- and VAD-free survival 
than those without CRT or SPS>12 (p<0.01; Figure). Survival was similar among pts 
with SPS>12 and those without CRT. Echo beneﬁt followed a similar pattern; among pts 
with NICM, SPSa12, SPS>12, and no CRT, the relative LVEF change was +59, +49, 
+17, and -2.8% (p<0.01) and the relative LVESD change was -9.4, -7.3, -3.6, and +1.4% 
(p=0.05), respectively. Controlling for age, gender, atrial ﬁbrillation, diabetes, baseline 
bundle-branch block pattern and renal function, and spironolactone use corroborated 
these ﬁndings (p<0.01).
Conclusions: Pts with ICM and signiﬁcant scar do not beneﬁt from CRT compared to 
those with ICM and low scar burden or NICM, and their survival and echo response are 
similar to pts with unsuccessful LV lead implants.
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physician into those that did or did not develop WRF over the ensuing 5 days of in-hospital 
treatment.
Results: In our study cohort (57% male, mean age 60±15 years, mean LVEF 30±15%), 
mean and median serum NGAL were 178 ± 85 and 164 [108 - 229] ng/ml, respectively. 
Thirty-four patients (37%) developed WRF within the 5-day follow-up. Patients who 
developed WRF versus those without WRF had signiﬁcantly higher baseline serum NGAL 
levels (210 ± 77 versus 159 ± 84 ng/ml, p=0.0019). In logistic regression analysis, high 
serum NGAL levels were associated with greater likelihood of developing WRF (Odds 
Ratio [OR]: 1.9, 95%CI: 1.2-3.1, p=0.0047). NGAL >140 ng/ml (deﬁned by Receiver 
Operator Characteristic curve analysis) had a sensitivity and speciﬁcity of 88% and 54% 
respectively to predict the development of WRF. The OR for development of WRF in 
patients with NGAL >140 ng/ml compared those <140 ng/ml was 8.7 (95%CI= 2.9-32.1, 
p-value <0.0001).
Conclusions: High NGAL levels predict the development of worsening renal function in 
patients admitted with ADHF.
3:00 p.m.
0907-7 Effect of Race on the Diagnostic Performance of Novel 
Cardiovascular Biomarkers in Patients With Dyspnea: 
Results From the BACH Multinational Study
Lori B. Daniels, Sonal Sakariya, Paul Clopton, Stefan D. Anker, Inder Anand, Robert 
Christenson, Salvatore DiSomma, Gerasimos Filippatos, Christopher Hogan, Michael 
Hudson, James McCord, Martin Möckel, Christian Müller, Sean-Xavier Neath, Leong 
Ng, Richard Nowak, W. Franklin Peacock, Piotr Ponikowski, Mihael Potocki, A. Mark 
Richards, Alan Wu, Alan S. Maisel, University of California, San Diego, San Diego, CA, 
Veterans Affairs San Diego Healthcare System, La Jolla, CA
Background: The Biomarkers in Acute Heart Failure (BACH) study examined the utility 
of a panel of novel prohormone cardiovascular biomarkers in diagnosing heart failure 
(HF), but little is known about how levels of these markers vary between racial groups.
Methods: 1641 patients presenting to the ED with acute dyspnea were enrolled in the 
prospective, multinational, 15-center BACH trial, and plasma levels of several prohormone 
biomarker fragments were measured. The diagnosis of HF was determined by 2 
independent cardiologists, blinded to the ED physicians’ diagnoses and to the biomarker 
levels being examined in the trial. Race was determined by self-report.
Results: Of the 1626 patients of known race, 67% were white and 29% were black. 
White patients were more likely to have a ﬁnal diagnosis of HF than black patients (40% 
vs. 25%, p <0.001). Median levels of all BACH markers except CT-proAVP were lower in 
blacks than in whites among patients with a ﬁnal diagnosis other than acute HF; in those 
with acute HF, levels differed by race only for MR-proANP, which was higher in blacks 
(519 pmol/L vs. 395 pmol/L, p=0.002). All BACH markers were stronger predictors of HF 
in blacks than in whites, with MR-proANP emerging as an especially powerful predictor in 
blacks (AUC=0.946, Figure). Adjusting for age did not materially alter the results. 
Conclusions: Novel prohormone biomarkers performed better in blacks than in whites 
for diagnosing acute HF. MR-proANP proved an especially accurate predictor in black 
patients.
2:15 p.m.
0907-4 Hyporesponsiveness to Endogenous Erythropoietin 
Predicts Mortality in a Large Cohort of Heart Failure 
Patients
Anne M.S. Belonje, Adriaan A. Voors, Peter van der Meer, Tiny Jaarsma, Dirk J. van 
Veldhuisen, University Medical Center Groningen, Groningen, The Netherlands
Background In a small cohort of heart failure (HF) patients, we recently demonstrated 
that elevated erythropoietin (Epo) levels, in particular when related to their haemoglobin 
(Hb) levels, were related to an increased mortality. In the present study we investigated 
the prognostic role of serial measurements of Epo, related to Hb, on mortality in a large 
cohort of HF patients. 
Methods In a cohort of 1023 patients hospitalized for HF, who were studied for 18 months, 
Epo levels were measured at discharge and after 6 months. Of the anemic patients the 
adequateness of Epo levels according to their Hb levels was determined by calculating 
the observed/predicted (O/P) ratio of Epo levels. 
Results Mean age of patients was 71±11 years, 63% was male, and mean LVEF was 
34±14%. Median Epo levels at baseline were 9.6 U/L and at 6 months 10.6 U/L. Higher 
Epo levels at baseline were independently related to an increased mortality (hazard 
ratio (HR) 2.01 per U/L; P<0.01). In addition, Kaplan Meier survival analysis showed that 
patients with persistently high Epo levels (>median) both at baseline and during follow-up 
were at higher risk, compared to patients with low Epo levels either at baseline or during 
follow-up (Log Rank P=0.01). The O/P ratio could be assessed in 135 anemic patients, of 
which 12 patients (9%) had Epo levels higher than expected. Multivariate Cox regression 
analysis revealed that patients with Epo levels that were higher than predicted on the 
basis of Hb levels, had an increased mortality risk (HR 3.52 per U/L; P=0.003).
Conclusion Epo levels predict mortality in HF patients, even when measured serially. 
In addition, anemic HF patients with Epo levels higher than expected have an impaired 
prognosis compared to patients with normal or lower than expected Epo levels. These 
elevated Epo levels might be an indication of hyporesponsiveness of the bone marrow to 
the effects of endogenous Epo.
2:30 p.m.
0907-5 The Novel Interleukin Receptor Family Member ST2 
Correlates With Cardiac Structure, Function, and 
Prognosis: Results From the PRIDE Echocardiographic 
Substudy
Ravi V. Shah, Roland RJ van Kimmenade, Annabel Chen-Tournoux, James L. Januzzi, 
Massachusetts General Hospital, Boston, MA
Background: ST2, a novel biomarker of myocyte stretch, is a powerful marker of poor 
outcomes in patients with acute dyspnea, including those with heart failure. Nothing is 
known regarding the relationship between ST2 and cardiac structure and function, and it 
remains unclear if ST2 is prognostically relevant in patients with echocardiographic data.
Methods: 139 patients admitted with acute dyspnea (age 69±14 years, mean left 
ventricular [LV] ejection fraction 49±15, 49% male), had echocardiography during index 
admission and were followed for vital status at 4 years. ST2 at presentation was correlated 
with echo, clinical and biochemical variables by Spearman regression. Cox proportional 
hazards analyses identiﬁed independent predictors of death at 4 years.
Results: ST2 correlated with several echocardiographic variables, including LV end-
systolic volume (  = 0.19, P =.03) and LV ejection fraction (  = -0.37, P <.001) as well as 
tissue Doppler Ea wave peak velocity (  = -0.26, P =.01). In addition, ST2 was associated 
with right ventricular (RV) fractional area change (  =-0.18, P =.05), RV systolic pressure 
(  = 0.26, P =.005) and tricuspid regurgitation severity (  = 0.28; P =.001). In multivariate 
linear regression, independent predictors of ST2 included LV ejection fraction (t = 2.2, P = 
.05), LV end-diastolic (t = 3.0, P = .005) and LV end-systolic (t = 2.6, P = .01) dimension, 
transmitral E to tissue Doppler Ea wave velocity ratio (t = -2.1, P = .03), tissue Doppler 
A wave velocity (t = 2.1, P = .05), RV systolic pressure (t = 2.3, P = .002), NT-proBNP (t 
= 3.3, P = .009), heart rate (t = 2.6, P = .01), and presence of jugular venous distension 
(t = 2.0, P = .05). ST2 was an independent predictor of 4-year mortality (hazard ratio, 
HR = 2.7; P =.003), even after echocardiographic, biomarker, or clinical variables were 
included in the model.
Conclusions: In patients with acute dyspnea, ST2 levels are independently associated 
with prevalent cardiac structure and functional abnormalities, and yet are strongly 
predictive of long-term mortality independent of these variables. Higher ST2 level on 
presentation is a marker of poor hemodynamics and prognosis independent of traditional 
clinical or serologic biomarkers of risk.
2:45 p.m.
0907-6 Neutrophil Gelatinase-Associated Lipocalin (NGAL) 
Levels Predict the Development of Worsening 
Renal Function in Patients Admitted With Acute 
Decompensated Heart Failure (ADHF)
Arash Aghel, Kevin Shrestha, W.H. Wilson Tang, Cleveland Clinic Foundation, 
Cleveland, OH
Background: The development of worsening renal function (WRF, deﬁned as creatinine rise 
>0.3 mg/dl) occurs frequently in the setting of ADHF and strongly predicts adverse clinical 
outcomes. NGAL is produced by the nephron in response to tubular epithelial damage and 
serves as an early marker for acute kidney injury. We sought to assess the predictive value 
of NGAL for the development of WRF in the setting of acute heart failure.
Methods: We measured serum NGAL (BioPorto diagnostic, Gentofte Denmark) in 90 
patients admitted to the hospital with ADHF. Patients were adjudicated by independent 
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MNCs by intra-ventricular delivery, followed by IM injection of CON (n=4) or CM (n=4), 
at 48h post-MI. At 7d post-MI, Cells+CM attenuated LV dilatation and dysfunction cf. 
Cells+CON (% change LVIDd, Cells+CM: +1.6±1.0 vs Cells+CON: +6.8±2.0%, p<0.05; 
% change FS, Cells+CM: +2.0±1.3 vs Cells+CON: -6.6±2.5%, p<0.05). Cells+CM also 
increased myocardial counts of DiI+ cells per HPF (Cells+CM: 40.9±10.8 vs Cells+CON: 
17.3±9.7, p<0.05) and augmented peri-infarct neovascularization (vWF+ vessels/HPF, 
Cells+CM: 27.9±4.8 vs Cells+CON: 15±5.7, p<0.05). In vitro, anti-VEGF MAb mitigated 
EPC migration in response to CM (migration index, CM: 1.9±0.2 vs VEGF MAb+CM: 
1.3±0.1, p<0.05).
Conclusion: The beneﬁcial effects of MPC therapy on LV dysfunction and remodeling 
post-MI are due, at least in part, to release of proangiogenic factors which enhance EPC 
mobilization and homing to the infarcted heart. These data may provide insight for the 
development of novel strategies to optimize cell therapy post-MI.
8:30 a.m.
0913-5 Stem Cell Therapy Affects Paracrine Signalling Pathway 
in Ischemic Myocardium
Kai Jaquet, Korff T. Krause, Martin Bergmann, Sigrid Boczor, Karl-Heinz Kuck, Asklepios 
Klinik St. Georg, Hamburg, Germany
Background: Bone marrow is a major reservoir of adult autologous stem cells distal from 
the heart. Adequate regulation of signalling between bone marrow, peripheral circulation 
and infarcted myocardium is important in orchestrating the process of myocardial 
regeneration. In this respect, we analyzed the mRNA expression of inﬂammatory, 
angiogenic, cell mobilizing/chemoattractant as well as cell adhesion genes. Especially, 
SDF-1 which is differentially expressed in ischemic myocardium pre- and post cell therapy 
seems to be crucial to stem cell mobilization.
Methods: Myocardial ischemia was generated in 15 pigs by implanting an ameroid 
constrictor around the LCX artery. Fourteen days later the animals were devided into 4 
groups: unselected BM was transplanted into 4 animals, 7 animals received mesenchymal 
stem cells (MSC), and 4 pigs got saline injections. Another 4 healthy animals (no ischemia, 
no cell therapy) served as negative controls. After a follow-up time of 28d the animals 
were sacriﬁced and hearts excised. mRNA analysis via Realtime-PCR was done on heart 
tissue specimen derived from ischemic and remote areas.
Results: On day 28 post cell therapy the mRNA expression levels of most inﬂammatory, 
angiogenic, cell mobilizing and/or chemoattractant as well as cell adhesion genes turned 
out to be normal. In contrast the mRNA of SDF-1 was highly overexpressed in placebo-
treated ischemic pig myocardium (p<0.05). In contrast, when pigs received a cell therapy 
either with bone marrow mononuclear cells (BMNC) or mesenchymal stem cells (MSC) the 
SDF-1 expression decreased to normal values comparable to healthy controls. BMNC- vs. 
MSC-group show no difference in SDF-1 expression levels. The corresponding receptor 
CXCR4 is not differentially regulated, since corresponding target cells are supposed to 
be located within BM.
Conclusion: 1. As a result of myocardial ischemia the SDF-1 expression rises 
dramatically indicating, that the paracrine SDF-1/CXCR4 signalling pathway is switched 
on. 2. An intramyocardial stem cell therapy switches the SDF-1 expression off again”. 3. 
These ﬁndings might be ﬁrst evidence that paracrine mechanisms play a role in stem cell 
action and recruitment in the heart.
8:45 a.m.
0913-6 Intravenous Injections of Hypoxia-Conditioned Bone 
Marrow-Derived Stem Cell Medium Improve Left 
Ventricular Function in Dogs With Heart Failure
Sharad Rastogi, Victor G. Sharov, Michael S. Sabbah, Hani N. Sabbah, Henry Ford 
Hospital, Detroit, MI
Background: Transplantation of bone marrow-derived stem cells (BMSC) into infarcted or 
failing myocardium can improve LV function by inducing angiogenesis through the release 
of growth factors rather than cell incorporation. This suggests that mechanisms other than 
BMSC incorporation, contribute to the hemodynamic improvement. We examined the in-
vitro expression of growth factors and cytokines in BMSC hypoxia-conditioned medium 
(BMSC-hcm) and the in-vivo effects of intravenous administration of BMSC-hcm (no cells) 
in dogs with microembolization-induced heart failure (HF).
Methods: BMSCs were obtained from adult dogs and cultured using Iscoves modiﬁed 
Dulbecco medium. Cultured BMSCs were exposed to hypoxia (95% Nitrogen, 5% Carbon 
Dioxide) in an incubator for 72 hours or to normoxia (95% room air and 5% Carbon 
Dioxide). RNA was extracted from the medium only and mRNA expression of growth 
factors was measured using real time PCR. In a pilot study, HF dogs were treated with 
intravenous injections (20 ml) of BMCS-hcm daily for 5 days.
Results: Compared to BMSC-nm, BMSC-hcm showed a 1.8 to 33 fold increase in the 
expression of growth factors and cytokines (Table). In HF dogs, LV ejection fraction 
increased from ~35% to ~46% at 6 weeks after treatment with BMSC-hcm.
Conclusions: An increase in mRNA expression of key growth factors and cytokines was 
observed in BMSC-hcm. In HF dogs, treatment with BMSC-hcm improved LV function. 
The observations support a novel concept of BMSC-hcm alone as a therapy for HF.
mRNA Expression of Growth Factors
Growth Factors Fold Increase with Hypoxia
Angiopoetin 8.73
Vascular endothelial growth factor 13.47
Fibroblast growth factor 33.31
Platelet derived growth factor 5.81
Transformin growth factor-beta 8.51
Tumor necrosis factor-alpha 1.79
Interleukin-6 5.82
Granulocyte-colony stimulating factor 19.16
Hepatocyte growth factor 14.54
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Myocardial Repair, Regeneration and 
Beyond
Tuesday, March 31, 2009, 8:00 a.m.-9:30 a.m.
Orange County Convention Center, Room W308A
8:00 a.m.
0913-3 Pravastatin Followed by Intracoronary Fibroblast 
Growth Factor (FGF-5) Synergistically Ampliﬁes 
Endogenous Cardiac Repair in Swine With Hibernating 
Myocardium
Gen Suzuki, Vijay S. Iyer, Arsalan Q. Shabbir, David Zisa, Beth A. Palka, Thomas 
Cimato, Te-chung Lee, John M. Canty, Jr., UNIVERSITY AT BUFFALO, Buffalo, NY
Background: Individually, pravastatin and AdvFGF-5 increase myocyte regeneration 
in swine with hibernating myocardium by increasing CD117+ cells in the circulation and 
myocardium. We hypothesized that administrating both would synergistically amplify 
cardiac repair.
Methods: Swine with a chronic LAD occlusion and hibernating myocardium received 
pravastatin (160mg/day, p.o.) followed by 2x1012 vp of intracoronary AdvFGF-5 (n=6, 
Statin+FGF-5 combined therapy). We assessed regional perfusion (microspheres) and 
function at baseline and 4-weeks after treatment. Myocyte size and nuclear density 
were compared to pravastatin (n=12), FGF-5(n=5), untreated hibernating myocardium 
(n=7) and sham (n=5). We quantiﬁed myocytes in the cell cycle with Ki-67 and phospho-
Histone H3 (pHH3) nuclear staining. Myocardial CD117+ cells colocalizing cardiac lineage 
markers were quantiﬁed using GATA4 and TnI staining.
Results: After combined therapy, LAD wall thickening increased from 3.0 ± 0.3 mm to 5.9 
± 0.6 mm (p<0.01) with no change in ﬂow. Immunohistochemistry (Table) demonstrated 
that combined therapy increased CD117+ cells and both Ki-67 and pHH3 positive 
myocytes signiﬁcantly more than pravastatin or FGF-5 alone. Myocardial CD117+ cells 
expressing cardiac lineage markers increased along with increases in myocyte nuclear 
density and a reduction in myocyte diameter.
Conclusion: Combined therapy with statins and AdvFGF-5 synergistically ampliﬁes 
endogenous cardiac repair.
Quantitative Histology / Immunohistochemistry
Hibernating LAD Sham LAD
Untreated
(n=7) Statin(n=12)
FGF-
5(n=5) Statin+FGF5(n=6) Sham(n=6)
Myocyte Nuclear 
Density (number/
mm2)
926±52 1054±19* 1057±50* 1217±44*†‡ 1212±42*
Ki67+ Myocytes 
(/106 myocytes) 447±212 1605±278* 1477±394* 4052±870*†‡ 284±69
pHH3+ Myocytes 
(/106 myocytes) 9±5 43±7* 27±4* 398±129*†‡ 2±2
CD117+cells
(/106 myocytes) 223±49 953±123* 1133±104* 1576±282*†‡ 20±11*
CD117+GATA4+ 
(%) 4±4 8.8±3.5 6.9±1.3 14.3±2.6*†‡ 0±0
CD117+cTnI+
(%) 0±0 2.2±0.7* 2.7±1.3* 9.3±1.7*†‡ 0±0
Myocyte 
Diameter (μm) 16.2±0.3 13.2±0.6* 14.5±0.5* 11.0±0.5*†‡ 13.8±0.4*
Mean ± SEM, *p<0.05 vs. Untreated, †p<0.05 Statin+FGF5 vs. Statin, ‡p<0.05 
Statin+FGF5 vs. FGF5
8:15 a.m.
0913-4 Adult Human Bone Marrow-Derived Mesenchymal 
Progenitor Cells Secrete Proangiogenic Factors Which 
Promote Mobilization and Recruitment of Circulating 
EPCs to the Infarcted Heart
Fiona See, Tetsunori Seki, Hugo Sondermeijer, Henry Krum, Darren Kelly, Silviu Itescu, 
Columbia University, New York, NY, University of Melbourne, Melbourne, Australia
Background: We have previously shown that the beneﬁts of mesenchymal progenitor 
cell (MPC) therapy post-MI occur in part via release of paracrine factors which augment 
myocardial neovascularization. We further sought to determine whether the proangiogenic 
effects of MPC-derived soluble factors might involve promotion of EPC mobilization and 
homing to the infarcted heart.
Methods & Results: Nude rats underwent LAD ligation. Baseline echocardiography was 
performed at 24h post-MI and rats received serum-free control medium (CON, n=6) or 
MPC (10^6) conditioned medium (CM, n=6) via intramyocardial (IM) injection at 48h post-
MI. Echocardiography was repeated on day 6 and on day 7 PBMNCs were collected prior 
to tissue harvest. In comparison to CON treatment, CM injection post-MI attenuated LV 
dilatation (% change LVIDd, CON: +10.1±4.1 vs CM: +4.3±1.3, p<0.05) and dysfunction 
(% change FS, CON: -11.9±5.2 vs CM: -4.8±2.6, p<0.05). PBMNCs were cultured and 
the number of acLDL+lectin+ EPCs was higher after CM treatment cf. CON (cells/mm2, 
CON: 21.9±9.2 vs CM: 52.5±8.3, p<0.05). To determine whether CM injection promotes 
EPC homing to the MI heart, additional rats received 2.5x10^6 DiI-labeled human CD34+ 
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1051-166 Long-Term Prognostic Value of Diastolic Dysfunction in 
Young Adults- The Coronary Artery Risk Development 
in Young Adults (CARDIA) Study
Kofoworola O. Ogunyankin, Laura Colangelo, Donald M. Lloyd-Jones, Kiang Liu, 
Northwestern University, Chicago, IL
Background: The prevalence and consequences of diastolic dysfunction in young adults 
are unknown. Methods: Asymptomatic adults aged 23-35 yrs (n= 3402) enrolled in the 
NHLBI’s CARDIA study were classiﬁed into groups (‘Normal’, ‘Abnormal relaxation’ (AR) 
or ‘Severe diastolic dysfunction’ (SDD)), based on 2-D and Doppler echocardiographic 
data obtained in 1990-1991. The hazards of all-cause death, myocardial infarction (MI), 
stroke, and heart failure (composite endpoint) and of CVD death and all CVD events 
(CHF, stroke, MI) were determined in the subjects at year 15 follow-up. Results:
Abnormal diastolic function was present in 9.6% (SDD 0.94%, AR 8.61%). Compared to 
Normal, the relative risk among those with SDD for the composite endpoint was 7.01 ( 
95% CI 3.16 - 15.55; p<0.0001) and for those with AR was 1.49 (0.82-2.70; p=0.19), after 
adjustment for age, sex, race, systolic blood pressure, body mass index, total and HDL 
cholesterol, smoking and diabetes. Hazards ratios for all CVD events were 15.03 (5.31-
42.50; p<0.0001) for SDD, and 0.87 (0.29-2.63; p=0.80) for AR respectively. The Cox 
proportional hazard model showed a signiﬁcant risk associated with diastolic dysfunction 
(X2 = 16.35, df=2 p- for likelihood ratio test = 0.0003). Figure 1 shows the risk factor 
adjusted survival plots for the 3 groups.
Conclusion: Despite a low prevalence in young adults, SDD is independently associated 
with substantially elevated risks for death and cardiovascular events. 
9:30 a.m.
1051-167 Cardiac Resynchronization Therapy Induces Major 
Structural and Functional Reverse Remodeling in Mild 
Heart Failure. Results From the Resynchronization 
Reverses Remodeling in Systolic Left Ventricular 
Dysfunction (REVERSE) Trial
Martin G. St. John Sutton, Stefano Ghio, Ted Plappert, Luigi Tavazzi, Laura Scelsi, 
Claude Daubert, William T. Abraham, Michael R. Gold, Christian Hassager, John M. 
Herre, Genevieve Derumeaux, Cecilia Linde, University of Pennsylvania Medical Center, 
Philadelphia, PA
Background: Cardiac resynchronization therapy (CRT) improves left ventricular (LV) 
structure and function and clinical outcomes in New York Heart Association (NYHA) 
Class III and IV heart failure (HF) with prolonged QRS. It has not been ﬁrmly established 
whether NYHA Class I/II systolic HF patients exhibit LV reverse remodeling with CRT 
and whether reverse remodeling is modiﬁed by the etiology of HF. The speciﬁc aims of 
this prospective study were to determine whether patients with NYHA Class I/II systolic 
HF exhibited LV reverse remodeling with CRT at one year, and if so, whether this reverse 
remodeling was modiﬁed by the etiology of HF.
Methods: Six hundred ten patients with NYHA Class I or II HF with a QRS q 120 ms, LV 
end-diastolic dimension q 55mm, and LV ejection fraction (LVEF) a 40% received a CRT 
device (± deﬁbrillator) and were randomly assigned to active CRT (CRT ON; n=419) or 
control (CRT OFF; n=191) for 12 months. Doppler echocardiograms were recorded at 
baseline, pre-hospital discharge, 6 and 12 months in all patients. LV volume indices, EF, 
LV mass and diastolic function were quantiﬁed at all time points by a Core Echo lab.
Results: LV end-diastolic and end-systolic volume indices decreased progressively (both 
p<0.0001) while LVEF increased (p<0.0001) from baseline through 12 months in CRT 
ON compared to CRT OFF. LV mass (calculated at end-diastole as: [5/6 x LV short axis 
myocardial area x LV length x 1.055]) and echo measures of LV diastolic function did not 
change signiﬁcantly in either group by 12 months. In the CRT ON group, there was a 
3-fold greater reduction in LVEDVi and LVESVi and a 3-fold greater increase in LVEF in 
patients with HF of a non-ischemic etiology.
Conclusions: CRT in patients with NYHA II or NYHA I HF resulted in major progressive 
LV reverse remodeling at 1 year with the greatest changes in patients with HF of a non-
ischemic etiology. Therefore, CRT may delay the natural disease progression and might 
play a new and important therapeutic role in NYHA class I/II HF patients, especially in 
those patients with HF of a non-ischemic etiology.
9:00 a.m.
0913-7 Transformation of Bone Marrow Stem Cells Into 
Cardiomyocytes by Tumor Necrosis Factor Alpha
Mayra Guerrero, Sharad Rastogi, Hani N. Sabbah, Henry Ford Hospital, Detroit, MI
Background: Tumor necrosis factor-alpha (TNF-alpha) can induce cardiogenic 
transformation of normal adult human mesenchymal stem cells. This directed 
differentiation of stem cells into cardiomyocytes represents a therapeutic strategy for 
treating heart failure (HF). This study tested whether bone marrow mesenchymal stem 
cells (BMMSC) harvested from dogs with HF and exposed to TNF-alpha also undergo 
cardiogenic transformation.
Methods: Bone marrow was extracted from dogs with coronary microembolization-
induced HF. BMMSC were obtained using the Ficoll method and cultured in Iscove’s 
Modiﬁed Dulbecco’s Medium (IMDM). BMMSC were then incubated in IMDM alone 
(untreated control) or IMDM with TNF-alpha for 4 or 7 days at concentrations of 30, 50, 75 
and 100 ng/ml. Cardiogenic transformation was evaluated in paraformaldehyde-ﬁxed cells 
by measuring expression of cardiac transcription factors Nkx2.5 and myocyte-speciﬁc 
enhancer binding factor (MEF2C) using immunocytochemistry.
Results: Expression of MEF2C and Nkx2.5 was observed in BMMSC cultured with TNF-
alpha at all doses and for both 4 and 7 days. BMMSC cultured in control IMDM did not 
express either factor (Figure).
Conclusions: TNF-alpha induces cardiogenic transformation of BMMSC obtained from 
dogs with chronic HF. To the extent that TNF-alpha mediated cardiogenic transformation 
of BMMSC represents a therapeutic pathway in HF, our observation conﬁrms that an 
autologous approach is possible, thus avoiding the need for a BMMSC donor pool.
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1051-165 Effect of Waon Therapy on Oxidative Stress in Patients 
With Chronic Heart Failure
Shoji Fujita, Masaaki Miyata, Takashi Kihara, Tsuyoshi Fukudome, Takuro Shinsato, 
Takuro Kubozono, So Kuwahata, Tsuyoshi Yamaguchi, Shuichi Hamasaki, Hiroyuki 
Torii, Chuwa Tei, Department of Cardiovascular, Respiratory and Metabolic Medicine, 
Kagoshima University, Kagoshima, Japan, Kagoshima city medical association hospital, 
kagoshima, Japan
Background:We developed a form of thermal therapy, namely Waon therapy, that differs 
from the traditional sauna. We have reported that Waon therapy improves cardiac function, 
vascular endothelial function, neurohormonal factors, and clinical symptoms in patients with 
chronic heart failure (CHF). Furthermore, we demonstrated that Waon therapy upregulated 
the expression of endothelial nitric oxide synthase in aorta of hamsters. The purpose of this 
study is to clarify the effect of Waon therapy on oxidative stress in patients with CHF.
Methods:We enrolled 40 patients with CHF in NYHA functional class II or III, who were 
admitted to our hospitals and divided into Control (n=20) and Waon therapy (n=20) groups. 
All patients received standard medications for CHF. Waon therapy group were treated with a 
far infrared-ray dry sauna at 60 degrees centigrade for 15 minutes and then kept on bed rest 
with a blanket for 30 minutes, once a day, for 4 weeks. Consentrations of hydoroxyperoxide 
as a marker of oxidative stress, stable metabolitis of nitric oxide (NO), and brain natriuretic 
peptide (BNP) were measured before and 4 weeks after treatment. Chest radiography and 
echocardiography were also performed before and 4 weeks after treatment.
Results:In Waon therapy group, chest radiography demonstrated that cardiothoracic ratio 
(CTR) signiﬁcantly decreased after 4-week Waon therapy (56.3±6.2 to 53.0±5.6%, P<0.001). 
Echocardiography also showed the signiﬁcant increase of ejection fraction (EF) after 4-week 
Waon therapy (31.8±11.3 to 35.8±13.1%, P<0.01). Concentrations of hydoroxyperoxide 
and BNP signiﬁcantly decreased after 4-week Waon therapy (hydoroxyperoxide: 422±116 
to 327±88 U.CARR, P<0.01; BNP: 438±293 to 212±141 pg/ml, P<0.01). In addition, 4-week 
Waon therapy increased NO levels (71.2±35.4 to 92.0±40.5 μmol/l, P<0.05). In contrast, 
none of the variables changed at the 4-week interval in Control group. In all patients, there 
was a positive correlation between the changes in hydoroxyperoxide and BNP levels before 
and 4 weeks after treatment (r=0.36, P<0.05).
Conclusions:Waon therapy decreased oxidative stress, increased NO, and improved 
cardiac function in patients with CHF.
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1051-170 Efﬁcacy of Adaptive Servo Ventilation in Patients With 
Heart Failure and Central Sleep Apnea That Is Not 
Sufﬁciently Treated with Continuous Positive Airway 
Pressure
Takatoshi Kasai, Koji Narui, Ryo Naito, Ken-ichi Maeno, Mitsue Kato, Fusae Kawana, 
Sugao Ishiwata, Minoru Ohno, Tetsu Yamaguchi, Shin-ichi Momomura, Sleep Center, 
Toranomon Hospital, Tokyo, Japan
Background: In heart failure (HF) patients, the presence of central sleep apnea (CSA) 
is associated with a poor prognosis. There are several studies showed the efﬁcacy of 
continuous positive airway pressure (CPAP) for such patients. However, a large-scale trial 
showed that CPAP did not improve survival. In this trial, CSA were not sufﬁciently treated 
with CPAP in nearly forty percent of patients and this might affect the results. Recently 
it was reported that adaptive-servo ventilation (ASV) can treat CSA very efﬁciently. 
However, there are no speciﬁc data which showed the efﬁcacy of ASV in patients with HF 
and CSA that is not sufﬁciently treated with CPAP.
Methods: Patients with HF due to depressed LVEF <50% complicated with CSA deﬁned 
as an apnea-hypopnea index q15 /h, of which q50% were central events, were enrolled if 
they met the following inclusion criteria: 1) having been treated with CPAP for q3 months, 
but their AHI was not suppressed below 15 /h; 2) remaining their LVEF <50% and NYHA 
functional class qII. Then, CPAP was switched to ASV with appropriate settings in each 
case. The LVEF, plasma BNP, urine norepinephrine level, and 6 minute walk distance 
(6MWD) were compared between baseline (at the time of enrollment) and after 3 months. 
In addition, the compliance with the ASV for 3 months was compared to that with CPAP 
for prior 3 months.
Results: Ten males (mean age: 63.3, BMI: 28.1) were enrolled. In all cases, ASV reduced 
their apnea-hypopnea index appropriately (21.7±5.7 to 1.5±0.8, P<0.05). Three months 
later, LVEF and 6MWD signiﬁcantly increased from 33.6±13.0 to 41.2±11.1 % (P<0.05), 
from 375.8±56.0 to 405.6±46.7 m (P<0.05), respectively. As well, plasma BNP and urine 
norepinephrine signiﬁcantly decreased from 156.7±68.2 to 118.4±77.4 pg/ml (P<0.05), 
from 266.5±138.9 to 161.5±35.0μg/L (P<0.05), respectively. Furthermore, the compliance 
with the device signiﬁcantly improved on ASV (4.4±1.6 to 5.3±1.2 h/night, p<0.01).
Conclusions: ASV efﬁciently treats CSA and improves compliance with the device in 
patients with HF and CSA that is not sufﬁciently treated with CPAP. ASV is promising as 
an effective alternative in these patients.
9:30 a.m.
1051-171 Cardiac Dyssybchrony Quantitiated by Time-to-Peak, 
Temporal Uniformity or Cross-Correlation of Strain 
Curves: Implications for Resynchronization Therapy
Paolo N. Marino, Chiara Cavallino, Elisa Rondano, Gabriele Dell’Era, Eraldo Occhetta, 
Miriam Bortnik, Giuliano Marti, Eastern Piedmont University Clinical Cardiology, Novara, 
Italy, Azienda Ospedaliero Universitaria “Maggiore della Carità”, Novara, Italy
Background: Time-to-peak standard deviation (TP-SD) of echographic strain has been 
proposed as index of dyssynchrony (DYS) in CHF pts who undergo CRT. Other indices like 
temporal uniformity (TUS) or cross-correlation of strain curves (CCSC), less conceptually 
limited, have been suggested. Aim of our study is to assess which of these 3 methods 
tracks the response in terms of LV remodeling and changes in ejection fraction (EF) in 
pts submitted to CRT. Methods: DYS was quantiﬁed in 75 pts computing longitudinal and 
transversal strain using speckle-tracking 2D analysis from 2 apical views (12 segments) 
pre- vs. 3 months post-CRT. Optimal LV lead position was deﬁned as concordance or 
immediate neighbouring of the segment with latest systolic strain prior-CRT and segment 
with assumed LV lead position, deﬁned as the segment with maximal temporal difference 
of peak strain before-to-on CRT. 3D apical LV volumes were computed. Results: 3 
groups were identiﬁed according to LV lead position and systolic volume (ESV) reduction 
>15%: group 0, non optimal lead position plus ESV reduction <15%; group 2, optimal 
lead position plus ESV reduction >15%; group 1, if only one criterion was met. Although 
there were no baseline differences, grouping exerted an interaction effect in terms of 
remodeling and pump performance, with only CCSC, among the asynchrony indexes, 
mirroring LV volume and EF changes pre/post-CRT (table). 
pre/post-CRT Group 0 (n=15) Group 1 (n=36) Group 2 (n=24) ANOVA
EDV (%) +4.2+9.8 -6.1+19.5 -22.8+16.2 <.001
EF (%) +1.3+10.7 +11.9+15.0 +23.2+17.2 <.001
TP-SD (%) -0.64+4.7 -1.83+5.6 -3.64+5.45 NS
TUS +0.02+0.13 +0.02+0.13 +0.06+0.13 NS
CCSC -0.03+0.09 +0.006+0.06 +0.03+0.05 .007
Conclusion: DYS indexed by CCSC yields greater quantitative results and CRT beneﬁts 
than TP-SD and TUS.
9:30 a.m.
1051-172 The Paracor HeartNetTM Ventricular Elastic Support 
Therapy Feasibility Study: Two-Year Follow-Up
Barry K. Rayburn, Juan M. Aranda, Jr., John P. Boehmer, Inder Anand, Helmut Klein, 
Russell J. Ivanhoe, William T. Abraham, University of Alabama, Birmingham, AL, 
University of Florida, Gainesville, FL
Introduction: The HeartNet System (Paracor Medical, Inc,
Sunnyvale CA) is a nitinol mesh device designed to improve clinical outcomes in patients 
with symptomatic heart failure (HF) and LV systolic dysfunction. The device is implanted 
via mini-thoracotomy using a custom designed delivery system and provides gentle 
9:30 a.m.
1051-168 Improved Cardiac Structure and Diastolic Flow 
Velocities in Early-Stage Heart Failure with Chronic 
Treatment Using an Implantable Device: Results From 
European and United States Trials of the Rheos®
System
John D. Bisognano, Peter W. de Leeuw, David S. Bach, Christopher L. Kaufman, Eric 
G. Lovett, University of Rochester, Rochester, NY, University Hospital of Maastricht, 
Maastricht, The Netherlands
Background: Early stage heart failure (HF) is associated with abnormalities in cardiac structure 
and function. Rheos Therapy reduces blood pressure (BP) in patients with hypertension (HTN) 
and improves left ventricular (LV) structure and systolic function in a canine HF model. It is 
unknown if Rheos Therapy improves cardiac structure and function in patients.
Methods: Stage A-B HF (stage II HTN) patients (systolic BP q160 mmHg) taking q3 anti-
HTN drugs were implanted with the Rheos System. Baseline data were acquired before 
implant. The Rheos System was activated 1 month after implant. Follow-up occurred 
after 3 and 12 months of therapy. Echocardiograms were reviewed at a blinded core lab. 
Changes at follow-up versus baseline were analyzed with paired t-tests.
Results: 33 subjects (18 M/15 F, Age 52.4±10.4 yr, BMI 33.0±7.3 kg/m2) were implanted 
at 5 centers. The Rheos System improved cardiac structure and function while reducing 
BP. Reduced mitral A wave velocity coupled with decreased left atrial dimension and 
LV mass index suggests that the therapy reduces LV diastolic ﬁlling pressure. No 
unanticipated adverse events occurred.
Conclusions: In addition to sustained BP reduction, chronic Rheos Therapy in early-
stage HF patients remodels left atrial and ventricular chambers and improves systolic 
function. Beneﬁts are incremental to those achieved with aggressive medical therapy. 
A feasibility study is now underway to assess the potential beneﬁt of Rheos Therapy in 
patients with more advanced HF.
Values: mean±SD °p<0.05 *pa0.01 †pa0.005 ‡p<0.001
Baseline
(N = 33)
$ 3 Months
(N = 33)
$ 12 Months
(N = 20)
LV Mass Index
(g/m2) 138.8 ± 35.4 -17.8 ± 16.0‡ -25.0 ± 18.3‡
Left Atrial Dimension (mm) 44.9 ± 6.5 -1.0 ± 2.7° -2.3 ± 3.5*
Mitral E Wave Velocity (cm/s) 78 ± 20 -1 ± 13 -5 ± 14
Mitral A Wave Velocity (cm/s) 83 ± 19 -2 ± 12 -11 ± 14†
Septal Wall Thickness (mm) 14.5 ± 3.0 -1.2 ± 1.3‡ -1.6 ± 1.9‡
LV Posterior Wall Thickness (mm) 14.0 ± 2.3 -0.9 ± 0.8‡ -1.5 ± 1.1‡
Midwall Fractional Shortening (%) 13.8 ± 2.8 +0.9 ± 2.2° +1.7 ± 2.7*
Ofﬁce Cuff Systolic BP (mmHg) 178.9 ± 25.1 -22.0 ± 30.3‡ -28.0 ± 24.4‡
Ofﬁce Cuff Diastolic BP (mmHg) 104.4 ± 17.4 -11.0 ± 19.6† -13.8 ± 19.9*
9:30 a.m.
1051-169 Cardiac Resynchronization Therapy in Mild 
Heart Failure: Is There Is Difference in Outcome 
Between NYHA Class I Versus II? Results From the 
Resynchronization Reverses Remodeling in Systolic 
Left Ventricular Dysfunction (REVERSE) Trial
Cecilia Linde, Robert Leman, Claude Daubert, William T. Abraham, Michael R. Gold, 
Karolinska University Hospital, Stockholm, Sweden
Background: The REsynchronization reVErses Remodeling in Systolic left vEntricular 
dysfunction (REVERSE) trial is the ﬁrst prospective randomized double-blind parallel trial 
that demonstrated that CRT plus optimal medical therapy (CRT ON) compared to CRT 
OFF could slow disease progression and reverse LV remodeling in patients (pts) with 
NYHA I-II HF, QRS > 120 ms and LV ejection fraction < 40%. The results over 12 months 
in relation to baseline NYHA class are reported here.
Methods: 610 pts randomized in 73 centres in the US, Canada and Europe. At baseline, the 
mean LVEF was 27.0 ± 6.6%, LVESVi was 100.0 ± 37.7, and QRS width was 153 +22 ms.
Results: Of 610 pts, 503 were in NYHA class II (82%, 159 CRT OFF, 344 CRT ON) and 
107 pts in NYHA I (18%, 32 CRT OFF, 75 CRT ON). NYHA I patients had better quality of 
life by the KCCQ and Minnesota scores than NYHA class II patients at 12 months. 5.8% 
of NYHA class I pts in CRT ON pts were hospitalized for heart failure compared to 6.3% 
in CRT OFF (p=0.80). In NYHA II pts 3.3% in CRT ON pts were hospitalized for heart 
failure vs. 8.2% in CRT OFF (p=0.02). The mean LVEF improved signiﬁcantly by CRT only 
in NYHA II (p<0.0001).The results with respect to LVESVi are shown in the ﬁgure. While 
randomization was a strong factor (p<0.0001), neither NYHA (p=0.68) nor the interaction 
of NYHA and randomization (p=0.49) were factors in the change in LVESVi.
Conclusions: The effects of CRT on remodeling appear to be similar in NYHA class I 
and II patients. 
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intolerant to positive airway pressure ventilation or non-compliant (usage in <50% of 
possible nights and/or <4hrs/night); 55 pts (ASV group: 65.2±10years; AHI: 35±12/h) were 
compliant (80±23% nights possible, 6:23±1:23 h:min per night). NYHA class improved in 
ASV (2.5±0.7 to 2.0±0.8; p<0.001) as well as in controls (2.7±0.7 to 2.3±0.8, p<0.05). NT-
proBNP signiﬁcantly decreased in the ASV group only (2826±4123pg/ml to 1494±1852pg/
ml, p<0.05 vs. 3113±3186 to 2258±2160pg/ml, ns). Left ventricular ejection fraction 
improved in ASV pts from 28.9±6% to 34.1±10% (p<0.001) and remained unchanged 
in controls (26.8±7% to 28.2±7%, ns). Predicted oxygen uptake during cardiopulmonary 
exercise testing increased in the ASV group (63±18% to 72±19%, p<0.01) and remained 
unchanged in controls (57±16% to 59±14%, ns). In addition, walking distance in 6 min 
exclusively increased in the ASV group (400±84m to 433±93m, p<0.05 vs. 336±150 to 
359±135m, ns).
Conclusions: ASV is able to improve cardiac function in selected and compliant pts 
with CHF and CSR. Whether this improvement is long-lasting and accompanied by an 
improved prognosis needs to be determined.
9:30 a.m.
1051-175 Relationship Between NTproBNP and Exercise Capacity 
in Chronic Heart Failure: Baseline Data from the HF-
ACTION Study
Gary Michael Felker, Faiez Zannad, Mark Donahue, Kirkwood F. Adams, Robert McKelvie, 
Robert Claire, William E. Kraus, David Whellan, Ileana Pina, Christopher M. O’Connor, for 
the HF-ACTION Investigators, Duke Clinical Research Institute, Durham, NC
Background: Natriuretic peptides such as NTproBNP are released in response to 
ventricular wall stress, and have been shown to be powerful diagnostic and prognostic 
biomarkers in chronic heart failure (HF). The relationship between NTproBNP and other 
measures of functional status such as exercise capacity has not been well studied.
Methods: We analyzed the relationship between baseline NTproBNP and maximal (peak 
V02) and sub-maximal (6 minute walk) exercise capacity in subjects enrolled in HF-ACTION, 
a randomized clinical trial of exercise training in chronic HF. NTproBNP (Roche Diagnostics) 
was analyzed at a core laboratory. Pearson correlation coefﬁcients were used to analyze 
the relationship between NTproBNP and peak V02 and 6 minute walk distance.
Results: 1445 patients enrolled in HF-ACTION had baseline NTproBNP data available 
for analysis. Mean age was 59 years, and mean ejection fraction was 25%. Mean 
KCCQ summary score was 67. The median NTproBNP level was 782 pg/mL. The mean 
peak VO2 was 14.8 ml/kg/min, and the mean 6 minute walk distance was 364 meters. 
NTproBNP was moderately correlated with both peak V02 (r= -0.30, p<0.001, see ﬁgure) 
and 6 minute walk distance (r=-0.22, p<0.001).
Conclusions: In this analysis of a large cohort of HF patients from the HF-ACTION study, 
baseline NTproBNP was moderately correlated with both maximal and sub-maximal 
exercise tolerance. These data suggest that hemodynamic factors are important but are 
not the sole determinants of exercise capacity in chronic HF. 
9:30 a.m.
1051-176 Acute Bi-Ventricular Pacing Reduces Dyssynchrony in 
Diastolic Heart Failure Patients With a Narrow QRS
Yi-Chih Wang, Chih-Chieh Yu, Kathryn Hilpisch, Vincent Splett, Rodolphe P. Katra, Chia-
Ti Tsai, Juey-Jen Hwang, Ling-Ping Lai, Jiunn-Lee Lin, Natl Taiwan University Hosp, 
Taipei, Taiwan,ROC, Medtronic Inc, Mounds View, MN
Background: Diastolic heart failure (DHF) is a highly prevalent cause of mortality and 
morbidity that remains poorly understood with little therapeutic advancements made for 
its management. Recent evidence suggests that DHF has comparable dyssynchrony to 
that of systolic HF. This study examines the acute effects of Bi-V pacing in DHF patients 
with signiﬁcant ventricular systolic dyssynchrony.
Methods: DHF patients with EF >50% (n=15) and mechanical dyssynchrony (using 
Tissue Doppler) were studied while undergoing cardiac catheterization studies. Patients 
were instrumented with temporary pacing catheters in the RA, LV and RV. Dyssynchrony 
and ECG were assessed at baseline and during a brief period of Bi-V pacing (5min). 
Patients were paced in VDD mode with AV timing selected to optimize transmitral ﬂow and 
simultaneous RV-LV timing. Dyssynchrony metrics assessed were: Basal and 12 segment 
septal to free wall (S-FW) delay; time to peak systolic velocity in 12 segments (mean Ts); 
dispersion of Ts; and 12 segment standard deviation of Ts.
Results: DHF patients were 69±10years old, non-ischemic (100%), with female majority 
(73%), NYHA functional class of 2.5±0.5, high body mass index (27±4Kg/m2), EF of 
65±10% and narrow QRS (93±9ms). Cardiac dimensions were not dilated (LVEDD: 
42±6mm and LVESD: 25±4mm). Bi-V pacing signiﬁcantly improved synchrony compared 
elastic restraint throughout the cardiac cycle to reduce wall stress and to induce reverse 
myocardial remodeling.
Methods: Pts with EF <= 35% and Class II/III HF on conventional medical and device 
therapy exhibiting progression of disease were enrolled. Pts with severe MR, coronary 
artery bypass grafts or recent cardiac procedure or event were excluded.
Results: Successful implantation was accomplished in 51/52 patients. Two year results: 
Baseline Change at 24 months
Age (yrs) 52
Male (%) 92
Nonischemic (%) 79
Biventricular pacing (%) 37
EF (%) n=28 24±6.1 0.5±0.9
LVEDD (cm) n=29 7±1 -0.8±0.8*
LVEDV (cm3) n=28 333±81 -33±59***
LVESD (cm) n=29 6±1 0.5±0.9**
LVESV (cm3) n=28 257±75 -24±64
MR n=25 1.3±0.9 -0.4±0.9****
6 Minute Walk Test (m) n=28 384±96 34±82****
MLWHF n=22 55±19 -13±18***
NYHA (I/II/III/IV) n=33 0/18/34/0 7/16/9/1*
# n=52; *p<.001** p < .005; ***p<.01; **** p < .05;
Of the 27 patients with follow up data for PVO2, 30% improved at least 1 ml/kg/min. There 
were two perioperative deaths and three deaths of non cardiac cause in long term follow 
up. One patient had successful emergency reoperation for an avulsed phrenic artery and 
four patients had either LVAD, transplant or both.
Conclusions: Implantation of the HeartNetTM bears high success rates. Early data 
suggest improvement in clinical parameters and signiﬁcant reverse remodeling for up to 2 
years post implant. PEERLESS-HF, a randomized controlled trial of the HeartNet™ in the 
management of HF due to LV systolic dysfunction is underway.
9:30 a.m.
1051-173 Relationship Between Right and Left Ventricular 
Function in Patients Selected for Surgical Ventricular 
Restoration
Marisa Di Donato, Serenella Castelvecchio, Marco Ranucci, Vincenzo Montericcio, 
Lorenzo Menicanti, IRCCS, Policlinico San Donato, Milan, Italy
Background: The prognostic value of right ventricular (RV) function in patients with 
chronic heart failure (CHF) is well established, but the data on patients undergoing 
Surgical Ventricular Restoration (SVR) are lacking.
Aim of the present study was to investigate the preoperative RV function, its correlations 
with left ventricular (LV) function parameters and prognostic implications in predicting the 
outcome in patients with CHF undergoing SVR.
Methods: 264 consecutive patients (65±9years, 50F) with previous anterior myocardial 
infarction and submitted to SVR at our Institution represent our study group. Indications 
for surgery were heart failure, angina and/or a combination of two. Baseline clinical and 
echocardiographic evaluation were obtained in all patients. Speciﬁcally, RV function was 
assessed by TAPSE (Tricuspid Annulus Plane Systolic Excursion) and patients were 
divided in three groups: N (n=103 with normal RV function, TAPSE > 20 mm), M (n=141 
with moderate RV dysfunction, TAPSE q 15 and a 20 mm) and S (n=20 with severe RV 
dysfunction, TAPSE a14 mm).
Results: At baseline patients with impaired, either moderately or severely, RV function 
showed higher NYHA class (p 0.000), larger end-diastolic and end-systolic volumes (p 
0.004 and 0.000, respectively), lower EF (p 0.000) and more severe diastolic dysfunction 
(p 0.001), as deﬁned by diastolic pattern.
30-day cardiac mortality was 6.8% (18/264) and was signiﬁcantly higher in patients with 
severe RV dysfunction (20% vs 5.6% and 5.8% in group M and N, respectively, p 0.0009). 
Average FUP was 31±18 months; survival for all cause mortality was signiﬁcantly lower in 
patients with severe RV dysfunction (at Kaplan-Maier survival function Log Rank p 0.03).
Conclusions: Before surgery RV dysfunction correlates with baseline LV systolic and 
diastolic dysfunction and it is an important predictor of early and mid-term outcome in 
patients with CHF undergoing to SVR.
9:30 a.m.
1051-174 Adaptive Servoventilation Improves Cardiac Function in 
Heart Failure Patients With Cheyne-Stokes Respiration
Olaf Oldenburg, Thomas Bitter, Roman Lehmann, Stefan Korte, Anke Schmidt, Lothar 
Faber, Christian Prinz, Christoph Langer, Dieter Horstkotte, Department of Cardiology, 
Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad 
Oeynhausen, Germany, Cardiac Research Unit, Bad Oeynhausen, Germany
Background: Cheyne - Stokes respiration (CSR) is common in patients (pts) with chronic 
heart failure (CHF) and accompanied by an impaired prognosis. Nocturnal adaptive 
servoventilation (ASV) was recently introduced to treat CSR in CHF. Aim of this study 
was the investigation of ASV effects on CHF parameters after 3 months in compliant pts 
versus controls.
Methods: In a 98 pts with CHF treated according to current guidelines (NYHA q II, LV-EF 
a 40%) moderate to severe nocturnal CSR (apnea-hypopnea-index [AHI] q 15/h) was 
documented by cardiorespiratory polygraphy (PG). All patients were informed about their 
PG results and ASV treatment was offered.
Results: 43 pts (control group: 63.7±13years; AHI 38±13/h) rejected ASV therapy, were 
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by this underutilization.
Number of Patients Eligible for ICD Number of Patients Without ICD (% total)
All Patients 97 42 (43%)
Female 26 17 (65%)
Male 71 25 (35%)
9:30 a.m.
1051-179 Decreased Global Longitudinal Strain in Diabetics With 
Preserved Ejection Fraction Post-Myocardial Infarction: 
A VALIANT Echo Sub-study
Amil M. Shah, Chung-Lieh Hung, Sung Hee Shin, Anil Verma, Lars Kober, Eric 
Velazquez, John J. V. McMurray, Frans Van de Werf, Marc A. Pfeffer, Scott D. Solomon, 
Brigham and Women’s Hospital, Boston, MA
Background: Diabetes is associated with an increased risk of death and heart failure (HF) 
following myocardial infarction (MI). Recent studies suggest that the risk of heart failure 
attributable to diabetes may be particularly high in patients with preserved left ventricular 
(LV) ejection fraction (EF). Mechanisms of heart failure in this subgroup of patients may 
differ between diabetics and non-diabetics, and from patients with reduced EF.
Methods: 603 post-MI patients with LV systolic dysfunction or HF were enrolled in the 
Valsartan in Acute Myocardial Infarction Trial Echo sub-study. 138 had a history of 
diabetes. Mean follow-up was 24.7 months. We analyzed baseline parameters of LV 
deformation (strain and strain rate) among diabetics and non-diabetics with preserved 
(EF q 40%, n = 299, mean EF 43.9%) and reduced (EF< 40%, n = 304, mean EF 34.7%) 
systolic function at baseline. Myocardial strain and strain rate were measured using 2D 
speckle tracking software (Siemens) in 380 subjects with adequate images (296 diabetics, 
84 non-diabetics).
Results: Among subjects with EF q 40%, diabetics had signiﬁcantly higher risk of death 
or HF hospitalization compared to non-diabetics (33.8% vs 14.7%, adjusted OR 2.91, 
95% CI 1.31-6.46). There was no signiﬁcant difference in EF between diabetics and non-
diabetics, although diabetics had signiﬁcantly higher diastolic and systolic volumes (110.8 
vs 103.7, p = 0.005; 66.2 vs 60.1, p = 0.005 respectively). Diabetics had signiﬁcantly lower 
global longitudinal strain compared to non-diabetics even adjusting for ejection fraction 
and differences in 12 baseline demographic characteristics (-8.06 vs -8.92, p=0.041). This 
difference in longitudinal strain between diabetics and non-diabetics was not observed in 
patients with EF < 40% (-6.5 vs -7.10, p=0.185).
Conclusions: Altered longitudinal strain, a more sensitive measure of myocardial 
contractility than ejection fraction, may partly account for the higher risk of heart failure in 
diabetics with preserved EF post-MI.
9:30 a.m.
1051-180 Early Experience With Percutaneous Left Ventricular 
Partitioning Device in Patients With Ischemic 
Cardiomyopathy
Farshad Raissi Shabari, Biswajit Kar, Pranav Loyalka, Kathy Vershave, Igor Gregoric, 
Reynolds M. Delgado, Texas Heart Institute, Houston, TX
Background: Percutaneous Ventricular Partitioning Device (VPD) implantation is a 
novel modality to isolate the dysfunctional segments of left ventricle (LV) in patients with 
symptomatic heart failure (HF) and anteroapical aneurysm. It is postulated that this may 
help restore the ventricular geometry, increase ventricular function and improve patients’ 
symptoms.
Methods: We report the preliminary results of the ﬁrst 2 VPD implants performed at our 
center. The patients with ischemic HF for at least 6 months and apical aneurysm with New 
York Heart Association (NYHA) Class III or IV were screened for this study. All patients 
had cardiac CT to ensure appropriate LV anatomy.
Results: The ﬁrst patient is a 52 year-old man with anterior myocardial infarction status 
post coronary intervention 10 years prior to study. He had NYHA Class III symptoms. 
Echocardiogram revealed EF of 25% with anteroapical wall motion abnormality. The device 
was successfully implanted through standard LV retrograde access from femoral artery. At 
one month, the patient’s symptoms improved to NYHA Class I and echocardiogram revealed 
a well-seated device at LV apex with LVEF 28%. Postimplant course was complicated with 
groin wound infection which has now resolved.The second patient is a 64 year-old man 
with myocardial infarction and coronary artery bypass grafting 8 months prior to study. 
The patient had experienced worsening HF symptoms. A nuclear perfusion study revealed 
scar in left anterior descending and obtuse marginal artery territories. The echocardiogram 
showed LVEF of 23% and apical wall motion abnormality. The patient underwent the VPD 
implant with no complications. At one-month follow-up, his symptoms improved to NYHA 
Class I. The echocardiogram showed the VPD at the apex and LVEF 30%.
Conclusion:Our very early experience shows possible feasibility and safety of VPD 
implantation. The patients’ symptoms improved after the device implantation. This device 
may help restore LV geometry in this particular group of patients. Long-term follow up of 
these patients and inclusion of subsequent patients in this ongoing study will elucidate the 
value of this device in treating selected patients with ischemic cardiomyopathy.
to baseline (basal S-FW: 104±36.3 vs 68±49ms; Ts Disp: 110±49 vs 87±37ms; 12seg 
Ts-SD: 50±16 vs 40±13ms, p<0.04), despite a signiﬁcant increase in mean QRS 
width with pacing (92±10 vs 131±17ms, p<0.01). Regional analysis of intra-ventricular 
electromechanical delay revealed a signiﬁcant contraction delay between septal and 
lateral regions (max delay=99ms). Interestingly, Bi-V pacing signiﬁcantly reduced this 
delay (max delay=78ms, p<0.04). Signiﬁcant improvement in E/E’ was also observed 
(16.9±8.6 to 11.6±4.4, p<0.01).
Conclusion: These data suggest that acute Bi-V pacing may improve ventricular 
dyssynchrony in a DHF population with baseline dyssynchrony and narrow QRS. Whether 
acute improvements in cardiac performance with Bi-V pacing translate to chronic 
therapeutic beneﬁt in this population will require further study.
9:30 a.m.
1051-177 Cardiac Resynchronization Therapy Increases Ejection 
Fraction In Right Bundle Branch Block With a Left 
Hemiblock
Ramesh Chandra, Ronald Zolty, Timothy J. Vittorio, Eugen C. Palma, Albert Einstein 
College Of Medicine, Bronx, NY, Monteﬁore Medical Center, Bronx, NY
Background: The current recommendation for Cardiac Resynchronization Therapy 
(CRT) in Chronic Heart Failure (CHF) patients is based on QRS duration, not on QRS 
morphology. It is not known whether patients with Right Bundle Branch Block (RBBB) 
respond to CRT.
Methods and Patient Population: 271 consecutive patients who underwent CRT 
at Monteﬁore Medical Center were analyzed. Baseline EKGs were analyzed by two 
reviewers for a RBBB and further classiﬁed into those with a co-existing Left Hemi-Block 
(LHB) and pure RBBB. Response to CRT was deﬁned to be an improvement in ejection 
fraction (EF) of at least 5% by a repeat echocardiogram 6 months after CRT.
44 patients with RBBB were identiﬁed: 18 had pure RBBB and 26 had a co-existing LHB. 
The two groups were similar in respect to baseline characteristics (p > 0.05): age, gender, 
body mass index, type of cardiomyopathy, QRS duration, co-morbidities ( Diabetes, 
Hypertension, Chronic Renal Failure), and medications ( ACE-Inhibitors/ Angiotensin 
Receptor Blockers, Beta Blockers, Spironolactone, Digitalis).
Results: Only 4 out of 18 patients with pure RBBB compared to 18 out of 26 with a LHB 
(p=0.005) had an improvement in EF > 5%. The mean delta EF was -1% in the RBBB 
group but +5.4% in those with LHB (p=0.0031)
Conclusion: Patients with a RBBB may respond to CRT if a co-existing LHB is present.
9:30 a.m.
1051-178 Underutilization of Device Therapy in Patients With 
Advanced Heart Failure
Daniel B. Sims, Luis I. Garcia, Andrea Mignatti, Paolo C. Colombo, Margaret Jones, 
Donna M. Mancini, Ulrich P. Jorde, Division of Cardiology, Columbia University Medical 
Center, New York, NY
Background: Internal cardioverter deﬁbrillators (ICDs) and cardiac resynchronization 
therapy (CRT) reduce mortality in advanced heart failure (HF). These modalities may 
be underutilized.
Methods: Retrospective chart review of 274 consecutive patients who underwent 
cardiopulmonary exercise testing after referral for heart failure/transplant evaluation 
at our center. Ejection fraction (EF), QRS width, and presence of ICDs and CRT were 
recorded to determine if patients who have an indication for device therapy based on 
current guidelines were appropriately treated.
Results: 202 of 274 patients had systolic dysfunction (LVEF a 35%) with an average 
EF of 22±7%. Patients were 54±13 years old and had a mean peak VO2 of 12.5±4.5 ml/
kg/min. 71 patients (35%) had ischemic cardiomyopathy and 131 patients (65%) had 
nonischemic cardiomyopathy. 97 of the 202 patients had QRS <120 ms and were thus 
eligible for ICD therapy, however, 42 (43%) did not have an ICD. Eligible female patients 
were more likely to be without an ICD than men (65% vs. 35%, p <0.009). Of 105 patients 
with QRS >120 ms who met criteria for CRT therapy, 48 (46%) did not have CRT.
Conclusions: At the time of evaluation at an advanced heart failure center, both ICD 
and CRT devices are underutilized. This may be due to under appreciation of ICD/CRT 
beneﬁts or the perception that ICD/CRT therapy should be initiated at specialized centers 
only despite nearly a decade experience. Female patients are disproportionately affected 
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1051-183 Systolic Ventricular Deformation and Rotation Are 
Reduced at Rest and on Exercise in Patients With Heart 
Failure and Normal Ejection Fraction
Yu-Ting Tan, Frauke W.G. Wenzelburger, Eveline Lee, Grant Heatlie, Francisco Leyva, 
Michael P. Frenneaux, John E. Sanderson, University of Birmingham, Birmingham, United 
Kingdom, University Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom
Background: Many patients presenting with symptoms of heart failure are found to have 
normal ejection fraction using standard 2D echocardiography and are labelled as having 
Diastolic Heart Failure or heart failure and normal ejection fraction (HFNEF). We used 
speckle tracking to study the overall systolic function by assessing longitudinal, radial and 
rotational function in this group of patients.
Methods: 27 aged-matched healthy controls and 56 patients with symptoms or signs 
of heart failure and documented normal left ventricular ejection fraction (LVEF) were 
recruited. All subjects underwent cardiopulmonary exercise test to determine their 
VO2max. Full echocardiographic assessment was performed at rest and on supine 
bicycle exercise. Speckle tracking analysis were performed ofﬂine on apical 4 and 2 
chamber views for longitudinal strain, midventricular parasternal short axis view for radial 
strain and apical short axis view for apical rotation. All images were analysed by two 
independent observers and results were averaged.
Results: 48 subjects (BMI 30.1±4.6kg/m2, biplane LVEF 61±7%, 35 female, age 72±8 
years) clinically diagnosed with HFNEF with reduced VO2max (17.6±3.8ml/min/kg vs 
30.9±4.6ml/min/kg, p= 0.000) and 24 age-matched controls (BMI 24.2±3.9kg/m2, biplane 
LVEF 63±8%, 16 female, age 70±8 years) had suitable images for analysis. Patients were 
found to have signiﬁcantly lower systolic longitudinal, radial strain and apical rotation at 
rest compared to controls (longitudinal strain: -18.9±3.5% vs -20.9±3.0%, p=0.018; radial 
strain : 41.8±13.5% vs 49.0±12.9%, p=0.003; apical rotation: 10.4±4.0 º vs 13.0±2.8º, 
p=0.015). On exercise the difference became more signiﬁcant between the two groups 
(longitudinal strain: -20.1±4.1% vs -23.8±2.5%, p=0.000; radial strain: 49.1±15.4% vs 
61.9±12.8%, p=0.002; apical rotation: 13.5±4.2º vs 17.7±3.6º, p=0.005).
Conclusions: Left ventricular strain and rotation are reduced in systole in patients with 
HFNEF. Abnormalities of ventricular function in HFNEF are more widespread than in 
diastole alone.
9:30 a.m.
1051-184 Rapid In Vitro and In Vivo Phosphorylation of 
Phospholamban by Cardiac Contractility Modulation 
Electrical Signals
Hani N. Sabbah, Sudhish Mishra, Ramesh C. Gupta, Sharad Rastogi, Benny Rousso, 
Yuval Mika, Henry Ford Hospital, Detroit, MI, Impulse Dynamics USA, Inc., Orangeburg, 
NY
Background: Therapy with non-excitatory cardiac contractility modulation (CCM) 
electrical signals improves LV ejection fraction and increases phosphorylation of 
phospholamban (P-PLB) in dogs with heart failure (HF). In patients and dogs with 
HF, CCM signals increase peak LV dP/dt within 1-5 min of application. We tested the 
hypothesis that the rapid increase in contractility by CCM signals is associated with a 
rapid increase in P-PLB.
Methods: CCM signals were delivered to the LV anterior wall from epicardial leads in 
open-chest HF dogs. Anterior wall biopsies were taken at baseline and at 1, 5, and 10 min 
after CCM application. Identical CCM signals were also applied in-vitro for 10, 20, and 30 
sec to suspensions of isolated HF dog cardiomyocytes. P-PLB at serine-16 (S-16) and 
threonine-17 (T-17) normalized to calsequestrin (CSQ), was measured from all biopsies 
and cardiomyocyte samples using Western blots.
Results: CSQ expression was unchanged in both experiments. In-vivo P-PLB at S-16 
and T-17 increased within one minute of CCM signal application and was associated with 
an increase of LV peak dP/dt (Table). Application of CCM signals in-vitro for as little as 10 
sec increased P-PLB in isolated cardiomyocytes at both S-16 and T-17 (Table).
Conclusions: CCM signals rapidly increase P-PLB in-vitro and in-vivo. The exact 
mechanism remains unknown. The observed increase in P-PLB observed can explain the 
rapid increase in LV contractility seen with initiation of therapeutic CCM signal delivery.
In-Vivo Studies
Time 0 min 1 min 5 min 10 min
P-PLB at S-16/CSQ 0.23 0.47 0.46 0.56
P-PLB at T-17/CSQ 0.23 0.54 0.55 0.57
LV dP/dt (mmHg/sec) 1270 1640 1590 1490
In-Vitro Studies
Time 0 sec 10 sec 20 sec 30 sec
P-PLB at S-16/CSQ 0.35 0.85 0.96 1.04
P-PLB at T-17/CSQ 0.76 0.96 0.99 1.16
9:30 a.m.
1051-181 BNP and Cardiac Troponin I as Predictors of Mode of 
Death in Patients With Advanced Heart Failure
Vamsi Krishna, Tamara B. Horwich, Gregg C. Fonarow, Ahmanson-UCLA 
Cardiomyopathy Center, University of California at Los Angeles Medical Center, Los 
Angeles, CA
Background: Prognosis and mode of death in heart failure (HF) patients vary. Predicting 
risk may facilitate more informed treatment decisions. B-type natriuretic peptide (BNP) 
and Troponin I (TnI) are predictive of mortality in HF patients, but their value for mode of 
death and urgent transplantation (UTx) is unclear.
Methods: We followed 1103 advanced HF patients (EF < 35%) from 1/1/00 to 7/7/08; 
684 had baseline BNP and TnI I determined. Patients were categorized into 4 groups: 
-BNP/-TnI (n=206), -BNP/+TnI (n=125), +BNP/-TnI (n=163), +BNP/+TnI (n=190). BNP 
was considered positive if > 602 pg/mL, based on ROC curves for all-cause mortality. TnI 
was considered to be positive if detectable (> 0.04 ng/mL).
Results: Mean age was 53 + 13, mean EF 23% + 7, and 74% were male. During a mean 
of 2 years of follow up, 43 (6%) died from pump failure; 32 (5%) died from sudden death 
(SD); 172 (25%) of any cause; and 177 (26%) required UTx. A detectable TnI and BNP 
> 602 were predictive of 5 year outcomes for pump death (OR 2.4, 95% CI 1.3-4.5), SD 
(2.4, 1.2 - 4.9), UTx (1.8, 1.3-2.6) and all-cause death (4.5, 3.1-6.6). On multivariate 
analysis, BNP and TnI were strong predictors of SD, UTx, and all-cause mortality; BNP 
but not TnI predicted pump death. BNP < 602 and non-detectable TnI were independent 
predictors for SD free survival.
Conclusions: BNP and TnI are strong predictors for all-cause mortality, SD, pump death 
and UTx in advanced HF. Prospective studies are needed to test if TnI and BNP can be 
used to accurately guide treatment decisions. 
9:30 a.m.
1051-182 Impaired Left Ventricular Rotation and Rotational 
Dyssynchrony in Heart Failure
Yu-Ting Tan, Eveline Lee, Frauke W.G. Wenzelburger, Grant Heatlie, Francisco Leyva, 
Michael P. Frenneaux, John E. Sanderson, University of Birmingham, Birmingham, 
United Kingdom, University Hospital of North Staffordshire, Stoke-on-Trent, United 
Kingdom
Background: Left ventricular (LV) rotation contributes signiﬁcantly to global LV function in 
normal subjects but the effect on heart failure is not clearly understood. We assessed LV 
rotation and rotational dyssynchrony in patients with a range of heart failure with reduced 
or normal LV ejection fraction (EF).
Methods: 36 patients with systolic heart failure (SHF): 28 female, age 69±7years, 
EF26±10%; 47 patients with heart failure with normal ejection fraction (HFNEF): 32 
female, age 73±6years, EF 60±7%; and 25 controls: 17 female, age 70±8years, EF 
64±8% were recruited. Standard echocardiography was performed and images were 
analysed ofﬂine. Apical rotation was examined using 2-dimensional (2D) speckle tracking. 
Peak apical rotation and time to peak rotation were recorded in 6 segments. Average peak 
rotation and standard deviation of the time to peak rotation (TrotSD) were calculated. At 
least 3 consecutive beats were analysed and read by two independent observers.
Results: The average apical rotation were 2.7±5.9º, 10.5±4.2º, 14.1±3.1º in SHF, 
HFNEF and controls respectively (one way ANOVA, p=0.000). TrotSD was 27.7±26.3ms, 
11.3±7.3ms, 9.9±8.6ms in SHF, HFNEF and controls respectively. SHF had signiﬁcantly 
more rotational dyssynchrony compared to HFNEF and controls (p<0.05). There was no 
difference in TrotSD between HFNEF and controls (p=0.48).
Conclusions: LV rotation is impaired and progresses through a spectrum of severity 
in heart failure. 2D speckle tracking detected regional systolic dysfunction which 
is unidentiﬁed with conventional echocardiography. SHF patients have rotational 
dyssynchrony in addition to known longitudinal and radial dyssynchrony.
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diabetes in American Indian population with high prevalence of obesity and diabetes.
Methods: Cases and controls were selected from the Strong Heart Study (SHS) cohort 
Participants with prevalent cardiovascular disease, prevalent HF, on dialysis and with 
creatinine >2.5mg/dl were excluded. Of eligible participants at baseline, 115 had incident 
HF in subsequent follow-up and had available stored serum specimens. Controls were 
matched for sex, age and center. CRP, ﬁbrinogen and myeloperoxidase (MPO) were 
measured by commercial assays. Albuminuria was deﬁned as urinary albumin-creatinine 
ratio >30 mg/g. Obesity was deﬁned as body mass index BMI>30.
Results: The 115 cases and matched controls had similar BMI (controls: 30.7+6.7 kg/
m2 and cases: 32.2+7.5kg/m2, P=0.09). Diabetes and hypertension were more prevalent 
in the cases (73.9% vs. 41.7%, P<0.01 for diabetes, and 64.4% vs. 47%, P<0.001 for 
hypertension). Cases had higher baseline ﬁbrinogen (392.5+89 mg/dl vs. 351.8+70 mg/
dl, P<0.01), higher CRP (8.7+11.2 mg/dl vs. 4.9+4.8 mg/dl, P=0.04) and more albuminuria 
(33% vs.15%, P<0.01). MPO levels were not signiﬁcantly different. Fibrinogen and 
albuminuria were associated with increased risk for HF even afer the adjustements for 
age, BMI, hypertension, diabetes and total/HDL cholesterol (OR 2.19 (C.I. 1.07-4.49) for 
ﬁbrinogen and OR 2.67 (C.I. 1.22-5.82) for albuminuria).
Conclusion: In a population with high prevalence of obesity and diabetes ﬁbrinogen and 
albuminuria are strongly and independently associated with incident HF.
9:30 a.m.
1051-188 Impact of an Enhanced Heart Failure Monitoring System 
on Emergency Room Visits and Hospitalizations in 
Older Patients With Heart Failure Who Were not on 
Optimal Medical Treatment
Ozlem Z. Soran, Faith Selzer, Gervasio A. Lamas, Ileana L. Piña, Sheryl F. Kelsey, John 
Pilotte, Arthur M. Feldman, University of Pittsburgh, Pittsburgh, PA
Background: Angiotensin converting enzyme inhibitors (ACE) and beta blockers (BB) 
are recommended by professional society guidelines for patients with systolic heart 
failure. However, almost 30% of the elderly population with heart failure is intolerant to 
these drugs. Prior studies suggest that disease management programs may be effective 
in improving clinical outcomes in patients with heart failure. Whether these types of 
programs can provide additional beneﬁt to the care of elderly patients with heart failure 
who are ACE or BB intolerant is unknown. In this study we assessed the impact of a 
Computer Based Telephonic Monitoring System (CBMS) on emergency room visits and 
hospitalizations in elderly patients with heart failure who were ACE or BB intolerant and 
could not be on optimal medical treatment.
Methods: This was a multicenter, randomized, controlled trial of enhanced CBMS vs 
standard heart failure care (SC) in patients with heart failure and systolic dysfunction. 
All patients received patient one on one education, education to clinicians and an 
effort to use optimal medical care. CBMS patients received an electronic scale and an 
individualized symptom response system linked to a computerized data base operated 
by trained nurses. Six month follow -up data from patients who were intolerant to ACE 
inhibitors or BB were analyzed to assess the impact of the CBMS on clinical outcomes.
Results: There were 55 patients in each treatment arm. The mean age was 77 years and 
all baseline characteristics and laboratory evaluations were equivalent in both treatment 
groups. The 6-month cumulative rate for all-cause emergency room visits were 48% in 
the SC arm and 53% in the CBMS (p=0.84). All cause hospitalization rates were 49% vs 
56%, respectively (p=0.48).
Conclusions: In this sub-set of patients, we were unable to identify any beneﬁts of the 
CBMS over a period of 6 months of follow-up when comparing all-cause emergency room 
visits and hospitalization rates in elderly patients intolerant to optimal medical therapy and 
randomized to CBMS or SC.
9:30 a.m.
1051-189 Effects of Reverse Remodeling With Cardiac 
Resynchronization Therapy in Mild Heart Failure on 
Left Ventricular Volume and Shape: Results From the 
REsynchronization reVErses Remodeling in Systolic 
left vEntricular Dysfunction (REVERSE) Trial.
Martin G. St. John Sutton, Stefano Ghio, Ted Plappert, Luigi Tavazzi, Laura Scelsi, 
Claude Daubert, William T. Abraham, Michael R. Gold, Christian Hassager, John M. 
Herre, Genevieve Derumeaux, Cecilia Linde, University of Pennsylvania Medical Center, 
Philadelphia, PA
Background. Cardiac Resynchronization Therapy (CRT) improves survival, symptoms 
and exercise capacity in heart failure (HF) and induces reverse remodeling that consists 
primarily of reduction in left ventricular (LV) volume. Little is known about the effects 
of volume reduction on LV shape. We hypothesized that reduction in LV volume would 
restore LV shape towards normal with CRT, that change in shape would correlate with 
the change in volume during remodeling and be associated with increase in LV ejection 
fraction (LVEF).
Methods. Patients in the REVERSE study had an EF a40%, a QRS q120ms and received 
optimal HF therapy for at least 1 month prior to enrollment. Echocardiograms recorded 
at baseline and 1 year were digitized to obtain LV volume indices, EF and LV shape. LV 
shape was computed as the ratio of LV volume to the volume of a sphere with a diameter 
equal to LV cavity length at end-diastole.
Results: Of 610 patients, 82% had NYHA class II and 18% had class I HF. Patients 
were randomized 2:1 to CRT ON (n=419) or CRT OFF (n=191). LV volume indices at 
end-diastole (EDV) and end-systole (ESV) decreased, LV shape became less spherical 
(by -0.044 ± 0.115 for CRT ON and -0.007 ± 0.099 for CRT OFF) and EF increased 
signiﬁcantly from baseline to 1 year in CRT ON compared to CRT OFF. The reduction 
in LVEDVi at 1 year in CRT ON correlated closely with change in LV shape (r=0.63, 
p<0.0001). Change in LV shape correlated with increased LVEF (r=0.23; p<0.001). 
9:30 a.m.
1051-185 Improvement in Tissue Doppler Derived Isovolumic 
Contraction Velocities, but Not Ejection Phase 
Velocities Underlie Reversal of Remodeling Following 
Cardiac Resynchronization Therapy in Both Ischemic 
and Nonischemic Heart Failure
Michael H. Arredondo, Luka Lipar, Eun Joo Cho, Daniel Ng, Komandoor 
Srivathsan, Gregory T. Altemose, Susan Wilansky, Steven J. Lester, Krishnaswamy 
Chandrasekaran, Bijoy K. Khandheria, Luis R. Scott, Partho P. Sengupta, Mayo Clinic 
Arizona, Scottsdale, AZ
Background: Results from PROSPECT trial highlighted the limitations of tissue Doppler 
(TD) based ejection-phase indices in characterizing cardiac dyssynchrony. Electro-
mechanical coupling and myocardial shortening during isovolumic contraction (IVC) 
stretch-activates the left ventricle (LV) for optimal ejection. We therefore hypothesized that 
assessment of LV mechanics during IVC will yield superior insights about the mechanism 
of LV function improvement following cardiac resynchronization therapy (CRT).
Methods: Total 59 heart failure patients (74±10 yrs., 42 men, etiology: 31 nonischemic 
and 28 ischemic) underwent CRT on the basis of four criteria: New York Heart Association 
(NYHA) class III and IV; QRS > 120 ms with a left bundle branch block pattern, and LV 
ejection fraction a 35% under optimal medical treatment. Pulsed-wave TD velocities and 
durations were measured from the LV lateral and septal annulus during IVC, ejection, 
isovolumic relaxation, early and late diastolic phases before and 263±125 days after 
CRT. LV reverse remodeling, deﬁned as improvement in end-systolic volume q 15%, was 
observed in 43 patients (73%).
Results: Following CRT, the lateral wall of the LV in responders showed a signiﬁcant 
increase in the IVC velocities (4.8±2.1 vs. 7.0±3.0 cm/s, P= 0.001) but not in ejection 
velocities. TD velocities averaged from the septum and lateral wall showed smaller 
improvement for ejection velocities, however, were signiﬁcantly lower than percent 
improvement seen for IVC velocities (12% vs. 48%, P=0.005). Subgroup analysis of 
ischemic and nonischemic responders showed consistent improvements in only IVC 
velocities (4.3±1.4 vs. 6.1±2.3 cm/s, P=0.02 and 5.4±2.4 vs. 7.6±3.3 cm/s, P = 0.02, 
respectively). LV prestretch velocities from the lateral wall of LV during IVC correlated with 
post-systolic shortening velocities in responders (r=0.78, P<0.001).
Conclusions: Variations in tissue Doppler derived IVC and stretch velocities in the late 
activated regions of LV, rather than systolic ejection velocities correlate with reversal of LV 
remodeling following CRT. Understanding LV mechanics during IVC phase may impact 
future algorithms for assessing the effects of CRT.
9:30 a.m.
1051-186 Adaptive Servoventilation as a Novel Therapeutic 
Approach for Patients With Diastolic Heart Failure and 
Cheyne-Stokes Respiration
Thomas Bitter, Lothar Faber, Detlef Hering, Christian Prinz, Dieter Horstkotte, Olaf 
Oldenburg, Department of Cardiology, Heart and Diabetes Center North Rhine-
Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
Background: A high prevalence of nocturnal Cheyne-Stokes respiration (CSR) has been 
documented in patients (pts) with diastolic heart failure (DHF). It is supposed that an increase 
in left ventricular ﬁlling pressures leads to disordered breathing with CSR. CSR itself may 
worsen heart failure and initiate a vicious cycle. Therefore, aim of the present study was to 
investigate the effects of adaptive servoventilation (ASV) for treatment of CSR on DHF.
Methods: In a total of 60 pts DHF was diagnosed clinically (NYHA class q II), by 
invasive (LVEDPq20mmHg) and non-invasive (echocardiography: EF>55%; E/e’>15) 
measurements. CSR was documented by cardiorespiratory polygraphy (apnea-hypopnea-
index (AHI) >15/h). ASV treatment was offered to all pts. Twenty-one pts rejected nocturnal 
ASV treatment (controls: 70±8years, 18men) whereas ASV therapy was initiated in 39 pts 
(ASV group: 67±8years, 33men). Echocardiography, cardiopulmonary exercise testing 
(CPX) and measurement of NT-proBNP were performed at baseline and at follow-up (10 
to 12 months).
Results: Exclusively in the ASV-group there was an improvement in NYHA-class 
(2.5±0.7 to 2.0±0.8, p<0.05; controls: 2.5±0.5 to 2.4±0.4, n.s.), NT-proBNP concentration 
(1240±1634pg/ml to 740±1110pg/ml, p>0.01, controls: 1620±1080mg/ml to 1480±890pg/
ml, n.s) as well as in peak oxygen uptake (14.6±4.5ml/min/kg to 17.6±5.5ml/min/kg, 
p<0.001; controls: 16.3±4.1m1ml/min/kg to 15.9ml/min/kg, n.s.). In addition, diameter of 
the left atrium 52.0± 5.5mm to 50.0±7.3, p<0.05 (controls: 48.2±6.0mm to 51.1±5.7mm, 
n.s.) and early diastolic mitral annular lengthening velocity (e´; 3.8±1.7m/s to 4.4±1.3m/s, 
p<0.05; controls: 4.6±1.1m/s to 4.3±1.6m/s, n.s.) improved in ASV, but not in the controls. 
In both groups, there was no signiﬁcant change in ratio of early (E) Doppler mitral ﬂow 
velocity to e´ (ASV: 17.2±7.2 to 17.9±5.8, n.s.; controls: 19.5±6.4 to 20.4±7.8, n.s.).
Conclusions: ASV-therapy seems to improve clinical and functional parameters in pts 
with DHF and CSR. Whether this is of prognostic value remains unclear and needs further 
investigations.
9:30 a.m.
1051-187 Inﬂammation and Albuminuria Are Associated With the 
Risk of Incident Heart Failure: The Strong Heart Study
Ana Barac, Washington Hospital Center, Washington, DC, Medstar Research Institute, 
Washington, DC
Background: Systemic inﬂammation and albuminuria may play a role in the pathophysiogy 
of heart failure (HF). The aim if this study was to assess the associations of markers of 
inﬂammation and albuminuria with incident HF, as well as their relationship with obesity and 
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vs 12±8 respectively; p=0.04). T pts had preserved contractility by NOGA compared to 
C (delta LLS -0.06±0.4% vs -2±0.6%; p=0.003). There was no difference in MVO2 from 
baseline to 3 and 6 mo f/u in T vs. C. T Pts <60 y had a signiﬁcant improvement in MVO2 
when compared to the correspondent C (Fig 1).
Conclusions:Patients <60 y had more preserved MSC function and may have a functional 
beneﬁt from cell therapy. TE injections of BMMNC in pts with severe IHF were safe. 
9:30 a.m.
1051-192 Right Ventricular Dysfunction Does not Improve More
With LVAD Than With Inotropic Support
Maryse Palardy, Neal Lakdawala, Garrick C. Stewart, Mahoto Kato, Patricia M. 
Campbell, Christopher W. May, Waleed A. Alhabeeb, Gregory S. Couper, Prem S. 
Shekar, Leslie M. Grifﬁn, Colleen M. Smith, Gilbert H. Mudge, Michael M. Givertz, Lynne 
W. Stevenson, Brigham and Women’s Hospital, Boston, MA
Background: LVAD therapy reduces left-sided ﬁlling pressures and right ventricular (RV) 
afterload, and should improve RV stroke volume. We sought to determine how RV dilation 
and function seen on inotropic therapy improve after 3 months of LVAD support.
Method: Patients inotrope dependent at Brigham and Women’s Hospital after 01/2007 
were identiﬁed for implant of isolated LVAD. Echocardiograms recording quantiﬁable 
parameters of RV function were obtained before surgery and after 3 months of follow 
up. Paired t-test and Wilcoxon signed-rank tests were used to analyze continuous and 
categorical variables.
Results: Before LVAD, 17 patients were receiving inotropic therapy, 5 also on IABP 
support. Mean age was 54±15 yrs, LVEF 18±7%, RAP 11±5 mm Hg, PCWP 23±9 mm 
Hg, and cardiac index 2.0±0.6 L/min/m2. RV diameter was 3.1±0.4 cm at the base and 3.5 
±0.6 cm at mid-RV, and global RV dysfunction was at least moderate in 53% of patients. 
Inotropes were discontinued within 3 weeks postoperatively. After 3 months of LVAD 
support, RV dilation remained unchanged at the base and slightly larger at mid-RV, and 
global RV function did not appear better (Figure 1)(NS).
Conclusions: RV dysfunction should not be expected to improve within 3 months after 
continuous inotropic support has been replaced by LVAD support. Until reverse RV 
remodeling can be demonstrated with different medical or device strategies, only patients 
in whom pre-operative RV function is adequate for rehabilitation should be selected for 
long-term LVAD. 
9:30 a.m.
1051-193 The Impact of Right Ventricular Dysfunction on In-
Hospital and Long Term Mortality in Patients With
Acute Myocardial Infarction
Robert Dragu, Michael Kapeliovich, Yoram Agmon, Diab Mutlak, Jonathan Lessick, 
Doron Aronson, Salim Dabah, Shimon Reisner, Haim Hammerman, Rambam Health 
Care Campus, Haifa, Israel
Background: To assess the impact of right ventricular (RV) dysfunction on in-hospital 
and long-term mortality in patients with acute myocardial infarction.
Methods: We prospectively studied 1217 consecutive patients with AMI and RV function 
assessed by echocardiography in the ﬁrst 24 hours from admission. They were followed-
up for a mean of 17 months.
Results: Mild RV dysfunction was detected in 6.2%, moderate in 2.7% and severe in 
1.3% of the patients. In hospital mortality was 21.7%, 34.9% and 70.6% respectively, with 
only 4.5% in normal RV function group (p<0.0001). The long term mortality was 32.0%, 
45.2% and 81.3% in mild, moderate and severe reduced RV function, and only 9.3% in 
the normal RV function group (p<0.0001). After adjusting for age, gender, Killip class, on-
admission blood pressure, diabetes mellitus, inferior wall involvement, ST-elevation AMI, 
Ischemic patients (n=236) did not reverse remodel as much as non-ischemic patients 
(n=183) with CRT ON with regard to LVEDVi (p<0.0001) or LV shape (p=0.008). However, 
there were strong correlations between change in LV shape and changes in LVEDVi and 
LVESVi, in both non-ischemic (r=0.54; r=0.51 respectively) and ischemic patients (r=0.68; 
r=0.64) with CRT ON.
Conclusions: LV reverse remodeling with CRT results in reduction in LV volumes and 
restoration of LV shape towards normal. Despite major differences in the extent of reverse 
remodeling between non-ischemic and ischemic patients, the strong correlation between 
reduction in LV volume and LV shape were conserved in both groups, emphasizing the 
importance of LV shape in reverse remodeling.
9:30 a.m.
1051-190 Attenuation of Left Ventricular Adverse Remodeling
With Epicardial Patching After Myocardial Infarction
Hung-Fat Tse, Chung-Wah Siu, Song-Yan Liao, Wing-Sze Chan, Ed X. Wu, Yin Wu, 
John M. Nicholls, Ronald Li, Michael E. Benser, Stuart P. Rosenberg, Euljoon Park, Chu-
Pak Lau, Cardiology Division, Department of Medicine, Queen Mary Hospital, Hong 
Kong, Hong Kong
Background: Experimental studies suggested that regional epicardial patch can prevent 
left ventricular (LV) remodeling early after myocardial infarction (MI); however, its effects 
in chronic phase of LV remodeling is unclear.
Methods: We compared the effects of passive dual-layer epicardial patch (polypropylene 
mesh and expanded polytetraﬂuoroethylene, Patch gp, n=12) implantation vs sham 
surgery (Control gp, n=12) in pigs with impaired LV ejection fraction (LVEF <50%) at 8 wks 
post-MI. Serial measurement of LV function and dimensions using invasive assessment 
and cardiac MRI were performed at 8 and 20 wks post-MI.
Results: In control gp, there were no differences in +dP/dt, and LV end-diastolic pressure 
(LVEDP) at 20 wks vs. 8 wks (P>0.05). In contrast, +dP/dt increased and LVEDP 
decreased in patch gp at 20 wks vs 8 wks (P<0.05). In both groups, LV end-diastolic and
end-systolic volumes increased at 20 wks vs 8 wks (Fig A & B). However, the increase in 
LV end-diastolic volume was greater in control gp vs patch gp (Fig D). Furthermore, LVEF 
signiﬁcantly increased at 20 wks vs 8 wks in patch gp but decreased in control gp (Fig C 
& D). Histological examination showed that LV wall thickness at infarct and adjacent peri-
infarct regions were signiﬁcant greater in patch gp vs. control gp (P<0.05).
Conclusions: Regional application of a simple, passive synthetic epicardial patch 
increased LV wall thickness at the infarct region, attenuated LV dilatation and improved 
LVEF and +dP/dt in a large animal model of chronic MI. 
9:30 a.m.
1051-191 FOCUS-HF: The First US Randomized Blinded
Controlled Trial of Transendocardial Injection of Bone
Marrow Mononuclear Cells in Chronic Severe Ischemic
Heart Failure Patients
Emerson C. Perin, Guilherme V. Silva, Marlos R. Fernandes, Timothy Henry, Warren 
Moore, Stephanie Coulter, James Patrick Herlihy, Ben Cheong, Scott Flamm, Sandi 
Shaw, Lynette Westbrook, Deirdre Smith, Yi Zheng, Cristiano Cardoso, John Canales, 
Rachel Olson, Jay Traverse, William Vaughn, Maria G. Cabreira, James T. Willerson, 
Texas Heart Institute, Houston, TX
Background:We described the initial experience of transendocardial (TE) bone-marrow 
derived mononuclear cell (BMMNC) injection in ischemic heart failure(IHF) pts. In the 
present study we evaluated BMMNC TE injection in severe IHF pts in a randomized 
blinded fashion.
Methods:30 pts with IHF (NYHA/CCS III/IV) with no option for revascularization were 
randomized (2:1) into treatment (TE injection of 30x106 BMMNC) or controls (C) (mock 
injection). Cell function analyses were perfomed. Primary endpoint of safety, and efﬁcacy 
endpoints (NOGA, Echo,SPECT, perfusion MRI, MVO2) were evaluated at baseline, 3 and 6 
mo f/u. Comparisons were made by repeated measures ANOVA or Mann-Whitney U test.
Results:There were no major peri-procedural complications. At 3 mos 1 treated pt had 
a NSTEMI. Overall treated (T) pts had functionally compromised BMMNC progenitor 
compartments. T pts had a mean of 18±14 mesenchymal colony forming units (CFU-F) 
per 106BMMNC (nl>30). T pts <60 y had signiﬁcantly higher CFU-F than older pts (27±17 
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to CorCap CSD + OMT or OMT only. Survival status, need for major cardiac procedures 
(MCP) and echocardiograms (Mayo Clinic Echo Core Lab) were followed for 5 years.
Results: At 5 years, the Kaplan-Meier estimate of overall mortality was 37% in the CSD 
group and 38% in the OMT group (p=0.92), conﬁrming that the CorCap is safe.
The CSD group had greater reductions in LVEDV (31.3 vs. 2.8 ml; p=0.03) and a trend for 
greater increases in sphericity index (0.107 vs. 0.071; p=0.29). There continues to be no 
clinical cases of pericardial constriction during long term follow up.
We previously reported a subset analysis which excluded pts who were “too well” 
(LVEDDi <30 mm/m2) or “too sick” (LVEDDi >40 mm/m2) to focus on pts who had an 
optimal response to CorCap. In this subset (Fig 1), CSD pts had a signiﬁcantly (p=0.03) 
lower rate of death or MCPs, including transplant (7% vs. 20%), LVAD (3% vs. 8%) and 
CRT (13% vs. 20%).
Conclusions: These results suggest that the beneﬁts of the Acorn CorCap CSD are 
durable to 5 years.
9:30 a.m.
1051-196 Allogeneic Mesenchymal Stem Cells Promote 
Recovery of Cardiac Function in Chronic Ischemic 
Cardiomyopathy Through Trilineage Differentiating 
Capacity
Henry C. Quevedo, Konstantinos E. Hatzistergos, Behzad N. Oskouei, Gary S. 
Feigenbaum, Jose E. Rodriguez, David Valdes, Pradip M. Pattany, Karl H. Schuleri, 
Qinghua Hu, Juan P. Zambrano, Ian McNiece, Alan W. Heldman, Albert C. Lardo, Joshua 
M. Hare, Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of 
Miami, Miami, FL, Division of Cardiology, Department of Medicine, Johns Hopkins 
University School of Medicine, Baltimore, MD
Background: Although allogeneic mesenchymal stem cells (aMSC) improve cardiac 
function after acute myocardial infarction (MI), whether this occurs in chronic infarcted 
myocardium remains uncertain. Here, we tested the hypothesis that aMSCs are effective 
at reducing infarct size and improving cardiac function in ischemic cardiomyopathy and 
that differentiation to cardiomyocytes and blood vessels contributes to this effect.
Methods: Three months after MI, ten female swine received transendocardial injections 
of 200 million male aMSC (n=6) or placebo (n=4) followed by serial cardiac magnetic 
resonance imaging. Twelve weeks later, in situ hybridization for the Y chromosome (Y 
pos) cells was assessed in infarct (IZ), border (BZ) and remote myocardium followed 
by characterization for cardiac (GATA-4/ a-sarcomeric actinin / connexin-43), vascular 
muscle (smooth muscle actinin) and endothelial (factor viii) lineages.
Results: MI reduced ejection fraction (from 47.7± 2.0% to 33.4± 1.0%; p<0.05, p=NS 
between groups) with similar scar size in both groups (aMSC= 18.3 ± 1.3%; placebo= 
18.4 ± 2.5%). Twelve weeks later, aMSC therapy but not placebo increased ejection 
fraction (16.5 ± 8.0%; p<0.01) and reduced scar size (29.0 ± 5.1%, p<0.01). Myocardial 
strain analysis of aMSC-treated hearts displayed an improved regional function in IZ 
(aMSC = -14.5 ± 1.7%; placebo = -6.8 ± 2.2 %, p<0.001) and BZ (aMSC = -15.6 ±1.8%; 
placebo = -6.4 ± 2.2%, p=0.001). Confocal imaging of IZ and BZ showed that 14.0 ± 4.0% 
of engrafted Y pos aMSC also co-stained for GATA-4 pos /a-sarcomeric actinin pos as well 
as connexin-43. In addition, Y pos cells co-localized with smooth muscle actinin pos (5.9 ± 
2.1%) and factor viii pos (3.9 ± 1.7%) and were incorporated into large and small vessels. 
Importantly, the degree of aMSC engraftment correlated with the recovery in regional wall 
motion (r= -0.82, p<0.05).
Conclusions: Together these ﬁndings demonstrate that aMSCs transplantation improves 
left ventricular function and decreases infarct size by clinically meaningful amounts 
in chronic cardiomyopathy, in a manner that correlates to deﬁnitive evidence of cell 
engraftment and differentiation into myocytes and vascular elements.
9:30 a.m.
1051-197 Effectiveness of Nurse led or Multidisciplinary Disease 
Management Programs in Improving Clinical Outcomes 
in Heart Failure Patients: A Meta-Analysis
Rohit Bhuriya, Navdeep Gupta, Updesh Bedi, Janos Molnar, Ahmad Khraisat, Param 
Puneet Singh, Amol Bahekar, Rohit Arora, The Chicago Medical School, North Chicago, IL
Background: Controversy persists regarding the effectiveness of nurse-led or 
multidisciplinary disease management programmes (DMP) to improve long term 
outcomes of heart failure (HF) patients. We performed a meta-analysis of randomized 
controlled trials (RCTs) comparing the effectiveness of nurse led or multidisciplinary DMP 
versus usual care in HF patients.
creatinine clearance and left ventricular systolic function, the odds ratio for mortality were 
3.07 (95% conﬁdence interval [CI], 1.25-7.53, p<0.01), 3.89 (95%CI, 1.22-12.34, p<0.02) 
and 21.66 (95%CI, 3.12-150.0, p<0.002) for mild, moderate and severe RV dysfunction 
respectively, as compared to normal RV function group. Figure 1 depicts the Kaplan-Meier 
cumulative probability for mortality curves for each group.
Conclusions: There is a graded independent association between the severity of RV 
dysfunction after AMI and long-term mortality. Even a mild dysfunction is associated with 
an increase in risk of death. 
9:30 a.m.
1051-194 Chronotropic Incompetence Is an Independent 
Predictor of Mortality in Patients With Advanced CHF
Luis I. Garcia, Daniel B. Sims, Andrea Mignatti, Paolo C. Colombo, Paula Karlin, Steve 
Holleran, Ayumi Goda, Donna M. Mancini, Ulrich P. Jorde, Columbia University Medical 
Center, New York, NY
Background: Chronotropic Incompetence (CI) is an emerging therapeutic target in 
CHF. Whether this inability to reach age adjusted maximal predicted heart rate (MPHR) 
is a maladaptive or protective mechanism in CHF remains unknown. Accordingly, we 
prospectively enrolled patients presenting to our center for CHF/transplant evaluation to 
determine if CI is an independent predictor of outcome.
Methods: Data for 274 consecutive pts, mean age 53.6+13yrs, LVEF 27.7 +12% and peak 
oxygen consumption (pVO2) 12.7 + 4.7 ml/kg/min were analyzed. Severe CI was deﬁned 
as MPHR <70%. The primary composite endpoint was time to one of the following events: 
Death, HTX, LVAD.
Results: Mean f/u time was 509 days. 25 HTX, 8 LVAD, and 11Death occurred. In univariate 
analysis MPHR, pVO2, Hgb, BNP,serum sodium and LVEF predicted time to event (p 
< 0.05). In multivariate analysis, only MPHR, LVEF and pVO2 remained signiﬁcant (p 
<0.05). Furthermore, using Kaplan-Meier analysis, the presence of severe CI conferred a 
2.5 times increased proportional hazard ratio in the 170 patients with peak VO2 < 14 (95% 
Conﬁdence Interval 1.12 - 5.17, p 0.02; Fig 1).
Conclusions: In subjects with advanced HF, severe CI is an independent predictor of 
death and/or the need for advanced surgical therapy. Severe CI does not appear to be 
a protective mechanism and its presence may be useful to further risk stratify subjects 
with pVO2 < 14. The prognostic impact of pacer-based CI modulation in subjects with 
advanced CHF and severe CI remains to be investigated.
9:30 a.m.
1051-195 Long-Term Results of the ACORN CorCap: Five-Year 
Follow-Up From the CSD Only Stratum of the ACORN Trial
Douglas L. Mann, Randall C. Starling, Hani N. Sabbah, Mariell Jessup, Michael A. Acker, 
Jae Oh, Spencer H. Kubo, Baylor College of Medicine, Houston, TX
Background: The Acorn CorCap Cardiac Support Device (CSD) is a polyester mesh 
that is ﬁtted around the heart to reduce wall stress and promote reverse remodeling in 
patients (pts) with heart failure (HF). We previously reported the Acorn Randomized Trial 
with follow-up of ~22 months. We now report the results of 5 year follow-up from the CSD 
only stratum.
Methods: The CSD only stratum enrolled 107 pts with HF (NYHA Class III - 99%; mean 
LVEF 21%; mean LVEDV 282 ml) on optimal medical therapy (OMT). Pts were randomized 
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simultaneous RV-LV timing. The dyssynchrony metrics assessed were: Basal and 
12-segment septal to free wall delay; times to peak systolic and diastolic velocities 
in 12 segments (mean Ts and Te); dispersion of Ts; and 12 segment standard 
deviation of times to peak systolic and diastolic velocities.
Results: Patients were 66±14 years old, male (77%), ischemic (54%) with NYHA 
class of 2.2±0.7, a body mass index of 26±4Kg/m2, a mean EF of 42±4% and a 
predominantly narrow QRS (110±26ms). Cardiac dimensions were mildly dilated 
(LVEDD: 56±10mm and LVESD: 43±10mm). Bi-V pacing did not signiﬁcantly alter 
dyssynchrony measures, but increased mean Ts and Te (Ts: 207±29 vs 247±42ms, 
p<0.01; Te: 615±43 vs. 651±51ms, p<0.01) compared to baseline. This increase was 
paralleled by a signiﬁcant increase in mean QRS width (111±26 vs. 142±19ms, 
p<0.01). There was a signiﬁcant increase in LVOT onset and end time (125±27 vs. 
167±33, p<0.01 and 416±32 vs. 456±34, p<0.01, respectively), a signiﬁcant reduction 
in E/E’ (16±9 vs. 11±4, p=0.03), and a signiﬁcant reduction of LVESD and LVEDD 
(43±10 vs. 41±9mm, p=0.01, and 56±10 vs. 54±10, p=0.03).
Conclusion: These data suggest that acute Bi-V pacing may improve cardiac 
dimensions and echo indices of hemodynamics in a HF population with a moderately 
reduced EF and mildly dilated hearts, despite the marked QRS prolongation. 
Whether these acute changes with Bi-V pacing are chronically therapeutic requires 
additional investigation.
9:30 a.m.
1051-200 Exercise Training in Diastolic Heart Failure: A 
Prospective, Randomized, Controlled, Multicenter Trial 
(ISRCTN 42524037)
Frank Edelmann, Hans-Dirk Duengen, Rolf Wachter, Götz Gelbrich, Silja Schwarz, 
Martin Halle, Christoph Hermann-Lingen, Gerd Hasenfuss, Burkert M. Pieske, University 
of Göttingen, Göttingen, Germany
Background: This trial was designed to tests the hypothesis that exercise training 
improves exercise capacity, quality of life, and diastolic function in patients with diastolic 
heart failure.
Methods: n=67 with symptomatic heart failure, proven diastolic dysfunction, LVEFq50%. 
Randomization (2:1) to supervised, combined endurance/resistance training on top 
on usual care (n=46/T) or usual care alone (n=21/C; control group). Spiroergometry 
(primary endpoint: peak VO2), diastolic function (echocardiography), quality of life, 
collagen turnover were recorded at baseline and after three months. Data analysis was 
by intention-to-treat principle.
Results: Patients were 65±7 years old (56% female, NYHA class II/III (84 vs. 16%), 
LVEF 67±7%. 64 patients completed the study (T n=44, C n=20). Peak VO2 (mL/min/
kg) increased signiﬁcantly (p<0.001) from 16.1±4.9 to 18.7±5.4 in the training group (T), 
but did not change (16.7±4.7 vs. 16.0±6.0; p=0.34) in the control group (C). The mean 
increase in peak VO2 with training was 3.3 mL/min/kg (95% CI, 1.8 to 4.8, P<0.001). The 
NNT to achieve an increase of peak VO2 by 3 mL/kg/min at an individual level was 3.5 
(p=0.006). ATVO2 increased in T (p<0.001) and remained unchanged in C (p=0.79; T vs. 
C p<0.001). Diastolic function was analysed in a blinded fashion: E/e’ ratio decreased from 
12.8±3.2 to 10.5±2.5 (p<0.001) in T and remained unchanged (13.5±4.6 vs. 14.1±3.9; 
p=0.26) in C (mean difference of changes -3.2, C.I. -4.3 to -2.1, P<0.001); é medial (cm/s) 
increased (p<0.001) in T and remained unchanged in C. LAVI (mL/m2) decreased from 
27.9+/-7.6 to 24.3±6.5 (p<0.001) in T and did not change (28.2±8.8 vs. 28.6±9.2; p=0.53) 
in C. Quality of life (MLWHFQ, SF-36) improved in T (p<0.001) and was unchanged in C. 
Median pro-collagen I (μg/L) decreased from 38 (25-51) to 34 (25- 42) in T (p=0.01) and 
remained stable in C (p=0.55).
Conclusions: A supervised 3 months exercise training program effectively improves 
exercise capacity, quality of life, diastolic function, and structural remodeling in patients 
with diastolic heart failure. Controlled lifestyle modiﬁcation with physical activity may 
emerge as a major therapeutic approach in this yet poorly treatable condition.
9:30 a.m.
1051-201 Does Exercise Systolic Tissue Velocity Predict Exercise 
Ability Compared to Other Resting Systolic and 
Diastolic Parameters? An Analysis Across Various 
Populations
Robert A. McIntosh, John C. Silberbauer, Louisa Beale, Gary Brickley, Rick Veasey, Paul 
Hong, Nik Patel, Stephen Furniss, Neil Sulke, Guy Lloyd, Eastbourne General Hospital, 
Eastbourne, United Kingdom
Background: A poor relationship between resting parameters of systolic and diastolic 
heart function and exercise ability has been previously observed, less is known about 
cardiac parameters during exercise. This study evaluated both resting and stress 
echocardiography (SE) parameters in a number of clinical settings and compared them 
with VO2 peak during cardiopulmonary exercise testing (CPET). Methods: 40 patients 
enrolled in various clinical trials were studied. Normal ﬁt adults (n=10, mean age 27) 
patients with AF awaiting AV node ablation (n=10, mean age 73) patients with mild to 
moderate heart failure (n=14, mean age 74) and age matched older controls (n=6, mean 
age 67). All underwent CPET using a bicycle ergometer and had simultaneous SE (peak 
readings taken after anaerobic threshold during exercise). 2D, spectral Doppler and tissue 
Doppler (TDI) parameters were recorded. Results: Linear regression demonstrated a 
strong relationship between VO2 peak and mean left ventricular peak TDI velocity (r2 = 
0.74 p<0.001), TDI judged contractile reserve (r2 = 0.74 p<0.001) and change in ejection 
fraction (r2 =0.2 p = 0.01). There was no relationship between resting heart parameters, 
including ejection fraction, E’ velocity or E/E’ ratio. Diastolic parameters on exertion were 
not related to VO2 max. When the population was dichotomised for ‘diastolic dysfunction’ 
(E/E’ > 12 taken from the lateral wall) the relationship between peak TDI velocities 
remained high despite the small numbers (r2 = 0.71 p =0.03). Conclusions: In the 
Methods: We performed a systemic literature search for RCTs, enrolling HF 
patients, and allocating them to usual care or nurse-led/multidisciplinary DMP. HF-
related hospitalizations and all-cause mortality were assessed for clinical outcomes. 
Heterogeneity of the studies was analyzed by Cochran’s Q statistic. Mantel-Haenszel 
random-effect model for HF-related hospitalizations, and ﬁxed-effect model for all-cause 
mortality, was used to calculate the relative risk (RR). A two-sided alpha error of less than 
0.05 was considered to be statistically signiﬁcant (p<0.05).
Results: Thirteen RCTs provided data on HF-related hospitalizations (N=3,348) 
and 16 RCTs provided data on all-cause mortality (N=3,783). The RR for HF-related 
hospitalizations was 0.504 (95% CI, 0.375 to 0.678; p = 0.000) in the intervention group 
compared to usual care group (ﬁgure below). The RR for all-cause mortality was 0.808 
(95% CI, 0.708 to 0.922; p = 0.002).
Conclusion: Nurse-led or multidisciplinary DMP signiﬁcantly reduce heart failure-related 
hospitalizations and all-cause mortality, in patients with heart failure, when compared to 
usual care.
9:30 a.m.
1051-198 Stroke Volume/End Systolic Volume Ratio Provides a 
Good Measure of Cardiac Function Following Surgical 
Ventricular Reconstruction
Marisa Di Donato, Giuseppe Barletta, Serenella Castelvecchio, Fabio Fantini, Lorenzo 
Menicanti, IRCCS, San Donato Hospital, San Donato Milanese, Italy, Careggi Hospital, 
University of Florence, Florence, Italy
Background:Ejection fraction (EF) is not considered a good measure of cardiac function 
following surgical ventricular reconstruction (SVR) being the ratio Stroke Volume (SV) to 
End diastolic volume (EDV) heavily modiﬁed by volume reduction induced by surgery. 
The arterial coupling (the ratio between arterial and ventricular elastance) reﬂects the 
ventricular energetic being the optimal ratio (about 2) related to the best mechanical 
efﬁciency (about 80%). The mathematical relationship between ventricular elastance, 
that may be accurately measured as End systolic pressure (ESP)/ESV in a single beat 
evaluation, and arterial elastance (SV/ESP) allows to approximate arterial coupling as 
SV/ESV. Aim of the present study was to analyze changes in SV/ESV induced by SVR 
and to compare them to EF changes.
Methods: Four-hundred-sixty-six patients (65±10 yrs, 89 F) undergoing SVR at our 
Center between July 2001 and July 2008 for ischemic dilated cardiomyopathy. LV EDV, 
end systolic volumes (ESV), LVEF and the SV/ESV ratio were measured by transthoracic 
echocardiogram before surgery and at discharge in all survivors and in 190 patients at 
FUP. SVR was conducted on arrested heart.
Results: All patients had SVR; CABG was associated in 93% and mitral repair in 25%.
LV EDV and ESV decreased (-32 and -40%, respectively), SV decreased (- 20%); LV 
EF improved (+18%) and SV/ESV increased (+35%) at discharge. All changes were 
signiﬁcant at p 0.0001 and were maintained at follow-up. Interestingly, while SV at 
discharge was signiﬁcantly reduced, SV/ESV was signiﬁcantly increased to a greater 
extent than the improvement in EF. Such improvement was maintained at FUP.
Conclusions: The SV/ESV ratio may be more informative than LVEF following a surgical 
procedure that strongly changes loading conditions. The improvement in SV/ESV 
indicates an improvement in cardiac energetics, thus overcoming the limitation of EF in 
this cohort of patients.
9:30 a.m.
1051-199 Acute Bi-ventricular Pacing Improves Cardiac Function 
in a Heart Failure Population With a Moderately 
Reduced Ejection Fraction
Yi-Chih Wang, Chih-Chieh Yu, Kathryn Hilpisch, Vincent Splett, Rodolphe P. Katra, Chia-
Ti Tsai, Juey-Jen Hwang, Ling-Ping Lai, Jiunn-Lee Lin, Natl Taiwan University Hosp, 
Taipei, Taiwan,ROC, Medtronic Inc, Mounds View, MN
Background: Cardiac resynchronization therapy (CRT) is an effective therapy for 
patients with a reduced ejection fraction (EF). However, the therapeutic beneﬁt of 
CRT in a heart failure (HF) population with a mildly reduced EF remains under-
explored. This study examines the acute effects of Bi-V pacing in a HF population 
with a mildly reduced EF.
Methods: Thirteen patients with EF between 35 and 50% undergoing cardiac 
catheterization were studied. Temporary pacing catheters were placed in the RA, LV 
and RV. LV systolic dyssynchrony by Tissue Doppler Echocardiography (TDI) and 
ECG were measured at baseline and during acute Bi-V pacing (5min). Patients were 
paced in VDD mode with AV timing selected to optimize transmitral ﬂow and with 
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9:30 a.m.
1051-204 Chronic Therapy With Vagus Nerve Stimulation Is 
Associated With Reduced Levels of Circulating Plasma 
Biomarkers of Heart Failure
Ramesh C. Gupta, Itamar Ilsar, Mengjun Wang, Alice Jiang, Asaph Zaretsky, Michael S. 
Sabbah, Hani N. Sabbah, Henry Ford Hospital, Detroit, MI, Technion, Haifa, Israel
Background: Plasma levels of the soluble intracellular adhesion molecule-1 (sICAM-1), 
interleukin-6 (IL-6), and atrial (ANP) and brain (BNP) natriuretic peptides are increased 
in heart failure (HF). We previously showed that chronic therapy with Vagus nerve 
stimulation (VNS) using the CardioFit system (BioControl Medical, Ltd.), when combined 
with beta-blockade (BB), signiﬁcantly increases LV ejection fraction (EF) in dogs with 
coronary microembolization-induced HF compared to BB alone. This study examined 
whether VNS therapy in combination with BB is associated with a greater reduction of 
plasma levels of these biomarkers.
Methods: Blood samples were obtained from HF dogs treated for 3 months with BB 
alone (n=6), BB + VNS (n=6), untreated HF dogs (n=6) and normal (NL) dogs (n=6). 
Plasma level of sICAM-1, IL-6, nt-pro-BNP and nt-pro-ANP were measured using speciﬁc 
ELISA kits.
Results: sICAM-1, IL-6, ANP, and BNP levels in plasma increased signiﬁcantly in untreated 
HF dogs compared to NL dogs (Table). Therapy with BB alone signiﬁcantly lowered plasma 
levels of all markers compared to untreated HF dogs. Compared to BB alone, combined 
VNS + BB therapy signiﬁcantly lowered all biomarkers tested except BNP.
Conclusions: In dogs with HF, combined VNS and BB therapy is associated with reduced 
plasma levels of biomarkers of worsening HF. This ﬁnding is consistent with our earlier 
observation of a greater improvement of LV EF in HF dogs treat with combined VNS and 
BB compared to BB alone.
NL HF-Control HF + BB HF + BB + VNS
sICAM-1 (μg/ml) 1.96 ± 0.30 10.82 ± 0.44* 5.66 ± 0.55† 2.66 ± 0.46‡
IL-6 (pg/ml) 145 ± 29 595 ± 92* 190 ± 29† 148 ± 12‡
nt-proBNP (fmol/ml) 587 ± 32 1038 ± 113* 633 ± 47† 580 ± 50
nt-proANP (nmol/ml) 13 ± 2 85 ± 7* 41 ± 3† 24 ± 2‡
*=p<0.05 vs. NL; †=p<0.05 vs. HF-Control; ‡=p<0.05 vs. BB
9:30 a.m.
1051-205 Prognostic Value of Anemia in Elderly Patients With 
Diastolic Heart Failure
Faramarz Tehrani, Anita Phan, Ryan Morrissey, Christopher Chien, Asim Raﬁque, Ernst 
R. Schwarz, Cedars Sinai Medical Center, Los Angeles, CA
Background: Anemia is prevalent in patients with heart failure and has been associated 
with increased mortality. There is a lack of consensus regarding the effect of anemia in 
elderly (> 75 years) patients with heart failure and preserved ejection fraction. The current 
study assessed the effects of anemia on long term survival in patients with pure diastolic 
heart failure.
Methods: Patients with heart failure and preserved systolic function, EFq50% (diastolic 
heart failure) were evaluated. Patients were separated into those anemic (group 1) and 
those non-anemic (group 2) at baseline (anemia deﬁned as Hgb<12g/dL females or 
Hgb<13g/dL males). A multivariate Cox proportional hazards regression was conducted 
to test whether hemoglobin levels are an independent predictor of 5-year hospitalization 
rate and mortality in patients with diastolic heart failure.
Results: Two hundred and ninety four patients were evaluated (group 1, n=162; group 2, 
n=132). Anemic patients had a shorter mean survival (37.8±1.8 versus 44.9±1.8, p=0.010) 
but no signiﬁcant difference in hospitalization rate (7.2±7.1 versus 7.5±6.3, p=0.677 for 
groups 1 and 2). In a subgroup analysis, anemia was a signiﬁcant predictor of higher 
mortality in the elderly patients (>75 years old) with diastolic heart failure (p=0.018).
Conclusions: Anemia is associated with increased long term mortality in patients with 
diastolic heart failure, and appears to be an independent predictor of worse outcomes in 
elderly patients with heart failure. 
absence of other extracardiac disease processes there is a strong relationship between 
contractile reserve judged by TDI and exercise ability during CPET. The relationship is 
robust in different groups of heart function and especially when diastole is abnormal. 
Heart failure with normal ejection fraction may be a failure of systole rather than of 
diastole as conventionally understood.
9:30 a.m.
1051-202 Mechanisms of Improvement of Mitral Regurgitation 
After Cardiac Resynchronization Therapy in Patients 
With Congestive Heart Failure
Katsuomi Iwakura, Hiroshi Ito, Atsunori Okamura, Yasushi Koyama, Motoo Date, 
Yoshiharu Higuchi, Koichi Inoue, Ryusuke Kimura, Hiroyuki Nagai, Yuko Toyoshima, 
Michio Imai, Makito Ozawa, Norihisa Ito, Yukinori Okazaki, Masahiko Shibuya, Hidetaka 
Suenaga, Asuka Kubota, Kenshi Fujii, Sakurabashi Watanabe Hospital, Osaka, Japan
Background: CARE-HF trial demonstrated that the severity of mitral regurgitation (MR) is 
one of the strongest predictor for mortality of patients with congestive heart failure (CHF) 
who receive cardiac resynchronization therapy (CRT) (J Am Coll Cardiol 2008; 52:438). 
Tethering of mitral valve leaﬂets associated with left ventricular remodeling is the major 
mechanism of functional MR. We investigated the effects of CRT on the tethering of mitral 
valve and on severity of MR.
Methods: We enrolled consecutive 32 patients with CHF eligible for CRT who had 
moderate to severe MR. They underwent echocardiography study before and 10±5 
months after the CRT. We assessed severity of MR as jet area of MR to left atrial area ratio 
on color-Doppler image, and deﬁned q20% reduction of the MR ratio as an improvement 
of MR. We measured midsystolic mitral annular area and mitral valve tenting height to 
estimate severity of tethering of mitral leaﬂet. We also assessed changes in left ventricular 
ejection fraction, end-diastolic and end-systolic volume (LVEDV and LVESV) after CRT.
Results: Among the 32 study patients, 15 patients (46.9%) showed the reduction of MR. 
There were no signiﬁcant differences in MR ratio, mitral annular area and tenting height 
before CRT between those with and without MR reduction. Patients showing improvement 
had signiﬁcant reduction of mitral annular area (2.3±0.5 cm2 to 1.1±0.4 cm2, p<.0001) 
and tenting height (1.1±0.2 to 0.6±0.1 cm, p<.001) after CRT, whereas those without 
improvement showed no signiﬁcant differences in these values (1.9±0.9 cm2 to 2.0±0.9 
cm2, p=.82 and 1.0±0.3 to 1.0±0.3 cm, p=.61). On the other hand, both groups showed 
signiﬁcant reduction in LVEDV (179±67 mL to 139±58 mL, p=.02, and 201±100 mL to 
174±104 mL, p=.03) and in LVESV (133±58 mL to 85±53 mL, p=.001, and 151±100 mL to 
118±95 mL, p=.001), and improvement in ejection fraction (28±10% to 43±16%, p<.001, 
and 29±12% to 38±16%, p=.006).
Conclusions: Improvement of functional MR by CRT is mediated through the correction 
of tethering of mitral valve leaﬂet, however, reduction of left ventricular volumes could not 
be the sole mechanism of these improvements.
9:30 a.m.
1051-203 Red Cell Distribution Width: A Novel Prognostic Marker 
in Pulmonary Hypertension
Chetan V. Hampole, Amit K. Mehrotra, Thenappan Thenappan, Mardi Gomberg-
Maitland, Sanjiv S. Shah, University of Chicago, Chicago, IL, Northwestern University, 
Chicago, IL
Background: Red cell distribution width (RDW), a widely available biomarker which 
independently predicts outcome in left-sided heart failure, has never been studied in 
pulmonary hypertension (PH). Based on our anecdotal experience that increased RDW 
is associated with severe PH, we hypothesized that RDW would be independently 
associated with increased mortality in PH.
Methods: In a prospective study of 187 consecutive patients with PH (mean PA pressure 
> 25 mmHg), we recorded RDW at time of right heart catheterization. Patients were 
then followed for 2.1±1.0 years and mortality was ascertained on all patients. We ﬁrst 
used linear regression with RDW as the dependent variable to determine which clinical, 
demographic, laboratory, and hemodynamic variables were associated with RDW. We 
then used univariate and multivariate Cox proportional hazards models to determine 
whether RDW was independently associated with death.
Results: Of the 187 study patients, 78% were female, 62% had pulmonary arterial 
hypertension (PAH), and mean age was 55±14 years. Overall, patients in this cohort had 
severe PH (right atrial pressure [RAP] 11±7 mmHg, mean PA pressure 48±13 mmHg, 
cardiac index 2.5±1.0, and pulmonary vascular resistance 9.6±6.2) and poor functional 
status (87% had functional class III-IV symptoms). Increased RDW was associated with 
decreased hemoglobin (Hgb), decreased serum sodium (Na), increased blood urea 
nitrogen (BUN), and increased serum creatinine (SCr). Of the hemodynamic variables, 
only RAP was associated with RDW. During follow-up, 26/187 (14%) of the patients 
died. On Cox regression analysis, the highest tertile of RDW predicted death (univariate 
HR 3.2, 95% CI 1.1-9.1, p=0.030; multivariate HR 4.2, 95% CI 1.1-16.4, p=0.041, after 
adjusting for age, sex, etiology of PH, RAP, Na, BUN, SCr, and Hgb). These associations 
were also present in the subgroup of patients with PAH.
Conclusions: RDW is an independent predictor of death in PH. RDW seems to be a 
marker of the overall heart failure syndrome, since it is associated with anemia, worse 
renal function, hyponatremia, and elevated RAP. Further study of abnormalities in RDW 
may provide insight into the pathogenesis and prognosis of PH.
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1051-206 Long-Term Effects of Intracoronary CD34+ Stem 
Cell Transplantation in Patients With Dilated 
Cardiomyopathy
Bojan Vrtovec, Gregor Poglajen, Dragoslav Domanovic, Matjaz Sever, Luka Lezaic, 
Peter Cernelc, Guillermo Torre-Amione, Ljubljana University Medical Center, Ljubljana, 
Slovenia, Methodist DeBakey Heart Center, Houston, TX
Background: Stem cell therapy appears to have beneﬁcial short-term effects in patients 
with dilated cardiomyopathy (DCM). We sought to investigate whether the early beneﬁts 
of intracoronary stem cell transplantation are sustained over time.
Methods: We performed intracoronary autologous CD34+ stem cell transplantation in 
17 DCM patients (15 male, 2 female; mean age: 55±7 years). Peripheral blood stem 
cells were mobilised by daily subcutaneous injections of ﬁlgrastim; CD34+ cells were 
collected via apheresis and labelled with technetium. Patients underwent myocardial 
perfusion scintigraphy for myocardial viability assessment and CD34+ cells were injected 
intracoronary in the artery supplying the segments of reduced tracer accumulation. 
Patients were reassessed at 1 and 12 months after the procedure. 
Results: At 1 month we found a signiﬁcant improvement in LVEF (from 24.1±6.3% to 
31.3±6.2%; P=0.001) and 6-minute walk test distance (from 361±114 m to 426±84 m; 
P=0.02), but no changes in LVEDD (from 6.9±0.9 cm to 6.8±0.7 cm; P=0.42), target wall 
thickness (from 1.1±0.2 cm to 1.3±0.2 cm; P=0.16), and plasma levels of TNF-alpha (from 
4.4±2.8 pg/ml to 3.0±1.9 pg/ml; P=0.07). The improvement in LVEF persisted throughout 
the 12-month period (-0.1±7.2%; P=0.96), and correlated with the numbers of the cells 
found at the site of intracoronary delivery (r2=0.71, P=0.01). Similarly, we found no 
additional changes in 6-minute walk test distance (+52±74 m; P=0.35), LVEDD (-0.2±0.2 
cm; P=0.40), or TNF-alpha (+0.8±2.0 pg/ml; P=0.14) between the 1st and 12th month. In 
contrast, a further increment in target ventricular wall thickness was found at 12 months 
after the procedure (+0.3±0.2 cm, P=0.02).
Conclusions: In DCM patients, the early beneﬁts of intracoronary stem cell transplantation 
evident at 1 month following the procedure appear to be sustained up to 12 months.
